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SUMMARY 
 Endothelial adhesion receptors ICAM-1 and VCAM-1 are key molecules for 
leukocyte extravasation to inflammatory foci. In this work, we demonstrate that both 
receptors together with the actin-cytoskeleton and related proteins such as ezrin, moesin, 
α-actinin, vinculin and VASP participate in the formation of a three-dimensional 
structure (endothelial docking structure) that arises from the apical surface of activated 
endothelial cells to partially embraced and firmly attached adherent lymphocytes, 
preventing their detachment under physiological hemodynamic conditions. The formation 
and maintenance of this cup-like structure is regulated by Rho/ROCK and 
phosphoinositide PIP2. Furthermore, tetraspanin proteins CD9 and CD151 laterally 
associate with ICAM-1 and VCAM-1 at the plasma membrane, co-localizing with these 
adhesion receptors at the endothelial docking structures. The insertion of ICAM-1 and 
VCAM-1 in tetraspanin microdomains is crucial for the proper adhesive functions of 
these endothelial receptors. In addition, ICAM-1 and VCAM-1 are able to co-cluster at 
docking structures in the absence of ligand engagement, actin anchorage and heterodimer 
formation. This phenomenon can be explained by their specific interactions within the 
tetraspanin microdomains (ICAM-1/CD9, VCAM-1/CD151, CD9/CD151). The analysis 
of the biophysical properties of tetraspanin and adhesion receptors demonstrate the 
existence of these organized microdomains containing CD9, CD151, ICAM-1 and 
VCAM-1 at the apical endothelial plasma membrane of living cells, with different 
diffusional properties compared to lipid rafts. These particular kind of microdomains has 
been termed endothelial adhesive platforms (EAP). Finally, EAP-induced nanoclustering 
of VCAM-1 and ICAM-1 represents a novel mechanism of supramolecular organization 
that regulate the efficient leukocyte integrin-binding capacity of both endothelial 
receptors. 
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INTRODUCCIÓN 
 
 
EL PROCESO DE EXTRAVASACIÓN 
  
 El proceso de extravasación leucocitaria, que tiene lugar durante la recirculación 
linfoide o la respuesta inflamatoria, requiere de cambios morfológicos drásticos que 
implican el agrupamiento de receptores de adhesión en estructuras protrusivas de la 
membrana plasmática, tanto en leucocitos como en células endoteliales. La 
extravasación es un proceso activo no sólo para los leucocitos sino también para el 
endotelio, lo que promueve la rápida y eficiente llegada de los leucocitos a los tejidos 
diana sin comprometer la integridad de la barrera endotelial. 
 Los receptores de adhesión regulan muchos procesos tales como la activación, 
migración, crecimiento, diferenciación y muerte celular (Frenette and Wagner, 1996a; 
Frenette and Wagner, 1996b) mediante la transducción directa de señales y la 
modulación de otras cascadas de señalización intracelular desencadenadas por 
diferentes factores de crecimiento (Aplin et al., 1998). Las interacciones celulares son 
críticas para la regulación de la hematopoyesis (Levesque et al., 1999; Verfaillie, 1998) 
y la respuesta inflamatoria (Butcher, 1991; Butcher and Picker, 1996). El 
funcionamiento coordinado de los receptores de adhesión, el citoesqueleto y las 
moléculas de señalización es crucial para la extravasación leucocitaria, un proceso 
central en la immunidad. Así, la correcta integración de señales “del exterior al interior” 
y “del interior al exterior” en leucocitos y endotelio durante cada paso de la 
extravasación es crítico para permitir la consecución de este fenómeno, el llamado 
paradigma multi-secuencial (Butcher, 1991; Springer, 1994). 
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Interacciones iniciales entre leucocitos circulantes y el endotelio: tethering y 
rodamiento mediado por selectinas y sus ligandos 
 Los leucocitos circulantes en el torrente sanguíneo deben establecer contacto y 
adherirse a la pared vascular soportando fuerzas de cizalla, para iniciar la respuesta 
inflamatoria o migrar a órganos linfoides secundarios (recirculación). El “tethering” y el 
rodamiento de los leucocitos sobre el endotelio activado son los primeros pasos del 
proceso secuencial de extravasación, seguidos de la adhesión firme y la migración 
transendotelial. Estos contactos iniciales están mediados mayoritariamente por 
selectinas y sus ligandos. Las selectinas (P-, E- y L-selectina) son glicoproteínas 
transmembrana tipo I que se unen a carbohidratos sialilados presentes en sus ligandos 
de forma dependiente de Ca2+. Aunque las selectinas y sus ligandos tienden a 
interaccionar con afinidad variable, la elevada frecuencia de asociación-disociación de 
sus interacciones les permiten mediar contactos transitorios entre leucocitos y endotelio 
(“tethering”) (Mehta et al., 1998; Nicholson et al., 1998). Estos contactos provocan la 
disminución de velocidad de los leucocitos y permiten su rodamiento sobre la superficie 
endotelial, lo que favorece las interacciones subsiguientes mediadas por integrinas y sus 
ligandos, aumentando la adherencia de los leucocitos, lo que finalmente provoca su 
parada en la pared venular (Evans and Calderwood, 2007). Además de las selectinas y 
sus ligandos, las integrinas α4β1 y α4β7 a través de su interacción con VCAM-1 y 
MAdCAM-1, respectivamente, pueden mediar de manera independiente estos contactos 
iniciales (Alon et al., 1995; Berlin et al., 1995). Por otra parte, la interacción LFA-
1/ICAM-1 coopera con la función de L-selectina, estabilizando la fase de tethering y 
disminuyendo la velocidad de rodamiento (Henderson et al., 2001; Kadono et al., 2002). 
La localización topográfica de los receptores de adhesión es necesaria para su 
correcto funcionamiento durante el tráfico leucocitario (von Andrian et al., 1995). Por 
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ello, las selectinas, sus ligandos y las integrinas α4 se encuentran agrupadas en los 
extremos de los microvilli. Por otra parte, el anclaje de las selectinas al citoesqueleto de 
actina mediante proteínas como α-actinina o moesina es necesario para su adecuado 
funcionamiento (Dwir et al., 2001; Ivetic et al., 2002; Pavalko et al., 1995). 
 
Papel central de las integrinas leucocitarias y sus ligandos endoteliales en los 
procesos de activación, parada, adhesión firme y locomoción 
El tráfico de los leucocitos a través de los diferentes tejidos y órganos, y su 
interacción posterior con otras células inmunes es esencial para el desarrollo de la 
inmunidad innata y adquirida (von Andrian and Mackay, 2000). Las integrinas son 
moléculas clave en la migración celular que controlan las interacciones intercelulares y 
célula-matriz extracelular durante la recirculación y la inflamación. Una de sus 
características más importantes estriba en la regulación de su actividad adherente de 
manera independiente a su nivel de expresión en membrana (Hynes, 2002). Así, los 
leucocitos circulantes en sangre mantienen sus integrinas en conformación inactiva para 
evitar contactos inespecíficos con paredes vasculares no inflamadas, pero cuando 
encuentran un foco inflamatorio, se produce una rápida activación in situ de sus 
integrinas (Campbell et al., 1998). Como en el caso de las selectinas, la distribución 
espacial de las integrinas y sus ligandos en estructuras de membrana especializadas es 
esencial para su apropiado funcionamiento. Esta organización topográfica requiere una 
precisa regulación del citoesqueleto para permitir el reclutamiento de intermediarios de 
señalización y segundos mensajeros que desencadenen la activación celular (Vicente-
Manzanares and Sanchez-Madrid, 2004).  
Las integrinas constituyen una familia de 24 receptores heterodiméricos, 
compuesto cada uno de ellos por una subunidad α y otra β. Son moléculas que regulan 
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dinámicamente sus propiedades adherentes mediante cambios conformacionales 
(afinidad) así como por redistribución espacial en la superficie celular (avidez)  
(Carman and Springer, 2003). Datos recientes predicen la existencia de tres estados 
conformacionales (plegado/con baja afinidad, extendido con afinidad intermedia y 
extendido con alta afinidad) (Beglova et al., 2002; Nishida et al., 2006). Las integrinas 
más relevantes para la adhesión leucocitaria al endotelio son miembros de la subfamilia 
β2, particularmente LFA-1 (CD11a/CD18 o αLβ2) y la integrina específica de linaje 
mieloide Mac-1 (CD11b/CD18 o αMβ2), así como las integrinas α4 VLA-4 (α4β1) y 
α4β7. La mayoría de sus ligandos son proteínas transmembrana que pertenecen a la 
superfamilia de las inmunoglobulinas. LFA-1 puede unirse a cinco moléculas de 
adhesión intercelular (ICAM-1 a -5), aunque las más relevantes son ICAM-1 e ICAM-3 
(Gahmberg et al., 1990). ICAM-1 se expresa en leucocitos, células dendríticas y células 
epiteliales. Además, su expresión es baja en células endoteliales quiescentes, 
aumentando con estímulos pro-inflamatorios (Dustin et al., 1986). ICAM-3 es 
expresado constitutivamente por todos los leucocitos (Acevedo et al., 1993), mientras 
que la molécula de adhesión de uniones intercelulares JAM-1, un ligando adicional de 
LFA-1, se concentra selectivamente en la region apical de las uniones estrechas (“tight 
junctions”) en células endoteliales (Ostermann et al., 2002). Por otra parte, Mac-1 
interacciona con ICAM-1, JAM-C y el receptor RAGE (Chavakis et al., 2003; Lamagna 
et al., 2005). La integrina VLA-4 interacciona con VCAM-1 (Elices et al., 1990), que es 
una molécula de adhesión que se expresa de novo tras la activación endotelial (Carlos 
and Harlan, 1994), y también se une a JAM-B (Cunningham et al., 2002). Además, 
VLA-4 interacciona con ADAM-28, fibronectina, osteopontina, trombospondina, el 
factor de coagulación von Willebrand y la proteína bacteriana invasina (Mittelbrunn et 
al., 2006). Finalmente, la integrina α4β7, aparte de interaccionar con VCAM-1 y 
                                                                                                                         Introducción  
 9
fibronectina, reconoce específicamente a MAdCAM-1, un receptor expresado en los 
tejidos linfoides de las mucosas (Berlin et al., 1993). 
 
Modulación de la actividad de las integrinas mediada por quimioquinas 
 Durante el establecimiento de los contactos iniciales con el endotelio vascular, 
los leucocitos disminuyen su velocidad de rodamiento y se activan al encontrar 
quimioquinas inmobilizadas y ligandos de integrinas expuestos en la superficie apical 
endotelial. Este paso de activación permite la parada y adhesión firme de los leucocitos 
al endotelio en condiciones de flujo fisiológico (Alon et al., 2003; Rot and von Andrian, 
2004). La activación del leucocito implica un marcado cambio morfológico: la célula 
redondeada circulante se transforma en una célula pro-migratoria con morfología 
polarizada en la cual se distinguen al menos dos regiones, el frente de avance y el 
urópodo (del Pozo et al., 1995). La polarización del leucocito permite a la célula la 
coordinación de las fuerzas intracelulares para producir la locomoción celular necesaria 
durante el proceso de extravasación (Geiger and Bershadsky, 2002). 
 Las quimioquinas unidas a los glicosaminoglicanos de la membrana apical 
endotelial actúan señalizando a través de receptores acoplados a proteínas G (GPCRs) 
localizados en los microvilli del leucocito, induciendo una gran variedad de señales “del 
interior al exterior” en fracciones de segundo, que conducen a cambios 
conformacionales múltiples en las integrinas (Constantin et al., 2000; Sanchez-Madrid 
and del Pozo, 1999; Shamri et al., 2005). Debido a la complejidad y al corto margen de 
tiempo de los mecanismos de señalización inducidas por quimioquinas que controlan la 
activación de integrinas, es posible la existencia de redes protéicas 
compartimentalizadas y pre-formadas (“signalosomas”) en los leucocitos (Laudanna and 
Alon, 2006). La presencia de quimioquinas específicas de diferentes lechos vasculares 
                                                                                                                         Introducción  
 10
contribuye a orquestar el reclutamiento selectivo de las diferentes subpoblaciones 
leucocitarias a los focos inflamatorios o a los órganos linfoides secundarios (Luster, 
1998). Además, las quimioquinas pueden ejercer un efecto diferencial sobre integrinas 
específicas dentro del mismo micro-ambiente (Laudanna, 2005). 
 
Modulación de la afinidad de las integrinas mediada por sus ligandos 
 
 Tras la activación inducida por las quimioquinas, la conformación de las 
integrinas cambia de manera reversible de inactiva (plegada) a extendida con afinidad 
intermedia. Este evento prepara a la integrina para unirse a su ligando endotelial. Las 
integrinas que contienen un dominio I insertado en sus subunidades α sufren un ulterior 
cambio conformacional tras la unión a ligando, que culmina en la activación total de la 
integrina y la parada del leucocito (Cabanas and Hogg, 1993; Jun et al., 2001; Salas et 
al., 2004). Por tanto, el estado conformacional de alta afinidad para la parada inmediata 
del leucocito sobre el endotelio requiere una inducción bidireccional por parte de las 
quimioquinas inmobilizadas y los ligandos de integrinas (Grabovsky et al., 2000; 
Shamri et al., 2005). Sin embargo, las integrinas α4, que contienen un dominio “I-like” 
en sus cadenas β, pueden interaccionar espontáneamente con sus ligandos endoteliales 
sin estimulación quimiotáctica previa (Alon et al., 1995).  
 La señalización inducida por la unión a ligando conlleva la separación de las 
regiones citoplásmicas de las subunidades de la integrina, lo que favorece su asociación 
con el citoesqueleto cortical de actina. Además, la unión al ligando aumenta el 
reclutamiento de integrinas adicionales para incrementar la adhesión firme del leucocito 
en condiciones de estrés de flujo (Dobereiner et al., 2006). Este agrupamiento de 
integrinas depende de la liberación de su anclaje al citoesqueleto de actina, que está 
mediada por la proteína kinasa C (PKC) y calpaína, para aumentar su movilidad lateral 
en la membrana (Stewart et al., 1998). En este sentido, se ha sugerido la presencia de 
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nano-agrupamientos de LFA-1 no unidos a ligando en la membrana plasmática de los 
leucocitos, que promueven la formación eficiente de los micro-agrupamientos inducidos 
por unión a ligando (Cambi et al., 2006). Por otra parte, varios estudios sugieren que el 
estrés de flujo también regula a las integrinas, reforzando sus enlaces e, incluso, 
aumentando su afinidad (Marschel and Schmid-Schonbein, 2002; Zwartz et al., 2004). 
La integración de la señalización derivada de las quimioquinas y las fuerzas externas 
para favorecer la transmigración se ha definido como el fenómeno de quimio-reotaxis 
(Cinamon et al., 2001). 
 
Regulación de la locomoción de los leucocitos por integrinas 
 Las señales implicadas en la adhesión firme de los leucocitos al endotelio 
mediadas por integrinas deben ser atenuadas para permitir la migración del leucocito 
hacia un sitio apropiado de transmigración. Las integrinas β2 parecen tener una 
implicación crítica en este proceso de locomoción, ya que su bloqueo o el de sus 
ligandos provoca migración al azar, fallo de posicionamiento en las uniones inter-
endoteliales y diapedesis defectiva (Schenkel et al., 2004). Tras su activación por unión 
a ligando, las integrinas activan diferentes efectores de contractilidad de miosina, 
GTPasas remodeladoras de actina y moléculas implicadas en la regulación de la red de 
microtúbulos tanto en el frente de avance como en el urópodo. Así, la integración de 
señales generadas en ambos polos celulares lleva a un movimiento coordinado del 
leucocito (Vicente-Manzanares and Sanchez-Madrid, 2004). 
 
Papel funcional de VCAM-1 e ICAM-1 en la captura de leucocitos 
 VCAM-1 e ICAM-1, miembros de la superfamilia de las inmunoglobulinas, son 
las principales moléculas de adhesión endotelial implicadas en la unión a las integrinas 
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VLA-4 y LFA-1, respectivamente (Elices et al., 1990; Marlin and Springer, 1987). 
Solamente ICAM-1 se expresa a bajo nivel en endotelio quiescente, mientras que se 
induce la expresión de ambas moléculas tras la activación celular por citoquinas pro-
inflamatorias tales como IL-1 y TNF-α (Carlos and Harlan, 1994; Dustin et al., 1986). 
Además, se ha descrito la unión de VCAM-1 e ICAM-1 al citoesqueleto de actina a 
través de dos miembros de la familia ERM, ezrina y moesina (Barreiro et al., 2002; 
Heiska et al., 1998). Estas moléculas funcionan como conectores de la membrana con el 
citoesqueleto de actina regulando la morfogénesis cortical y la adhesión celular. Las 
proteínas ERM están implicadas en la formación de estructuras protrusivas de la 
membrana plasmática tales como filopodia, microespículas o microvilli (Mangeat et al., 
1999; Yonemura and Tsukita, 1999). Estructuralmente, todos los miembros de la 
familia son muy parecidos entre sí y parecen ser funcionalmente redundantes, como lo 
sugiere el fenotipo aparentemente normal del ratón knockout para moesina (Doi et al., 
1999). El dominio N-terminal de las ERM es capaz de interaccionar con proteínas 
integrales de membrana, mientras que su extremo C-terminal se une a F-actina (Turunen 
et al., 1994). Su funcionamiento está conformacionalmente regulado, cambiando 
reversiblemente de la forma plegada o inactiva a la forma extendida o activa. La unión 
de fosfatidilinositol 4,5-bisfosfato y la fosforilación de un residuo específico de treonina 
en su porción C-terminal promueven la conformación activa de las ERM (Barret et al., 
2000; Nakamura et al., 1999). La ruta de señalización Rho/ROCK y la producción de 
PIP2 son los principales mecanismos de regulación para la activación de las ERM, 
induciendo su fosforilación y translocación a la membrana (Hirao et al., 1996; Matsui et 
al., 1998;  Shaw et al., 1998).  Por otra  parte,   las  proteínas   ERM   activadas   pueden  
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secuestrar Rho-GDI, permitiendo la activación de Rho, lo que a su vez promueve un 
mecanismo positivo de retro-alimentación de su propia activación (Takahashi et al., 
1997). 
 En cuanto a la transducción de señales, VCAM-1 e ICAM-1 son capaces de 
transmitir señales tras su unión con el ligando. VCAM-1 está implicada en la apertura 
de las uniones interendoteliales para facilitar la extravasación de los leucocitos. De 
hecho, VCAM-1 induce la activación de la NADPH oxidasa y la producción de especies 
reactivas de oxígeno (ROS) de manera dependiente de Rac GTPasa, con la consiguiente 
activación de metaloproteinasas de matriz y pérdida de la adhesión mediada por VE-
cadherina (Cook-Mills, 2002; van Wetering et al., 2002; van Wetering et al., 2003). Por 
otra parte, VCAM-1 e ICAM-1 son capaces de inducir un rápido incremento de las 
concentraciones de Ca2+ intracelular, produciendo la activación de Src kinasa y la 
subsiguiente fosforilación de cortactina (Etienne-Manneville et al., 2000; Lorenzon et 
al., 1998). ICAM-1 también puede activar RhoA induciendo la formación de fibras de 
estrés y la fosforilación de FAK, paxilina y p130Cas, que a su vez, están implicados en 
rutas de señalización que implican a JNK y p38 (Greenwood et al., 2002; Hubbard and 
Rothlein, 2000; Thompson et al., 2002a; Wang and Doerschuk, 2002). Además, también 
se ha descrito la inducción de la transcripción de c-fos y rhoA via ICAM-1 (Thompson 
et al., 2002). Finalmente, ICAM-1 también puede inducir su propia expresión y la de 
VCAM-1, como un mecanismo de regulación para facilitar la transmigración 
leucocitaria (Clayton et al., 1998). 
 
Integrinas y sus ligandos durante la transmigración endotelial 
 Las señales implicadas en la adhesión firme de los leucocitos al endotelio deben 
ser revertidas, debilitando los contactos originales lo suficiente para permitir la 
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migración y extravasación de los leucocitos. Durante la transmigración endotelial 
(TEM), las uniones endoteliales se deshacen parcialmente, evitando el daño de la 
monocapa o importantes cambios de permeabilidad. Así, las membranas del leucocito y 
el endotelio se mantienen en estrecho contacto durante la diapedesis y, posteriormente, 
las membranas endoteliales vuelven a sellar sus conexiones.  
 Una vez que los leucocitos encuentran un sitio apropiado para transmigrar 
(preferencialmente en las uniones intercelulares), extienden pseudópodos exploratorios 
entre dos células endoteliales adyacentes. A continuación, los pseudópodos evolucionan 
a una lamella que va atravesando el espacio abierto en la monocapa. Durante este 
proceso, LFA-1 es la integrina que tiene el papel preponderante. Esta molécula se 
relocaliza  rápidamente, formando un agrupamiento en forma de anillo en la interfase de 
contacto leucocito-endotelio, donde interacciona con ICAM-1 y, en algunos otros 
modelos celulares, con JAM-A. Cuando el proceso de transmigración concluye, LFA-1 
se concentra finalmente en el urópodo (Sandig et al., 1999; Shaw et al., 2004).  
 En el contexto de transmigración leucocitaria, además de la ruta clásica de 
diapedesis, en la que los leucocitos cruzan a través de uniones interendoteliales (ruta 
paracelular), existen crecientes evidencias que indican la existencia de una ruta 
alternativa, en la que los leucocitos podrían migrar a través de células endoteliales 
individuales (ruta transcelular) (Carman and Springer, 2004; Engelhardt and Wolburg, 
2004). Este proceso tiene lugar preferencialmente en células endoteliales de 
microvasculatura. Nuevos datos sobre el mecanismo de este proceso de migración 
transcelular han sido aportados recientemente. Parece que, inicialmente, los leucocitos 
generan podosomas invasivos dependientes de la actividad de Src kinasa y de WASP 
para palpar la superficie endotelial que, posteriormente, evolucionan para formar el poro 
transcelular. En el endotelio es necesaria la fusión de membranas regulada por calcio y 
                                                                                                                         Introducción  
 15
complejos que contienen SNARE (Carman et al., 2007). Otro estudio describe la 
translocación de ICAM-1 a caveolas tras la adhesión leucocitaria y la posterior 
formación de una especie de canal multivesicular, que contiene ICAM-1 y caveolina-1, 
alrededor del pseudópodo leucocitario que penetra a través de la célula endotelial. 
Ambas proteínas, ICAM-1 y caveolina, siguen el paso de todo el leucocito, moviéndose 
hacia la membrana endotelial basal (Millan et al., 2006). Además, la proteína de 
filamentos intermedios vimentina también parece tener un papel importante en la ruta 
transcelular (Nieminen et al., 2006). 
 
MICRODOMINIOS DE TETRASPANINAS  
Las tetraspaninas son una superfamilia de proteínas que cuenta con al menos 28 
genes clonados en humanos. Son proteínas de bajo peso molecular,  con una estructura 
secundaria común que atraviesa cuatro veces la membrana plasmática y con ambos 
extremos N- y C-terminal en el citosol. Estas proteínas presentan baja homología en su 
secuencia exceptuando varios dominios de carácter probablemente estructural, la 
mayoría en las regiones transmembrana, y algunas cisteínas implicadas en putativos 
puentes disulfuro en el segundo bucle extracelular (Maecker et al., 1997). Estas 
proteínas, que son bastantes ubicuas, son capaces de asociarse consigo mismas 
formando homo- y hetero-multímeros (Kovalenko et al., 2005; Stipp et al., 2003). 
Además, pueden asociarse lateralmente en la membrana plasmática con diversas 
proteínas transmembrana, principalmente a través de su segundo bucle extracelular, y, 
así, modular las funciones de los receptores asociados. Entre estas proteínas asociadas 
se incluyen moléculas endoteliales y leucocitarias de adhesión (Barreiro et al., 2005; 
Feigelson et al., 2003; Levy et al., 1998; Mannion et al., 1996; VanCompernolle et al., 
2001), integrinas relacionadas con uniones intercelulares y célula-matriz extracelular 
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(Berditchevski, 2001; Lammerding et al., 2003; Yanez-Mo et al., 1998), el complejo 
CD19/CD21-BCR (receptor de células B) (Cherukuri et al., 2004), el complejo principal 
de histocompatibilidad (MHC) unido a péptido (Kropshofer et al., 2002; Vogt et al., 
2002), receptores Fc (Moseley, 2005), receptores acoplados a proteínas G (Little et al., 
2004), y metaloproteinasas (Andre et al., 2006; Takino et al., 2003; Yan et al., 2002). 
Las asociaciones de las tetraspaninas con receptores de membrana ocurren a través del 
segundo bucle extracelular que es muy divergente, lo que apoya la idea de que dichas 
asociaciones son realmente muy específicas. Las tetraspaninas también pueden 
asociarse a través de sus dominios intracelulares con mediadores de señalización 
citoplásmicos tales como la PI4K tipo II o diferentes isoformas de PKC (Yauch and 
Hemler, 2000; Zhang et al., 2001).  
Recientes estudios bioquímicos, proteómicos y estructurales apoyan la existencia 
de microdominios ricos en tetraspaninas que podrían desempeñar una labor como 
organizadores de complejos moleculares en la membrana plasmática, integrando 
receptores de membrana y moléculas intracelulares de señalización, y con una 
composición específica y diferente a la de las balsas lipídicas (Hemler, 2005; Le Naour 
et al., 2006; Min et al., 2006; Nydegger et al., 2006). Estos microdominios ricos en 
tetraspaninas se formarían gracias a la habilidad de estas proteínas para interaccionar 
simultáneamente entre ellas y con una gran variedad de moléculas, organizando 
compartimentos definidos pero dinámicos en la membrana plasmática. Aparte de su 
capacidad para actuar como adaptadores en la organización de la membrana, las 
tetraspaninas también están implicadas en la regulación del tráfico y el procesamiento 
biosintético de sus receptores asociados (Berditchevski and Odintsova, 2007). Aunque 
los microdominios enriquecidos en tetraspaninas difieren en sus propiedades de las 
balsas lipídicas, no están carentes de interacciones lipídicas, ya que son proteínas 
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altamente palmitoiladas que unen colesterol y gangliósidos (Charrin et al., 2003; 
Hakomori, 2002; Yang et al., 2004). La composición de estos microdominios así como 
otras características específicas, pueden variar en función del tipo cellular. La deleción 
génica, el silenciamiento o la sobre-expresión protéica y los experimentos de 
mutagénesis han revelado el papel principal de las tetraspaninas en muchos procesos 
fisiológicos fundamentales. Entre ellos, cabe destacar la fusion óvulo-esperamatozoide 
(Le Naour et al., 2000; Rubinstein et al., 2006), la presentación antigénica 
(Delaguillaumie et al., 2004; Levy and Shoham, 2005b; Mittelbrunn et al., 2002; 
Unternaehrer et al., 2007), diversos procesos que tienen lugar durante la infección viral 
(Gordon-Alonso et al., 2006; Martin et al., 2005; Pileri et al., 1998), la actividad 
metaloproteinasa (Fujita et al., 2006; Hong et al., 2006; Hong et al., 2005; Takino et al., 
2003), la angiogénesis (Takeda et al., 2007; Wright et al., 2004), la función renal 
(Sachs et al., 2006), el crecimiento de neuritas (Stipp and Hemler, 2000), la 
organización de hemidesmosomas (Sterk et al., 2000), la unión específica de los 
exosomas a las células dendríticas (Morelli et al., 2004), y la adhesión celular, 
migración e invasión (Barreiro et al., 2005; Chattopadhyay et al., 2003; Garcia-Lopez 
et al., 2005; Hemler, 2003; Kovalenko et al., 2007; Longo et al., 2001; Yanez-Mo et al., 
1998; Yanez-Mo et al., 2001). El hecho de que se hayan encontrado muy pocos 
ligandos de tetraspaninas en “trans” sugiere que el papel regulador de las tetraspaninas  
en los procesos citados anteriormente ocurre de manera indirecta, a través de la unión 
en “cis” a sus receptores asociados (Hemler, 2001). Sin embargo, continúan siendo 
desconocidos los mecanismos moleculares subyacentes a esta actividad reguladora de 
las tetraspaninas. 
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ESTUDIO DE LAS PROPIEDADES BIOFÍSICAS DE LAS PROTEÍNAS 
MEDIANTE TÉCNICAS DE MICROSCOPÍA ANALÍTICA 
 Para comprender la complejidad y la dinámica de los procesos biológicos es 
necesario entender cómo las células organizan y compartimentalizan físicamente los 
receptores de adhesión y las moléculas señalizadoras en redes especializadas y 
eficientemente reguladas. En este sentido, se propone que las balsas lipídicas ricas en 
colesterol y esfingolípidos funcionan como plataformas para exportar componentes 
específicos a la membrana, incluyendo proteínas ancladas a membrana por 
glicosilfosfatidilinositol (GPI), y para proporcionar sitios específicos para el ensamblaje 
de complejos citoplásmicos de señalización (Anderson and Jacobson, 2002; Simons and 
Toomre, 2000). La existencia de las balsas lipídicas ha sido estudiada de manera 
extensiva haciendo uso de innovadores métodos de microscopía analítica (Kenworthy et 
al., 2004; Larson et al., 2005; Sharma et al., 2004; Suzuki et al., 2007a; Suzuki et al., 
2007b). Sin embargo, no se ha documentado hasta la fecha ningún estudio demostrando 
la existencia de microdominios ricos en tetraspaninas en la membrana plasmática de 
células vivas y caracterizando sus propiedades dinámicas.   
 Las propiedades dinámicas de una proteína son cruciales para determinar su 
función dentro de la célula y para entender cómo, cuándo y dónde puede interaccionar 
físicamente con otras proteínas y macromoléculas en respuesta a estímulos 
extracelulares. El reciente desarrollo de potentes técnicas analíticas microscópicas y 
espectroscópicas complementarias permite el análisis espacio-temporal de complejos 
proteícos, así como el estudio de su composición y el cálculo de su estequiometría, 
estado de oligomerización, propiedades difusivas, etc. 
 Los complejos macromoleculares tienen dimensiones nanométricas, por lo que 
no son directamente accesibles mediante estudios de colocalización con microscopía 
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confocal convencional, que se encuentra limitada por su resolución óptica. Sin embargo, 
la detección de interacciones moleculares en células vivas se puede llevar a cabo 
fusionando una proteína fluorescente donadora a una de las proteínas de interés y una 
proteína fluorescente aceptora a la otra proteína del par protéico en estudio, y midiendo 
la transferencia de energía de resonancia de Föster (FRET) del fluoróforo donador al 
aceptor, que ocurre en un rango de decenas de amstrongs, y que sólo puede tener lugar 
si las proteínas se encuentran interaccionando de manera directa . Como consecuencia 
del FRET, el tiempo de vida de la fluorescencia del donador decrece y éste es un 
parámetro que se puede medir en células vivas mediate la técnica microscópica 
denominada FLIM. Esta técnica es mucho más reproducible y sensible que los métodos 
clásicos para medir FRET basados en intensidad de fluorescencia. Además, el método 
de FLIM es lo suficientemente rápido para ser aplicado en células vivas (Caiolfa et al., 
2007; Wallrabe and Periasamy, 2005). 
 Las proteínas se localizan en dominios en equilibrio dinámico en la membrana 
plasmática. La difusión protéica se puede estudiar a escala microscópica considerando 
una población molecular en su conjunto. Para ello, se utiliza una técnica denominada 
recuperación de fluorescencia tras el fotoblanqueo (FRAP) que consiste en el quemado 
de la fluorescencia en una región de interés dentro de una célula viva y, a continuación, 
la medida de la tasa de recuperación de fluorescencia en esa región para obtener un 
coeficiente de difusión aparente de la proteína marcada fluorescentemente (Phair and 
Misteli, 2001). Alternativamente, se pueden utilizar proteínas fotoactivables o 
fotoconvertibles para marcar de manera específica una subpoblación molecular en una 
célula viva y estudiar su movilidad en el tiempo. Por otro lado, se pueden realizar 
estudios de difusión a nivel de molécula individual utilizando el método denominado 
espectroscopía de correlación de fluorescencia (FCS), o bien, extender el análisis 
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cuantitativo a dos especies moleculares que co-difunden en los mismos complejos 
usando espectroscopía de cross-correlación de fluorescencia (FCCS). La técnica de FCS 
analiza las fluctuaciones de la intensidad de fluorescencia de un sistema en equilibrio. 
De este modo, la FCS y el análisis del histograma del contaje de fotones (PCH) 
permiten obtener información dinámica de una región específica en la célula (un femto-
volumen), así como la estimación de la concentración local y el estado de 
oligomerización de las especies moleculares difusibles. Finalmente, la variante para 
doble color (FCCS), complementa los estudios de FLIM-FRET, monitorizando las 
interacciones moleculares entre especies difusibles y obteniendo la estequiometría de 
los complejos, así como la cinética de dichas interacciones (Muller et al., 2003).  
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INTRODUCTION 
 
EXTRAVASATION PROCESS  
Leukocyte extravasation during homing and inflammation requires drastic cell 
morphological changes, involving cytoskeletal-directed clustering of adhesion receptors 
in specialized protrusive membrane structures in leukocytes and endothelial cells. 
Extravasation is an active process not only for leukocytes but also for endothelial cells, 
which promote the rapid and efficient entry of leukocytes to the target tissues, without 
disturbing the integrity of the endothelial barrier.  
Cell adhesion receptors regulate many cellular processes such as activation, 
migration, growth, differentiation and death (Frenette and Wagner, 1996a; Frenette and 
Wagner, 1996b), by both signal transduction and the modulation of intracellular signaling 
cascades triggered by different growth factors (Aplin et al., 1998). Cellular interactions 
are critical for regulation of hematopoiesis (Levesque et al., 1999; Verfaillie, 1998) and 
inflammatory responses (Butcher, 1991; Butcher and Picker, 1996). The coordinate 
function of adhesion receptors, cytoskeleton and signaling molecules is crucial for 
leukocyte extravasation, a central process in immunity. Hence, the correct integration of 
“outside-in” and “inside-out” signals in leukocytes and endothelium during each stage of 
extravasation is critical to allow the completion of this phenomenon, the so-called “multi-
step paradigm” (Butcher, 1991; Springer, 1994).  
 
Initial interactions between circulating leukocytes and the endothelium: tethering 
and rolling mediated by selectins and their ligands 
Free-flowing leukocytes contact with and adhere to the vascular wall under shear 
forces to initiate an inflammatory response or to migrate into a secondary lymphoid organ 
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(homing). Leukocyte tethering and rolling on activated endothelial cells are the first steps 
of the sequential process of extravasation, followed by the firm adhesion and 
transendothelial migration of leukocytes. These initial contacts are largely mediated by 
selectins and their ligands. Selectins (P-, E- and L-selectin) are type I transmembrane 
glycoproteins that bind to sialylated carbohydrate moieties present on ligand molecules in 
a calcium-dependent manner. Although selectins and their ligands tend to interact with a 
variable affinity, their rapid association and dissociation rates mediate transient contacts 
between leukocytes and endothelium (“tethering”) (Mehta et al., 1998; Nicholson et al., 
1998). Tethering results in the slowing of leukocytes in the bloodstream and their rolling 
on the surface of endothelium, which favors subsequent interactions with endothelial 
cells mediated by integrins and their ligands, increasing the adhesiveness of leukocytes, 
that leads to their final arrest on the vessel wall (Evans and Calderwood, 2007). In 
addition to selectins and their ligands, α4 integrins (α4β1 and α4β7) through their 
interaction with VCAM-1 and MAdCAM-1, respectively, support leukocyte tethering, 
rolling, and arrest (Alon et al., 1995; Berlin et al., 1995). Moreover, the interaction of 
LFA-1/ICAM-1 cooperates with L-selectin, by stabilizing the tethering phase and 
decreasing the rolling velocity (Henderson et al., 2001; Kadono et al., 2002).  
Adhesion receptor distribution on cell membrane has a key role in leukocyte 
interactions and is an important regulatory mechanism for leukocyte trafficking (von 
Andrian et al., 1995). Selectins, their ligands and α4 integrins are clustered at the tips of 
microvilli, and this localization is critical for tethering and rolling. L-selectin is anchored 
to the actin cytoskeleton through the constitutive association of its cytoplasmic tail to 
alpha-actinin, and its cell activation-dependent binding to moesin (Ivetic et al., 2002; 
Pavalko et al., 1995). Although the association with alpha-actinin is not essential for its 
targeting to microvilli (Pavalko et al., 1995), its cytoplasmic anchorage to the actin 
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cytoskeleton is necessary to control L-selectin function (Alon and Feigelson, 2002; Dwir 
et al., 2001). 
 
Figure 1. The first step of  the extravasation process. As shown in the diagram, free-flowing leukocytes 
establish transient contacts with activated endothelial cells (tethering), being slowed down. These initial 
contacts allow leukocytes to roll on the endothelial wall to become activated and finally arrest. The main 
molecules that participate during this process are presented in detail in the inset: E- and P-selectin in 
endothelium as well as L-selectin and PSGL-1 in leukocytes are localized at specialized protrusions 
(microvilli) supported by the actin cytoskeleton, which is linked to the adhesion receptors via ERM 
proteins, alpha-actinin and other cytoskeletal components. All these molecules interact with their 
corresponding receptors through carbohydrate residues such as Sialyl Lewisx. Thus, L-selectin binds to 
several endothelial counterreceptors (E-selectin among them) and leukocyte PSGL-1 interacts with 
endothelial E- and P-selectin. In addition, The binding of PSGL-1 with its ligands allows the recruitment of 
the tyrosine kinase Syk via ERM proteins, which triggers signaling cascades that culminate in the 
activation of expression of several genes (e.g., SRE and c-fos) in leukocytes. 
 
 
Central role of leukocyte integrins and their endothelial ligands in the activation, 
arrest, firm adhesion and locomotion processes  
Trafficking of leukocytes throughout different tissues and organs, and their 
subsequent interactions with other immune cells are crucial for the development of innate 
and adaptive immunity (von Andrian and Mackay, 2000). In this regard, integrins have a 
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central role in cell migration by controlling intercellular and cell-matrix interactions 
during homing and inflammation. One of the most important features of these receptors 
relies on the regulation of their adhesion activity independently of their membrane 
expression. Thus, leukocytes modify their adhesive properties to be properly adapted to 
every immune scenario (Hynes, 2002). Hence, free-flowing leukocytes maintain their 
integrins in non-adhesive conformation, to avoid unspecific contacts with non-inflamed 
vascular walls, but upon encountering localized inflammatory foci, a rapid in situ 
activation of leukocyte integrins by endothelium-displayed activating signals takes place 
(Campbell et al., 1998). The spatial distribution of integrins and their ligands in 
specialized membrane structures is also of key importance for the proper accomplishment 
of their adhesive functions. This topographic organization requires a finely regulated 
cellular cytoskeleton that also enables the recruitment of signaling intermediates and 
second messengers that lead to cellular activation (Vicente-Manzanares and Sanchez-
Madrid, 2004).  
Integrins constitute a large family of 24 heterodimeric adhesion receptors, each one 
composed of an α and a β subunits. These molecules regulate dynamically their 
adhesiveness by conformational changes as well as by redistribution on cell surface 
(Carman and Springer, 2003). Recent data predict the existence of three conformational 
states for integrins, which differ in their localization on the plasma membrane and in 
conformation (folded/low affinity, extended with intermediate affinity and extended with 
high affinity) (Beglova et al., 2002; Nishida et al., 2006). The overall strength of 
adhesiveness (avidity) depends on the affinity of each individual receptor-ligand bond 
and the number of these interactions. Therefore, the regulation of integrin avidity 
involves both the modulation of receptor and ligand density and their redistribution on 
specialized membrane structures (Carman and Springer, 2004). 
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The most relevant integrins for leukocyte adhesion to endothelium are members of 
the β2 subfamily, particularly LFA-1 (CD11a/CD18 or αLβ2) and the myeloid specific 
integrin Mac-1 (CD11b/CD18 or αMβ2), as well as the α4 integrins VLA-4 (α4β1) and 
α4β7. Most of the cellular counterreceptors for leukocyte integrins are transmembrane 
proteins that belong to the immunoglobulin superfamily. LFA-1 binds five distinct 
intercellular cell adhesion molecules (ICAM-1 to -5), although the most relevant among 
them seem to be ICAM-1 and ICAM-3 (Gahmberg et al., 1990). ICAM-1 is found in 
leukocytes, dendritic cells, epithelial cells and is expressed at low levels in resting 
endothelial cells, becoming highly upregulated upon inflammatory stimuli (Dustin et al., 
1986). ICAM-3 is constitutively expressed by all leukocytes (Acevedo et al., 1993), 
whereas the junctional adhesion molecule JAM-A, an additional ligand for LFA-1, is 
selectively concentrated at the apical region of intercellular tight junctions in endothelial 
cells (Ostermann et al., 2002). On the other hand, Mac-1 interacts with ICAM-1, JAM–C, 
and the endothelial receptor RAGE (Chavakis et al., 2003; Lamagna et al., 2005). The 
integrin VLA-4 interacts with VCAM-1 (Elices et al., 1990), which is expressed de novo 
upon endothelial cell activation (Carlos and Harlan, 1994) and also binds JAM-B 
(Cunningham et al., 2002). Alternatively, VLA-4 interacts with ADAM-28, fibronectin, 
osteopontin, thrombospondin, von Willebrand Factor, and the bacterial protein invasin 
(Mittelbrunn et al., 2006). Finally, the α4β7 integrin, apart from its interaction with 
fibronectin and VCAM-1, specifically recognizes MadCAM-1, a receptor expressed in 
mucosal lymphoid tissues (Berlin et al., 1993).  
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Figure 2. Main molecules involved in tethering, rolling, activation and firm arrest. Image adapted 
from (von Andrian and Mackay, 2000). 
 
Chemokine modulation of integrin activity 
During the initial establishment of contacts with the vascular endothelium, 
leukocytes slow down their rolling velocity and become activated by encountering 
immobilized chemokines and integrin ligands displayed at the endothelial apical surface. 
This activation step allows the arrest and firm adhesion of leukocytes to endothelium 
under shear flow (Alon et al., 2003; Rot and von Andrian, 2004). Leukocyte activation 
involves a marked shape change from the round free-flowing cell to a polarized pro-
migratory morphology with two distinct regions: the leading edge and the uropod (del 
Pozo et al., 1995). Leukocyte polarization enables the cell to turn intracellular forces into 
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net cell locomotion necessary to accomplish the extravasation process (Geiger and 
Bershadsky, 2002). 
The chemokines coupled to apical endothelial glycosaminoglycans act by signaling 
through leukocyte GPCRs and induce an array of “inside-out” signals within fractions of 
seconds, leading to multiple conformational changes of integrins with important effects 
on leukocyte adhesion and morphology (Constantin et al., 2000; Sanchez-Madrid and del 
Pozo, 1999; Shamri et al., 2005). Both, the endothelium-immobilized chemokines and the 
chemokine receptors expressed on leukocytes are concentrated on microvilli to facilitate 
their interaction. Due to the complexity and timeframes of the signaling mechanisms 
controlling integrin activation, it is conceivable the existence of preformed 
compartmentalized protein networks (“signalosomes”) in leukocytes encountering 
endothelial chemokines (Laudanna and Alon, 2006). The presence of specific 
chemokines on different vascular beds contributes to orchestrate the selective recruitment 
of leukocyte subsets to inflammation foci or secondary lymphoid organs (Luster, 1998). 
In addition, chemokines may exert a differential effect on specific integrins within the 
same microenvironment. Accordingly, it has been described that chemokines can only 
mediate lymphocyte arrest dependent on VLA-4/VCAM-1 when binding their GPCRs 
with high affinity and with high relative occupancy, but this signal threshold-dependent 
effect is not observed with chemokine-stimulated β2 integrins (Laudanna, 2005).  
 
Ligand modulation of integrin affinity 
Upon the “inside-out” chemokine-mediated signaling in leukocytes, integrin 
conformation reversibly and readily switches from the inactive (folded) to the extended 
conformation with intermediate affinity. This event primes the integrin to bind its 
endothelial ligand. Integrins containing the “inserted” I-domain in their α subunits 
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undergo a further conformational shift from this intermediate affinity extended 
conformation upon ligand binding, resulting in full integrin activation and leukocyte 
arrest (Cabanas and Hogg, 1993; Jun et al., 2001; Salas et al., 2004). Therefore, high 
affinity conformational state for leukocyte immediate arrest requires bidirectional 
induction from both immobilized chemokines and integrin ligands (Grabovsky et al., 
2000; Shamri et al., 2005). However, α4 integrins, which contain an I-like domain in 
their β subnits,  can spontaneously interact with their endothelial ligands without 
previous chemokine stimulation (Alon et al., 1995). Therefore, it is possible that these 
integrins exist in overall extended conformations with high accessibility to their ligands, 
due to their preferential localization at microvilli. Finally, the “outside-in” ligand-driven 
signaling results in further separation of the integrin subunit cytoplasmic tails 
(unclasping), which favors their association with the cortical actin cytoskeleton (Nishida 
et al., 2006).  
Ligand binding enhances the recruitment of additional integrins (microclustering), 
further increasing the integrin-dependent adhesiveness of leukocytes under shear stress, 
to support their firm adhesion to endothelium (Dobereiner et al., 2006). This clustering is 
dependent on integrin release from the actin cytoskeleton by PKC and calpain in order to 
increase their lateral mobility (Stewart et al., 1998). In this regard, it has been suggested 
the presence of ligand-independent LFA-1 nanoclusters at the plasma membrane of 
leukocytes, which promote the efficient formation of ligand-triggered microclusters 
(Cambi et al., 2006). Accordingly, a recent study has revealed that a large proportion of 
LFA-1 molecules in extended conformation rather than low affinity folded molecules are 
anchored to the cytoskeleton prior to ligand binding (Cairo et al., 2006). However, key 
differences between α4 and β2 integrins regarding their increase in avidity mediated by 
cytoskeleton may occur. The α4 integrins can bind paxillin upon dephosphorylation of 
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Ser988 in their cytoplasmic domain. Paxillin regulates α4 integrin function (tethering and 
firm adhesion) in immune cells (Yang et al., 2005), enhancing their rate of migration and 
reducing their spreading. On the other hand, it has been described that LFA-1 and Mac-1 
may use the adaptor molecules talin, α-actinin, filamin and 14-3-3 to properly anchor to 
the actin cytoskeleton (Fagerholm et al., 2005; Pavalko and LaRoche, 1993).  
On the other hand, several studies suggest that integrins are directly regulated by 
shear stress (Marschel and Schmid-Schonbein, 2002). Shear flow promotes additional 
stretching of integrin bonds, increasing outside-in signals that coordinate leukocyte and 
endothelial adhesion machineries to promote productive diapedesis. Recent findings also 
point out to a shear stress-mediated conformational activation of VLA-4, resulting in 
increased affinity (Zwartz et al., 2004). The integration of chemokine- and external force-
derived signaling to enhance migration has been defined as the phenomenon of 
chemorheotaxis (Cinamon et al., 2001). In terms of subcellular localization, the integrins 
displayed on leukocyte microvilli distribute more readily high disruptive forces along the 
microvillar axis. Remarkably, it has been recently addressed the importance of shear 
forces for the integration of signals from apical and subendothelial chemokines, rendering 
an increase in chemotaxis towards the subendothelial compartment (Schreiber et al., 
2006). 
 
Regulation of leukocyte locomotion by integrins 
The signals involved in leukocyte firm adhesion to endothelium mediated by 
integrins are subsequently attenuated to allow leukocyte migration towards an appropriate 
site of transmigration. β2 integrins appear to have a critical involvement in this process of 
locomotion, since blockade of these integrins or their correspondent endothelial ligands 
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results in random locomotion, failure in correct positioning at the endothelial junction 
and defective diapedesis (Schenkel et al., 2004).  
Upon interaction with their ligands, integrins activate distinct myosin contractility 
effectors, actin-remodeling GTPases and molecules involved in microtubule network 
regulation at the leading and trailing edges of motile leukocytes (Hogg et al., 2003; Smith 
et al., 2003). During cell polarization, Cdc42, MLCK, Rac, RAPL, Rap1, mDia, Myosin-
IIA and chemokine receptors are redistributed to the cellular front, participating in the 
formation of exploratory filopodia and in the extension of lamellipodia. In contrast, Rho 
and ROCK (both involved in trailing edge retraction), the microtubule-organizing center 
(MTOC) and the adhesion receptors ICAM-1, ICAM-3, CD44 and CD43 move towards 
the rear pole (Vicente-Manzanares and Sanchez-Madrid, 2004). Interestingly, the 
redistribution of integrin ligands to the uropod seems to be involved in the recruitment of 
bystander leukocytes through this cellular structure (del Pozo et al., 1996). Hence, the 
integration of signals generated in both cellular poles leads to a coordinate movement of 
the leukocyte.  
 
VCAM-1 and ICAM-1 play an essential role in leukocyte capture  
VCAM-1 and ICAM-1, members of the Ig superfamily, are the two major 
endothelial adhesion molecules involved in the binding to leukocyte integrins VLA-4 
and LFA-1, respectively (Elices et al., 1990; Marlin and Springer, 1987b). ICAM-1 but 
not VCAM-1 is expressed at low levels in resting endothelium, and both molecules are 
induced upon cell activation by pro-inflammatory cytokines such as IL-1 and TNF-
α (Carlos and Harlan, 1994; Dustin et al., 1986). Furthermore, it has been described that 
VCAM-1 and ICAM-1 are anchored to the actin cytoskeleton through members of the 
ERM family, mainly ezrin and moesin (Barreiro et al., 2002; Heiska et al., 1998; 
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Helander et al., 1996). These molecules function as membrane-actin cytoskeleton 
linkers regulating cortical morphogenesis and cell adhesion. Accordingly, they play a 
key role in the formation of protrusive plasma membrane structures such as filopodia, 
microspikes or microvilli (Arpin et al., 1994; Vaheri et al., 1997; Yonemura and 
Tsukita, 1999). Structurally, they are closely related to each other and seem to be 
functionally redundant, as suggested by the apparently normal phenotype of moesin 
knockout mice (Doi et al., 1999). Their amino-terminal domains interact with integral 
membrane proteins, whereas their carboxy-terminal domains bind F-actin (Tsukita and 
Yonemura, 1997; Turunen et al., 1994). These functions are conformationally regulated 
by reversible changes from inactive to functionally active forms. Binding of PI(4,5)P2 
and phosphorylation of a specific C-terminal threonine residue unmask the F-actin and 
membrane binding sites and stabilize the active conformation (Barret et al., 2000; 
Nakamura et al., 1999; Simons et al., 1998). The Rho/p160 ROCK signaling pathway 
and the phosphatidylinositol turnover are the major regulatory mechanisms for ERM 
activation inducing their phosphorylation and translocation into apical membrane/actin 
protrusions (Hirao et al., 1996; Matsui et al., 1998; Shaw et al., 1998). On the other 
hand, activated ERM proteins can sequestrate Rho-GDI to permit Rho activation, 
providing a positive feedback pathway (Takahashi et al., 1997). 
VCAM-1 and ICAM-1 are capable of transducing signals after ligand binding. 
VCAM-1 is involved in the opening of the “endothelial passage” through which 
leukocytes can extravasate. In this regard, VCAM-1 ligation induces NADPH oxidase 
activation and the production of reactive oxygen species (ROS) in a Rac-mediated 
manner, with subsequent activation of matrix metalloproteinases and loss of VE-
cadherin-mediated adhesion. This signaling pathway can be blocked by TGFbeta1 and 
IFNgamma (Cook-Mills, 2002; Hordijk, 2003; van Wetering et al., 2002; van Wetering et 
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al., 2003). On the other hand, cross-linking of both VCAM-1 and ICAM-1 induces a 
rapid increase in intracellular Ca2+ concentration (Etienne-Manneville et al., 2000; 
Lorenzon et al., 1998). ICAM-1-mediated calcium signaling has been mostly studied in 
brain endothelial cells. In this cellular model, it has been found that ICAM-1-mediated 
calcium increase triggers activation of Src and subsequent phosphorylation of cortactin 
(Etienne-Manneville et al., 2000). ICAM-1 is also able to activate RhoA inducing stress 
fiber formation (Thompson et al., 2002b) and phosphorylation of FAK, paxillin and 
p130Cas, which in turn trigger different signaling pathways involving JNK or p38 
(Greenwood et al., 2002; Hubbard and Rothlein, 2000; Wang and Doerschuk, 2002). 
Moreover, ICAM-1 cross-linking stimulate c-fos and rhoA transcription (Thompson et 
al., 2002b). Finally, the ICAM-1 cross-linking can also induce its own expression as well 
as that of VCAM-1, as a regulatory mechanism to facilitate leukocyte transendothelial 
migration (TEM) (Clayton et al., 1998). 
 
Integrins and their ligands during transendothelial migration 
The signals involved in the firm adhesion of leukocytes to endothelium must be 
reverted, weakening the original contact sufficiently to allow the migration and 
extravasation of leukocytes. During TEM, endothelial junctions must be loosened to a 
limited extent, thereby avoiding cell monolayer damage or important changes in 
permeability. Thus, the leukocyte and endothelium membranes are kept in close contact 
and show prominent associated cytoskeletal structures. Subsequently, the endothelial 
membranes reseal their connections over the trailing end of the leukocyte. 
 Once the leukocyte finds a proper site for transmigration, mostly at intercellular 
junctions, it extends exploratory pseudopodia in between the two adjacent endothelial 
cells. Subsequently, pseudopodia evolve into a lamella squeezed into the monolayer gap.  
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Figure 3. The heterotypic leukocyte-endothelium interactions during transendothelial migration. 
Most of the crucial molecules involved in leukocyte transmigration are shown, including members of the 
tight junctions (ESAM and the JAM family), the VE-cadherin complex and other molecules such as PECAM-1 
and CD99. Most of them interact homophilically, being express by the endothelium as well as by leukocytes. On 
the other hand, the processes of lamellipodia formation at the leukocyte leading edge and tail retraction, the 
phenomenon of chemorheotaxis and the existence of a subendothelial soluble chemoattractant gradient to guide 
the extravasated leukocytes to the target tissue are also illustrated. 
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During this process, LFA-1 is the integrin with a more prominent role. This 
molecule is rapidly relocalized, forming a ring-like cluster at the leukocyte-endothelial 
interface, where it interacts with ICAM-1 and, in some cellular models, with JAM-A. 
When the transmigration process is over, LFA-1 is finally concentrated at the uropod 
(Sandig et al., 1997; Shaw et al., 2004). 
In the context of leukocyte transmigration, in addition to the classical pathway of 
diapedesis, in which the leukocytes cross through inter-endothelial junctions without 
disrupting the integrity of the endothelium (paracellular pathway), there are increasing 
evidences indicating the existence of an alternative pathway, in which leukocytes could 
migrate across an individual endothelial cell (transcellular pathway) (Carman and 
Springer, 2004; Engelhardt and Wolburg, 2004). New insights into the mechanism of this 
process have been recently reported. It seems that lymphocytes used invasive podosomes 
to palpate the surface of endothelium and form transcellular pores. These lymphoid 
structures are dependent on Src kinase and WASP, whereas membrane fusion events 
dependent on the SNARE-containing membrane fusion complex and intracellular 
calcium are required in endothelium (Carman et al., 2007). Another study describes the 
translocation of ICAM-1 to caveolae upon leukocyte adhesion, and the subsequent 
formation of a sort of multivesicular channel, containing ICAM-1 and caveolin-1 around 
the penetrating leukocyte pseudopod. Both proteins follow the passage of the whole cell, 
moving towards the basal side of the endothelial membrane (Millan et al., 2006). In 
addition, the protein of intermediate filaments vimentin also seems to play a role in the 
transcellular pathway (Nieminen et al., 2006).  
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TETRASPANIN MICRODOMAINS 
Tetraspanins are a superfamily of proteins with, at least, 28 genes cloned in 
humans. They are proteins of low molecular weight, with a common secondary structure 
that spans four times de plasma membrane and with both N- and C-terminal domains in 
the cytoplasm.Tetraspanins present little homology in their sequence, except for several 
structural domains, most of them in transmembrane regions, and several cysteins 
involved in disulphide bonds from the large second extracellular loop (Maecker et al., 
1997). Tetraspanins are ubiquitous proteins able to organize themselves by homo- and 
hetero-oligomerization (Kovalenko et al., 2005; Stipp et al., 2003). These molecules can 
also associate laterally at the plasma membrane with partners via their second 
extracellular loop, modulating partner functions, as reported for a plethora of membrane 
integral receptors such as leukocyte and endothelial adhesion molecules (Barreiro et al., 
2005; Feigelson et al., 2003; Levy et al., 1998; Mannion et al., 1996; VanCompernolle et 
al., 2001), intercellular junction- and extracellular matrix-related integrins (Berditchevski, 
2001; Lammerding et al., 2003; Yanez-Mo et al., 1998), CD19/CD21-B cell antigen 
receptor complex (Cherukuri et al., 2004), MHC-peptide complex (Kropshofer et al., 
2002b; Vogt et al., 2002), Fc receptors (Moseley, 2005), G-protein-coupled receptors 
(Little et al., 2004), or metalloproteinases (Andre et al., 2006; Takino et al., 2003; Yan et 
al., 2002). Tetraspanins also associate intracellularly with a number of cytoplasmic 
signalling mediators such as type II PI4K or different PKC isoforms (Yauch and Hemler, 
2000; Zhang et al., 2001).  
Recent biochemical, proteomics and structural studies have bolstered that 
tetraspanin-enriched microdomains (TEM) also play a key role in organizing molecular 
complexes at the plasma membrane with different protein composition compared to 
typical lipid rafts (Hemler, 2005; Le Naour et al., 2006; Min et al., 2006; Nydegger et al., 
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2006). Thus, the concept of TEM emerges from the ability of tetraspanins to dynamically 
interact among them and simultaneously with a wide range of molecules, organizing 
discrete compartments throughout the plasma membrane. Apart from acting as adapters 
for membrane organization, tetraspanins are also involved in the regulation of trafficking 
and biosynthetic processing of associated receptors (Berditchevski and Odintsova, 2007). 
Although TEM nature seems to be different from lipid rafts, they are not devoid of lipid 
interactions, since tetraspanins are highly palmitoylated proteins that bind cholesterol and 
gangliosides (Charrin et al., 2003; Hakomori, 2002; Yang et al., 2004). Tetraspanin and 
associated partner composition as well as specific characteristics of TEM may vary 
depending on the cellular type. A number of experimental strategies including tetraspanin 
genetic deletion, knocking-down, over-expression, or mutation have unveiled a key 
functional role for these proteins in multiple central physiological processes, namely, 
egg-sperm fusion (Le Naour et al., 2000; Rubinstein et al., 2006), antigen presentation 
(Delaguillaumie et al., 2004; Levy and Shoham, 2005b; Mittelbrunn et al., 2002; 
Unternaehrer et al., 2007), leukocyte-endothelial adhesion and transendothelial migration 
(Barreiro et al., 2005), cellular entry and budding during viral infection as well as virus-
promoted syncytia formation (Gordon-Alonso et al., 2006; Martin et al., 2005; Pileri et 
al., 1998), metalloproteinase activity (Fujita et al., 2006; Hong et al., 2006; Hong et al., 
2005; Takino et al., 2003), angiogenesis (Takeda et al., 2007; Wright et al., 2004), renal 
function (Sachs et al., 2006), neurite outgrowth (Stipp and Hemler, 2000), 
hemidesmosomes organization (Sterk et al., 2000), exosome targeting to dendritic cells 
(Morelli et al., 2004), or cell adhesion, migration and invasion (Chattopadhyay et al., 
2003; Garcia-Lopez et al., 2005; Hemler, 2003; Kovalenko et al., 2007; Longo et al., 
2001; Yanez-Mo et al., 1998; Yanez-Mo et al., 2001). Since there are very few described 
ligands in trans for tetraspanins, most of the reported regulatory effects may be exerted in 
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cis on their laterally-associated partners (Hemler, 2001). However, the molecular 
mechanisms underlying the regulation by tetraspanins still remain elusive. 
 
Figure 4. Scheme of the molecular structure of tetraspanins and a model of tetraspanin-enriched 
microdomain at the plasma membrane. Images adapted from Levy and Shoham, Nat Rev Immunol 
2005). 
 
 
STUDY OF THE BIOPHYSICAL PROPERTIES OF PROTEINS USING 
ANALYTICAL MICROSCOPY TECHNIQUES 
How cells physically organize and compartmentalize receptors and signalling 
molecules into specialized, efficient, regulated networks is of critical importance to 
understand complexity and dynamics of biological processes. In this regard, cholesterol 
and sphingolipid-enriched rafts have been proposed as platforms for the sorting of 
specific membrane components including glycosylphosphatidylinositol (GPI)-anchored 
proteins and to provide sites for the assembly of cytoplasmic signalling complexes 
(Anderson and Jacobson, 2002; Simons and Toomre, 2000). The existence and physical 
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properties of lipid rafts has been extensively studied taking advantage of innovative 
analytic methods (Kenworthy et al., 2004; Larson et al., 2005; Sharma et al., 2004; 
Suzuki et al., 2007a; Suzuki et al., 2007b). Nonetheless, no study demonstrating the 
existence of tetraspanin-enriched microdomains on the plasma membrane of living cells 
and characterizing their dynamic features has been documented so far.  
The dynamic properties of a protein have a crucial role in determining what its 
cellular function and how, when and where it may physically interact with other 
proteins and macromolecules in response to extracellular stimuli. The combination of 
several complementary analytical microscopy and spectroscopy approaches allow the 
spatial and temporal analysis of complex protein assemblies within living cells, leading 
to the determination of their stoichiometry, oligomerization state, molecular 
composition, and diffusional mechanisms. 
Microscopy techniques are intrinsically limited by optical resolution. Therefore, 
molecular complexes that occur on the scale of nanometers are not directly accessible 
by colocalization studies performed with standard confocal microscopes. The detection 
of molecular interactions within living cells, however, can be achieved by fluorescently 
tagging the pair of proteins of interest and measuring the Förster resonance energy 
transfer (FRET) from the donor fluorophore to the acceptor one, that occurs in the range 
of tenths of amstrongs (i.e., few nanometers), only attainable if proteins directly 
interact. As consequence of FRET, the fluorescence lifetime of the donor molecule 
decreases. The fluorescence lifetime is of the order of few nanoseconds for all 
fluorescent genetically encoded dyes, and it can be measured in live cells by 
Fluorescence Lifetime Imaging Microscopy (FLIM). This technique is a more reliable 
and sensitive than the classical fluorescence intensity-based FRET approaches. This 
method is fast enough for being applied to live cells, in that avoids the approximate 
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decomposition of complex fluorescence decays, and recovers robust FRET efficiencies 
between fluorescent protein-tagged interacting molecules (Caiolfa et al., 2007; Wallrabe 
and Periasamy, 2005). 
 The proteins that localize in the plasma membrane at steady state are in dynamic 
domains, which might control functions such as ligand binding and signaling. Diffusion 
of proteins can be studied considering an overall molecular population at a microscopic 
scale. For this purpose, a technique termed fluorescence recovery after photobleaching 
(FRAP) is used. FRAP method is based on the photobleaching of a region of interest 
within a living cell and the measurement of fluorescence recovery rate to obtain an 
apparent diffusion coefficient for the fluorescently tagged protein. Alternatively, 
photoactivatable or photoconvertible fluorescent proteins might be used for the specific 
labelling of a molecular subpopulation within a living cell and the study of its mobility 
over time. On the other hand, studies of the diffusion of single protein species can be 
approached by FCS (fluorescence correlation spectroscopy), and extended to the 
quantitative analyses of co-diffusing protein assemblies, using the FCCS variant 
approach. FCS analyzes the fluctuation of the fluorescence intensity of a system at 
equilibrium. Thus, FCS recovers dynamic information on a specific region of a cell (a 
femto-volumen) together with the estimation of the local concentration of the diffusing 
species. In addition, coupled with the analysis of the photon counting histogram (PCH), 
FCS can better explore the state of oligomerization of the diffusing particles. Finally, 
using the dual-color variant, FCCS, complements FRET-FLIM studies by monitoring 
molecular interactions between diffusing molecules and recovering the stoichiometry of 
the diffusing protein assemblies, as well as the kinetics of the interactions (Muller et al., 
2003).  
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OBJECTIVES 
Aims to study: 
 
1. Dynamic recruitment of endothelial adhesion receptors VCAM-1 and ICAM-1 during 
lymphocyte firm adhesion and transendothelial migration, and their binding to actin-
cytoskeleton through ERM proteins. 
 
2. Endothelial docking structures formed to adhere firmly leukocytes and prevent their 
detachment under physiological flow conditions. Structural and regulatory components. 
 
3. Localization of endothelial tetraspanins CD9 and CD151 during leukocyte-
endothelium adhesion. Biochemical association between tetraspanins and adhesion 
receptors and functional role of CD9 and CD151 in the regulation of the adhesive 
properties of ICAM-1 and VCAM-1. 
  
4. Recruitment of ICAM-1 or VCAM-1 adhesion receptors to the docking structure in 
the absence of ligand engagement and actin anchorage. Involvement of tetraspanin 
microdomains. 
 
5. Biophysical properties, dynamics and molecular features of organized microdomains 
at the apical membrane of human primary living endothelial cells containing tetraspanin 
and adhesion receptors.  
 
6.  Tetraspanin regulation of endothelial adhesion receptor avidity within endothelial 
adhesive platforms. 
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MATERIALS AND METHODS 
 
Cells and cell cultures 
Human umbilical vein endothelial cells (HUVEC) were obtained and cultured as 
previously described (Yanez-Mo et al., 1998). Cells were used up to the third passage in 
all assays. To activate HUVEC, TNF-α (20 ng/ml)(R&D Systems, Minneapolis, MN) 
was added to the culture media 20 h before the assays were performed. K562 
erythroleukemic cells, which endogenously express β1 integrin,  were stably transfected 
with the α4 (termed as 4M7 cells or K562 α4 and expressing functional VLA-4 at the 
plasma membrane) or LFA-1 integrins (Munoz et al., 1996; Nueda et al., 1995). K562 
transfectants were grown in RPMI 1640 medium (Gibco BRL, Gaithersburg, MD) 
supplemented with 10% FCS, 50 IU/ml penicillin, 50 µg/ml streptomycin, and 1 mg/ml 
of G418 (Calbiochem, La Jolla, CA). Human peripheral blood lymphocytes (PBLs), 
monocytes and neutrophils were obtained and cultured as described (Barreiro et al., 
2002). T lymphoblasts were derived from freshly isolated human peripheral blood 
lymphocytes (PBLs) by activation with phytohemagglutinin-L (PHA-L) (1 µg/ml; Sigma-
Aldrich, St Louis, MO) for 48 h followed by culture for 5-7 days in the presence of 
recombinant human interleukin-2 (rhIL-2; 100 U/ml) provided by the National Institutes 
of Health AIDS Research and Reference Reagent program, Division of AIDS. Adhesion 
of K562 LFA-1 transfectants to Colo320 cells colocarcinoma cell line or to activated 
endothelial cells was performed in the presence of 1mM Mn2+ to induce integrin 
activation. Colo320-CD9 and chimeric Colo320-CD9x82 and Colo320-CD82CCG9 are 
stably transfected clones derived from those previously described (Gutierrez-Lopez et al., 
2003). Integrin inhibitors BIO5192 and BIRT377 were kindly provided by Biogen Idec 
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(Cambridge, MA) and Boehringer-Ingelheim Pharmaceuticals (Ridgefield, CT), 
respectively.  
 
Antibodies and reagents 
The TEA1/31 anti-VE cadherin and TS2/16 anti-β1 integrin (Yanez-Mo et al., 
1998), the HP2/1 anti-α4 integrin, TS1/11 anti-αL integrin, and TP1/24 anti-ICAM-3 
(Serrador et al., 1997) mAb have been described elsewhere. The 4B9 and P8B1 (anti-
VCAM-1), Hu5/3 (anti-ICAM-1) and 297S (anti-phosphorylated forms of ERM proteins) 
mAb were kindly provided by Dr. R. R. Lobb (Biogen Inc., Cambridge, MA), Dr. E. A. 
Wayner (Fred Hutchinson Cancer Research Center, Seattle, WA), Dr. F. W. Luscinskas 
(Brigham and Women’s Hospital and Harvard Medical School, Boston, MA), and Dr. S. 
Tsukita (Faculty of Medicine, Kyoto University, Japan), respectively. The moesin-
specific polyclonal antiserum 95/2 and the ezrin-polyclonal antiserum 90/3 have been 
previously described (Serrador et al., 2002). The anti-tubulin and anti-vinculin mAb were 
purchased from Sigma (St Louis, MO). The anti-talin pAb was a kind gift of Dr. K. 
Burridge (University of North Carolina at Chapel Hill, NC). Monoclonal antibodies 
(mAb) anti-CD151 (LIA1/1), anti-E-Selectin (TEA2/1), anti-CD44 (HP2/9) anti-CD63 
(Tea3/18) and anti-CD9 (VJ1/20) have been previously described (Montoya et al., 1999; 
Penas et al., 2000; Serrador et al., 1997; Yanez-Mo et al., 1998). TS82 (anti-CD82), 10B1 
(anti-CD9), 8C3 (anti-CD151), I.33.22 (anti-CD81) mAb were kindly provided by Dr. E. 
Rubinstein (INSERM U268, Villejuif, France), Dr. K. Sekiguchi (Osaka University, 
Japan), and Dr. R. Vilella (Hospital Clinic, Barcelona, Spain), respectively. Anti-GST 
goat polyclonal Ab was purchased from Amersham Biosciences (Uppsala, Sweden), and 
anti-vimentin mAb from Sigma Chemical Co. (St. Louis, MO). Anti-caveolin Ab was 
purchased from Sigma. The 40 nm gold-coupled anti-mouse and 15 nm gold-coupled 
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streptavidin were purchased from British Biocell. International (Cardiff, UK). The 
monoclonal IgG1,κ from the P3X63 myeloma cell line was used as negative control. 
Recombinant human fibronectin (FN) was purchased from Sigma. The p160 ROCK 
inhibitor Y-27632, the PI3K inhibitor Ly 294002, and the classic PKCs inhibitor Gö6976 
were purchased from Calbiochem. The LEL-GST peptides of wild type human CD9 or 
the mutated forms in the Cys residues have been described (Higginbottom et al., 2003). 
The corresponding CD151-LEL-GST peptide presented a low rate of proper folding in 
solution which precluded its use in functional studies. 
 
Recombinant DNA constructs and proteins, cell transfections 
The fusion protein GST-VC, containing the cytoplasmic tail of VCAM-1, was 
obtained by PCR amplification using as template the human VCAM-1 cDNA, and 
[TATGGATCCAGAAAAGCCAACATGAAG] and 
[TGGAATTCATAGATGGGCATTTC] as 5’ and 3’ primers, respectively. The PCR 
product was cloned as a BamHI/EcoRI fragment into pGEX-4T (Pharmacia LKB 
biotechnology, Uppsala, Sweden). The cytoplasmic tail of ICAM-3 fused to GST (GST-
IC3) and a truncated form of it (GST-Y9, Y490stop) have been described 
elsewhere(Serrador et al., 1997).  
VCAM-1-GFP and ICAM-1-GFP were obtained using the corresponding human 
cDNAs as templates to amplify by PCR the complete encoding region of these molecules 
without the stop codon. A Xho I site was added to the 5’ end and a Xma I site at the 3’ 
end of VCAM-1 cDNA. Likewise, HindIII and BamHI sites were added to the 5’ and 3’ 
ends of ICAM-1 cDNA, respectively. The PCR products were then cloned into pEGFP-
N1 (Clontech Laboratories, Inc. Palo Alto, CA) resulting in an in-frame fusion of EGFP 
                                                                                                        Materials and Methods 
 44
to the C-terminus of VCAM-1 and ICAM-1. The VCAM-1- and ICAM-1-GFP proteins 
behaved similarly to the corresponding endogenous proteins in terms of their binding to 
ezrin and moesin. The generation of the GFP fusion construct containing the GFP cDNA 
inserted at the carboxy-terminal end of the rat full length moesin (moesin-GFP, residues 
1-577) has been previously described (Amieva et al., 1999). α-actinin-GFP and paxillin-
GFP were kind gifts of Dr. A. F. Horwitz (University of Virginia, Charlottesville, VA). 
VASP-GFP, PLCδ-PH-GFP, and GRP1-PH-GFP, were kindly provided by Dr. J. V. 
Small (Institute of Molecular Biology, Salzburg, Austria), Dr. T. Balla (NICHD, National 
Institutes of Health, Bethesda, MA), and Dr. A. Gray (University of Dundee, Dundee, U. 
K.), respectively.  
CD9-, and CD151-EGFP tagged proteins have been described (Barreiro et al., 2002; 
Garcia-Lopez et al., 2005; Longo et al., 2001). The VCAM-1 truncated protein lacking its 
cytoplasmic tail (VCAM∆Cyt) (that retains only the first cytoplasmic charged residue for 
proper membrane insertion) was generated by PCR using as template the human VCAM-
1 cDNA, and [CTCGAGTCTCATCACGACAGCAAC] and 
[CTATCTTGCAAAGTAAATTATC] as 5’ and 3’ primers, respectively. The PCR 
product containing a stop codon at position 722 was cloned into pcDNA3.1/V5-His-
TOPO vector (Invitrogen, Carlsbad, CA) and the correct expression of the protein at the 
plasma membrane was tested. The ICAM-1-tailless construct was a kind gift of Dr. W.F. 
Luscinskas (Yang et al., 2005). For the FCS, FCCS, FLIM-FRET studies, monomeric 
green and red variants of ICAM-1, VCAM-1, CD9 and CD151 were generated. 
Monomeric EGFP constructs were obtained by point mutation at the position A206K 
(Zacharias et al., 2002; Zhang et al., 2002) using the Quick Mutagenesis Kit (Stratagene, 
La Jolla, CA). The mRFP variants were generated by subcloning of the corresponding 
EGFP constructs into the mRFP vector that was kindly provided by Dr. Tsien (UCSD, La 
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Jolla CA). GPI-EGFP construct was a kind gift of Dr. M.A. del Pozo (CNIC, Madrid, 
Spain). 
Expression of GST-fusion proteins in BL21 bacteria and purification were carried 
out following the manufacturer’s instructions. The LEL of wild type human CD9 was 
cloned in the pGX-KG vector and expressed in protease negative BL21 cells. LEL-GST 
fusion proteins were obtained as previously described (Barreiro et al., 2005).  
Transiently transfected HUVEC were generated by electroporation at 200 V and 
975 µF using a Gene Pulser (Bio-Rad Labs, Hercules, CA), and adding 20 µg of each 
DNA construct or using lipofectin (Invitrogen) following manufacturer’s protocol. 
Transfected cells were grown to confluence on glass bottom dishes for 24-48 h (WillCo 
Wells, Amsterdam, The Netherlands) pre-coated with fibronectin (20 µg/ml). Cells were 
activated with TNF-α for 20 h and subsequently used for FRAP, FLIM-FRET or FCS 
experiments. 
 
Flow cytometry analysis, immunofluorescence and confocal microscopy 
For flow cytometry analysis and immunofluorescence experiments, cells were treated as 
previously described (Yanez-Mo et al., 1998). Rhodamine Red-X-Affinipure goat anti-
mouse IgG (H+L), Rhodamine Red-X-Affinipure streptavidin, Alexa Fluor 488 rabbit 
anti-mouse, goat anti-mouse IgG (H+L) or goat anti-rabbit IgG (H+L) conjugate highly 
cross-adsorbed, and Phalloidin Alexa Fluor 568 were used as fluorescent reagents 
(Molecular Probes, Eugene, OR). Staining with the 297S mAb was performed as 
previously described (Hayashi et al., 1999). Series of optical sections were obtained with 
a Leica TCS-SP1, SP2 or SP5 confocal laser scanning unit equipped with Ar and He/Ne 
laser beams and attached to a Leica DMIRBE inverted epifluorescence microscope 
(Leica Microsystems, Heidelberg, Germany), using a 63x oil or glycerol immersion 
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objective (NA: 1.4 or 1.3, respectively). Image analysis and colocalization histograms 
were obtained with Leica Confocal Software.  
 
Co-immunoprecipitation, Western blot, in vitro translation, and protein binding 
assays 
Lysates from activated HUVEC, immunoprecipitation and Western blot were 
performed as described(Serrador et al., 1997). The pCR3 plasmids carrying the inserts of 
untagged moesin and ezrin amino-terminal regions (amino acid residues 1-310) were 
transcribed, translated and isotope-labeled in vitro using a TNT-coupled rabbit 
reticulocyte lysate system (Promega, Madison, WI). Then, binding assays using these 
isotope-labeled recombinant proteins and the GST-fusion proteins (GST-VC, GST-IC3, 
GST-Y9, and GST alone) were carried out as previously described (Serrador et al., 1997).  
Coimmunoprecipitation experiments of tetraspanins and adhesion receptors were 
performed as previously described (Yanez-Mo et al., 1998) with TNF-α-activated 
HUVEC lysates obtained in 1% Brij96 in 1 mM Ca2+, 1 mM Mg2+ TBS with protease 
inhibitors.  
 
Adhesion  and transendothelial migration assays 
For cellular adhesion assays, HUVEC were grown to confluence in 96-microwell 
plates (Costar) and activated with TNF-α for 20 h. K562 cells or human PBLs were 
labeled with 1 µM of BCECF-AM for 15 min at 37ºC, pre-incubated with different 
purified mAb and allowed to adhere to activated HUVEC for 15 min at 37ºC as 
previously described (Yanez-Mo et al., 1998). Fluorescence intensity was measured in a 
microplate reader (Biotek FL500).  
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Alternatively, HUVEC were grown to confluence onto coverslips pre-coated with 
FN (20 µg/ml). Then, cells were activated with TNF-α (20 ng/ml) for 20 h. For adhesion 
experiments, medium was removed and K562 stable transfectants or T lymphoblasts 
resuspended in 500 µl of complete 199 medium were added. Adhesion of K562 LFA-1 
transfectants to activated HUVEC monolayers was performed in the presence of 1mM 
Mn2+ to induce integrin activation.  Pretreatment of T lymphoblasts with BIO5192 (10 
µg/ml) or BIRT377 (10 µM) for 5 min prior to adhesion assays was performed when 
indicated. After incubation time (5-10 min for lymphoblasts, at least 30 min for K562 
cells), samples were washed and fixed with 4% paraformaldehyde to proceed with 
immunofluorescence. Alternatively, TNF-α-activated HUVEC cells were incubated for 
30 min with anti-tetraspanin, anti-VCAM-1 or anti-VE-cadherin mAb-coated dynabeads 
(Dynal Biotech ASA, Oslo, Norway), fixed and stained with biotinylated anti-ICAM-1 
mAb. Representative confocal sections are shown. Arrows point to the position of the 
attached beads.  
T lymphoblast or PBL migration through a confluent monolayer of activated 
HUVEC was assayed in 3 µm-pore Transwell cell culture chambers (Costar, Corning 
Inc., Corning, NY). HUVEC were seeded and grown to confluence on these Transwell 
inserts pre-coated with 1% gelatin or 20 µg/ml of fibronectin and activated with TNF-α 
for 20 h. In some experiments, 150 µg/ml of the LEL-GST fusion proteins were added at 
the time of TNF-α stimulation, and other times endothelial cells were previously treated 
to knock down tetraspanin proteins. Cultured lymphoblasts (2x105 in 100 µl of complete 
199 medium/well) were incubated with 10 µg/ml of different purified mAbs for 20 min at 
4ºC, and then added to the upper chambers. Alternatively, freshly isolated PBLs (2x105 in 
100 µl /well) were added to the upper chambers. In the lower well, 600 µl of complete 
199 medium, containing or not 100 ng/ml of human recombinant SDF-1α (R&D 
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Systems), were poured. Cells were incubated for 90 min at 37ºC (lymphoblasts) or for 2-
7h (PBLs), and migrated cells were recovered from the lower chamber. The number of 
migrated lymphocytes, that ranged from 5 to 20%, were recovered from the lower 
chamber was estimated by flow cytometry.      
 
Time-lapse fluorescence confocal microscopy 
HUVEC transfected with different GFP constructs were grown to confluence on 
glass-bottomed dishes (WillCo Wells, Amsterdam, The Netherlands) pre-coated with 
fibronectin (20 µg/ml). Then, cells were activated with TNF-α for 20 h, and placed on the 
microscope stage. 4Μ7 cells or T lymphoblasts resuspended in 500 µl of complete 199 
medium were added. During the observation time, plates were maintained at 37ºC in a 
5% CO2 atmosphere using an incubation system (La-con GBr Pe-con GmbH). Confocal 
series of fluorescence and differential interference contrast (DIC) images, distanced 0.4 
µm in the z axis, were simultaneously obtained at 30 s or 1 min intervals, with a 63x oil 
immersion objective. Images were processed and assembled into movies using the Leica 
Confocal Software. 
 
Parallel plate flow chamber analysis of endothelial-lymphocyte interactions 
The parallel plate flow chamber used for leukocyte adhesion and transmigration 
under defined laminar flow has been described in detail (Luscinskas et al., 1994). PBLs 
(1x106/ml) were drawn across activated confluent monolayers at an estimated wall shear 
stress of 1.8 dynes/cm2 for perfusion times from 30 s to 10 min. Lymphocyte rolling on 
the endothelium were easily visualized since they travelled more slowly than free-
flowing cells. Lymphocytes were considered to be adherent after 20 s of stable contact 
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with the monolayer. Transmigrated lymphocytes were determined as being beneath the 
endothelial monolayer. Lymphocytes were considered to be detached when they returned 
to free-flowing after having been completely arrested on endothelium. The number of 
rolling, adhered, transmigrated and detached cells was quantified by direct visualization 
of different fields (20x phase-contrast objective), each one observed for 30 s starting at 
min 3,5 and ending at time point 6,5.Digitalization was performed with Optimas software 
(Bioscan). Coverslips were fixed immediately in PFA 4% at room temperature for 10 
min, washed with HBSS, and stained for VCAM-1, ICAM-1 or ezrin.  
For detachment experiments, peripheral blood lymphocytes were allowed to adhere 
for 15 min at 37ºC to activated HUVEC monolayers, either incubated with LEL-GSTs for 
20h, or transfected with siRNA oligos. Then, shear stress was applied by pulling assay 
buffer (HBSS buffer with 2% FCS) through the flow chamber with a programmable 
syringe pump, starting at 2 dyn/cm2 and increasing up to 30 dyn/cm2 at 1 min intervals. 
The number of cells attached after each shear stress interval was quantified in 4-8 fields 
(20x phase-contrast objective). Cell detachment was obtained from the difference in 
adhered cells after substracting the percentage of cells that had transmigrated during the 
assay.  
 
Small interference RNA assay 
 To selectively knock down the expression of endothelial tetraspanins CD9 and 
CD151, a screening of different target sequences for each protein was performed using 
siRNA expression cassettes (Ambion, Austin, TX). We found the silencing sequences 
GAGCATCTTCGAGCAAGAA and CATGTGGCACCGTTTGCCT for CD9 and 
CD151, respectively. RNA duplexes corresponding to these target sequences, as well as a 
negative oligonucleotide that does not pair with any human mRNA, designed by 
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Eurogentec (Seraing, Belgium) were used. Oligos were transfected in HUVEC with 
oligofectamine (Invitrogen, Carlsbad, CA) following manufacturer´s instructions. For 
CD9 interference, cells were transfected on day 0, further splitted on day 2 and 
retransfected on day 3. In parallel, on day 3, cells were transfected only once for CD151 
knocking down. Then cells were trypsinized on day 6 and negatively selected with anti-
CD9 or anti-CD151 magnetic coated beads (Dynabeads M450 Goat anti-Mouse IgG, 
Dynal Biotech ASA, Oslo, Norway), in order to enrich the tetraspanin low-expressing 
population. Cells thus selected were counted, seeded to confluence for the different 
experiments and activated or not with TNF-α for 20h.  
  
Paracellular monolayer permeability measurements 
HUVEC monolayer paracellular permeability measurements were performed in 0.4 
µm pore diameter Transwells (Costar) with 77 KDa FITC-labelled dextran (Sigma) as 
described (Dominguez-Jimenez et al., 2001). 
 
Heterotypic intercellular binding assays 
Colo320 colocarcinoma cells or different stable transfectants derived from this cell 
line were transiently transfected with ICAM-1-GFP or VCAM-1-GFP by electroporation 
in an ElectroSquarePorator ECM 830 (BTX, VWR Int., San Diego, CA). A total of 5x105 
cells of each condition were mixed with with 2x105 of K562 cells, either untransfected or 
stably transfected with α4 or LFA-1 integrins, which had been previously loaded with the 
CM-TMR red fluorescent dye (Molecular Probes). Then, cells were allowed to adhere at 
room temperature under rotatory conditions for 90 min in RPMI medium without 
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supplements. The relative number of heterotypic intercellular binding was estimated by 
flow cytometry.  
 
Sucrose density gradient fractionation 
Confluent TNF-α-activated HUVEC were rinsed with phosphate-buffered saline 
(PBS) and lysed for 20 min in 250 µl of 25 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 % 
Brij96 at 4°C. The cell lysate was homogenized by passing the sample through a 22-
gauge needle. The extract was brought to 40% sucrose (w/w) in a final volume of  4 ml 
and placed at the bottom of an 8-ml 5-30% linear sucrose gradient. Gradients were 
ultracentrifuged to equilibrium for 20 h at 39,000 rpm at 4°C in a Beckman SW41 rotor 
(Beckman Coulter, Fullerton, CA). Fractions (1ml) were harvested from the bottom of 
the tube. Aliquots from each fraction were subjected to SDS-PAGE and Western blot 
with appropriate Abs.  
 
Fluorescence Recovery after Photobleaching  
Cells transfected with EGFP-fusion proteins (VCAM-1-, ICAM-1-, CD9-, 
CD151-, ICAM-1∆Cyt-, GPI-EGFP) were plated on 25mm glass coverslips coated with 
20 µg/ml of FN. After 24h, cells were stimulated with 20 ng/ml TNF-α in the presence 
or absence of CD9-LEL-GST and FRAP experiments were performed before 48h after 
plating. To analyse FRAP at the endothelial docking structure, an adhesion assay was 
conducted under static conditions using K562 cells expressing VLA-4 (α4β1) or LFA-1 
(αLβ2) at the plasma membrane. Live-cell microscopy was performed with a Leica 
SP2 laser scanning confocal microscope using the 488-nm Ar laser line and an X 63 
glycerol objective. During the observation period, plates were maintained at 37ºC in a 
5% CO2 atmosphere using an incubation system (La-con GBr Pe-con GmbH). Laser 
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power for bleaching was maximal, whereas it was attenuated to 10% of the bleach 
intensity for imaging. Ten single-section prebleach images were acquired, followed by 
three iterative bleach pulses of 1.686 sec each. Then, ten single-section images were 
collected at 1.686 sec intervals, followed by 20 images collected every 10 sec and, 
finally, 15 images every 30 sec for a total experimental time of 650 sec aprox. 
Fluorescence recovery in the bleached region was measured as average signal 
intensity. Although the size of the measured region was dependent on docking structure 
dimension, it was very homogenous. Signal loss in unbleached regions during the 
recovery period was less than 5 % of the initial fluorescence signal. All recovery curves 
were generated from background-subtracted and bleaching-corrected images. 
Fluorescence signal measured in a region of interest (ROI) was normalized to the 
prebleach signal in the same ROI.  
The mobile fraction (Mf) corresponds to the final value of the recovered 
fluorescence intensity, and the immobile fraction is obtained as 1-Mf. 
The half-time of recovery is the time from the bleach to the time point where the 
fluorescence intensity reaches the half of the final recovered intensity. All these three 
variables were directly obtained from the normalized mean fluorescence recovery 
curves. To assess the statistical significance of differences found between two given 
families of curves characterized by measurements at identical time-points, a point-to-
point comparison based on a Student’s t-test was implemented. The Benjamini and 
Hochberg (BH) method (Benjamini and Hochberg, 1995) was employed to control for 
the false discovery rate associated with multiple testing. The analysis was accomplished 
using R (R Development Core Team, 2006).  
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Hetero-fluorescence resonance energy transfer by donor fluorescence lifetime 
imaging microscopy in intact living cells  
HUVEC were single transfected with different mEGFP standards or co-
transfected with combinations of mEGFP-mRFP1 pairs and seeded on FN-coated glass-
bottomed Petri-dishes as described above. After 24h, and without TNF-α treatment, 
culture medium was replaced with phenol red-free medium for optimal image 
acquisition. FLIM was performed using a laser scanning microscope assembled at the 
Laboratory for Fluorescence Dynamics, (Irvine, CA, USA) using the photon counting 
regime of the photomultiplier detector in conjunction with time-resolved frequency-
domain data acquisition hardware (Colyer et al., submitted). The data is processed 
automatically by software which accumulates a phase histogram of photon counts 
across the cross-correlation period, and then automatically calculates the phase and 
modulation of the emission. From the phase and modulation, the fluorescence lifetime 
ensembles in live cells was analyzed using the phasor-FLIM approach recently 
described (Digman et al., submitted; Caiolfa et al., 2007).  The system was based on an 
Olympus Fluoview 1000 microscope, connected to a modulated ISS 471nm diode laser 
and equipped with a 470 +/- 5 nm excitation filter and a BA 505-525 nm emission filter 
(ISS Inc., Champaign, IL, USA). The laser was guided into the microscope by x-y 
galvano-scanner mirrors (Model 6350; Cambridge Technology, Watertown, MA), 
driven in a raster scan movement using the ISS 3-axis card (ISS, Inc. Champaign, IL) 
and synchronized with data acquisition with a Becker and Hickl SPC830 card. Data 
were acquired and processed by the SimFCS software developed at the LFD. A 
photomultiplier tube (R7862, Hamamatsu Photonics, Battlesboro, NJ) was used for the 
detection in the photon counting mode. The objective was a 40X water immersion 
(Zeiss, Germany) with 1.2 N.A. The scan area (256x256 pixels) corresponds to 32x32 
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µm2. Before measurement, a slide with concentrated fluorescein at pH 9 was measured. 
The lifetime of fluorescein, 4.04 ns, was determined separately in an ISS Inc 
fluorometer.  
 
Fluorescence Correlation Spectroscopy 
Endothelial cells were transiently single or double transfected as for FLIM 
analysis. The dual-channel confocal fluorescence correlation spectrometer, ALBA (ISS 
Inc., Champaign, IL, USA), was equipped with avalanche photodiodes and interfaced 
to a Nikon TE2000 inverted microscope equipped with a dichroic set C-74610 
(z488/594 dbx z488/594rpc) + emission filter z 488/594m (Chroma Technology, USA). 
The objective used was a 60X Plan Apo (1.2 NA, water immersion).  Excitation at 488 
nm was provided by a tunable argon ion laser (Melles Griot, USA) and at 594 nm by a 
HeNe Laser (Melles Griot, USA). The diameter and power of the two beams were 
controlled by the ISS laser launcher system. The two laser lines were combined by a 
suitable external dichroic mirror (Chroma Technology, USA). Inside the ALBA box an 
additional dichroic (Chroma Technology, USA) separated the mRFP1 and mEGFP 
emissions in the two channels (set C74612 (570 dclp, 520/30m, 610 lp). Every day, the 
power of the light passing through the objective in the absence of any immersion liquid 
was adjusted to 1 microW. An x,y,z computer-controlled piezoelectric actuator with a 
step resolution of less than 50 nm warranted the nanometric positioning. An ISS 
acquisition card received the data stream from the detectors. Data were stored for 
further processing by VISTA (ISS Inc.) and simFCS (LFD). Acquisition was in time-
mode, and sampling frequency was 20 kHz. The waist (ω0) of the excitation beam was 
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calibrated before each day’s experiments using Rhodamine 110 at 488 nm and 
Sulphorhodamine at 594 nm. Typical ω0 values were 0.34-0.38 µm.  
The autocorrelation functions (ACFs) were best-fitted using the anomalous 
diffusion model (Banks and Fradin, 2005), according to the equation:  
where N is the average number of molecules in the excitation volume, τD is the diffusion 
time, and α is the anomality coefficient.  
Accordingly, the diffusion coefficient (D) is derived from the relationship:  
                                                           D= ω2/4τα 
 
Scanning electron microscopy 
Endothelial monolayers were activated for 20h with TNF-α 20 ng/ml in the 
absence or presence of 250 µg/ml of active or heat-inactivated (5 min, 90ºC) CD9-
LEL-GST peptide. Cells were then fixed in 2% paraformaldehyde in PBS and subjected 
to regular immunolabeling with P8B1 (anti-VCAM-1), Hu5/3 (anti-ICAM-1) or 
biotinylated MEM-111 (anti-ICAM-1) as primary antibodies and 40 nm gold-coupled 
anti-mouse antibody or 15 nm gold-coupled streptavidin (BBInt.) as detection reagents. 
After immunolabeling, samples were fixed in 2.5% glutaraldehyde in PBS and then 
dehydratated by sequential passages through 30, 50, 70, 90%, and absolute ethanol.  
The ethanol was substituted by liquid CO2, and the specimens were critical-point dried 
using a Polaron E3000 apparatus. Then, samples were transferred onto appropriate 
microscope slides and covered with a carbon layer up to 5 nm using a high vacuum 
evaporator (Edwards 12E6/1266). Images were obtained with a Hitachi S-4100 
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scanning electron microscope at an acceleration voltage of 12kV and a working 
distance of 4mm. Images were processed with Metamorph software (Universal Imaging 
Corporation, Molecular Devices Corporation, Downington, PA). Receptor clustering 
was evaluated by nearest neighbour analysis using a custom-written software based on 
R software. The developed method allowed us to establish similarities and 
discrepancies between different treatments in terms of aggregation and dipersion of the 
objects (gold particles) in the images. 
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RESULTS 
 
 
VCAM-1 interacts with moesin and ezrin at the apical surface of activated 
endothelial cells  
The subcellular distribution of VCAM-1, ezrin and moesin was analyzed by 
confocal microscopy in TNF-α activated HUVEC. VCAM-1 colocalized with ezrin (Fig. 
5 a-c) and moesin (Fig. 5 e-g) in the microspikes and microvilli that protrude from the 
apical surface of these cells.  
 
Fig. 5.- VCAM-1 colocalizes with moesin and ezrin at the apical surface of activated HUVEC.  
Confluent HUVEC were activated with 20 ng/ml TNF-α for 20 h. Thereafter, cells were fixed, permeabilized and 
stained with the anti-ezrin pAb 90/3 (a and i) (green), anti-moesin pAb 95/2 (e) (green), anti-VCAM-1 mAb P8B1 (b 
and f) (red) or anti-VE-cadherin mAb Tea1/31 (j) (red). Merged images are shown in panels c, g and k, where 
colocalizations are observed (yellow). Images represent confocal laser scanning micrographs showing horizontal 
projections or the corresponding orthogonal section of the same field. Insets correspond to the amplified image of the 
zones pointed to by arrows. Colocalization histograms of green and red signals corresponding to these images are 
shown on the right (d, h, l). The corresponding colocalization percentages are 65.7% (d), 67.6% (h) and 13.3% (l). Bar: 
20 µm. 
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Colocalization analysis confirmed these observations (Fig. 5 d, h). By contrast, VE-
cadherin did not colocalize with ERM proteins (Fig. 5 i-k).  
To assess whether this codistribution in activated HUVEC is correlated with the 
formation of complexes between VCAM-1 molecules and ERM proteins, 
immunoprecipitation assays were carried out. As shown in Fig. 6A, moesin and ezrin co-
immunoprecipitated with VCAM-1. To determine whether these interactions are direct, 
binding assays were performed using a GST fusion protein containing the cytoplasmic 
tail of VCAM-1 (GST-VC). The fusion protein containing the cytoplasmic tail of ICAM-
3, GST-IC3, which has been demonstrated to bind ERM, as well as the partially truncated 
form GST-Y9, which shows a considerable reduced binding to moesin and ezrin 
(Serrador et al., 2002), were used as positive and negative controls, respectively. 35S-Met-
labeled N-moesin and N-ezrin were added to Sepharose beads coupled to the GST fusion 
proteins. Strong binding of VCAM-1 to ezrin and moesin was observed, which was much 
higher in comparison to ICAM-3 (Fig. 6B). Altogether these data demonstrate that 
VCAM-1 can directly associate with ezrin and moesin in vitro and presumably also at the 
apical membrane sites of endothelial cells. 
 
Differential contribution of VCAM-1, ICAM-1, and ERM proteins to the 
extravasation process. 
The functional role of the VCAM-1/ERM association in the endothelial cell-
lymphocyte interaction was analyzed and compared with another adhesion receptor that 
also interacts with ERM proteins, namely ICAM-1 (Heiska et al., 1998). For this purpose, 
we used T lymphoblasts, that express high levels of VLA-4 and LFA-1, ligands of 
VCAM-1 and ICAM-1, respectively (Fig. 7A). 
                                                                                                                                  Results 
 59
 
Fig. 6.- Association of VCAM-1 with moesin and ezrin. 
A. Cytokine-activated HUVEC were lysed and immunoprecipitated with the anti-VCAM-1 mAb 4B9 or 
Gly-Sepharose. Immunoprecipitates were then resolved on a 10% SDS-PAGE, and sequentially 
immunoblotted with the anti-VCAM-1 mAb 4B9, the anti-moesin pAb 95/2, and the anti-ezrin pAb 90/3. 
Molecular weights (kDa) are indicated on the right side. 
B. GST or the GST fusion proteins GST-VC, GST-IC3 and GST-Y9 were bound to glutathione-Sepharose 
beads and incubated with 35S-Met-N-moesin or 35S-Met-N-ezrin (upper and lower panels, respectively). 
After incubation, beads were boiled in sample buffer and eluted proteins were analyzed by 10% SDS-
PAGE, autoradiography and fluorography. Lanes with isotope-labeled N-moesin and N-ezrin (*) indicate 
the molecular mass of these truncated proteins. Densitometric diagrams normalized to the loading controls 
of GST-proteins are shown on the right. 
 
Both integrins were active since mAb against them blocked T lymphoblast TEM 
(Fig. 7B). These cells were allowed to adhere and migrate across an activated HUVEC 
monolayer and confocal microscopic analysis of endogenous endothelial VCAM-1 and 
ICAM-1 distribution was performed. When lymphoblasts were spread on the apical 
surface of endothelium, VCAM-1 clustered around these cells (Fig. 7C, a). However, 
such VCAM-1 clusters were neither observed during the passage of lymphoblasts across 
the endothelium nor after transmigration (Fig. 7C, b). The orthogonal section showed two 
lymphoblasts migrating across adjacent endothelial cells, where clustered VCAM-1 
molecules colocalized with endothelial ezrin only at the apical surface of the 
lymphoblast-endothelial cell contact area (Fig. 7C, c). On the other hand, ICAM-1 was 
clustered around lymphoblasts during all the lymphoblast adhesion and transmigration 
processes (Fig. 7C, d and e), colocalizing with endothelial ezrin (Fig. 7C, f). 
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Fig. 7.- Distribution of endogenous VCAM-1, ICAM-1 and ezrin during lymphoblast TEM. 
A. Expression of α4-integrin (thick line), and αL-integrin (thin line) on T lymphoblasts as determined by 
flow cytometry analysis. P3X63 (dotted line) was used as negative control. 
B. Transendothelial migration assay of T lymphoblasts pre-treated with the blocking anti-α4 mAb HP2/1, 
the blocking anti-αL mAb TS1/11, the mixture of anti-α4 plus αL mAb, or the anti-ICAM-3 mAb TP1/24 
as negative control. Values correspond to the arithmetic mean ± SD of a representative experiment run by 
duplicate out of 3 independent ones. Statistically significant values, as defined by unpaired Student’s t-test, 
are indicated with * (p<0.05) or ** (p<0.015) compared with no Ab treatment. 
C. T lymphoblasts were allowed to transmigrate across an activated HUVEC monolayer, and then cells 
were fixed, permeabilized and stained with the anti-VCAM-1 mAb P8B1 (a-c) (red), the anti-ICAM-1 mAb 
Hu5/3 (d-f) (red) or the anti-ezrin pAb 90/3 (c and f) (green). Representative confocal horizontal images 
showing an apical section of endothelium with adhered lymphoblasts on top (a, d) and a basal section with 
transmigrated lymphoblasts beneath the endothelium (b, e) are presented.  DIC images are shown overlaid 
with VCAM-1 (a, b) or ICAM-1 staining (d, e). Arrows point to VCAM-1 or ICAM-1 clusters at the 
contact area. Representative orthogonal sections corresponding to the white line in panel a or panel d are 
shown in panels c and f, respectively. Green signal corresponds to ezrin staining both in lymphoblasts and 
endothelium. Arrowheads point to the sites of VCAM-1/ezrin or ICAM-1/ezrin clustering at the apical 
surface of endothelial cells. Bars: 20 µm (a-b), 8 µm (d-e). 
 
To dynamically assess the changes in distribution of VCAM-1, ICAM-1, and ERM 
proteins, HUVEC transiently transfected with VCAM-1-, ICAM-1-, or moesin-GFP were 
separately monitored by live time-lapse confocal microscopy after addition of 
lymphoblasts. As observed previously for endogenous molecules, VCAM-1- and moesin-
GFP fusion proteins redistributed to sites of contact during lymphoblast initial adhesion 
and spreading. However, only moesin was concentrated in the transmigration cleft and 
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apparently participated in subsequent interactions, when lymphoblasts migrated beneath 
the activated endothelium (Fig. 8A). Interestingly, moesin-GFP exhibited a dynamic 
behavior similar to ICAM-1-GFP (Fig. 8B), presumably because this adhesion molecule 
binds to ERM proteins to actively participate in TEM. Digital movies showing more 
clearly the differential dynamic distribution of these molecules are included as additional 
material.  
 
Fig. 8A.- Dynamic changes in the localization of VCAM-1, ICAM-1 and moesin during lymphoblast 
TEM. 
A. Lymphoblasts were allowed to transmigrate across activated HUVEC transfected with moesin- or 
VCAM-1-GFP. Videosequences tracking the spatial and temporal distribution of moesin (a-f) and VCAM-
1 (g-l) were obtained using live time-lapse fluorescence confocal microscopy. Each image represents a 
projection of several representative horizontal sections of a confocal image-stack depicted from the 
videosequence at the specified times. DIC and fluorescence images are merged and presented at the lower 
side of each panel. Arrows point to the GFP proteins clustering during the lymphoblast-endothelium 
interaction. Arrowheads indicate the absence of VCAM-1-GFP from the contact area between the 
transfected endothelial cell and a migrated lymphoblast placed beneath the endothelial monolayer. 
Corresponding digital videosequences are available in Appendix I Supplemental material. Bars: 20 µm. 
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Fig. 8B.- Dynamic changes in the localization of VCAM-1, ICAM-1 and moesin during lymphoblast 
TEM. 
B. Lymphoblast transmigration across activated HUVEC transfected with ICAM-1-GFP was analyzed by 
live time-lapse fluorescence confocal microscopy. Two representative horizontal sections from the apical 
and the basal side of the endothelial cell belonging to the same confocal stack depicted from the 
videosequence are presented. ICAM-1-GFP signal is shown in panels a and d. DIC images and the overlaid 
images are presented in panels b, e and c, f, respectively. The corresponding videosequence is available in 
Appendix I Supplemental Material. Bar: 5 µm.  
 
 
Redistribution of VCAM-1, ICAM-1 and ERM proteins at a docking structure 
during endothelium-leukocyte interaction.  
To focus our study on the role of ERM interaction with endothelial adhesion 
receptors during the initial adhesion of leukocytes to the endothelium, to which VCAM-1 
involvement was mainly restricted, we used K562 cells stably transfected with α4 
integrin (4M7 cells) (Munoz et al., 1996). These cells expressed high levels of VLA-4 , 
but negligible amounts of LFA-1 (Fig. 9A). In addition, their adhesion to activated 
endothelium was dependent on VLA-4, since it was inhibited by the blocking anti-α4 
HP2/1 mAb, and induced by the activating anti-β1 TS2/16 mAb (Fig. 9B). 4M7 cells 
adhered to activated endothelium mainly via VLA-4, but these cells were unable to 
progress to TEM (data not shown). When the distribution of endogenous endothelial 
VCAM-1 was examined during 4M7 cell adhesion, we found that it was strongly 
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concentrated around attached leukocytes (Fig. 9C, c). Endogenous ezrin colocalized with 
VCAM-1 at the endothelial-leukocyte contact area (Fig. 9C, d), and antibodies to ezrin 
also stained the leukocyte membrane (Fig. 9C, b). Furthermore, a three-dimensional 
reconstruction of the site of adhesion showed that VCAM-1 and ezrin were contained in a 
unique docking structure that was raised above the level of the endothelial cell surface 
and that surrounded the adherent leukocyte in a cup-like fashion. Both proteins were 
preferentially concentrated in microspikes of this structure that presumably served to 
anchor the attached leukocyte (Fig. 9C, e-g). The redistribution of VCAM-1 and moesin 
to the leukocyte-endothelium contact area was tracked separately by live time-lapse 
fluorescence confocal microscopy during the interaction of 4M7 cells with VCAM-1- or 
moesin-GFP transfected HUVEC. The dynamic studies demonstrated that VCAM-
1/VLA-4 engagement was associated with the progressive concentration of VCAM-1 and 
moesin at the specialized anchoring structure formed between the two interacting cells, 
which was progressively strenghtened and sustained with time (Fig. 9D). 
To ascertain the physiological relevance of this docking structure, we analyzed the 
redistribution of VCAM-1, ICAM-1, and ezrin to the contact area of migrating peripheral 
blood lymphocytes (PBLs) allowed to adhere under fluid shear conditions, using a 
physiological wall shear stress (1.8 dyn/cm2) for perfusion periods from 30s to 10 min. 
We found these endothelial molecules colocalizing in clusters at the docking structures 
formed around spreaded PBLs (Fig. 10A), at early time points during the arrest of 
lymphocytes. This structure was also observed during the interaction of activated 
HUVEC with T lymphoblasts in static conditions (Fig. 10B, and data not shown). 
Similarities in three-dimensional VCAM-1 distribution around 4M7 cells, T lymphoblasts 
or peripheral blood lymphocytes supported the generality of the docking structure (Fig. 
10B).  
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Fig. 9.- Localization of VCAM-1 and ezrin at the contact area of activated HUVEC with leukocytes. 
A. Expression of α4-integrin (thick line), and αL-integrin (thin line) on 4M7 cells as determined by flow 
cytometry analysis. P3X63 (dotted line) was used as negative control. 
B. Adhesion to activated HUVEC of 4M7 cells pre-treated with the blocking anti-α4 mAb HP2/1, the 
activating anti-β1 m Ab TS2/16, or the blocking anti-αL mAb TS1/11. Values correspond to the arithmetic 
mean ± SD of a representative experiment run by triplicate out of 3 independent ones. Statistically 
significant values, as defined by unpaired Student’s t-test, are indicated with * (p<0.005) or ** (p<0.0001), 
compared with no Ab treatment. 
C. 4M7 cells interacting with activated endothelial cells were fixed, permeabilized and stained with the 
anti-ezrin pAb 90/3 (green) and the anti-VCAM-1 mAb P8B1 (red). Representative horizontal sections of 
confocal laser scanning images (b,c) are merged in panel d. The corresponding DIC image is shown in 
panel a. The corresponding three-dimensional reconstruction is presented in panels e-g. Bar: 5 µm.  
D. 4M7 cells were allowed to adhere to activated HUVEC transfected with moesin- or VCAM-1-GFP. GFP 
staining was monitored using live time-lapse fluorescence confocal microscopy. Horizontal sections 
showing the staining of moesin- (a) or VCAM-1-GFP (b) after 60 min of leukocyte-endothelium 
interaction. Arrows point to the GFP proteins clustered in the anchoring structure. Bar: 20 µm. 
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Relocation of cytoskeletal components to the endothelial docking structure.  
The cytoskeletal components involved in the generation of this endothelial structure were 
analyzed. Samples of 4M7 cells adhered to activated HUVEC and stained for VCAM-1 
and F-actin revealed a considerable enrichment of endothelial actin within the docking 
structure (Fig. 11A, a-b). Interestingly, this apical actin scaffold appeared not to be 
connected to basal stress fibers (Fig. 11A, c-d). On the contrary, tubulin was not present 
with F-actin at the anchoring structure (Fig. 11A, e-h).  
 
Fig. 10.- Formation of the endothelial docking structure for adhered lymphocytes under flow. 
A. Transendothelial migration assay of peripheral blood lymphocytes under fluid shear conditions. After 10 
min of perfusion, cells were fixed and stained for ICAM-1 (b, d) (green), VCAM-1 (c, d, g, h) (red), and 
ezrin (f, h) (green). The corresponding DIC images are shown in panels a and e. Merged images are shown 
in panels d and h. Bar: 3,5 µm. B. Three-dimensional reconstruction of VCAM-1 staining during 4M7 cell 
(a), T lymphoblast (b), or PBLs under flow (c) adhesion.  
 
Vinculin and α-actinin-GFP also redistributed to this structure with a punctuate 
pattern (Fig. 11B, c-d, and Fig. 11C a-c). Likewise, VASP-GFP colocalized with VCAM-
1 (Fig. 11C, f-g), whereas talin and paxillin-GFP were only found colocalizing with 
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VCAM-1 at some adhesion structures (Fig. 11B, a-b, and Fig. 11C, d-e). These data 
indicate that the endothelial docking structure was supported by the actin cytoskeleton, 
actin-bundling proteins such as α-actinin, actin-nucleating proteins such as VASP, and 
focal adhesion proteins such as vinculin, talin or paxillin. The formation of this structure 
was associated with a remarkable change in distribution of several of these proteins, in 
particular vinculin, talin and paxillin, from their normal subcellular localization at focal 
adhesions at the basal surface to the docking structure at the apical surface. 
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Fig. 11.- Characterization of the endothelial docking structure formed during leukocyte adhesion. 
A. 4M7 cells were allowed to adhere to activated HUVEC cells, then fixed, permeabilized and stained for 
VCAM-1 (a) (green), F-actin (b-d, f, and h) (red), and tubulin (e and g) (green). Representative horizontal 
sections of confocal image-stacks are presented in panels (a-b, e-f). The panel c shows the projection of all 
the horizontal sections corresponding to the image presented in panels a-b. Three-dimensional 
reconstructions of F-actin (d, h) and tubulin (g) stainings are also shown. Bars: 20 µm.  
B. 4M7 cells adhered to activated HUVEC were fixed, permeabilized and stained for talin (a-b) (green), 
VCAM-1 (a-b) (red), or vinculin (c-d) (green). Representative horizontal sections of confocal images are 
presented in panels a and c. Three-dimensional reconstructions are shown in panels b and d. Bar: 5 µm. 
C. 4M7 cells were allowed to adhere to activated HUVEC transfected with α-actinin, paxillin-, and VASP-
GFP. Thereafter, cells were fixed and stained with the anti-VCAM-1 mAb P8B1 (a, d, f) (red). Green 
signal corresponds to GFP fusion proteins (b, c, e, g). Representative horizontal sections of confocal image-
stacks are presented in all panels except for panel c, which shows the three-dimensional reconstruction of 
α-actinin-GFP signal. Bars: 5 µm. 
 
The docking structure is regulated by PI(4,5)P2 and Rho/p160 ROCK.  
To assess whether the clustering of ERM proteins at the endothelial-leukocyte 
contact area is associated with an activated state of these proteins, immunofluorescence 
studies using the 297S mAb, which recognizes a C-terminal threonine phosphorylated in 
ERM proteins (Matsui et al., 1998), were conducted. A high concentration of 
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phosphorylated ERM proteins was evident at the endothelial anchoring structure 
generated after VCAM-1/VLA-4 interaction (Fig. 12A).  
We have also studied two important regulators of ERM activation, namely 
phosphoinositides and components of the Rho/p160 ROCK pathway. The subcellular 
localization of different phosphoinositides was determined by using as probes the PH 
domain of PLCδ, which binds PI(4,5)P2, and that of GRP1, which binds PI(3,4,5)P3 and 
PI(3,4)P2, fused to GFP (Gray et al., 1999; Várnai et al., 1999). Upon endothelial cell 
transfection, both probes colocalized with VCAM-1 at the endothelial docking structure 
(Fig. 12B, a-b and d-e). PLCδ-PH-GFP showed a higher concentration at microspike tips 
 
Fig. 12.- Localization of phosphorylated ERM proteins and phosphoinositides at the anchoring 
structure. 
A. 4M7 cells adhered to activated HUVEC were fixed, permeabilized and stained with the mAb 297S. 
Representative horizontal section of a confocal micrograph (a), and a three-dimensional reconstruction of a 
series of horizontal sections (b) are shown. Bar: 5 µm.  
B. HUVEC cells were transfected with PLCδ-PH- and GRP1-PH-GFP and then, 4M7 cells were allowed to 
adhere. Thereafter, cells were fixed, permeabilized and stained with the anti-VCAM-1 mAb P8B1 (a, d). 
Green signal corresponds to GFP fusion proteins (b, e). Panels c and f show three-dimensional 
reconstructions of horizontal sections corresponding to the green signal. Bars: 5 µm.  
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(Fig. 12B, c), whereas GRP1-PH-GFP appeared to be more diffusely distributed and 
localized throughout the entire structure (Fig. 12B, f).  
Next, blocking studies with chemical inhibitors were carried out before and after 
HUVEC-leukocyte adhesion. The p160 ROCK inhibitor Y-27632 strongly inhibited the 
generation and maintenance of the anchoring structure (Fig. 13A). On the other hand, the 
PI3K inhibitor Ly 294002 only had a minor effect on the generation of this structure, but 
moderately inhibited its maintenance (Fig. 13A). The classic PKCs inhibitor Gö6976 did 
not exert a significant inhibitory effect neither on the generation nor in the maintenance 
of the anchoring structure (Fig. 13A). Dynamic studies using VCAM-1-GFP transfected 
HUVEC showed that the p160 ROCK inhibitor Y-27632 acted by destroying the docking 
structure, as observed in Fig. 13B. Finally, the effect of this inhibitor was assayed on 
endothelium during lymphocyte adhesion and transmigration under flow conditions. We 
found a diminished lymphocyte rolling and adhesion after Y-27632 treatment with regard 
to control conditions. Furthermore, some cells that were initially adhered, began to roll 
and finally detached from the monolayer, indicating an abnormal adhesion process. 
Accordingly, all these events led to a significant inhibition of transmigration (Fig. 13C). 
Furthermore, immunofluorescence analysis revealed that most of adhered lymphocytes 
were not tightly anchored by an endothelial docking structure (data not shown).  
In conclusion, these findings suggest that both, PI(4,5)P2 and the Rho/p160 ROCK 
pathway, are important for the generation as well as for the maintenance of the 
endothelial docking structure. 
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Fig. 13.- Rho/p160 ROCK pathway regulates the generation and maintenance of the VCAM-1-
mediated docking structure. 
A. Activated HUVEC were pretreated with Y27632 (30 µM), Ly294002 (20 µM), or Gö6976 (1 µM) for 
20 min before or 30 min after the addition of 4M7 cells. Total adhesion time was in both cases 60 min. 
Quantification of leukocyte adhesion and endothelial docking structure formation was carried out by 
staining with the mAb anti-VCAM-1 P8B1 and counting 300 adhered cells of each treatment. A 
representative experiment out of 4 independent ones is presented. B. Kinetics of the endothelial anchoring 
structure dissolution after the addition of the p160 ROCK inhibitor Y-27632. The inhibitor Y-27632 (30 
µM) was added after the formation of the docking structure in an adhesion assay performed as above. 
Representative horizontal sections captured every 15 min are shown in panels a-c. DIC and fluorescence 
images are merged and presented in the lower side of each panel. Arrows indicate the clustering of GFP 
proteins. Bar: 10 µm. C. Effect of Y-27632 on lymphocyte adhesion and TEM under flow conditions. 
Activated endothelium was pretreated or not with Y-27632 (30µM) for 30 minutes. Thereafter, PBLs were 
allowed to adhere and transmigrate under flow conditions for 10 min. Quantification of rolling (R), 
adhesion (A), transmigration (T) and detachment (D) events during the last min of perfusion was carried 
out. Values correspond to the arithmetic mean ± SD of 4 different fields belonging to a representative 
experiment. Statistically significant values, as defined by unpaired Student’s t-test, are indicated with 
*(p<0.01) or **(p<0.002) compared with no inhibitory treatment. 
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Tetraspanins are components of the endothelial docking structure for adherent 
leukocytes by their association with ICAM-1 and VCAM-1 
Tetraspanin proteins are low molecular weight polypeptides that are able to 
associate with a variety of transmembrane proteins via their extracellular domain, 
forming multiproteic domains in the plasma membrane. They have been involved in 
several cellular functions including intercellular homotypic and heterotypic adhesion 
(Yanez-Mo et al., 2001), however genetic approaches directed to tetraspanins did not 
render clearcut information on their individual funcional roles. HUVEC cells express 
several of these proteins (CD9, CD81, CD151, CD63), both at intercellular contacts and 
intracellular vesicles (Sincock et al., 1999; Yanez-Mo et al., 1998).  
 
Figure 14A. Endothelial tetraspanin proteins relocalize to the contact site with adherent leukocytes 
and associate with ICAM-1 and VCAM-1.  
A. T lymphoblasts were adhered to TNF- –activated HUVEC monolayers, fixed, and double-stained for 
CD9 and VCAM-1 or ICAM-1. Maximum projections of the relevant sections from the confocal stacks and 
the merge of both channels are shown. Asterisks in differential interference contrast (DIC) images highlight 
the T lymphoblasts around which the docking structures shown in the 3-dimensional (3D) reconstructions 
are formed. Scale bars equal 10 µm. 
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On the other hand, T lymphoblasts express CD81 and low levels of CD151, 
whereas the expression of CD9 is heterogeneous, ranging from completely negative to 
high expressing cells, and the relative amount of each population varies in different 
human donors. Upon T lymphoblast adhesion onto activated HUVEC monolayers, 
endothelial tetraspanins redistributed, together with ICAM-1 and VCAM-1, to the 
docking structure that emerges from the apical surface to firmly attach the transmigrating 
cell (Barreiro et al., 2004; Barreiro et al., 2002) (Figure 14A and B and data not shown). 
Tetraspanin redistribution was also observed under flow conditions around adherent 
peripheral blood lymphocytes, neutrophils or monocytes (Fig 14C for CD9, and data not 
shown).  
 
Figure 14B (left) and C (right). Endothelial tetraspanin proteins relocalize to the contact site with adherent 
leukocytes and associate with ICAM-1 and VCAM-1.  
B.  T lymphoblasts were adhered to TNF- –activated HUVEC monolayers, fixed, and stained with antitetraspanin 
mAbs VJ1/20 (anti-CD9), I.33.2.2 (anti-CD81), and LIA1/1 (anti-CD151). Confocal stacks were obtained and 
representative apical horizontal and vertical sections together with the corresponding DIC images are shown. Arrows 
point to the positions of the adhered lymphoblasts. Arrowheads and lines point to the position of the adhered 
lymphoblasts shown in the vertical sections. Scale bar equals 10 µm. C. Human PBLs, neutrophils, or monocytes were 
perfused at physiologic flow rate (1.8 dyn/cm2), fixed, and stained with anti-CD9 VJ1/20 mAb. Confocal stacks were 
obtained and maximum projections of the whole series or a representative section together with the corresponding DIC 
images are shown. Arrows point to the position of the adhered leukocytes. Scale bar = 20 µm.  
 
 
To determine the subcellular localization of endothelial tetraspanins during the 
whole transendothelial migration process, T lymphoblasts were allowed to transmigrate 
across TNF-α-activated HUVEC monolayers. CD9 clustering was evident in those 
lymphocyte-endothelial interactions occurring at the apical surface of the monolayer (Fig 
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14D, white arrows). In contrast, almost no redistribution of CD9 could be observed at the 
ventral surface of endothelial cells in contact with transmigrated lymphoblasts (Fig 14D, 
grey arrows). On the other hand, CD151 relocalization around lymphoblasts was clearly 
detected at both the apical and basal surface of the endothelial cell (Fig 14D; white and 
grey arrows, respectively) paralleling the behavior of ICAM-1.  
 
Figure 14D. Endothelial tetraspanin proteins relocalize to the contact site with adherent leukocytes and associate 
with ICAM-1 and VCAM-1.  
D. Analysis of the localization of endogenous endothelial CD9 or CD151, compared with ICAM-1, at apical and 
ventral contact sites with transmigrating lymphocytes. Human T lymphoblasts were allowed to transmigrate through 
TNF- –activated HUVECs, fixed, and double-stained with antitetraspanin mAbs and biotin-conjugated anti–ICAM-1. 
Confocal stacks were obtained and representative sections at apical or ventral positions of the same field together with 
the corresponding DIC image are displayed. White arrows and asterisks mark apically adhered lymphocytes, and gray 
arrows and black asterisks mark those lymphocytes that have transmigrated. Arrowheads and lines point to the position 
of the adhered or transmigrated lymphoblast shown in the vertical sections. Scale bar equals 10 µm.  
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Similarly to that observed with the endogenous protein stainings, CD9-GFP was 
more clearly relocalized to the contact site with T lymphoblasts at the endothelial apical 
surface, although some clustering occurred around transmigrated lymphoblasts 
locomoting underneath the endothelium. On the other hand, CD151-GFP was strongly 
concentrated at the contact with lymphoblasts throughout all the transmigration process. 
These data point to the existence of different tetraspanin microdomains at the apical and 
ventral endothelial surfaces and suggest a complex dynamic regulation of these 
membrane domains. 
 
Figure 14E. Endothelial tetraspanin proteins relocalize to the contact site with adherent leukocytes 
and associate with ICAM-1 and VCAM-1. 
E. ICAM-1 and VCAM-1 are associated with tetraspanins in TNF- –activated HUVECs. Cell lysates were 
obtained in 1% Brij96 and immunoprecipitated with the different mAbs specific for endothelial adhesion 
molecules or tetraspanins. After washing, immunoprecipitates were resolved in sodium dodecyl sulfate–
polyacrylamide gel electrophosphoresis (SDS-PAGE) gels and revealed by Western blot for VCAM-1 
(P8B1), ICAM-1 (HU5/3), CD151 (8C3) or CD9 (VJ1/20). 
 
Tetraspanin interactions are biochemically detected by extraction with Brij 96/97 
detergents. Although HUVEC tetraspanins were mostly associated with EWI-F and β1 
integrins ((Yanez-Mo et al., 1998) and data not shown), CD9 and CD151 were also able 
to pull down ICAM-1 and VCAM-1 (Fig 14E). Conversely, ICAM-1 mAbs were also 
able to coprecipitate CD9, whereas VCAM-1 coprecipitated mainly CD151. No 
detectable signal for ICAM-1 was observed in β1 immunoprecipitates (not shown), 
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suggesting that tetraspanin-integrin complexes are different to tetraspanin/ICAM-
1/VCAM-1 complexes. Coprecipitation of CD9 and CD151 with ICAM-1 and VCAM-1 
could also be faintly detected upon extraction with 1% digitonin (not shown), conditions 
in which most interactions among tetraspanins are lost and direct tetraspanin-partner 
associations are observed (Serru et al., 1999). These results indicate that ICAM-1 and 
VCAM-1 are included into tetraspanin microdomains.  
 
Tetraspanin microdomains are critical for a proper expression and function of 
ICAM-1 and VCAM-1  
In order to gain insights in the relevance of the inclusion of ICAM-1 and VCAM-1 
into tetraspanin microdomains at endothelial cells, we used a siRNA approach against 
tetraspanins CD9 and CD151 in primary human endothelial cells. Endothelial tetraspanin 
CD9 and CD151 expression was considerably knocked down with specific siRNA oligos. 
In no case was the expression completely abolished, but a significant reduction (40-70%) 
was attained (Fig 15A and B, flow cytometry analysis being depicted in logarithmic scale 
and mean fluorescence quantified in Figure 15C). In immunofluorescence analyses a 
clear reduction of tetraspanin staining could be observed, with some cells showing 
expression levels even below the detection threshold (Fig 15D). A compensation effect 
on the expression of other tetraspanins was observed (Fig 15B, C and D).  
HUVEC cells thus treated were viable and clearly responded to TNF-α increasing 
ICAM-1, VCAM-1 and E-Selectin expression over resting levels (ICAM-1 expression 
increases 10-30 folds upon TNF-α treatment, whereas VCAM-1 and E-Selectin are 
undetectable in resting cells) (Fig 16A dotted line). The siRNA transfection procedure 
slightly affected the inducible expression of these adhesion receptors when compared to 
untransfected cells, as determined with a negative oligonucleotide control that does nor 
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pair with any human mRNA (not shown). In CD9 or CD151 tetraspanin-interfered cells, 
a selective reduction in the expression of ICAM-1 and VCAM-1, but not that of E-
selectin or CD44 was observed (Fig 16A, thick versus thin line). This reduction was of 
60% for ICAM-1 and 80% for VCAM-1 when compared to their expression in negative 
oligonucleotide-transfected cells to exclude any off-target effect due to siRNA 
transfection (Fig 16B).  
 
Figure 15: siRNA knocking down of tetraspanins CD9 and CD151 in HUVEC cells. A. Analysis by Western blot 
of the expression of tetraspanins CD9 and CD151 in total cell lysates of siRNA transfected cells. Loading control for 
vimentin is also shown. Densitometric analysis of the experiment shown gave a reduction in the total protein amount of 
70% for CD151 and of 40% for CD9 expression. B. Flow cytometry analysis of the expression of tetraspanins (anti-
CD9 VJ1/20, anti-CD151 LIA1/1, anti-CD81 I.33.2.2) in tetraspanin siRNA-treated HUVEC cells. Negative siRNA 
treated cells are shown in thin line. Thick line corresponds to the expression in tetraspanin siRNA transfected cells. 
Negative control PX63 is shown in dotted line. The histograms are depicted in a logarithmic scale. C. Quantitative 
analysis of the mean fluorescence intensity of CD9, CD151 and CD81 in tetraspanin siRNA transfected cells. Data 
represent the mean of two independent experiments ±S.D. as the percentage of the expression referred to that of 
negative control siRNA transfected cells. D. Immunofluorescence analysis of CD9, CD151 expression and localization 
in HUVEC transfected with siRNA specific for endothelial tetraspanins CD9 and CD151. Images were acquired by 
confocal microscopy using the same photomultipliers parameters in control and tetraspanin-interfered cells. A maximal 
projection of the whole confocal image stack is shown. Bar 20µm.  
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These data further emphasize the importance of tetraspanin microdomains in 
ICAM-1 and VCAM-1 expression and suggest that their association with tetraspanins 
occurs early in the biosynthetic processing of these Ig adhesion molecules, or that it is 
necessary for their proper membrane insertion or retention.  
 
Despite the expression of ICAM-1 and VCAM-1 being lower in tetraspanin-
interfered HUVEC cells, no difference was observed in peripheral blood lymphocytes 
(PBL) adhesion to interfered monolayers when performed under static conditions (Fig 
16C). However, when HUVEC cells treated with siRNA oligos were seeded onto 
transwell insets to perform chemotactic transmigration assays with human PBLs, a strong  
 
Figure 16A, B and C: Tetraspanin-interference affects ICAM-1 and VCAM-1 expression and 
function. A. Flow cytometry analysis of the expression of adhesion molecules ICAM-1 (HU5/3), VCAM-1 
(P8B1), E-Selectin (TEA2/1) and CD44 (HP2/9) in tetraspanins siRNA-treated HUVEC. TNF-α activated 
negative siRNA-treated cells are shown in red line. Blue line corresponds to the expression in TNF-α 
activated tetraspanin siRNA-transfected cells. Expression of the different adhesion molecules in resting 
cells is shown in green line. The histograms are depicted in a logarithmic scale. B. Quantitative analysis of 
the mean fluorescence intensity of ICAM-1, VCAM-1 and E-Selectin in TNF-α activated tetraspanin 
siRNA transfected cells. Data represent the mean of two independent experiments ±S.D. as the percentage 
of the expression referred to that of TNF-α activated negative control siRNA transfected cells. C. Analysis 
of the adhesion of PBLs to tetraspanin interfered cells under static conditions. PBLs were loaded with 
BCECF-AM fluorescent probe and let to adhere in serum free medium on confluent TNF-α activated 
HUVEC monolayers for 15 min at 370C. After washing the percentage of adhesion was quantified in a 
fluorimeter and depicted as the mean ±S.D. respect to the adhesion levels of the negative siRNA 
transfected cells in three different experiments performed by triplicate. 
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inhibition of lymphocyte transmigration was observed with both CD9 and CD151 
siRNA-treated endothelial monolayers as compared with cells transfected with the 
negative control oligonucleotide (Fig 16D).   
Given that ICAM-1 and VCAM-1 are components of a docking structure whose 
relevance in leukocyte firm adhesion was unveiled under flow conditions (Barreiro et al., 
2002), we assessed the role of tetraspanin microdomains on the strength of lymphocyte 
adhesion to endothelial cells by measuring their resistance to detachment under 
increasing shear stress. After 15 min, PBL adhesion to TNF-α-activated HUVEC cells 
was highly resistant to laminar flow, and most cells still remained attached at 10 dyn/cm2 
(5 folds over physiological shear stress) in control HUVEC monolayers (Fig 16E). In 
contrast, a great proportion of the PBLs adhered on tetraspanin-intefered monolayers 
started to detach even at low flow rates (Fig 16E). When extravasation assays using 
tetraspanin-interfered endothelium were performed under physiological flow conditions, 
a significant reduction in the number of adherent lymphocytes was also observed (Fig 
16F). Furthermore, a tendency to decrease was consistently observed in rolling and 
transmigration. All these differences might be related to the lower ICAM-1 and VCAM-1 
expression levels in tetraspanin interfered cells or, additionally, the insertion of these 
molecules into tetraspanin-based microdomains might be critical for their proper function 
under shear stress conditions.  
 
Tetraspanin soluble peptides interfere with ICAM-1 and VCAM-1 function without 
affecting their surface expression 
Tetraspanin associations with other transmembrane proteins occur through their 
LEL (Stipp et al., 2003a). We thus generated soluble GST-LEL peptides from human 
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CD9 (Fig 17A) and point mutants to Ala of any of the four Cys residues in the LEL of 
CD9, which show altered disulphide bond formation and tertiary conformation (Fig 17A). 
 
Figure 16D, E and F: Tetraspanin-interference affects ICAM-1 and VCAM-1 expression and function.  
D. siRNA transfected HUVEC monolayers were seeded onto Transwell insets and activated with 20ng/ml of TNF-α for 
20h. Then, human peripheral blood lymphocytes were added to the upper compartment and SDF-1α (100 ng/ml) 
containing medium to the lower compartment. Cells were allowed to migrate for 2 h and analyzed by flow cytometry. 
Data represent the mean ± S.D. of a representative experiment performed by triplicate. ** p<0.005 in a Student T-test.  
E. Tetraspanin interference augments PBL detachment under shear stress. The percentage (mean ± S.D.) of remaining 
adherent cells is represented for the different flow rates in 4 fields of a representative experiment. * p<0.02; ** p<0.005 
in a Student T-test. F. Effect of tetraspanin siRNA on lymphocyte adhesion and transmigration under flow conditions. 
Activated endothelium transfected with specific siRNA oligos for tetraspanins CD9 or CD151 or the negative control 
oligonucleotide were activated with TNF-α. Thereafter, PBLs were allowed to adhere and transmigrate under 
physiological flow conditions (1.8 dyn/cm2) for 10 min. Quantification of rolling, adhesion, transmigration, and 
detachment events was performed from minutes 3,5 to min 6,5 of perfusion. Values correspond to the arithmetic mean 
± S.E.M. of the total number of PBLs interacting with the endothelial monolayer in the 6 different fields analyzed (20x 
objective) from a representative experiment. The total number of PBLs (n) interacting with the HUVEC monolayer in 
each condition is depicted in the legend of the X axis. * p<0.02 in a Student T-test.  
 
Although some degree of degradation of the soluble peptide occurs, a great 
proportion of the material eluted from the columns was reactive with CD9 mAb in 
Western blot under non-reducing conditions (Fig 17A). Incubation of HUVECs with 
GST-LEL peptides did neither affect the expression levels of ICAM-1 and VCAM-1 
induced by TNF-α (Fig 17B), nor cell viability (Fig 17C) or monolayer permeability (Fig 
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17D). The soluble peptides were added to the preparations at the time of addition of TNF-
α so that they were accessible at the earliest time of inducible expression of both 
adhesion receptors. Thus, these peptides allowed us to interfere with tetraspanin-based 
microdomains without altering the expression levels of ICAM-1 or VCAM-1 induced by 
TNF-α.  
 
Figure 17: Characterization of the soluble peptide CD9-LEL-GST and its mutants. A. LEL-GST fusion proteins 
of human CD9, as well as point mutations to Ala of Cys 152, 153, 167 and 181 were generated, produced in bacterial 
cultures and isolated by affinity columns of Glutation-Sepharose. Eluted purified proteins were then analyzed by 
Ponceau staining and Western blot against CD9 (VJ1/20 mAb) or GST. B. Flow cytometry analysis of the expression 
of ICAM-1 and VCAM-1 in HUVEC cells preincubated with CD9-GST or its point mutants. Thin line in the upper 
panel corresponds to the expression of resting cells. Thin line on the following panels corresponds to cells treated with 
TNF-α alone. Thick line corresponds to the expression in cells treated for 20h with TNF-α alone (upper panels) or in 
combination with the different soluble LEL-GST peptides. C. Propidium iodide profiles of cells treated with for 20h 
with TNF-α alone or in combination with the different soluble LEL-GST peptides. D. Paracellular permeability 
analysis of HUVEC monolayers preincubated with the different soluble LEL-GST peptides. Thrombin was added at 0.1 
U/ml at the time of addition of the fluorescent dextran. Data represent the mean ±S.D. of a representative experiment 
performed by duplicate.  
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Incubation of HUVEC cells with CD9-LEL-GST, but not the mutated forms, 
significantly inhibited transendothelial migration of lymphocytes (Fig 18A), whereas they 
did not affect lymphocyte chemotaxis across nude transwells (data not shown). When 
adhered PBLs were subjected to increasing shear stress, a higher PBL detachment rate 
was also observed upon treatment of HUVEC cells with CD9-LEL-GST (Fig 18B), but 
not with the point mutants. In these experiments the number of lymphocytes that 
transmigrated along the assay was also significantly reduced in those preparations treated 
with CD9-GST (not shown). All these data demonstrate that tetraspanin microdomains 
are important not only for proper ICAM-1 and VCAM-1 expression on the plasma 
membrane but also for their efficient adhesive function under flow conditions.   
 
Figure 18: CD9-LEL-GST inhibits leukocyte transendothelial migration and promotes cell 
detachment under flow. A. CD9-LEL-GST peptide inhibits transendothelial lymphoid migration in 
Transwells. HUVEC monolayers were activated with TNF-α alone or in combination with the different 
LEL-GST peptides. Then, human PBLs were added to the upper compartment and allowed to migrate for 
5-7 h. Cell migration was analyzed by flow cytometry and represented as the mean ± S.E.M. respect to 
control untreated monolayers, of four independent experiments performed by duplicate. ** P<0.005 in a t-
Student test. B. Preincubation with CD9 LEL-GST fusion protein augments detachment under flow 
conditions. The percentage of detachment of PBLs was analysed in 8-10 fields under increasing flow rates 
and represented as the mean ± S.E.M. ** p<0.005 in a Student T-test. 
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Enhanced ICAM-1 and VCAM-1 adhesive function requires an appropriate 
tetraspanin environment 
 To address the relevance of the repertoire of tetraspanin microdomains in the 
presentation of ICAM-1 and VCAM-1 adhesion molecules, we used Colo320 
colocarcinoma cells and a CD9 stable transfectant in this cell line. Colo320 cells express 
similar levels of CD151 and CD81, CD63 and CD82 on the plasma membrane than 
endothelial cells, without expression of CD9, ICAM-1 or VCAM-1 (Fig 19A). A 
downregulation of CD81 and CD63 was also observed upon stable transfection of these 
cells with CD9 (Fig 19A). Then, Colo320 and Colo320-CD9 were transiently transfected 
with VCAM-1- or ICAM-1- GFP to allow their heterotypic binding to α4- or LFA-1-
transfected K562 cells. The levels of ICAM-1 and VCAM-1 expression attained by 
transient transfection varied among the different cell lines and experiments, but only cells 
with comparable high expression were analyzed in functional assays. This cell system 
allowed us to assess the adhesion mediated independently by ICAM-1 or VCAM-1 in the 
presence or the absence of CD9. As shown in Fig. 19B, binding of K562 transfectants to 
Colo320 cells was selective and completely dependent on the expression of ICAM-1 or 
VCAM-1, since no significant binding was observed with untransfected K562 cells or to 
untransfected Colo320 or Colo320CD9 cells (Fig 19B and data not shown). Interestingly, 
VCAM-1 and ICAM-1-mediated binding was augmented by the presence of CD9 on 
Colo320 cells (Fig 19B). In the case of ICAM-1/LFA-1 binding, the experiments required 
the addition of Mn2+ for LFA-1 activation on K562 cells, that resulted in a strong 
aggregation with Colo320 cells which partially masks the effect of CD9 (Figure 19B).    
To further assess the specific contribution of CD9 in the generation of adhesion 
molecules/tetraspanins microdomains, we assayed the heterotypic binding of K562 α4 
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transfectants with Colo320 cells that stably express chimeric proteins made up of CD9 
and CD82. All chimeric proteins were efficiently expressed at the plasma membrane (Fig 
19C, flow cytometry analysis) .The first chimera used coded for the N-terminal region of 
CD9 and the whole LEL and fourth transmembrane region belonged to CD82 (Colo320-
CD9x82) and behaved as Colo320 wt cells in regard to VCAM-1 mediated binding (Fig 
19C). 
To map the functionally relevant region of CD9, we used a second chimera with a 
chimeric LEL comprising the first half of CD82 LEL and the second half of CD9 LEL, 
where important residues for association with other transmembrane proteins reside 
(Colo320-CD82CCG9). This chimeric protein was able to enhance VCAM-1-mediated 
adhesion, even though not to the same extent that wild-type CD9 (Fig.19C). These data 
suggest that CD82 is not capable to replace CD9 in the organization of endothelial-like 
tetraspanin-based domains in Colo320 cells and confirm that the LEL is an important 
functional region in CD9. Altogether, these data indicate that proper tetraspanin 
microdomains are necessary for the adhesive function of VCAM-1 and ICAM-1.  
 
Figure 19A: Enhanced ICAM-1 and VCAM-1 adhesive function requires an appropriate tetraspanin 
environment. A. Flow cytometry analysis of the expression of β1 integrin (TS2/16 mAb), tetraspanins (anti-CD9 
VJ1/20, anti-CD151 LIA1/1, anti-CD81 I.33.2.2, anti-CD82 TS82, anti-CD63 TEA3/18 mAbs), ICAM-1 (HU5/3) and 
VCAM-1 (P8B1) in Colo320 cells (green line) or CD9-stably transfected Colo320 cell line (pink line). Negative 
control PX63 is shown in black thin line. 
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Figure 19B and C: Enhanced ICAM-1 and VCAM-1 adhesive function requires an appropriate 
tetraspanin environment. B. Heterotypic intercellular binding of K562 cell lines (parental and K562 α4 
and K562 LFA-1 integrin transfectants) to Colo320 and Colo320CD9 cells transiently transfected with 
GFP-tagged versions of VCAM-1 and ICAM-1. Data are calculated as the ratio of double positive 
aggregates (GFP-Colo320/CM-TMR K562) versus the non aggregated GFP+ cells. Graph depicts the 
relative binding referred to the aggregation obtained with parental K562 cells (that ranged from 10 to 20% 
of the total GFP+ cells in the different transient transfections in the experiment shown). C. Heterotypic 
intercellular binding of K562α4 integrin stable transfectant to VCAM-1-GFP transiently transfected 
Colo320 cells and the different chimeric clones of CD9/CD82. Data are calculated as the ratio of double 
positive aggregates (GFP-Colo320/CM-TMR K562) versus the total number of GFP+ cells. Graph depicts 
relative binding referred to the aggregation of Colo320-VCAM-1-GFP cells (11% of the total GFP+ cells in 
the experiment depicted). On the right, flow cytometry analysis of the expression with anti-CD9 (10B1, 
that also recognizes the chimeric CD9/CD82 loop) (red line) and CD82 (TS82) (blue line) of the different 
chimeric clones is shown. 
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Endothelial ICAM-1 and VCAM-1 cluster at the docking structure independently 
of counterreceptor engagement and actin anchorage  
At contacts with adherent leukocytes, activated endothelial cells form three-
dimensional actin-based docking structures which cluster endothelial VCAM-1 and 
ICAM-1. To analyze the mechanisms regulating the dynamic recruitment of adhesion 
molecules to these endothelial docking structures, we induced their formation with 
K562 leukocytes stably expressing either α4β1 (K562 α4) or αLβ2 (K562 LFA-1) 
integrins, which adhere to activated endothelial cells exclusively via VCAM-1 or 
ICAM-1, respectively. Remarkably, both ICAM-1 and VCAM-1 clustered at the 
docking structure formed around both types of K562 transfectant cells, regardless of 
whether they were directly engaged by their corresponding integrin receptor (Fig. 20A). 
Furthermore, similar co-recruitment effects were observed in a more physiological 
setting, in which lymphoblasts, which express significant amounts of LFA-1 and VLA-
4, were treated with specific inhibitors of either LFA-1 (BIRT377) or VLA-4 
(BIO5192) (Fig. 20B). 
To assess the extent to which this ligand-independent adhesion molecule 
clustering is dependent on the actin cytoskeleton, we transiently transfected resting 
HUVEC with a cytoplasmic tail-truncated mutant of VCAM-1 (VCAM∆Cyt). Under 
these conditions, HUVEC bear low levels of ICAM-1 and negligible levels of 
endogenous VCAM-1. Upon engagement of VCAM∆Cyt by either K562 α4 cells or 
anti-VCAM-1 coated beads, discrete clusters containing VCAM∆Cyt and ICAM-1 
were observed around adhered cells, but in no case was a well developed three-
dimensional structure formed (Fig. 20C and data not shown).  
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Figure 20A and B: VCAM-1 and ICAM-1 are co-presented at lymphocyte-endothelium contact 
independently of ligand binding and actin anchorage.  
A. VCAM-1 and ICAM-1 co-localize at the endothelial docking structure in the absence of integrin 
engagement. K562 transfected with α4 or LFA-1 integrin were allowed to adhere to TNF-α-activated 
HUVEC for 30 min, and cells were fixed and double stained with anti-VCAM-1 (P8B1) and biotin-
conjugated anti-ICAM-1 (MEM111). Confocal stacks were obtained and orthogonal maximal projections 
and vertical 3D reconstructions of the whole series are displayed. Scale bars = 20 µm. B. VCAM-1 and 
ICAM-1 are co-recruited to the endothelial contact area with human T lymphoblasts previously treated to 
inactivate VLA-4 or LFA-1. Human T lymphoblasts were pre-treated for 5 minutes with the LFA-1 
inhibitor BIRT377 (10µM) or the VLA-4 inhibitor BIO5192 (10µg/ml) and then added to a TNF-α 
activated HUVEC monolayer for 5 min. Cells were fixed and double stained for VCAM-1 and ICAM-1 
as in 1A. Confocal stacks were obtained and a representative section from each treatment is shown 
together with its corresponding colocalization histogram and a mask showing the distribution within the 
cell of double green-red pixels from the region marked on the histogram. Scale bars = 10 µm. 
 
In contrast, when ICAM-1 was directly engaged by K562 αLβ2 transfectants, a 
proper docking structure was formed, also containing VCAM∆Cyt (Fig. 20C). These 
data indicate that the engagement of one endothelial adhesion receptor (ICAM-1 or 
VCAM-1) by its corresponding leukocyte integrin is sufficient to induce the co-
recruitment of the other endothelial receptor towards the contact area with the 
leukocyte. This co-clustering must involve the extracellular and/or transmembrane 
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domains of both adhesion molecules, because it occurs with cytoplasmic-truncated 
forms. However, the subsequent reorganization of the endothelial actin cytoskeleton 
into the protrusive cup depends on actin anchorage of the cytoplasmic tail of the 
endothelial adhesion molecule bound to its ligand, as indicated by quantitative analysis 
of the formation of VCAM-1-mediated docking structures in VCAM-1wt- vs. VCAM-
1∆Cyt-transfected resting HUVEC (50.33% vs. 6%, respectively).  
 
Figure 20C: VCAM-1 and ICAM-1 are co-presented at lymphocyte-endothelium contact 
independently of ligand binding and actin anchorage.  
C. VCAM∆Cyt is co-recruited to ICAM-1-mediated docking structures but is unable to trigger the 
formation of VCAM-1-mediated docking structures. Resting HUVEC were transfected with the 
VCAM∆Cyt construct and incubated either with K562 leukocytes expressing VLA-4 (K562 α4) or LFA-
1 integrin or with T-lymphoblasts. Cells were then fixed and double stained with anti-VCAM-1 
(VCAM∆Cyt being the only VCAM-1 molecular species detected) and biotin-conjugated anti-ICAM-1. 
Confocal stacks were obtained and a representative section or vertical reconstructions of the whole series 
are displayed. Arrows point to the position of the adhered leukocytes. Scale bars = 20 µm.  
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Analysis of ICAM-1 and VCAM-1 hetero- and homo-dimers in living endothelial 
cells  
Since cytoskeletal anchorage cannot account for adhesion receptor co-recruitment, 
we investigated the potential formation of VCAM-1/ICAM-1 heterodimers at the apical 
membrane of intact, living primary endothelial cells. This analysis was based on hetero-
FRET, assessed by the donor fluorescence lifetime quenching in TCSPC-FLIM 
measurements. We generated functional VCAM-1 and ICAM-1 chimaeras fused to 
monomeric enhanced green (mEGFP, donor, termed also green) or red (mRFP1, 
acceptor, termed also red) fluorescent proteins (Campbell et al., 2002; Zacharias et al., 
2002). The spontaneous dimerization of EGFP, which could interfere with “bona fide” 
protein-protein interactions, was avoided by introducing the A206K point mutation in 
the sequence. The constructs were transiently co-transfected into primary HUVEC 
under resting conditions, to prevent up-regulation of endogenous VCAM-1 and ICAM-1 
expression and thus minimize possible interference that might decrease the efficiency of 
dimmer formation by exogenous molecules. We analyzed the percentage of FRET 
efficiency (FRETeff) of the following pairs: ICAM-1mEGP/ICAM-1mRFP1, VCAM-
1mEGFP/VCAM-1mRFP1, ICAM-1mEGFP/VCAM-1mRFP1 and VCAM-
1mEGFP/ICAM-1mRFP1, comparing the fluorescence lifetime of the donor (mEGFP 
construct) in each co-transfection with that of ICAM-1mEGFP or VCAM-1mEGFP in 
single transfections. Representative experiments are shown in Fig. 21 and Supplemental 
Figure 1 (for donor standards). For each donor/acceptor pair in Figure 21, the 
fluorescence intensity image (in pseudocolour scale), phasor plots and the 
corresponding FLIM images (pink mask) are shown. As previously described (Caiolfa 
et al., 2007) for this representation, the fluorescence decay of the donor molecule in 
each pixel of the image gives a point in the phasor plot.  
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Figure 21: VCAM-1 and ICAM-1 are not displayed as heterodimers at the plasma membrane. Endothelial cells were co-transfected 
with different mEGFP-mRFP1 pairs (ICAM-1/ICAM-1, VCAM-1/VCAM-1, ICAM-1/VCAM-1 and VCAM-1/ICAM-1). FLIM-FRET 
analysis was performed using the phasor-FLIM analysis as explained in Material and Methods. For each pair of proteins, a representative 
analysis of a co-transfected cell is shown. The fluorescence intensity images of the scanned sections are in pseudocolour scale (left 
panels) and correspondent mEGFP lifetime distributions are shown in contour plots after the phasor transformation (phasor plots, right 
panels). In each phasor plot, the experimentally derived green-line represents the mean phasor distribution for unquenched mEGFP 
fluorescence lifetimes with different contribution of cell autofluorescence (see Suppl. Fig. 1). The yellow line marks the computed 
trajectory of mEGFP donors quenched by 50% FRET (Föster distance) and at different contribution of autofluorescence (Caiolfa et al., 
2007). In the ICAM-1/ICAM-1 cell, two major phasor distributions are observed and selected in the phasor plot (black circles). The first 
one includes the majority, more than 80%, of the pixels in the image. In these pixels, which are rather homogenously distributed at the 
cell membrane (their localization is shown in the FLIM image, pink mask), FRET is negligible (< 8%). The second distribution includes 
only 16% of pixels in which FRET varies from 16 to 32% (mean 24%), and localize few clusters on the cell membrane. The other protein 
pairs do not show significant quenching due to FRET, as their phasor distributions are not distinguishable from that of the correspondent 
pure donor cells (Suppl. Fig. 1). In each of these examples, more than 95% of pixels are selected (black circles) in the non-FRET area of 
the phasor plot and are localized in the correspondent FLIM image. 
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The ensemble of these donor phasors is represented as contour plot. This plot can 
be scanned by software (Digman et al., submitted) for localizing in the image pixels at 
high as well as low FRETeff. The black circle in the phasor plot selects a sub-
population of pixels in which similar FRET efficiencies were observed, and highlights 
them in the correspondent image.  For the ICAM-1-mEGFP/ICAM-1-mRFP1 pair 
depicted in Fig. 21, the majority of pixels do not show significant FRET (selection 
average < 8% FRET).  However, a small 16% of the pixels in the image, do show FRET 
efficiency in the range of 24 + 8% (fairly above the detection limit of the FRET 
analysis), which are localized in clusters at the membrane. We analyzed 4 replicate 
experiments and obtained average FRET efficiencies in the range from 5 to 15.5 in 65% 
of clustered pixels. In contrast, the other pairs of proteins, VCAM-1-mEGFP/VCAM-1-
mRFP1, ICAM-1-mEGFP/VCAM-1-mRFP1 and VCAM-1-mEGFP/ICAM-1-mRFP1, 
did not show any significant quenching of the donor fluorescence lifetime (i.e., FRET) 
(Fig. 21), as compared to the phasor distribution of “pure” donor control cells (Suppl. 
Fig. 1). This analysis demonstrates that, under these conditions, VCAM-1/VCAM-1 
homodimers and VCAM-1/ICAM-1 heterodimers are absent from the plasma 
membrane. These data thus suggest a separate organization of VCAM-1 and ICAM-1 at 
the plasma membrane, excluding the formation of VCAM-1/ICAM-1 heterodimers as a 
prerequisite for the recruitment of one of these receptors to the docking structure in the 
absence of integrin engagement and cytoskeleton anchorage. 
 
Tetraspanin microdomains mediate the association of endothelial adhesion 
receptors to form specialized endothelial adhesive platforms 
Since ICAM-1 and VCAM-1 co-clustering at the docking structure is dependent 
on their extracellular and/or transmembrane domains, but does not result from direct 
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interaction, we examined the possible intermediary involvement of tetraspanin proteins. 
Several tetraspanins, such as CD9 and CD151, are concentrated at docking structures 
around primary human leukocytes together with VCAM-1 and ICAM-1, and can co-
precipitate with these endothelial adhesion receptors (Barreiro et al., 2005). Tetraspanin 
proteins were also recruited to docking sites in the K562 α4 and LFA-1 adhesion 
models (Figure 22A). However, no specific tetraspanin ligand has been described in 
leukocytes. 
Figure 22A: Tetraspanins are localized at docking structures mediated by the engagement of 
ICAM-1 or VCAM-1. LFA-1+ or α4+ K562 cells were allowed to adhere to a TNF-α−activated 
endothelial monolayer for 30 min. Left panels: Cells were fixed and double stained for VCAM-1 (P8B1, 
red) and CD9 (biotinylated VJ1/20, green). Right panels: Cells were stained for CD9 (VJ1/20, green) and 
ICAM-1 (biotinylated MEM-111, red). Confocal stacks were obtained and orthogonal maximal 
projections and vertical 3D reconstructions of the whole series are displayed. White arrows point to 
endothelium-leukocyte contact areas (docking structures). 
 
Furthermore, ICAM-1 and VCAM-1 were both recruited when either CD9 or 
CD151 was engaged with specific antibodies coupled to magnetic   beads.  In   parallel, 
anti-VCAM-1- and anti-ICAM-1-coated beads were also able to cluster each other and 
the tetraspanins, whereas anti-VE-cadherin-coated beads did not induce significant 
recruitment of ICAM-1, VCAM-1 or tetraspanins above basal levels (Fig. 22B, 
quantified in Fig. 22C, and data not shown). 
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To assess the relationship between endothelial adhesion molecules and 
tetraspanin microdomains in more detail, Brij96 lysates of TNF-α-activated HUVEC 
were fractioned on a continuous 5-40% sucrose gradient. Most tetraspanins were 
soluble under these conditions and migrated with the heavy fractions (F1-F7) together 
with ICAM-1 and VCAM-1, which were not found in fractions containing caveolin 
(used as a marker of detergent-resistant membrane fractions, containing lipid rafts) 
(Fig. 22D). These results suggest that endothelial tetraspanin microdomains, containing 
VCAM-1   and   ICAM-1   adhesion   receptors,   clearly   stand   apart   from   classical 
biochemically-defined lipid rafts and are in fact distinct organized membrane 
structures, which we term endothelial adhesive platforms (EAP). 
 
Diffusional properties of endothelial adhesive platforms at nude membrane and at 
docking structures 
Experimental evidence for the existence of tetraspanin microdomains is mainly 
based on biochemical approaches or microscopy techniques that analyze fixed cells 
(Claas et al., 2001; Min et al., 2006; Nydegger et al., 2006). In an attempt to 
demonstrate the existence of tetraspanin-based EAP in living cells, as physical entities 
with specific molecular dynamic features distinct from lipid rafts, we made use of the 
fluorescence recovery after photobleaching (FRAP) technique. First, we analyzed the 
dynamic behaviors of EGFP-tagged versions of CD9, CD151, VCAM-1 and ICAM-1 at 
the apical plasma membrane  of  primary  HUVEC  and compared these behaviors with 
that of GPI-EGFP, used as a lipid raft marker (Kenworthy et al., 2004; Sharma et al., 
2004) (Fig. 22E). 
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Figure 22B, C and D: Dynamic behaviour of EAP components at the “nude” plasma membrane. 
B. Anti-tetraspanin-coated beads recruit both VCAM-1 and ICAM-1. TNF-α-activated HUVEC were 
incubated with magnetic beads coated with anti-CD9, anti-CD151, anti-VCAM-1 or anti-VE-cadherin for 
30 min and then, stained with biotinylated anti-ICAM-1 mAb. Representative confocal sections are 
shown. Arrows point to the position of the attached beads. C. Quantification of ICAM-1-, VCAM-1- or 
CD9-EGFP clustering around beads coated with the indicated antibodies and attached to transfected 
resting or TNF-α-activated HUVEC. Data are the means ± S.D. of two independent experiments. D. 
ICAM-1 and VCAM-1 are recovered together with tetraspanins in the heavy fractions of a continuous 
sucrose gradient. TNF-α-activated HUVEC were lysed in 1% Brij96 and lysates were loaded onto a 
continuous 5-40% sucrose gradient. After ultracentrifugation, samples were recovered in 1 ml fractions 
and analyzed by Western blot for VCAM-1, ICAM-1, CD151, CD9, or caveolin. Fractions were 
recovered from the bottom of the gradient, so that the soluble non-floating fractions were collected first. 
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Figure 22E, F and G: Dynamic behaviour of EAP components at the “nude” plasma membrane. 
E. FRAP analysis showing differences in the diffusion of tetraspanins and adhesion receptors compared with the lipid raft marker 
GPI at the plasma membrane. Endothelial cells were transiently transfected with the indicated EGFP-tagged protein constructs and 
activated with TNF-α 20h before microscopy observation. Mean fluorescence recovery curves for CD9-, CD151-, ICAM-1-, 
VCAM-1- and GPI-EGFP were calculated (n ranged from 5 to 21 independent experiments for each protein) and are depicted 
together on the same graphic. Statistical significance was assessed by a point-to-point comparison based on a Student’s t-test. p 
values were adjusted for multiple testing by using the Benjamini and Hochberg method to control for false discovery rate (fdr). 
Tests were considered to be significant when adjusted p values from 80% of the points out of the plateau were < 0.05. This ensures 
that the expected fdr is < 5%. (See Suppl. Fig. 2) F. Comparison of mobility parameters among tetraspanins, adhesion receptors and 
GPI-anchored protein at the endothelial plasma membrane. The average half-time recovery rate was calculated considering the mean 
mobility fraction for each protein. G. The retarded mobility of adhesion receptors compared with tetraspanins can be explained by 
their differential engagement to the actin cytoskeleton. Mean fluorescence recovery curves of ICAM-1∆Cyt-, ICAM-1- and CD9-
EGFP were calculated (n ranged from 12 to 21) and are compared on the same graph. Deletion of the ICAM-1 cytoplasmic tail 
significantly increased recovery rate compared with wild-type protein. Statistical analysis was performed as in D. 
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Quantification of recovery half-time data indicated that tetraspanin CD9 and 
CD151 diffuse 2-3 times more slowly than GPI-EGFP, and that VCAM-1 and ICAM-1 
are even slower (3-4 times longer recovery half-time as compared with GPI-EGFP) 
(Fig. 22F). The differences observed between the diffusional behaviors of tetraspanin 
proteins and endothelial adhesion receptors might be due to differential anchorage to 
the actin cytoskeleton. To examine this possibility, we analyzed the dynamics of a C-
terminally truncated EGFP-tagged ICAM-1 protein, ICAM-1∆Cyt-EGFP, which lacks 
the cytoplasmic domain and, therefore, lacks actin-cytoskeleton linking activity (Fig. 
22G). This truncated ICAM-1, freed of cytoskeletal constraints, diffused more rapidly 
than the full-length receptor. Furthermore, ICAM-1∆Cyt-EGFP diffused faster than 
CD9, but in this case the difference was not significant, strengthening the notion of 
EAP as organized lateral-association domains at the plasma membrane.  
To assess the influence of leukocyte adhesion on the dynamic behaviour of each 
EAP component, FRAP was used to examine endothelial docking structures induced by 
binding of α4+- or LFA-1+-K562 cells (Fig. 23A). The most notable effects were that, 
when endothelial adhesion receptors were dynamically and specifically bound to their 
ligands, a greater proportion were included in the immobile fraction and the mobility of 
the mobile fraction was retarded (Fig. 23B and C, for ICAM-1 and VCAM-1). The rest 
of EAP components analyzed were affected to a lesser extent, exhibiting a variable 
slow-down in fluorescence recovery compared with the FRAP analyses of the same 
molecules at other regions of the plasma membrane (Fig. 24). Statistical analyses 
showed that the effect on CD9  mobility  was  greater  upon  engagement  of  ICAM-1,  
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Figure 23: Dynamic behavior of endothelial adhesive platform components within the endothelial docking structure. 
 A. Representative FRAP analysis of an endothelial docking structure. The prebleaching image shows a TNF-α-activated 
endothelial cell transiently transfected with ICAM-1-EGFP; docking structures formed around attached K562 LFA-1 cells are 
visible as circles of concentrated EGFP fluorescence. The docking structure in the boxed area, shown at high magnification in the 
inset, was selected for photobleaching measurements show the fluorescence recovery at the structure over time. Scale bar = 20 µm. 
B. CD9 mobility is tightly regulated in ICAM-1-mediated docking structures. Mean fluorescence recovery curves are shown for 
ICAM-1-, VCAM-1-, CD9- and CD151-EGFP at docking structures formed around K562 cells expressing LFA-1 (activated by 1 
mM Mn2+, which does not affect endothelial molecule mobility); n ranged from 4 to 16 experiments for each transfected protein. 
Statistical analysis was based on p value adjusted for multiple testing (see Methods and Fig. 3D for details). C. CD151 and VCAM-
1 mobilities are correlated at VCAM-1-mediated docking structures. Mean fluorescence recovery curves are shown for ICAM-1, 
VCAM-1-, CD9- and CD151-EGFP at docking structures formed around K562 cells expressing VLA-4 (K562 α4);  n ranged from 
5 to 16 experiments for each protein. Statistical analysis was performed as in B. D. Actin-cytoskeleton anchorage stabilizes the 
interaction of ICAM-1 with its ligand LFA-1. Mean fluorescence recovery curves are shown for ICAM-1∆Cyt- and ICAM-1-EGFP 
at ICAM-1-mediated docking structures (n=7 for both proteins). Statistical analysis was performed as in B. 
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while CD151 was more affected by engagement of VCAM-1 (Numerical data on Fig. 
23B and C). These data thus reveal a degree of specificity among tetraspanin-partner 
interactions within the endothelial tetraspanin microdomains. In contrast, GPI-EGFP 
diffusion was not altered at docking structures (data not shown). 
 
Figure 24: Comparison of dynamic behaviors of each EAP constituent at nude plasma membrane 
and at ICAM-1- and VCAM-1-mediated docking structures. The graphs show the mean fluorescence 
recovery curves at nude plasma membrane and at ICAM-1 and VCAM-1-mediated docking structures for 
each EAP component studied: CD9-, CD151-, VCAM-1- or ICAM-1-EGFP. Statistical analysis was 
performed as indicated in previous figures. 
 
The tailless ICAM-1 mutant IC1∆Cyt-EGFP showed a faster fluorescence 
recovery rate than the wild-type molecule at docking sites with LFA-1+-K562 cells, 
which indicates that stabilization of the interaction between ICAM-1 and LFA-1 also 
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occurs on the endothelial side, by the anchorage of ICAM-1 to the F-actin cytoskeleton 
(Fig. 23D). 
 
Diffusional characteristics of individual endothelial adhesive platform constituents 
determined by FCS and FCCS single-molecule measurements 
Because of technical limitations of FRAP, we could not accurately measure the 
diffusion coefficients of EAP components, which exhibit an anomalous diffusion 
because of cytoskeleton and ligand binding constraints. To overcome this limitation, we 
applied fluorescence correlation spectroscopy (FCS) on fluorescent protein-tagged 
ICAM-1, VCAM-1, CD9 and CD151 expressed in primary human living endothelial 
cells (Fig. 25A). The autocorrelation functions were always best-fitted using the 
anomalous diffusion model (see Materials and Methods section). The range of the 
diffusion (D) and anomality (α) coefficients was similar for all tested proteins (Fig. 
25B). Nevertheless, the analysis in Fig. 5B indicates that, the diffusion of VCAM-1 and 
ICAM-1 is overall slower than that of CD9 and CD151. Hence, the FCS measurements 
of each individual EAP component was in agreement with previous FRAP analyses, 
indicating that tetraspanins are characterized by faster lateral mobility than adhesion 
receptors. Further analyses will be performed to sub-classify the results as 
corresponding to fast and slow molecular subsets. On the other hand, most of the D 
coefficients obtained for all these proteins are much slower than those reported for 
prototypic lipid raft proteins (Lenne et al., 2006). Finally, evidence of dynamic 
membrane complexes containing several EAP constituents was attained by fluorescence 
cross-correlation spectroscopy, as shown in Fig. 26. 
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Figure 25. FCS analysis on the components of endothelial adhesive platforms.  
A. The panels show representative FCS measurements performed at the plasma membrane of transiently-
transfected primary endothelial cells expressing very low levels of ICAM-1-, VCAM-1-, CD9-, and 
CD151-mEGFP. For each experiment are documented: the fluorescence intensity image, the point in 
which the laser beam was positioned for the measurement (white circle), the ACF (black line), the best-
fitted curve (red line), and the fitted parameters, diffusion time (TauD) and anomality coefficient 
(α, ranging from 0 to 1), from which the diffusion coefficient (D) was derived as described (See under 
Materials and Methods section). The corresponding scale bar is shown in each image. kCPS: kilo counts 
per second. B. Scatter plots of the diffusion and anomality coefficients determined by FCS analysis on 
the four proteins of interest. Each point is an individual measurement. Horizontal lines = medians.  
 
Complexity of inter-molecular interactions within endothelial adhesive platforms 
The colocalization studies previously performed with a conventional spectral 
confocal microscope, which has an optical resolution limit of 200-250 nm, cannot allow  
us to further discriminate between direct and indirect interactions within EAP. To 
explore   the  complex inter-relationships which might take place within the  endothelial  
adhesive platforms and could account for the recruitment of adhesion receptors, we 
extended the FLIM-FRET analysis to determine whether direct associations occur 
among CD9, CD151, ICAM-1 and VCAM-1 molecules. First, we confirmed the 
formation of tetraspanin homo- and heterodimers (CD9mEGFP-CD9mRFP and 
CD9mEGFP-CD151mRFP) (Fig. 27A), which was previously suggested mainly on the 
basis of biochemical studies (Hemler, 2005). We then assessed the direct association of 
tetraspanins with their endothelial partners. Again, a certain degree of specificity was 
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found inside the microdomains, indicating that CD9 preferentially interacted with 
ICAM-1   and   CD151   with   VCAM-1;   moreover, the  FRET  efficiencies  of  these 
  A 
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Figure 26: Examples of Fluorescence Cross-correlation Spectroscopy measurements within 
endothelial adhesive platforms. The figure shows representative measurements performed at the plasma 
membrane of HUVEC double transfected with ICAM-1mEGFP/ICAM-mRFP1 (A) or 
CD9mEGFP/CD151mRFP1 (B). For each experiment are documented: the fluorescence intensity image 
from both channels (red and green), the point in which the laser beam was positioned for the 
measurement (white circle), the ACF (black line), the best-fitted curve (red line), the cross-correlation 
function for the pair, and the fitted parameters, diffusion time (TauD) and anomality coefficient (α), from 
which the diffusion coefficient (D) was derived. The corresponding scale bar is shown in the images. 
kCPS: kilo counts per second. 
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associations were close to those of tetraspanin pairs (Fig. 27B). In contrast, VCAM-
1/CD9 and ICAM-1/CD151 pairs exhibited low occurrence of high FRETeff, and 
FRET in the remaining pixels of the cell was very close to the detection threshold of the 
technique (data not shown). Control experiments examining interaction between 
ICAM-1 and uPAR, a cell-surface receptor related to lipid rafts, showed the absence of 
interaction between these two molecules from distinct membrane microdomains 
(Fig.28). These results confirm the suggested specific intra-domain interactions in EAP 
observed in FRAP analysis and in the fluorescence cross-correlation measurements.  
   A 
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Figure 27: Direct and indirect interactions within endothelial adhesive platforms. Endothelial cells 
were co-transfected with different mEGFP-mRFP1 pair constructs (A: CD9/CD9 and CD9/CD151; B: 
ICAM-1/CD9 and VCAM-1/CD151). FLIM-FRET analysis was performed as described (Material and 
Methods, Fig. 2 and Suppl. Fig. 1). For each FRET pair, the figure shows: the fluorescence intensity 
image of the scanned section (in pseudocolour scale), the phasor plot, and the FLIM image correspondent 
to the cursor selection of phasors (black circle) illustrating the pixel localization of phasor selection. Two 
selections are shown for each FRET pair corresponding to phasors at low (11-14%) and high (24%) 
FRET efficiency.  
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Figure 28: uPAR/ICAM FRET pair confirming the non interaction of a lipid raft-related protein 
and an EAP constituent. FLIM-FRET analysis of uPARmEGFP and ICAM-1-mRFP1 in HEK 293 cells. 
The intensity image (in pseudocolour scale), the phasor plot and the FLIM image correspondent to the 
cursor selection (black circle) are shown. This result indicates that FRET does not occur between the two 
proteins, as the phasor distribution of uPAR-green is identical to that of single transfected cells (data not 
shown, Caiolfa et al., 2007). It also shows that the localization and distribution of the phasors of mEGFP-
constructs is not affected by the kind of protein linked to the fluorophore and by the cells in which they 
are expressed; while the contribution of other species such as fibronectin (not present in HEK293 
samples) and cell autofluorescence varies depending on the cell culture conditions and expression levels 
of the tagged-proteins.  
 
 
Modulation of nanoclustering and diffusion within the endothelial adhesive 
platforms by tetraspanin blocking peptides 
The spatial organization of VCAM-1 and ICAM-1 receptors at the plasma 
membrane of endothelial cells was studied by immunogold labeling combined with 
scanning electron microscopy (SEM) (Fig. 29A i). Both ICAM-1 and VCAM-1 form 
heteroclusters at the plasma membrane (Fig. 29A ii), and localized higher-density 
clustering was found at the microvilli of docking structures around adherent leukocytes, 
as shown for ICAM-1 (Fig. 29A iii). 
To shed light on the mechanism that controls the tetraspanin-mediated co-
clustering of adhesion receptors at the apical plasma membrane of endothelial cells, we 
used a tetraspanin-derived blocking peptide (CD9-LEL-GST). This soluble peptide 
interferes with the various functions regulated by CD9-containing tetraspanin 
microdomains, such as egg-sperm fusion or HIV infection (Ho et al., 2006; Zhu et al., 
2002), and decreases VCAM-1- and ICAM-1-mediated lymphocyte adhesion strength 
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and transmigration under flow conditions (Barreiro et al., 2005). Although the 
functional  effect  of  these  peptides  has  been  well  documented,  there  have  been no 
 
Figure 29A: Tetraspanin regulates endothelial adhesion receptor nanoclustering.  
A. i) TNF-α activated endothelial cells were fixed and stained with anti-VCAM-1 (P8B1) or anti-ICAM-1 (Hu5/3), 
followed by 40 nm gold-immunolabeling. Then, samples were processed for SEM observation. Representative SEM 
negative images of 1.75 µm2 areas of the endothelial plasma membrane are shown. ii) TNF-α-activated endothelial 
cells were fixed and double stained with anti-VCAM-1 (P8B1) and biotinylated anti-ICAM-1 (MEM-111), followed 
by 40 nm and 15 nm gold-labeling, respectively. Then, samples were processed for SEM observation. The left-hand 
panel shows a representative SEM negative image of 0.35 µm2 area of the endothelial plasma membrane displaying 
VCAM-1 (40 nm gold particles) and ICAM-1 (15 nm gold particles, white asterisks). High magnification images 
show detail of VCAM-1 and ICAM-1 heteroclustering. iii) T lymphoblasts were allowed to adhere to an activated 
endothelial monolayer for 5 min. Cells were then fixed, stained with anti-ICAM-1 (Hu5/3) followed by 40 nm gold-
inmunolabeling, and subjected to SEM processing. A representative SEM positive image shows the preferential 
localization of gold particles at the microvilli of the endothelial docking structure formed around a lymphoblast. The 
inset shows the leukocyte-endothelial contact area at lower magnification. Scale bar = 1.50 µm. 
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reported insight into the molecular mechanism through which CD9-LEL-GST exerts its 
inhibitory action. Nearest neighbour analysis of immunogold-labeled adhesion 
receptors in the presence of CD9-LEL-GST showed that receptor spacing augmented in 
    B 
  
 
Figure 29B: Tetraspanin regulates endothelial adhesion receptor nanoclustering.  
B. i) Endothelial cells were activated for 20h with TNF-α in the presence of 250 µg/ml of active or heat-inactivated 
(5 min 90ºC) CD9 blocking peptide (CD9-LEL-GST). Cells were then fixed and stained for VCAM-1 or ICAM-1 as 
in A i). Representative images of 1.75 µm2 areas of the endothelial plasma membrane are shown. ii) Gold particles in 
SEM images were counted, and coordinates were assigned to each object using Metamorph software. Inter-particle 
distances were calculated using a custom-written k-nearest neighbour (knn) distance algorithm based on R software. 
Graphs show knn distances from 2 representative images of each condition (VCAM-1 or ICAM-1 staining with 
active or inactive CD9 blocking peptide).   
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ii) 
 
 
Figure 29C: Tetraspanin regulates endothelial adhesion receptor nanoclustering.  
C. i) Panels show representative FCS measurements performed at the plasma membrane of endothelial 
cells transiently-transfected with CD9- or CD151-mEGFP and treated with 250 µg/ml of active or heat-
inactivated CD9-LEL-GST. For each experiment are documented: the fluorescence intensity image, the 
point in which the laser beam was positioned for the measurement (white circle), the ACF (black line), 
the best-fitted curve (red line), and the fitted parameters, diffusion time (TauD) and anomality coefficient 
(α), from which the diffusion coefficient (D) was derived. The corresponding scale bar is shown in each 
image. kCPS: kilo counts per second. ii) Scatter plots of the diffusion and anomality coefficients 
determined by FCS analysis. Each point is an individual measurement. Horizontal lines = medians.  
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comparison with samples treated with heat-inactivated CD9-LEL-GST. This effect 
might be due to the insertion of functional blocking peptides within the EAP, 
competing with endogenous CD9 for association with partners (Fig. 29B). Consistently, 
FCS analysis revealed that the CD9-LEL peptide, but not heat-inactivated CD9-LEL, 
decreased the diffusion coefficient of CD9mEGFP molecules. Furthermore, the 
diffusion coefficient of CD151 was also affected, showing that blocking peptide 
insertion in EAP modifies the general dynamics within the platforms due to the 
increasing molecular crowding (Fig. 29C). Together these data suggest that the 
blocking peptide compete with endogenous CD9 for binding to partners and other 
tetraspanins. This prevents adequate interactions and imposes steric hindrance, resulting 
in a net slower diffusion and reduced receptor clustering.  
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DISCUSSION 
 
Identification and characterization of the endothelial docking structure for adherent 
leukocytes 
VCAM-1 is one of the major endothelial receptors that mediates leukocyte adhesion 
to the vascular endothelium (Carlos et al., 1990). Recent data obtained with neonatally 
deficient VCAM-1 mice have strongly suggested that VCAM-1 plays an important role 
for lymphocyte homing and for T cell-dependent humoral immune responses (Koni et al., 
2001; Leuker et al., 2001). In addition, VCAM-1 may play an important role in the 
pathogenesis of diseases such as atherosclerosis (Cybulsky et al., 2001), rheumatoid 
arthritis (Carter and Wicks, 2001), and multiple sclerosis (Alon, 2001). Thus, the 
elucidation of VCAM-1 function in leukocyte adhesion and transmigration is crucial, as 
this molecule could constitute a molecular target for therapeutic intervention.  
The cytoskeletal components involved in the redistribution of VCAM-1 at the 
leukocyte-endothelial cell contact area have not been studied previously. Among 
potential candidates, ERM proteins seemed likely to mediate this process as these 
molecules play an important role in the remodelling of the plasma membrane, as reported 
for ICAMs (Heiska et al., 1998; Helander et al., 1996; Serrador et al., 1997). We found 
that endogenous VCAM-1 colocalizes and is physically associated with moesin and ezrin 
in microspikes and microvilli of the apical surface of cytokine-activated endothelial cells. 
Furthermore, the cytoplasmic tail of VCAM-1 and the active N-terminal domain of 
moesin or ezrin are capable to directly bind in vitro. These data strongly suggest that 
ERM proteins are directly involved in the redistribution of VCAM-1. However, it cannot 
be ruled out completely that adaptor proteins such as EBP50 or E3KARP (Bretscher et 
al., 2000), also play a role. It has been reported that ERM proteins bind to a positively 
charged amino acid cluster in the juxta-membrane cytoplasmic domain of CD44, CD43, 
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and ICAM-2 (Yonemura et al., 1998). In addition, we have found recently that a novel 
serine-rich motif within the cytoplasmic tail of ICAM-3 is critical for its interaction with 
ERM proteins (Serrador et al., 2002). The amino acid sequence comparison of VCAM-1 
and ICAM-3 cytoplasmic tails suggests that VCAM-1 contains a similar serine-rich 
motif, likely accounting for ERM association. 
To study the VCAM-1/ERM interaction during the extravasation of lymphoblasts, 
we have made extensive use of a live cell system in combination with time-lapse 
fluorescence microscopy and GFP fusion proteins. This afforded us with information on 
dynamic relationships of the two molecules during early adhesion and later stages of 
TEM. While both, VCAM-1 and moesin, clustered around spreading lymphoblasts on the 
apical endothelial surface, only moesin remained at lymphoblast-endothelial contacts 
during the passage of lymphoblasts across the endothelium and their subsequent 
migration beneath the endothelial monolayer. However, it has been reported that VCAM-
1 actively participates in T lymphoblast transmigration across high endothelial venules 
and monocyte extravasation (Faveeuw et al., 2000; Meerschaert and Furie, 1995). These 
discrepancies point to a differential role of VCAM-1 that might be both leukocyte and 
endothelial cell-type specific. Our data on moesin dynamics clearly indicate that another 
receptor linked to moesin could drive this migration. In this regard, we have found that 
the dynamic behavior of ICAM-1 is similar to that of moesin during lymphoblast 
transmigration. The differential dynamic behavior of VCAM-1 and ICAM-1 during 
lymphoblast adhesion and transmigration on the one hand, and of moesin on the other, 
could suggest a mechanism by which ERM proteins are able to regulate the distribution 
of both molecules independently.  
As VCAM-1/ERM interaction was mostly restricted to leukocyte tight adhesion and 
spreading, we took advantage of a cellular model based mainly on VLA-4/VCAM-1. In 
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this model, leukocytes are restricted to a sustained tight adhesion and are unable to 
progress to TEM, allowing a detailed study of the endothelial VCAM-1/ERM interaction. 
In this cell model, VCAM-1 and both, moesin and ezrin, clustered around adherent 
leukocytes, participating in the formation of an actin-rich docking structure that was 
attached to and partially engulfed the leukocyte. Similar docking structures were formed 
around spreading lymphoblasts in static conditions or PBLs adhered to endothelium 
under flow, in which VCAM-1 and ICAM-1 were concentrated together with ERM 
proteins. In physiological conditions, these structures rapidly vanished as lymphoblasts or 
lymphocytes began to migrate through the endothelial monolayer.  
Our findings highlight the remarkable active role played by the endothelium during 
leukocyte adhesion. Thus, the initial VCAM-1 and ICAM-1 engagement trigger their 
clustering and the subsequent activation and clustering of endothelial moesin and ezrin at 
the site of cell-cell contact. In turn, phosphorylated active ERM proteins would 
participate in concert with α-actinin, an actin-bundling protein, in the rearrangement of 
the actin cytoskeleton to create the docking structure. Several focal adhesion proteins 
such as vinculin, talin and paxillin seem to be involved as well. Interestingly, the 
endothelial docking structure is reminiscent of nascent receptor-mediated phagosomes, in 
that the subcellular distribution of all these structural proteins is similar in both structures 
(Allen and Aderem, 1996). In this regard, it has been proposed that focal adhesions and 
complement receptor-mediated phagosomes could share some conserved mechanisms 
requiring the same molecules (May and Machesky, 2001). A similar argument could be 
made to functionally link the former structures and the novel leukocyte-endothelium 
docking structure described here. On the other hand, VASP is concentrated in the 
docking structure. This protein is present in actin-based protrusions, where it cooperates 
with WASp-Arp2/3 complex, as occurs in phagosomes (Castellano et al., 2001). Its 
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presence at the docking structure could indicate the existence of actin polymerization 
supporting this endothelial structure, and suggests common mechanisms for de novo actin 
assembly in all these structures. Interestingly, ERM proteins have been also implicated in 
the de novo actin assembly on mature Fc receptor-mediated phagosomes (Defacque et al., 
2000). 
As ERM activation occurred during the formation of the anchoring structure, we 
studied the regulatory mechanisms involved. These proteins are regulated by the interplay 
of PI(4,5)P2 metabolism and components of the Rho GTPase signaling pathway, thereby 
linking events occurring at the plasma membrane with cytoskeletal remodelling (Sechi 
and Wehland, 2000). Interestingly, these regulatory molecules are also important in 
phagocytosis (Botelho et al., 2000; Chimini and Chavrier, 2000). We found that 
PI(3,4)P2, PI(3,4,5)P3, and more abundantly PI(4,5)P2, colocalized with VCAM-1 and 
ERM proteins in the endothelial docking structure. Notably, PI(4,5)P2 was preferentially 
concentrated at the microspike tips, whereas the other phosphoinositides exhibited a more 
diffuse pattern. These observations point to a prominent role of PI(4,5)P2 in regulating 
molecular events during endothelial docking of leukocytes. One such event could be the 
activation of moesin and ezrin through its binding to their N-terminal domain. PI(4,5)P2 
production could be mediated by Rho, since PI4P5K is a down-stream RhoGTPase 
effector. On the other hand, the presence of PI(3,4)P2 and PI(3,4,5)P3 could be related to 
PI3K activity. Inhibitors of PI3K only mildly affected the generation and maintenance of 
the docking structure, a finding that is in agreement with its role in phagocytosis, namely 
to mediate phagosome closure (Cox et al., 1999). In our experimental model, the 
endothelial anchoring structure does not progress to engulf the leukocyte, and hence, it is 
less PI3K-dependent. In contrast, the p160 ROCK inhibitor Y27632 inhibited the 
formation of the anchoring structure and induced its dissolution as well. Abnormal 
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formation of the endothelial docking structure was also observed under flow conditions 
after the treatment with Y-27632, which rendered an inhibitory effect in lymphocyte 
adhesion and transmigration. In addition, the phenomenon of rolling was also decreased. 
This finding is in agreement with previous reports describing the existence of an E-
selectin/actin cytoskeleton adhesion complex induced  by leukocyte adhesion (Yoshida et 
al., 1996; Lorenzon et al., 1998), which it is likely to be also affected by the inhibition of 
the Rho/p160 ROCK pathway. Our results concur with the previously described 
regulation of the VCAM-1, ICAM-1, and E-selectin clustering by the GTPase Rho during 
monocyte adhesion (Wojciak-Stothard et al., 1999). Furthermore, the key role of the 
Rho/p160 ROCK signaling pathway in the regulation of the adhesion receptor/ERM/actin 
cytoskeleton interaction and remodelling, which results in the formation of this protrusive 
structure, is further strengthened by the implication of this pathway in the regulation of 
CR-mediated phagosomes (Caron and Hall, 1998).  
In conclusion, our results provide novel insights into the links between the actin 
cytoskeleton and adhesion receptors involved in leukocyte adhesion and TEM during 
inflammation. Further analysis will be focused on molecules involved in the regulation of 
the endothelial docking structure disruption to allow diapedesis, and the signaling 
pathways that interconnect both processes. 
 
Functional role of the inclusion of endothelial adhesion receptors in tetraspanin-
enriched microdomains 
It is well established that tetraspanins interact in multiproteic domains with other 
transmembrane proteins (Berditchevski, 2001; Boucheix and Rubinstein, 2001; Yanez-
Mo et al., 2001; Yauch et al., 1998). Moreover, antibody crosslinking of tetraspanins 
usually triggers the same cellular responses than antibodies directed to their associated 
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partners indicating that they conform functional entities (Hemler, 2001; Yauch et al., 
1998). Herein, we describe the lateral association of ICAM-1 and VCAM-1 with 
tetraspanins at the contact area between leukocytes and endothelial cells. Remarkably, the 
function of these endothelial adhesion molecules can be directly modulated by the 
tetraspanin-associated moieties.  
In contrast to lipid rafts, tetraspanins form a network based on protein-protein 
interactions, which might be modulated by differential protein expression or post-
translational modifications. In addition, tetraspanins are palmitoylated proteins that 
interact directly with cholesterol (Berditchevski et al., 2002; Charrin et al., 2002; Charrin 
et al., 2003; Yang et al., 2002) and under certain conditions are also recovered in the light 
fractions of sucrose gradients (Claas et al., 2001). Thus tetraspanin webs or 
microdomains could be envisaged as a subtype of lipid rafts. In this regard, it has been 
suggested that the size of tetraspanin-based microdomains can be as small as lipid rafts 
(Kropshofer et al., 2002). Moreover, tetraspanin microdomains can be also important for 
intracellular signalling events, since they are able to associate with PI4-K (Berditchevski 
et al., 1997) and PKCs (Zhang et al., 2001). Our studies indicate that the composition of 
endothelial tetraspanin microdomains changes during the transmigration process. Thus, 
apical domains would be enriched in CD9, whereas in ventral domains CD151 is more 
highly represented. On the other hand, tetraspanins are also associated with integrin 
receptors at endothelial intercellular junctions (Chattopadhyay et al., 2003; Yanez-Mo et 
al., 1998). These data suggest the existence of different tetraspanin microdomains, which 
might coalesce and diverge during cell activation, adhesion or transmigration. 
Furthermore, both ICAM-1 and VCAM-1 are anchored to the actin cytoskeleton through 
the association of ERM proteins to their cytoplasmic tails (Barreiro et al., 2002; Heiska et 
al., 1998). The linkage of Ig receptors to the cytoskeleton might indicate that tetraspanin 
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microdomains are not floating freely on the plasma membrane but connected to the 
cortical actin cytoskeleton. 
Tetraspanins have been implicated in several cellular functions, mainly by the use 
of monoclonal antibodies (Berditchevski, 2001; Boucheix and Rubinstein, 2001; Hemler, 
2001; Yanez-Mo et al., 2001). Our results show that soluble CD9-LEL-GST peptides or 
tetraspanin-specific siRNA inhibit leukocyte transmigration and enhance their 
detachment by shear stress, supporting the functional role of tetraspanins in 
transendothelial migration. Similar GST-fusion proteins have been reported to be 
inhibitory in sperm-egg fusion assays (Higginbottom et al., 2003; Zhu et al., 2002). These 
LEL-GSTs are a valuable tool, without the effects of detergents or cholesterol depleting 
agents, which affect the physical properties of the plasma membrane. The tertiary 
structure of these LEL proteins is very dependent on the proper disulphide bonds 
formation. Thus, mutation of any of the four Cys in CD9 greatly reduces the recognition 
in Western blot by an anti-CD9 mAb and completely abolishes functional activity. 
Endothelial tetraspanins are highly expressed and show a very slow turnover, so 
that partial protein knocking down by siRNA is observed only after 3-6 days. Although 
no complete abrogation of tetraspanin expression is attained, it turned out to be more than 
sufficient to exert a significant functional effect. Interestingly, a compensatory effect on 
other tetraspanin expression was observed, suggesting that a tight regulation of the 
overall tetraspanin load at the plasma membrane exists. Nevertheless, as demonstrated 
also by the heterologous Colo320 cell system, the repertoire of tetraspanins is also crucial 
for the proper adhesive function of ICAM-1 and VCAM-1. Tetraspanin siRNA affected 
ICAM-1 and VCAM-1 expression, which suggest a possible role for tetraspanins in early 
biosynthetic events. In this regard, it has been previously described that CD9 associates 
with the β1 integrin precursor prior to reaching the plasma membrane (Rubinstein et al., 
                                                                                                                            Discussion 
 119
1997). In a similar way, CD19 expression was selectively reduced in CD81 deficient 
mice, being the defect located after the endoplasmic reticulum (Shoham et al., 2003). 
However, tetraspanin interference only affected ICAM-1- and VCAM-1- mediated 
adhesion when assayed under stringent flow conditions. Moreover, CD9-LEL-GST 
peptide incubation had no effect on ICAM-1 and VCAM-1 induction but it did also affect 
their function under shear stress. These data make both experimental approaches 
complementary and strongly suggest that membrane presentation into the appropriate 
microdomains of these receptors is functionally relevant for their proper adhesive 
function. Furthermore, the direct regulation of ICAM-1 and VCAM-1 adhesive function 
by the proper tetraspanin environment is revealed in the heterologous system of 
aggregation between Colo320 cells and K562 transfectants. Our data with Colo320 cells 
also rule out the possible involvement of a putative tetraspanin ligand on leukocytes, 
since their heterotypic adhesion is completely dependent on ICAM-1 or VCAM-1 
expression. 
The fact that ICAM-1 and VCAM-1 are included in tetraspanin-based 
microdomains might favour the efficient transition from the rolling step, in which 
VCAM-1 is involved (Alon et al., 1995; Berlin et al., 1995), to the firm adhesion of 
leukocytes via both VCAM-1 and ICAM-1 ligation (Butcher, 1991; Springer, 1994), to 
finally proceed to diapedesis. The possibility of selectins or other endothelial adhesion 
molecules being constituents of these endothelial tetraspanin microdomains cannot be 
ruled out and deserves further analyses. In this scenario, it could be postulated that 
tetraspanin microdomains would act as specialized platforms that cluster the appropriate 
adhesion receptors necessary for the rapid kinetics of leukocyte transendothelial 
migration process. 
Inclusion of ICAM-1 and VCAM-1 into tetraspanin domains is necessary for their 
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proper function under dynamic conditions such as shear stress. This phenomenon could 
be explained by a possible role of tetraspanins in the preclustering or avidity regulation of 
endothelial adhesion receptors. Avidity regulation of the mitogenic activity of the 
membrane-anchored HB-EGF by its association with CD9 has been demonstrated 
(Higashiyama et al., 1995; Nakamura et al., 2000). Recent observations show that 
tetraspanin networks are able to cluster class II MHC molecules bearing restricted 
repertoires of peptides (Kropshofer et al., 2002), thus facilitating antigen peptide 
presentation. Furthermore, CD81 also regulates VLA-4 and VLA-5-mediated adhesion 
by enhancing integrin avidity independently of ligand binding (Feigelson et al., 2003). 
This phenomenon also facilitated leukocyte firm adhesion by strengthening VLA-
4/VCAM-1 interaction acting on the leukocyte side.  
The inclusion of adhesion receptors into tetraspanin domains could also affect their 
conformation up-regulating their binding to integrins. In this regard, we have recently 
described a monoclonal antibody that preferentially recognizes CD9 when associated 
with α6β1 integrin (Gutierrez-Lopez et al., 2003). The possibility of reciprocal 
conformational changes in tetraspanin-associated proteins cannot be excluded. In this 
regard, CDw78 mAbs recognize HLA-DR only when included into tetraspanin domains 
(Drbal et al., 1999), although the possibility of a conformational change in HLA-DR due 
to its interaction with tetraspanins has not been determined. Lately, CD151 knockout 
mice show a mild deficiency in outside-in activation of αIIbβIII integrin in platelets (Lau 
et al., 2004). Thus, several lines of evidence support a functional role for tetraspanin-
based microdomains in different cellular functions. In this report we demonstrate by 
different complementary experimental approaches, both on primary cells and assessing 
endogenous proteins, and in an heterologous system, that the adhesive function of ICAM-
1 and VCAM-1 is directly modulated by their inclusion in a microdomain containing the 
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appropriate repertoire of tetraspanins. This effect was shown to be crucial in an important 
physiological process such as leukocyte extravasation.  
 
 
Figure 30: Model of molecular interactions during firm adhesion. The slowing-down of leukocytes facilitates their 
interaction with chemokines exposed on endothelium, triggering the activation of leukocyte integrins by increasing 
their affinity and avidity to allow the final arrest of adherent leukocytes. This activated state involves a drastic 
morphological change from the round shape of circulating leukocytes to the polarized shape typical of migrating cells. 
The acquisition of polarity implies the segregation of adhesion molecules (ICAM-1, ICAM-3, CD43, CD44, PSGL-1, 
etc) to the rear pole of the cell (uropod), which is lumen-orientated for the recruitment of bystander leukocytes; 
whereas the integrins localized to the contact area with endothelium to allow the spreading of the cell body onto the 
vascular wall. On the other hand, the endothelium also plays an active role in firm adhesion by creating docking 
structures around the attached leukocytes. These endothelial docking structures are formed as a result of VCAM-1 and 
ICAM-1 engagement by their integrin counterreceptors (VLA-4 and LFA-1, respectively), and are supported by a 
cortical actin scaffold in which ERM proteins, alpha-actinin, vinculin,VASP and other actin-related proteins 
participate. In addition, members of the tetraspanin family also cooperate with the endothelial adhesion receptors in the 
docking structure formation. The principal regulatory molecules involved in the formation of the above-mentioned 
structure and in leukocyte integrin activation are also shown in the inset. 
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Endothelial adhesive platforms as a model for the biophysical study of 
tetraspanin-enriched microdomains                      
The existence of organized membrane domains distinct from those based on lipid-
protein interactions (lipid rafts) has not been demonstrated previously in living cells. 
Biochemical analysis and microscopy studies on fixed samples have indicated that a 
network of specific protein-protein interactions may occur at cell membranes between 
tetraspanin members and associated partners (Levy and Shoham, 2005a). In the current 
study, we have used an array of cutting-edge analytical microscopy and spectroscopy 
techniques, including single molecular analysis, to characterize in depth the dynamic 
features and biophysical properties of TEM in living cells. The transiently transfected 
primary human endothelial cells used in this study are a physiologically relevant cell 
model that expresses an appropriate repertoire of membrane tetraspanins and adhesion 
receptors. In addition, the study of four proteins in combination, two tetraspanins and 
two essential endothelial adhesion receptors, provides a valuable global overview of the 
behavior of the specialized type of TEM named endothelial adhesive platforms (EAP).  
Endogenous expression of CD9 and CD151 tetraspanins and ICAM-1 and 
VCAM-1 adhesion receptors in endothelial cells reduces the probability of interaction 
between transiently-transfected tagged proteins in the FLIM-FRET analyses. To 
minimize this problem, FLIM quantifications were performed in resting HUVEC, in 
which tetraspanin expression is unaltered, ICAM-1 levels are low and VCAM-1 
expression at plasma membrane is negligible. Given that the expression of CD151 and, 
especially, CD9 is much higher than ICAM-1 in resting cells, it is possible that 
FRETeff values from measurements involving tetraspanin proteins might be 
underestimated. Furthermore, in the case of CD9, CD151 and ICAM-1, which are able 
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to homodimerize, the possible association of two green or two red molecular species 
makes the occurrence of heteroFRET even more improbable. Finally, another potential 
problem, dimerization of chimeric proteins through their fluorescent tags, was 
overcome by using monomeric versions of EGFP and mRFP1. Despite the drawbacks 
of FRET analysis in complex living cell systems, high FRETeff was detected for 
ICAM-1/CD9, VCAM-1/CD151, CD9/CD9, CD9/CD151 and ICAM-1/ICAM-1 pairs 
and clear-cut differences were detected with respect to non-interacting pairs (VCAM-
1/ICAM-1, VCAM-1/VCAM-1). Examination of average FRETeff values and the 
percentage of pixels exhibiting the highest FRETeff values for each pair showed that 
tetraspanin homo- and heterodimers and tetraspanin-partner interactions occur 
preferentially compared with ICAM-1 dimers, strengthening the concept of EAP as the 
basic organization of endothelial adhesion receptors on the endothelial apical plasma 
membrane. In fact, the existence of ICAM-1 dimers had been described before as a 
small proportion from the whole molecular ICAM-1 population using biochemical 
approaches (Miller et al., 1995). Besides, BIAcore affinity measurements revealed that 
a single ICAM-1 monomer, not dimeric ICAM-1, represents the complete, fully 
competent LFA-1-binding surface (Jun et al., 2001). 
The innovative technique used to quantify FRET was completely independent of 
the concentration of fluorescent species, and is therefore well-suited to analyze and 
compare data from different transient transfections. Furthermore, the FLIM-FRET 
approach permitted us to spatially resolve the fretting population within a whole cell, 
generally yielding a patchwork pattern for the higher FRETeff population. To further 
substantiate the experimental data on the absence of ICAM-1-VCAM-1 heterodimer 
formation, ICAM-1 or VCAM-1 was indistinctly used as donor in FLIM-FRET 
experiments. We inverted the labeling fluorophores on the two receptors, showing that 
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the lack of FRET was not due to artifacts introduced by the fluorescent constructs. 
Additional control experiments also demonstrated that the protein in the mEGFP 
constructs affects negligibly the fluorescence lifetime distribution of the fluorophore 
(i.e., the phasor distribution in phasor-FLIM analysis).  
Finally, the observations that the GPI-anchored protein, uPAR, used as a marker 
of lipid rafts, did not interact with ICAM-1 (used as an EAP marker) in FLIM-FRET 
experiments, and that the two receptors were sorted to the plasma membrane in 
different vesicles (data not shown), further sustain the notion that tetraspanins might 
form discrete and specific microdomains at the cell membrane. 
The diffusional behaviour of the EAP components was investigated by combining 
FRAP and FCS analyses. The possible perturbation of membrane dynamics that might 
result from exogenous expression of tagged proteins was overcome in FRAP 
experiments by making a large number of measurements in several batches of 
transiently-transfected primary cells and making an exhaustive statistical analysis of the 
data. Photobleaching experiments were all performed under pro-inflammatory 
conditions (TNF-α treatment) in order to promote proper formation of docking 
structures around adherent leukocytes mostly through the mediation of endogenous 
VCAM-1 or ICAM-1. Although the integrin-expressing K562 adhesion model used in 
our experiments is a simplification of the dynamic physiological firm adhesion process 
that takes place under hemodynamic flow conditions, this model has allowed us to 
perform diffusion analyses that would be unfeasible under more physiological but 
complex conditions.  
FRAP analysis examines the diffusion rate of an overall molecular population 
within a microscopic area. These experiments have provided us with valuable 
information on the global diffusional behavior of VCAM-1, ICAM-1, CD9, CD151 and 
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GPI molecular subsets in comparable areas of nude membrane and at sites of leukocyte 
anchorage. A mixed steady-state molecular population (comprising proteins bound or 
unbound to cytoskeleton, coupled to partners, in the form of dimers, and so on) is 
considered for each measurement. From FRAP data collected at nude plasma 
membrane, we could distinguish differences in the net mobilities of tetraspanins and 
receptors. Tetraspanins showed the fastest diffusion rate, although this did not differ 
significantly from the rate for ICAM-1, whereas VCAM-1 population was slower and 
displayed a higher immobile fraction. The reason for this difference in diffusion 
behaviour between the two adhesion receptors remains still unsolved. Close interaction 
between ICAM-1 and CD9 is supported by the experiments with the C-terminally 
truncated ICAM-1, ICAM-1∆Cyt, which is unable to interact with the actin 
cytoskeleton via ERM proteins (Barreiro et al., 2002). The lateral mobility of ICAM-
1∆Cyt-EGFP was not significantly different from that of CD9, supporting the notion 
that these molecules can interact in the absence of ICAM-1 cytoplasmic tail. 
Conversely, GPI-EGFP, a prototypic lipid raft- related molecule widely used in 
microscopy studies (Kenworthy et al., 2004; Varma and Mayor, 1998), moved much 
faster and its recovery was complete, with no significant immobile fraction. Moreover, 
the diffusion properties of CD9, CD151, ICAM-1 and VCAM-1 were altered in the 
context of docking structures, whereas GPI-EGFP is unaffected by engagement of 
integrin-bearing leukocytes. These observations strongly argue in favor of these 
proteins being constituents of physical entities with intrinsic properties and biophysical 
features distinct from classical lipid rafts.  
The delay observed for non-ligand-engaged EAP components at the docking 
structures could be well due to their transient interaction with ligand-immobilized 
ICAM-1 or VCAM-1. In this way, these immobile complexes at docking sites could act 
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as physical constraints on the mobility of the overall molecular populations analyzed, 
which would produce a net reduction in diffusion rate (Suppl Fig. 3). The fact that 
VCAM-1 is no more affected than tetraspanins by ligand engagement of ICAM-1 
supports a model in which VCAM-1 is co-recruited to ICAM-1/LFA-1-mediated 
docking structures as a result of both VCAM-1 and ICAM-1 being components of the 
EAP. The same argument is applicable to the recruitment of ICAM-1 into VCAM-
1/VLA-4 induced docking structures.  
Remarkably, our data show that CD9 mobility is more strongly affected by the 
engagement of ICAM-1, while CD151 is more affected by engagement of VCAM-1, 
confirming the results of previous biochemical analyses, in which ICAM-1 
preferentially associated with CD9 and VCAM-1 associated with CD151 (Barreiro et 
al., 2005). FRET analysis confirmed a degree of specificity inside the preexisting EAP 
prior to leukocyte binding. The preferential interactions of ICAM-1 with CD9 and 
VCAM-1 with CD151 are evident in the FRETeff for these pairs, which are close to 
those of tetraspanin pairs, even though in tetraspanin-partner interactions there are 
fewer obstacles that can reduce FRETeff.  
The diffusional analyses by FCS complemented the FRAP data. Thus, FRAP 
provided a general view of diffusion within EAP in the presence or absence of adherent 
leukocytes and in comparison with lipid rafts at a microscopic level, and FCS allowed 
us to move toward the nanoscopic scale to precisely determine diffusion coefficients of 
EAP proteins at the single-molecule level. The amounts of exogenously expressed 
fluorescently-labeled proteins on the surface of cells used for FCS and FCCS analyses 
was negligible compared with the corresponding endogenous proteins, assuming that 
there were no alterations in dynamic behaviour due to increased molecular density at 
the membrane. However, the existence of a mixture of endogenous and exogenous 
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protein populations precludes determination of the stoichiometry of submicron-size 
endothelial tetraspanin domains, even though the FCCS studies did provide insights 
into the lifespan of tetraspanin-partner complexes. 
In conclusion, this study performed with this particular type of TEM from the 
apical membrane of endothelium constitutes the first description of tetraspanin 
microdomains as physical entities in living cells, with dynamic features that clearly 
differ from lipid rafts. 
 
Regulation of the avidity of endothelial adhesion receptors by their inclusion in 
tetraspanin-enriched endothelial adhesive platforms    
It is a common error to assume that the demonstration of co-localization of 
molecules at the microscopic level provides irrefutable evidence of spatial association; 
the optical resolution limit of classical confocal fluorescence microscopy techniques 
falls far short that required to identify molecular interactions that take place over a 
distance of few nanometers. Our data from advanced microscopy techniques 
demonstrate that the co-localization of two tetraspanins and two receptors at the nude 
endothelial apical plasma membrane and at specialized adhesive structures does indeed 
correspond to highly specific and organized interactions among them. Furthermore, this 
organization confers the appropriate spatial distribution for ICAM-1 and VCAM-1 
receptors to exert their efficient adhesion functions. 
The regulation of leukocyte integrin activity has been extensively characterized. 
These proteins can be regulated by conformational changes (affinity) and/or clustering 
at the plasma membrane (avidity) (Carman and Springer, 2003; Luo et al., 2007). In 
contrast, no regulatory mechanism, apart from the transcriptional level, has been 
described previously  for the adhesive function of endothelial integrin ligands (Collins 
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et al., 1995). Our study thus provides novel insights into adhesion receptor regulation, 
showing how the insertion of two key endothelial receptors, ICAM-1 and VCAM-1, 
into tetraspanin-enriched microdomains promotes the homo- and hetero-clustering of 
both molecules at the contact area with the adhered leukocyte, independently of ligand 
binding and actin cytoskeleton anchorage. The tetraspanin-mediated clustering of 
endothelial receptors enhances firm adhesion, since disturbance of interactions using 
tetraspanin blocking peptides or alteration in composition by tetraspanin knock-down 
decreases the adhesive properties of VCAM-1 and ICAM-1 in transendothelial 
migration experiments performed under flow conditions and in detachment experiments 
under increasing shear flows (Barreiro et al., 2005). Whether ICAM-1 or VCAM-1 can 
undergo any conformational alteration due to their interaction with tetraspanins remains 
undetermined, in the absence of appropriate reagents to tackle this possibility.  
The ability of tetraspanins to mediate the homo- and hetero-clustering of adhesion 
receptors, which is enhanced by integrin engagement, arises from their ability to 
laterally associate with each other and with non-tetraspanin partners simultaneously. 
Therefore, CD9 could promote ICAM-1 homo-avidity by interacting with other CD9 
molecules bound to this receptor, whereas CD151 could reproduce the same effect with 
VCAM-1. Then, the hetero-clustering of ICAM-1 and VCAM-1 could be explained by 
the interaction of CD9 with CD151. The involvement of other tetraspanins in these 
organized microdomains cannot be ruled out; indeed, we have observed the inclusion of 
tetraspanin CD81 at EAP (Barreiro et al., unpublished observations). Conceptually, 
endothelial receptor homo-avidity would be similar to the avidity phenomenon 
described for their counter-receptors, the integrins α4β1-VLA-4 (for VCAM-1) and 
αLβ2-LFA-1 (for ICAM-1) integrins. In fact, a role has been reported for CD81 as 
homeostatic avidity facilitator of multivalent VLA-4 strengthening in the adhesion to 
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VCAM-1 (Feigelson et al., 2003). Therefore, it is also conceivable that such 
tetraspanin-mediated co-organization of specific VLA-4 and LFA-1 integrin subsets 
takes place within leukocyte membranes. Futhermore, the novel concept of hetero-
clustering raised here for VCAM-1 and ICAM-1 can be envisaged as a kind of 
tetraspanin-mediated cross-talk between adhesion receptors; that is, a cellular 
mechanism to spatio-temporally organize molecules with similar characteristics and 
functions so as to facilitate their efficient co-ordinated action in critical processes such 
as extravasation, which occurs over a short time-frame. Moreover, VCAM-1 and 
ICAM-1 are unlikely to be the only receptors inserted in these tetraspanin 
microdomains at the apical endothelial plasma membrane; we have also identified other 
adhesion proteins such as CD44, PECAM-1 and, more importantly, E-selectin in 
association with EAP (Barreiro et al., unpublished observations). These organized 
membrane microdomains thus appear to integrate a plethora of adhesion receptors 
involved in subsequent steps of the extravasation process, and for this reason we have 
named them endothelial adhesive platforms. These organized platforms are dynamic, 
since they coalesce or diverge depending on the stimuli received (ligand engagement by 
tetraspanin partners, and so on).  
In sum, our data clearly demonstrate that tetraspanin microdomains account for 
the specific recruitment of endothelial adhesion receptors to the leukocyte contact area, 
providing a mechanism to increase avidity at these sites and enhance firm adhesion. 
This constitutes a novel supramolecular level of regulation in the function of VCAM-1 
and ICAM-1 endothelial receptors not envisaged previously for integrin ligands. In the 
light of these observations, new pharmacological agents that could specifically prevent 
the interaction of tetraspanin with endothelial adhesion receptors in vivo could 
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constitute novel therapeutical estrategies for the treatment of chronic inflammatory and 
autoimmune diseases.   
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CONCLUSIONS        
 
1. Endothelial adhesion receptors ICAM-1 and VCAM-1 together with the actin-
cytoskeleton and related proteins such as ezrin, moesin, α-actinin, vinculin and VASP, 
participate in the formation of a three-dimensional structure that arises from the apical 
surface of activated endothelial cells to partially embraced and firmly attached adherent 
lymphocytes, preventing their detachment under physiological hemodynamic conditions. 
The formation of this cup-like structure is regulated by Rho/ROCK pathway and 
phosphoinositide PIP2. 
 
2. Tetraspanin proteins CD9 and CD151 laterally associate with ICAM-1 and VCAM-1 
at the plasma membrane, co-localizing with these adhesion receptors at the endothelial 
docking structures. The insertion of ICAM-1 and VCAM-1 in tetraspanin microdomains 
is crucial for the proper adhesive properties of these endothelial receptors. 
 
3. The co-recruitment of ICAM-1 and VCAM-1 adhesion receptors to the docking 
structures in the absence of ligand engagement, actin anchorage and heterodimer 
formation, can be explain due to the existence of specific interactions within the 
tetraspanin microdomains (ICAM-1/CD9, VCAM-1/CD151, CD9/CD151). 
 
4. The biophysical properties of tetraspanin and adhesion receptors demonstrate the 
existence of these organized microdomains containing CD9, CD151, ICAM-1 and 
VCAM-1 at the apical plasma membrane of living endothelial cells. This particular kind 
of microdomains, which presents diffusional properties different from those of lipid rafts, 
has been termed endothelial adhesive platform. 
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5. Endothelial adhesive platform-induced nanoclustering of VCAM-1 and ICAM-1 
represents a novel mechanism of supramolecular organization that regulates the efficient 
leukocyte integrin-binding capacity of both endothelial receptors. 
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CONCLUSIONES 
 
1. Los receptores endoteliales de adhesión ICAM-1 y VCAM-1 junto con el cito-
esqueleto de actina y proteínas relacionadas, tales como ezrina, moesina, α-actinina, 
vinculina y VASP, participan en la formación de una estructura tridimensional que 
emerge de la superficie apical de las células endoteliales activadas para rodear 
parcialmente y adherir firmemente a los linfocitos, impidiendo su desunión en 
condiciones hemodinámicas fisiológicas. La formación de esta estructura con forma de 
copa está regulada por la ruta de señalización Rho/ROCK  y el fosfoinosítido PIP2. 
 
2. Las tetraspaninas CD9 y CD151 colocalizan con ICAM-1 y VCAM-1 en las 
estructuras endoteliales de anclaje, asociándose lateralmente a estos receptores en la 
membrana plasmática. La integración de ICAM-1 y VCAM-1 en microdominios de 
tetraspaninas es necesaria para el correcto funcionamiento adherente de estos receptores 
endoteliales. 
 
3. El co-reclutamiento de los receptores de adhesión ICAM-1 y VCAM-1 a las 
estructuras de anclaje en ausencia de ligando, unión a actina y formación de 
heterodímeros, puede ser explicado por la existencia de interacciones específicas dentro 
de los microdominios de tetraspaninas (ICAM-1/CD9, VCAM-1/CD151, CD9/CD151). 
 
4. Las propiedad biofísicas de las tetraspaninas y los receptores de adhesión demuestran 
la existencia de microdominios organizados en la membrana apical de células 
endoteliales vivas que contienen CD9, CD151, ICAM-1 y VCAM-1. Este tipo particular 
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de microdominios presenta propiedades difusivas diferentes a las de las balsas lipídicas, 
por lo que se les ha denominado “plataformas endoteliales adherentes”. 
 
5.  La distribución espacial nanométrica de VCAM-1 e ICAM-1 inducida por las 
plataformas endoteliales adherentes representa un nuevo mecanismo de organización 
supramolecular que regula la eficiente capacidad de unión a integrinas leucocitarias de 
ambos receptores endoteliales. 
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SUPPLEMENTAL MATERIAL 
 
Supplemental Figure 1 
Standards for the phasor-FLIM analysis of FRET.  
Cells expressing only the mEGFP-tagged chimeras of ICAM-1, VCAM-1-or CD9 
were used for defining the phasor distributions (i.e., fluorescence lifetime distributions) 
of each FRET-unquenched donor protein. ICAM-1-mEGFP is the reference for ICAM-
1-mEGFP/ICAM-1-mRFP1, ICAM-1mEGFP/VCAM-1mRFP1 and ICAM-
1mEGFP/CD9mRFP1 pairs. VCAM-1mEGFP is the reference for VCAM-
1mEGFP/VCAM-1mRFP1, VCAM-1mEGFP/ICAMmRFP1 and VCAM-
1mEGFP/CD151mRFP1. CD9mEGFP is the reference for CD9mEGFP/CD9mRFP1 
and CD9mEGFP/CD151mRFP1. 
Fluorescence lifetime decays were acquired in the classical TCSPC-FLIM mode 
and transformed in the phasor representation as described (Digman et al., submitted; 
Caiolfa et al., 2007). Briefly, by this novel analytical approach, the fluorescence decay 
in each pixel of the image gives a point in the phasor plot. The phasors ensemble of the 
image is shown in contour plot. The phasor plot is simply a polar, s,g, coordinate graph, 
in  which only single exponential decays fall on the universal circle (right top panel), 
and different molecular species occupy distinct positions in the plots (Digman et al., 
submitted). As in our cells seeded on fibronectin matrices, if the decay at one pixel is a 
convolution of lifetimes, due to multiple species (i.e., unquenched donor + cell 
autofluorescence) contributing the fluorescence intensity in that pixel, the phasor falls 
inside the universal circle, and it is simply the algebraic sum of phasors from each 
component (Clayton et al., 2004; Gratton et al., 1984; Redford and Clegg, 2005) (right 
top panel). The phasor distribution in donor-transfectected cells indicates the presence 
of pixels at different contribution of mEGFP and autofluorescence lifetimes. The latter 
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was evaluated in independent experiments on untrasfected cells and the mean of its 
phasor distribution is reported in the phasor plot (+, right top panel). As it was recently 
shown (Digman et al., submitted), the phasors corresponding to the fibronectin 
background and the cellular autofluorescence are spread over a larger area of the phasor 
plot, due to the low intensity images, the fibronectin background and also the pixel 
heterogeneity for the cellular autofluorescence are detected. Despite that, the majority 
(> 95%) of pixels is included in a narrow, distinct area of the plot (black circle in the 
phasor plot), and are uniformly localized in the image, regardless the variability of the 
local fluorescence intensity.  In these pixels, mEGFP is the predominant species that 
gives rise to the measured fluorescence lifetime decays. The phasor distribution of the 
three donor constructs (top, mid and bottom panels) is comparable and depicts the area 
in the phasor plot in which mEGFP-constructs localize in the presence of fibronectin 
and cell autofluorescence and in the absence of quenching due to FRET (green line).  
Once we know the phasors of the unquenched donors and of the fibronectin-cell 
autofluorescence, we can calculate the FRET trajectory in the phasor plot according to 
the classical relationship: FRET eff = [1- (tau donor-acceptor)/tau donor], and define the mean 
phasors of mEGFP-constructs quenched by 50% FRET and with different contributions 
of fibronectin-cell autofluorescence (yellow line). In all our experiments, phasors 
resulting from any combination of unquenched-donors, FRET-quenched-donors and 
fibronectin-cell autofluorescence have been found within the area delimited by the 
green and yellow lines in the phasor plot.  
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Supplemental Figure 2  
Example statistical analysis of a FRAP experiments. For each time point, the table 
shows mean fluorescence intensities for ICAM-1 and ICAM-1∆Cyt (measured at the 
plasma membrane) raw p values, and adjusted p values obtained for multiple testing 
using the Benjamini and Hochberg’s (BH) method.  
Typically, an acceptance criterion of a single event takes the form of a 
requirement that the observed data be highly unlikely under a default assumption (null 
hypothesis). As the number of independent applications of the acceptance criterion 
begins to outweigh the high unlikelihood associated with each individual test, it 
becomes increasingly likely that one will observe data that satisfies the acceptance 
criterion by chance alone (even if the default assumption is true in all cases). These 
errors are considered false positives because they positively identify a set of 
observations as satisfying the acceptance criterion while that data in fact represents the 
null hypothesis. Many mathematical techniques have been developed to counter the 
false positive error rate associated with making multiple statistical comparisons. To 
avoid these multiple comparison problems, we used the Benjamini and Hochberg’s 
(BH) method for the statistical analysis of our FRAP experiments. 
 The accompanying graph shows mean fluorescence recovery curves of ICAM-1 
and ICAM-1∆Cyt at the plasma membrane. The adjusted p values shown in the table 
correspond to the maximum adjusted p value out of the plateau region. The plateau 
region is marked on the table and the graph and was not considered for the statistical 
analysis. 
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Video MOESIN-GFP: In this video, a lymphoblast that contacts with a moesin-GFP 
transfected endothelial cell, and immediately transmigrates and moves beneath the 
endothelium is observed. Moesin is clustered around the lymphoblast along the whole 
process. 
 
Video VCAM-1-GFP: In this video a lymphoblast (upper site) that adheres to, spreads 
on, and moves towards a lateral junction of the VCAM-1-GFP transfected endothelial 
cell is observed. Then, it transmigrates and moves beneath the endothelium. Another 
lymphoblast (lower site) remains spread on the endothelial cell. VCAM-1 is clustered 
around lymphoblasts adhered to the apical surface of endothelium (arrows), but it is not 
concentrated around migrating lymphocytes beneath the endothelium (arrowheads). 
 
Video ICAM-1-GFP: In this video, a lymphoblast that adheres to, spreads on and 
moves towards a lateral junction of the ICAM-1-GFP transfected endothelial cell (black 
arrows) is observed. Then, it transmigrates and moves beneath the endothelium (white 
arrows). ICAM-1 is clustered around the lymphoblast along the whole process. 
 
In all these three videos, the apical endothelial surface is at a plane remote from the 
observer. 
 
Video CD9-GFP: Dynamics of tetraspanin CD9 during T lymphoblast transendothelial 
migration. Timelapse video sequence of lymphoblast transmigration through CD9-
GFP-transfected TNF-α-activated HUVEC monolayers. The maximal projection of the 
informative sections from the GFP confocal image stack is merged with DIC image. 
White arrows mark the position of apically-adhered lymphocytes. Black arrows point to 
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transmigrated lymphocytes interacting with the ventral surface of endothelium. 
 
Video CD151-GFP: Dynamics of tetraspanin CD151 during T lymphoblast 
transendothelial migration. Time-lapse video sequence of lymphoblast transmigration 
through CD151-GFP-transfected TNF-α-activated HUVEC monolayers. The maximal 
projection of the informative sections from the GFP confocal image stack is merged 
with DIC image. White arrows mark the position of apical adhered lymphocytes. Black 
arrows point to transmigrated lymphocytes interacting with the ventral surface of 
endothelium. 
 
Video CD9 siRNA: Extravasation under flow with control and CD9 siRNA transfected 
HUVEC cells. Time-lapse video sequence of an extravasation assay under physiological 
flow rate conditions of 1.8 dyn/cm2. Three different fields, recorded for 30s with a 10x 
phase contrast objective, starting at min 6:30 of perfusion of PBLs on TNF-α-activated 
control or CD9 siRNA transfected HUVEC cells are shown. 
 
Video CD151 siRNA: Extravasation under flow with control and CD151 siRNA 
transfected HUVEC cells. Time-lapse video sequence of an extravasation assay under 
physiological flow rate conditions of 1.8 dyn/cm2. Three different fields, recorded for 
30s with a 10x phase contrast objective, starting at min 6:30 of perfusion of PBLs on 
TNF-α-activated control or CD151 siRNA transfected HUVEC cells are shown. 
 
Video: Dynamics of transendothelial migration under flow conditions: HUVEC 
were transiently transfected with ICAM-1-GFP and then mounted on a parallel flow 
chamber to observe leukocyte-endothelium interactions under physiological flow 
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conditions. PBLs stained in vivo with a neutral monoclonal anti-LFA-1 directly coupled 
to Alexa 568 (TS2/4) were perfused at 1.8 dyn/cm2. A lymphocyte migrating across an 
intercellular junction is observed. The ring-like structure of LFA-1 and ICAM-1 in the 
transmigration passage is shown. As transendothelial migration progresses, the 
endothelial junction becomes resealed. (This video was performed in collaboration with 
Ziv Shulman from the laboratory of  Dr. Ronen Alon at the Weizmann Institute of 
Science, Israel).  
 
Video: Example of extravasation steps under flow conditions. Freshly isolated PBLs 
were perfused at physiological rate (1.8 dyn/cm2). Rolling, adhered, transmigrating and 
transmigrated lymphocytes can be observed in the videosequence. 
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ABBREVIATIONS: 
 
ERM: Ezrin, Radixin and Moesin  
DIC: Differential Interference Contrast 
GFP: Green Fluorescent Protein 
GST: Glutathione-S-transferase 
HUVEC: Human Umbilical Vein Endothelial Cells 
ICAM-1: Intercellular Adhesion Molecule-1 
PBL: Peripheral Blood Lymphocyte 
PI(4,5)P2: Phosphatidylinositol 4,5-bisphosphate 
TEM: Transendothelial Migration (according to text) 
VCAM-1: Vascular Cell Adhesion Molecule-1 
LEL: Large Extracellular Loop 
siRNA: Small Interference RNA 
LFA-1: Lymphocyte Function-associated Antigen 1 
VLA-4: Very Late Antigen-4 
FRAP: Fluorescence Recovery After Photobleaching 
TCSPC-FLIM-FRET: Time-Correlated Single Photon Counting-Fluorescence Lifetime 
Imaging-Fluorescence Resonance Energy Transfer 
FCS: Fluorescence Correlation Spectroscopy 
FCCS: Fluorescence Cross-correlation Spectroscopy 
SEM: Scanning Electron Microscopy 
TEM: Tetraspanin-enriched Microdomains (according to text) 
EAP: Endothelial Adhesive platforms 
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zrin, radixin, and moesin (ERM) regulate cortical
morphogenesis and cell adhesion by connecting
membrane adhesion receptors to the actin-based cy-
toskeleton. We have studied the interaction of moesin and
ezrin with the vascular cell adhesion molecule (VCAM)-1
during leukocyte adhesion and transendothelial migration
(TEM). VCAM-1 interacted directly with moesin and ezrin
 
in vitro, and all of these molecules colocalized at the api-
cal surface of endothelium. Dynamic assessment of this
interaction in living cells showed that both VCAM-1
and moesin were involved in lymphoblast adhesion and
spreading on the endothelium, whereas only moesin
participated in TEM, following the same distribution pattern
E
 
as ICAM-1. During leukocyte adhesion in static or under
flow conditions, VCAM-1, ICAM-1, and activated moesin
and ezrin clustered in an endothelial actin-rich docking
structure that anchored and partially embraced the leukocyte
containing other cytoskeletal components such as 
 

 
-actinin,
vinculin, and VASP. Phosphoinositides and the Rho/p160
ROCK pathway, which participate in the activation of ERM
proteins, were involved in the generation and maintenance
of the anchoring structure. These results provide the first
characterization of an endothelial docking structure that
plays a key role in the firm adhesion of leukocytes to the
endothelium during inflammation.
 
Introduction
 
Leukocyte extravasation across the endothelial barrier is a
fundamental requirement in a wide variety of physiological
and pathological scenarios, including immunity and inflamma-
tion. This phenomenon is an active, multistep process that
requires drastic morphological changes involving cytoskeletal-
directed clustering of adhesion receptors in both leukocytes
and endothelial cells (Butcher, 1991). Among adhesion
receptors, the integrins 
 

 
4
 

 
1 (VLA-4) and 
 

 
L
 

 
2 (LFA-1)
play a major role in the tight adhesion of leukocytes to en-
dothelium (González-Amaro and Sánchez-Madrid, 1999).
Their main ligands on endothelium are vascular cell adhesion
molecule (VCAM)*-1 and intercellular adhesion molecule
(ICAM)-1, respectively (Marlin and Springer, 1987; Elices
et al., 1990). ICAM-1 but not VCAM-1 is basally expressed
in resting cells, and both molecules are induced upon activation
by proinflammatory cytokines such as IL-1 and TNF-
 

 
(Carlos and Harlan, 1994). Although it has been described
that both VLA-4/VCAM-1 and LFA-1/ICAM-1 interactions
mediate the firm adhesion of leukocytes, only the latter
molecular pair seems to be required for lymphocyte diapedesis
(Oppenheimer-Marks et al., 1991).
The interaction of adhesion molecules with cytoskeletal
components is of critical importance for cell–cell and cell–
substratum adhesion as well as for receptor internalization.
The cortical cytoskeleton regulates the membrane localization
of several adhesion receptors, such as ICAMs, CD43, and
CD44, through one or more members of the ezrin, radixin,
and moesin (ERM) family of proteins (Serrador et al., 1997;
Heiska et al., 1998; Yonemura et al., 1998). These molecules
function as membrane-actin cytoskeleton linkers regulating
cortical morphogenesis and cell adhesion. Accordingly, they
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play a key role in the formation of protrusive plasma mem-
brane structures such as filopodia, microspikes, or microvilli
(Mangeat et al., 1999; Yonemura and Tsukita, 1999). Struc-
turally, they are closely related to each other and seem to be
functionally redundant, as suggested by the apparently normal
phenotype of moesin knockout mice (Doi et al., 1999). Their
NH
 
2
 
-terminal domains interact with integral membrane pro-
teins, whereas their COOH-terminal domains bind F-actin
(Turunen et al., 1994). These functions are conformationally
regulated by reversible changes from inactive to functionally
active forms. Binding of phosphatidylinositol 4,5-biphosphate
 
(
 
PI[4,5]P
 
2
 
) and phosphorylation of a specific COOH-terminal
threonine residue unmask the F-actin and membrane binding
sites and stabilize the active conformation (Nakamura et al.,
1999; Barret et al., 2000). The Rho/p160 ROCK signaling
pathway and the phosphatidylinositol turnover are the major
regulatory mechanisms for ERM activation, inducing their
phosphorylation and translocation into apical membrane/actin
protrusions (Hirao et al., 1996; Matsui et al., 1998; Shaw et
al., 1998). On the other hand, activated ERM proteins can se-
questrate Rho-GDI to permit Rho activation, providing a pos-
itive feedback pathway (Takahashi et al., 1997).
These proteins have been studied in a variety of cellular
types, but thus far their functions have not been addressed in
endothelial cells. Herein, we describe the direct interaction
of VCAM-1 with moesin and ezrin, the two members of the
ERM family most highly expressed in endothelium (Me-
nager et al., 1999). We also describe the dynamic distri-
bution of VCAM-1, ICAM-1, and moesin during leuko-
cyte adhesion and lymphoblast transendothelial migration
(TEM), using live time-lapse fluorescence confocal micros-
copy. Our data indicate that an endothelial docking struc-
ture is formed during leukocyte-endothelium interaction in
static and under flow conditions. VCAM-1, ICAM-1, and
activated ERM proteins participate in this novel anchoring
structure together with structural and regulatory molecules
typical of nascent phagosomes.
 
Results
 
VCAM-1 interacts with moesin and ezrin at the apical 
surface of activated endothelial cells
 
The subcellular distribution of VCAM-1, ezrin, and moesin,
was analyzed by confocal microscopy in TNF-
 

 
–activated
human umbilical vein endothelial cells (HUVEC). VCAM-1
colocalized with ezrin (Fig. 1, a–c) and moesin (Fig. 1, e–g)
in the microspikes and microvilli that protrude from the api-
cal surface of these cells. Colocalization analysis confirmed
these observations (Fig. 1, d and h). By contrast, VE-cad-
herin did not colocalize with ERM proteins (Fig. 1, i–l).
To assess whether this codistribution in activated HUVEC
is correlated with the formation of complexes between
VCAM-1 molecules and ERM proteins, immunoprecipita-
tion assays were performed. As shown in Fig. 2 A, moesin and
ezrin coimmunoprecipitated with VCAM-1. To determine
whether these interactions are direct, binding assays were per-
formed using a glutathione-
 
S
 
-transferase (GST) fusion pro-
tein containing the cytoplasmic tail of VCAM-1 (GST–VC).
The fusion protein containing the cytoplasmic tail of ICAM-3,
GST–IC3, which has been demonstrated to bind ERM, as
Figure 1.  VCAM-1 colocalizes with 
moesin and ezrin at the apical surface 
of activated HUVEC. Confluent HUVEC 
were activated with 20 ng/ml TNF- for 
20 h. Thereafter, cells were fixed, 
permeabilized, and stained with the 
anti-ezrin pAb 90/3 (a and i, green), 
anti-moesin pAb 95/2 (e, green), anti–
VCAM-1 mAb P8B1 (b and f, red), or 
anti–VE-cadherin mAb Tea1/31 (j, red). 
Merged images are shown in c, g, and k, 
where colocalizations are observed 
(yellow). Images represent confocal laser 
scanning micrographs showing horizontal 
projections or the corresponding 
orthogonal section of the same field. 
Insets correspond to the amplified image 
of the zones pointed to by arrows. 
Colocalization histograms of green and 
red signals corresponding to these images 
are shown on the right (d, h, and l). The 
corresponding colocalization percentages 
are 65.7% (d), 67.6% (h), and 13.3% (l). 
Bar, 20 m.
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well as the partially truncated form GST-Y9, which shows a
considerable reduced binding to moesin and ezrin (Serrador et
al., 2002), were used as positive and negative controls, respec-
tively. 
 
35
 
S-Met–labeled NH
 
2
 
-terminal domain of moesin,
N-moesin, and the NH
 
2
 
-terminal domain of ezrin, N-ezrin,
were added to Sepharose beads coupled to the GST fusion
proteins. Strong binding of VCAM-1 to ezrin and moesin was
observed, which was much higher in comparison to ICAM-3
(Fig. 2 B). Altogether, these data demonstrate that VCAM-1
can directly associate with ezrin and moesin in vitro and pre-
sumably also at the apical membrane sites of endothelial cells.
 
Differential contribution of VCAM-1, ICAM-1, and 
ERM proteins to the extravasation process
 
The functional role of the VCAM-1/ERM association in the
endothelial cell–lymphocyte interaction was analyzed and
compared with another adhesion receptor that also interacts
with ERM proteins, namely ICAM-1 (Heiska et al., 1998).
For this purpose, we used T lymphoblasts, that express high
levels of VLA-4 and LFA-1, ligands of VCAM-1 and ICAM-1,
respectively (Fig. 3 A). Both integrins were active since mAb
against them blocked T lymphoblast TEM (Fig. 3 B). These
cells were allowed to adhere and migrate across an activated
HUVEC monolayer and confocal microscopic analysis of
endogenous endothelial VCAM-1 and ICAM-1 distribution
was performed. When lymphoblasts were spread on the api-
cal surface of endothelium, VCAM-1 clustered around these
cells (Fig. 3 C, a). However, such VCAM-1 clusters were
neither observed during the passage of lymphoblasts across
the endothelium nor after transmigration (Fig. 3 C, b). The
orthogonal section showed two lymphoblasts migrating
across adjacent endothelial cells, where clustered VCAM-1
molecules colocalized with endothelial ezrin only at the api-
cal surface of the lymphoblast-endothelial cell contact area
(Fig. 3 C, c). On the other hand, ICAM-1 was clustered
around lymphoblasts during all the lymphoblast adhesion
and transmigration processes (Fig. 3 C, d and e), colocaliz-
ing with endothelial ezrin (Fig. 3 C, f).
To dynamically assess the changes in distribution of
VCAM-1, ICAM-1, and ERM proteins, HUVEC transiently
transfected with VCAM-1–, ICAM-1–, or moesin–green flu-
orescent protein (GFP) were separately monitored by live
Figure 2.  Association of VCAM-1 
with moesin and ezrin. (A) Cytokine-
activated HUVEC were lysed and 
immunoprecipitated with the anti–
VCAM-1 mAb 4B9 or Gly-Sepharose. 
Immunoprecipitates were then resolved 
on a 10% SDS-PAGE, and sequentially 
immunoblotted with the anti-VCAM-1 
mAb 4B9, the anti-moesin pAb 95/2, 
and the anti-ezrin pAb 90/3. Molecular 
weights (kD) are indicated on the right 
side. (B) GST or the GST fusion proteins 
GST–VC, GST–IC3 and GST–Y9 were 
bound to glutathione-Sepharose beads 
and incubated with 35S-Met-N-moesin or 
35S-Met-N-ezrin (top and bottom, 
respectively). After incubation, beads 
were boiled in sample buffer and eluted 
proteins were analyzed by 10% 
SDS-PAGE, autoradiography, and 
fluorography. Lanes with isotope-labeled 
N-moesin and N-ezrin (*) indicate the 
molecular mass of these truncated 
proteins. Densitometric diagrams 
normalized to the loading controls of 
GST proteins are shown on the right.
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time-lapse confocal microscopy after addition of lympho-
blasts. As observed previously for endogenous molecules,
VCAM-1– and moesin–GFP fusion proteins redistributed to
sites of contact during lymphoblast initial adhesion and
spreading. However, only moesin was concentrated in the
transmigration cleft and apparently participated in subse-
quent interactions, when lymphoblasts migrated beneath the
activated endothelium (Fig. 4 A). Interestingly, moesin–GFP
exhibited a dynamic behavior similar to ICAM-1–GFP (Fig.
4 B), presumably because this adhesion molecule binds to
ERM proteins to actively participate in TEM. Digital movies
showing more clearly the differential dynamic distribution of
these molecules are included as additional material.
 
Redistribution of VCAM-1, ICAM-1, and 
ERM proteins at a docking structure during 
endothelium–leukocyte interaction
 
To focus our study on the role of ERM interaction with endo-
thelial adhesion receptors during the initial adhesion of leuko-
cytes to the endothelium, to which VCAM-1 involvement was
mainly restricted, we used K562 cells stably transfected with
 

 
4 integrin (4M7 cells) (Muñoz et al., 1996). These cells ex-
pressed high levels of VLA-4, but negligible amounts of LFA-1
(Fig. 5 A). In addition, their adhesion to activated endothe-
lium was dependent on VLA-4, as it was inhibited by the
blocking anti-
 

 
4 HP2/1 mAb, and induced by the activating
anti-
 

 
1 TS2/16 mAb (Fig. 5 B). 4M7 cells adhered to acti-
vated endothelium mainly via VLA-4, but these cells were un-
able to progress to TEM (unpublished data). When the distri-
bution of endogenous endothelial VCAM-1 was examined
during 4M7 cell adhesion, we found that it was strongly con-
centrated around attached leukocytes (Fig. 5 C, c). Endoge-
nous ezrin colocalized with VCAM-1 at the endothelial–leuko-
cyte contact area (Fig. 5 C, d), and antibodies to ezrin also
stained the leukocyte membrane (Fig. 5 C, b). Furthermore, a
three-dimensional reconstruction of the site of adhesion
showed that VCAM-1 and ezrin were contained in a unique
docking structure that was raised above the level of the endo-
Figure 3.  Distribution of endogenous VCAM-1, ICAM-1, and ezrin during lymphoblast TEM. (A) Expression of 4-integrin (thick line), and 
L-integrin (thin line) on T lymphoblasts as determined by flow cytometry analysis. P363 (dotted line) was used as negative control. 
(B) Transendothelial migration assay of T lymphoblasts pretreated with the blocking anti-4 mAb HP2/1, the blocking anti-L mAb TS1/11, 
the mixture of anti-4 plus L mAb, or the anti–ICAM-3 mAb TP1/24 as negative control. Values correspond to the arithmetic mean  SD of 
a representative experiment run by duplicate out of three independent ones. Statistically significant values, as defined by unpaired Student’s t 
test, are indicated with * (P  0.05) or ** (P  0.015) compared with no mAb treatment. (C) T lymphoblasts were allowed to transmigrate 
across an activated HUVEC monolayer, and then cells were fixed, permeabilized, and stained with the anti–VCAM-1 mAb P8B1 (a–c, red), 
the anti-ICAM-1 mAb Hu5/3 (d–f, red), or the anti-ezrin pAb 90/3 (c and f, green). Representative confocal horizontal images showing an 
apical section of endothelium with adhered lymphoblasts on top (a and d) and a basal section with transmigrated lymphoblasts beneath the 
endothelium (b and e) are presented.  DIC images are shown overlaid with VCAM-1 (a and b) or ICAM-1 staining (d and e). Arrows point to 
VCAM-1 or ICAM-1 clusters at the contact area. Representative orthogonal sections corresponding to the white line in panel a or panel d are 
shown in panels c and f, respectively. Green signal corresponds to ezrin staining both in lymphoblasts and endothelium. Arrowheads point to 
the sites of VCAM-1/ezrin or ICAM-1/ezrin clustering at the apical surface of endothelial cells. Bars: (a and b) 20 m; (d and e) 8 m.
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Figure 4.  Dynamic changes in the localization of VCAM-1, ICAM-1, and 
moesin during lymphoblast TEM. (A) Lymphoblasts were allowed to transmigrate 
across activated HUVEC transfected with moesin- or VCAM-1–GFP. Video 
sequences tracking the spatial and temporal distribution of moesin (a–f) and 
VCAM-1 (g–l) were obtained using live time-lapse fluorescence confocal 
microscopy. Each image represents a projection of several representative 
horizontal sections of a confocal image stack depicted from the video 
sequence at the specified times. DIC and fluorescence images are merged and 
presented at the lower side of each panel. Arrows point to the GFP proteins 
clustering during the lymphoblast–endothelium interaction. Arrowheads 
indicate the absence of VCAM-1–GFP from the contact area between the 
transfected endothelial cell and a migrated lymphoblast placed beneath the 
endothelial monolayer. Corresponding digital video sequences are available 
at http://www.jcb.org/cgi/content/full/jcb.200112126/DC1. Bars, 20 m. 
(B) Lymphoblast transmigration across activated HUVEC transfected with 
ICAM-1–GFP was analyzed by live time-lapse fluorescence confocal microscopy. 
Two representative horizontal sections from the apical and the basal side of 
the endothelial cell belonging to the same confocal stack depicted from the 
video sequence are presented. ICAM-1–GFP signal is shown in panels a and 
d. DIC images and the overlaid images are presented in panels b and e, and c 
and f, respectively. The corresponding video sequence is available at http://
www.jcb.org/cgi/content/full/jcb.200112126/DC1. Bar, 5 m. 
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thelial cell surface and that surrounded the adherent leukocyte
in a cup-like fashion. Both proteins were preferentially concen-
trated in microspikes of this structure that presumably served
to anchor the attached leukocyte (Fig. 5 C, e–g). The redistri-
bution of VCAM-1 and moesin to the leukocyte–endothelium
contact area was tracked separately by live time-lapse fluores-
cence confocal microscopy during the interaction of 4M7 cells
with VCAM-1– or moesin–GFP transfected HUVEC. The
dynamic studies demonstrated that VCAM-1/VLA-4 engage-
ment was associated with the progressive concentration of
VCAM-1 and moesin at the specialized anchoring structure
formed between the two interacting cells, which was progres-
sively strengthened and sustained with time (Fig. 5 D).
To ascertain the physiological relevance of this dock-
ing structure, we analyzed the redistribution of VCAM-1,
ICAM-1, and ezrin to the contact area of migrating periph-
eral blood lymphocytes (PBLs) allowed to adhere under
fluid shear conditions, using a physiological wall shear stress
(1.8 dyn/cm
 
2
 
) for perfusion periods from 30 s to 10 min.
We found these endothelial molecules colocalizing in clus-
ters at the docking structures formed around spread PBLs
(Fig. 6 A), at early time points during the arrest of lympho-
cytes. This structure was also observed during the interac-
tion of activated HUVEC with T lymphoblasts in static
conditions (Fig. 6 B; unpublished data). Similarities in
three-dimensional VCAM-1 distribution around 4M7 cells,
T lymphoblasts or peripheral blood lymphocytes supported
the generality of the docking structure (Fig. 6 B).
 
Relocation of cytoskeletal components to the 
endothelial docking structure
 
The cytoskeletal components involved in the generation of
this endothelial structure were analyzed. Samples of 4M7
cells adhered to activated HUVEC and stained for VCAM-1
and F-actin revealed a considerable enrichment of endothe-
lial actin within the docking structure (Fig. 7 A, a–b). Inter-
estingly, this apical actin scaffold appeared not to be con-
nected to basal stress fibers (Fig. 7 A, c–d). On the contrary,
tubulin was not present with F-actin at the anchoring struc-
ture (Fig. 7 A, e–h). Vinculin and 
 

 
-actinin–GFP also redis-
tributed to this structure with a punctuate pattern (Fig. 7 B,
c and d, and C, a–c). Likewise, VASP-GFP colocalized with
VCAM-1 (Fig. 7 C, f–g), whereas talin and paxillin-GFP
were only found colocalizing with VCAM-1 at some adhe-
sion structures (Fig. 7 B, a and b, and C, d and e). These
data indicate that the endothelial docking structure was sup-
ported by the actin cytoskeleton, actin bundling proteins
such as 
 

 
-actinin, actin-nucleating proteins such as VASP,
and focal adhesion proteins such as vinculin, talin or paxil-
lin. The formation of this structure was associated with a re-
markable change in distribution of several of these proteins,
in particular vinculin, talin, and paxillin, from their normal
Figure 5.  Localization of VCAM-1 and 
ezrin at the contact area of activated 
HUVEC with leukocytes. (A) Expression of 
4-integrin (thick line), and L-integrin 
(thin line) on 4M7 cells as determined by 
flow cytometry analysis. P363 (dotted 
line) was used as negative control. 
(B) Adhesion to activated HUVEC of 4M7 
cells pretreated with the blocking anti-4 
mAb HP2/1, the activating anti-b1 mAb 
TS2/16, or the blocking anti-L mAb 
TS1/11. Values correspond to the 
arithmetic mean  SD of a representative 
experiment run by triplicate out of three 
independent ones. Statistically significant 
values, as defined by unpaired Student’s t 
test, are indicated with * (P  0.005) or 
** (P  0.0001), compared with no mAb 
treatment. (C) 4M7 cells interacting with 
activated endothelial cells were fixed, 
permeabilized, and stained with the 
anti-ezrin pAb 90/3 (green) and the anti–
VCAM-1 mAb P8B1 (red). Representative 
horizontal sections of confocal laser 
scanning images (b and c) are merged in d. 
The corresponding DIC image is shown in 
a. The corresponding three-dimensional 
reconstruction is presented in e–g. Bar, 5 
m. (D) 4M7 cells were allowed to adhere 
to activated HUVEC transfected with 
moesin- or VCAM-1–GFP. GFP staining 
was monitored using live time-lapse 
fluorescence confocal microscopy. 
Horizontal sections showing the staining 
of moesin- (a) or VCAM-1–GFP (b) after 60 
min of leukocyte–endothelium interaction. 
Arrows point to the GFP proteins clustered 
in the anchoring structure. Bar, 20 m.
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subcellular localization at focal adhesions at the basal surface
to the docking structure at the apical surface.
 
The docking structure is regulated by PI(4,5)P
 
2
 
 and 
Rho/p160 ROCK
 
To assess whether the clustering of ERM proteins at the en-
dothelial-leukocyte contact area is associated with an acti-
vated state of these proteins, immunofluorescence studies
using the 297S mAb, which recognizes a COOH-terminal
threonine phosphorylated in ERM proteins (Matsui et al.,
1998), were conducted in the 4M7 cell adhesion model. A
high concentration of phosphorylated ERM proteins was
evident at the endothelial anchoring structure generated
after VCAM-1/VLA-4 interaction (Fig. 8 A). We have also
studied two important regulators of ERM activation,
namely phosphoinositides and components of the Rho/p160
ROCK pathway. The subcellular localization of different
phosphoinositides was determined by using as probes the
PH domain of PLC
 

 
, which binds PI(4,5)P
 
2
 
, and that of
GRP1, which binds PI(3,4,5)P
 
3
 
 and PI(3,4)P
 
2
 
, fused to
GFP (Gray et al., 1999; Várnai et al., 1999). Upon endothe-
lial cell transfection, both probes colocalized with VCAM-1
at the endothelial docking structure (Fig. 8 B, a and b; d
and e). PLC
 

 
-PH–GFP showed a higher concentration
at microspike tips (Fig. 8 B, c), whereas GRP1-PH–GFP
appeared to be more diffusely distributed and localized
throughout the entire structure (Fig. 8 B, f).
Next, blocking studies with chemical inhibitors were per-
formed before and after HUVEC-4M7 cell adhesion. The
p160 ROCK inhibitor Y-27632 strongly inhibited the gener-
ation and maintenance of the anchoring structure (Fig. 9 A).
On the other hand, the PI3K inhibitor Ly 294002 only had a
minor effect on the generation of this structure, but moder-
ately inhibited its maintenance (Fig. 9 A). The classical, PKCs
inhibitor Gö6976 did not exert a significant inhibitory effect
neither on the generation nor in the maintenance of the an-
choring structure (Fig. 9 A). Dynamic studies using VCAM-
1–GFP transfected HUVEC showed that the p160 ROCK
inhibitor Y-27632 acted by destroying the docking structure
formed around 4M7 cells, as observed in Fig. 9 B. Finally, the
effect of this inhibitor was assayed on endothelium during pe-
ripheral blood lymphocyte adhesion and transmigration un-
der flow conditions. We found a diminished lymphocyte roll-
ing and adhesion after Y-27632 treatment with regard to
control conditions. Furthermore, some cells that were initially
adhered, began to roll and finally detached from the mono-
layer, indicating an abnormal adhesion process. Accordingly,
all these events led to a significant inhibition of transmigra-
tion. The effect of the inhibitor Y-27632 was analyzed at dif-
ferent time periods (3, 6, 8, and 10 min of perfusion), being
persistent at any time tested, but only the last time is shown,
as representative (Fig. 9 C). Furthermore, immunofluores-
cence analysis revealed that most of adhered lymphocytes were
not tightly anchored by an endothelial docking structure (un-
published data). In conclusion, these findings suggest that
both, PI(4,5)P
 
2
 
 and the Rho/p160 ROCK pathway, are im-
portant for the generation as well as for the maintenance of
the endothelial docking structure.
 
Discussion
 
VCAM-1 is one of the major endothelial receptors that medi-
ates leukocyte adhesion to the vascular endothelium (Carlos
and Harlan, 1994). Recent data obtained with neonatally de-
ficient VCAM-1 mice have strongly suggested that VCAM-1
plays an important role for lymphocyte homing and for T
cell-dependent humoral immune responses (Koni et al., 2001;
Leuker et al., 2001). In addition, VCAM-1 may play an im-
Figure 6.  Formation of the endothelial 
docking structure for adhered 
lymphocytes under flow. 
(A) Transendothelial migration assay of 
peripheral blood lymphocytes under 
fluid shear conditions. After 10 min of 
perfusion, cells were fixed and stained 
for ICAM-1 (b and d, green), VCAM-1 
(c, d, g, and h, red), and ezrin (f and h, 
green). The corresponding DIC images 
are shown in panels a and e. Merged 
images are shown in panels d and h. 
Bar, 3.5 m. (B) Three-dimensional 
reconstruction of VCAM-1 staining 
during 4M7 cell (a), T lymphoblast (b), 
or PBL under flow (c) adhesion. 
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portant role in the pathogenesis of diseases such as atheroscle-
rosis (Cybulsky et al., 2001), rheumatoid arthritis (Carter and
Wicks, 2001), and multiple sclerosis (Alon, 2001). Thus, the
elucidation of VCAM-1 function in leukocyte adhesion and
transmigration is crucial, as this molecule could constitute a
molecular target for therapeutic intervention.
The cytoskeletal components involved in the redistribu-
tion of VCAM-1 at the leukocyte-endothelial cell contact
area have not been studied previously. Among potential can-
didates, ERM proteins seemed likely to mediate this process
as these molecules play an important role in the remodelling
of the plasma membrane, as reported for ICAMs (Helander
et al., 1996; Serrador et al., 1997; Heiska et al., 1998). We
found that endogenous VCAM-1 colocalizes and is physi-
cally associated with moesin and ezrin in microspikes and
microvilli of the apical surface of cytokine-activated endo-
thelial cells. Furthermore, the cytoplasmic tail of VCAM-1
and the active NH
 
2
 
-terminal domain of moesin or ezrin are
capable to directly bind in vitro. These data strongly suggest
that ERM proteins are directly involved in the redistribution
of VCAM-1. However, it cannot be ruled out completely
that adaptor proteins such as EBP50 or E3KARP (Bretscher
et al., 2000), also play a role. It has been reported that ERM
proteins bind to a positively charged amino acid cluster in
the juxta-membrane cytoplasmic domain of CD44, CD43,
and ICAM-2 (Yonemura et al., 1998). In addition, we have
found recently that a novel serine-rich motif within the cy-
toplasmic tail of ICAM-3 is critical for its interaction with
ERM proteins (Serrador et al., 2002). The amino acid se-
quence comparison of VCAM-1 and ICAM-3 cytoplasmic
tails suggests that VCAM-1 contains a similar serine-rich
motif, likely accounting for ERM association.
To study the VCAM-1/ERM interaction during the ex-
travasation of lymphoblasts, we have made extensive use of a
live cell system in combination with time-lapse fluorescence
microscopy and GFP fusion proteins. This afforded us with
information on dynamic relationships of the two molecules
during early adhesion and later stages of TEM. Although both
VCAM-1 and moesin clustered around spreading lympho-
blasts on the apical endothelial surface, only moesin remained
at lymphoblast-endothelial contacts during the passage of
lymphoblasts across the endothelium and their subsequent
migration beneath the endothelial monolayer. However, it has
been reported that VCAM-1 actively participates in T lym-
Figure 7.  Characterization of the 
endothelial docking structure formed 
during leukocyte adhesion. (A) 4M7 cells 
were allowed to adhere to activated 
HUVEC cells, then fixed, permeabilized 
and stained for VCAM-1 (a, green), F-actin 
(b–d, f, and h, red), and tubulin (e and g, 
green). Representative horizontal sections 
of confocal image-stacks are presented 
in a and b and e and f. The panel c 
shows the projection of all the horizontal 
sections corresponding to the image 
presented in a and b. Three-dimensional 
reconstructions of F-actin (d and h) and 
tubulin (g) stainings are also shown. Bars, 
20 m. (B) 4M7 cells adhered to activated 
HUVEC were fixed, permeabilized, and 
stained for talin (a and b, green), VCAM-1 
(a and b, red), or vinculin (c and d, green). 
Representative horizontal sections of 
confocal images are presented in a and 
c. Three-dimensional reconstructions 
are shown in b and d. Bar, 5 m. 
(C) 4M7 cells were allowed to adhere to 
activated HUVEC transfected with 
-actinin, paxillin-, and VASP-GFP. 
Thereafter, cells were fixed and stained 
with the anti-VCAM-1 mAb P8B1 
(a, d, and f, red). Green signal corresponds 
to GFP fusion proteins (b, c, e, and g). 
Representative horizontal sections of 
confocal image stacks are presented in 
all panels except for c, which shows the 
three-dimensional reconstruction of 
-actinin–GFP signal. Bars, 5 m.
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phoblast transmigration across high endothelial venules and
monocyte extravasation (Meerschaert and Furie, 1995; Fa-
veeuw et al., 2000). These discrepancies point to a differential
role of VCAM-1 that might be both leukocyte and endo-
thelial cell-type specific. Our data on moesin dynamics clearly
indicate that another receptor linked to moesin could drive
this migration. In this regard, we have found that the dynamic
behavior of moesin is similar to that of ICAM-1 during lym-
phoblast transmigration, a finding that is in accordance with
previous reports describing the distribution of ICAM-1 on the
lumenal and basal surfaces of the endothelium and its involve-
ment in TEM (Oppenheimer-Marks et al., 1991; Randolph
and Furie, 1996). The differential dynamic behavior of
VCAM-1 and ICAM-1 during lymphoblast adhesion and
transmigration on the one hand, and of moesin on the other,
could suggest a mechanism by which ERM proteins are able
to regulate the distribution of both molecules independently.
As VCAM-1/ERM interaction was mostly restricted to
leukocyte tight adhesion and spreading, we took advantage of
a cellular model based mainly on VLA-4/VCAM-1. In this
model, leukocytes are restricted to a sustained tight adhesion
and are unable to progress to TEM, allowing a detailed study
of the endothelial VCAM-1/ERM interaction. In this cell
model, VCAM-1 and both, moesin and ezrin, clustered
around adherent leukocytes, participating in the formation of
an actin-rich docking structure that was attached to and par-
tially engulfed the leukocyte. Similar docking structures were
formed around spreading lymphoblasts in static conditions
or PBLs adhered to endothelium under flow, in which
VCAM-1 and ICAM-1 were concentrated together with
ERM proteins. The fact that both adhesion receptors actively
participate in such endothelial structure would reinforce the
concept of cross-talk between their ligands VLA-4 and LFA-1
Figure 8.  Localization of phosphorylated ERM 
proteins and phosphoinositides at the anchoring 
structure. (A) 4M7 cells adhered to activated 
HUVEC were fixed, permeabilized and stained 
with the mAb 297S. Representative horizontal 
section of a confocal micrograph (a), and a three-
dimensional reconstruction of a series of horizontal 
sections (b) are shown. Bar, 5 m. (B) HUVEC cells 
were transfected with PLCs-PH- and GRP1-PH-GFP 
and then, 4M7 cells were allowed to adhere. 
Thereafter, cells were fixed, permeabilized and 
stained with the anti-VCAM-1 mAb P8B1 (a and d). 
Green signal corresponds to GFP fusion proteins 
(b and e). Panels c and f show three-dimensional 
reconstructions of horizontal sections corresponding 
to the green signal. Bars, 5 m. 
Figure 7 (continued)
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during lymphocyte adhesion (Chan et al., 2000; Rose et al.,
2001). Under these physiological conditions, docking struc-
tures rapidly vanished as lymphoblasts or lymphocytes began
to migrate through the endothelial monolayer.
Our findings highlight the remarkable active role played by
the endothelium during leukocyte adhesion. Thus, the initial
VCAM-1 and ICAM-1 engagement trigger their clustering
and the subsequent activation and clustering of endothelial
Figure 9.  Rho/p160 ROCK pathway regulates the generation and maintenance of the VCAM-1–mediated docking structure. (A) Activated 
HUVEC were pretreated with Y27632 (30 M), Ly294002 (20 M), or Gö6976 (1 M) for 20 min before or 30 min after the addition of 4M7 
cells. Total adhesion time was in both cases 60 min. Quantification of leukocyte adhesion and endothelial docking structure formation was 
carried out by staining with the mAb anti–VCAM-1 P8B1 and counting 300 adhered cells of each treatment. A representative experiment out 
of four independent ones is presented. (B) Kinetics of the endothelial anchoring structure dissolution after the addition of the p160 ROCK 
inhibitor Y-27632. The inhibitor Y-27632 (30 M) was added after the formation of the docking structure in a 4M7 adhesion assay performed 
as above. Representative horizontal sections captured every 15 min are shown in a–d. DIC and fluorescence images are merged and 
presented in the lower side of each panel. Arrows indicate the clustering of GFP proteins. Bar, 10 m. (C) Effect of Y-27632 on peripheral 
blood lymphocyte adhesion and TEM under flow conditions. Activated endothelium was pretreated or not with Y-27632 (30 M) for 30 min. 
Thereafter, PBLs were allowed to adhere and transmigrate under flow conditions for 10 min. Quantification of rolling (R), adhesion (A), 
transmigration (T), and detachment (D) events during the last minute of perfusion was carried out. Values correspond to the arithmetic
mean  SD of four different fields belonging to a representative experiment. Statistically significant values, as defined by unpaired Student’s t 
test, are indicated with *(P  0.01) or **(P  0.002) compared with no inhibitory treatment.
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moesin and ezrin at the site of cell–cell contact. In turn, phos-
phorylated active ERM proteins would participate in concert
with -actinin, an actin-bundling protein, in the rearrange-
ment of the actin cytoskeleton to create the docking structure.
Several focal adhesion proteins such as vinculin, talin, and
paxillin seem to be involved as well. Interestingly, the endo-
thelial docking structure is reminiscent of nascent receptor-
mediated phagosomes, in that the subcellular distribution of
all these structural proteins is similar in both structures (Allen
and Aderem, 1996). In this regard, it has been proposed that
focal adhesions and complement receptor-mediated phago-
somes could share some conserved mechanisms requiring the
same molecules (May and Machesky, 2001). A similar argu-
ment could be made to functionally link the former structures
and the novel leukocyte–endothelium docking structure de-
scribed here. On the other hand, VASP is concentrated in the
docking structure. This protein is present in actin-based pro-
trusions, where it cooperates with WASp-Arp2/3 complex, as
occurs in phagosomes (Castellano et al., 2001). Its presence at
the docking structure could indicate the existence of actin po-
lymerization supporting this endothelial structure, and sug-
gests common mechanisms for de novo actin assembly in all
these structures. Interestingly, ERM proteins have been also
implicated in the de novo actin assembly on mature Fc recep-
tor-mediated phagosomes (Defacque et al., 2000).
As ERM activation occurred during the formation of the
anchoring structure, we studied the regulatory mechanisms
involved. These proteins are regulated by the interplay of
PI(4,5)P2 metabolism and components of the Rho GTPase
signaling pathway, thereby linking events occurring at the
plasma membrane with cytoskeletal remodelling (Sechi and
Wehland, 2000). Interestingly, these regulatory molecules are
also important in phagocytosis (Botelho et al., 2000; Chimini
and Chavrier, 2000). We found that PI(3,4)P2, PI(3,4,5)P3,
and more abundantly PI(4,5)P2, colocalized with VCAM-1 and
ERM proteins in the endothelial docking structure. Nota-
bly, PI(4,5)P2 was preferentially concentrated at the mi-
crospike tips, whereas the other phosphoinositides exhibited a
more diffuse pattern. These observations point to a prominent
role of PI(4,5)P2 in regulating molecular events during endo-
thelial docking of leukocytes. One such event could be the ac-
tivation of moesin and ezrin through its binding to their
NH2-terminal domain. PI(4,5)P2 production could be medi-
ated by Rho, as PI4P5K is a down-stream RhoGTPase effec-
tor. On the other hand, the presence of PI(3,4)P2 and
PI(3,4,5)P3 could be related to PI3K activity. Inhibitors of
PI3K only mildly affected the generation and maintenance of
the docking structure, a finding that is in agreement with its
role in phagocytosis, namely to mediate phagosome closure
(Cox et al., 1999). In our experimental model, the endothelial
anchoring structure does not progress to engulf the leukocyte;
therefore, it is less PI3K dependent. In contrast, the p160
ROCK inhibitor Y27632 inhibited the formation of the an-
choring structure and induced its dissolution as well. Abnor-
mal formation of the endothelial docking structure was also
observed under flow conditions after the treatment with
Y-27632, which rendered an inhibitory effect in lymphocyte
adhesion and transmigration. In addition, the phenomenon of
rolling was also decreased. This finding is in agreement with
previous reports describing the existence of an E-selectin/actin
cytoskeleton adhesion complex induced by leukocyte adhe-
sion (Yoshida et al., 1996; Lorenzon et al., 1998), which it is
likely to be also affected by the inhibition of the Rho/p160
ROCK pathway. Our results concur with the previously de-
scribed regulation of the VCAM-1, ICAM-1, and E-selectin
clustering by the GTPase Rho during monocyte adhesion
(Wojciak-Stothard et al., 1999). Furthermore, the key role of
the Rho/p160 ROCK signaling pathway in the regulation of
the adhesion receptor/ERM/actin cytoskeleton interaction
and remodelling, which results in the formation of this pro-
trusive structure, is further strengthened by the implication of
this pathway in the regulation of complement receptor–medi-
ated phagosomes (Caron and Hall, 1998).
In conclusion, our results provide novel insights into the
links between the actin cytoskeleton and adhesion receptors
involved in leukocyte adhesion and TEM during inflamma-
tion. Further analysis will be focused on molecules involved
in the regulation of the endothelial docking structure dis-
ruption to allow diapedesis, and the signaling pathways that
interconnect both processes.
Materials and methods
Cells and cell cultures
HUVEC were obtained and cultured as previously described (Yáñez-Mó et
al., 1998). Cells were used up to the third passage in all assays. To activate
HUVEC, TNF- (20 ng/m; R&D Systems) was added to the culture media
20 h before the assays were performed. Human PBLs and T lymphoblasts
were obtained and cultured as described elsewhere (Serrador et al., 1997).
K562 cells stably transfected with the 4 integrin chain gene (4M7 cells) were
grown in RPMI 1640 medium (GIBCO BRL) supplemented with 10% FCS, 50
IU/ml penicillin, 50 g/ml streptomycin, and 1 mg/ml of G418 (Calbiochem).
Antibodies and reagents
The TEA1/31 anti-VE cadherin and TS2/16 anti-1 integrin (Yáñez-Mó et al.,
1998), the HP2/1 anti-4 integrin, TS1/11 anti-L integrin, and TP1/24 anti-
ICAM-3 (Serrador et al., 1997) mAb have been described elsewhere. The 4B9
and P8B1 (anti–VCAM-1), Hu5/3 (anti–ICAM-1), and 297S (antiphosphory-
lated forms of ERM proteins) mAb were provided by Dr. R.R. Lobb (Biogen
Inc.), Dr. E.A. Wayner (Fred Hutchinson Cancer Research Center, Seattle,
WA), Dr. F.W. Luscinskas (Brigham and Women’s Hospital and Harvard
Medical School, Boston, MA), and Dr. S. Tsukita (Faculty of Medicine, Kyoto
University, Japan), respectively. The moesin-specific polyclonal antiserum
95/2 and the ezrin-polyclonal antiserum 90/3 have been previously described
(Serrador et al., 2002). The anti-tubulin and -vinculin mAb were purchased
from Sigma-Aldrich. The anti-talin polyclonal antibody (pAb) was a gift of Dr.
K. Burridge (University of North Carolina, Chapel Hill, NC). The monoclonal
IgG1,	 from the P363 myeloma cell line was used as negative control. Re-
combinant human fibronectin was purchased from Sigma-Aldrich. The p160
ROCK inhibitor Y-27632, the PI3K inhibitor Ly 294002, and the classical
PKCs inhibitor Gö6976 were purchased from Calbiochem.
Recombinant DNA constructs and cell transfections
The fusion protein GST–VC, containing the cytoplasmic tail of VCAM-1, was
obtained by PCR amplification using as template the human VCAM-1
cDNA, and [TATGGATCCAGAAAAGCCAACATGAAG] and [TGGAAT-
TCATAGATGGGCATTTC] as 5
 and 3
 primers, respectively. The PCR prod-
uct was cloned as a BamHI/EcoRI fragment into pGEX-4T (Pharmacia LKB
Biotechnology). The cytoplasmic tail of ICAM-3 fused to GST (GST-IC3), and
a truncated form of it (GST-Y9, Y490stop) have been described elsewhere
(Serrador et al., 2002). Expression of GST fusion proteins in BL21 bacteria
and purification were performed following the manufacturer’s instructions.
VCAM-1–GFP and ICAM-1–GFP were obtained using the correspond-
ing human cDNAs as templates to amplify by PCR the complete encoding
region of these molecules without the stop codon. A Xho I site was added
to the 5
 end and a Xma I site at the 3
 end of VCAM-1 cDNA. Likewise,
HindIII and BamHI sites were added to the 5
 and 3
 ends of ICAM-1
cDNA, respectively. The PCR products were then cloned into pEGFP-N1
(CLONTECH Laboratories, Inc.) resulting in an in-frame fusion of en-
hanced GFP to the COOH terminus of VCAM-1 and ICAM-1. The VCAM-1-
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and ICAM-1–GFP proteins behaved similarly to the corresponding endoge-
nous proteins in terms of their binding to ezrin and moesin. The generation
of the GFP fusion construct containing the GFP cDNA inserted at the
COOH-terminal end of the rat full-length moesin (moesin-GFP, residues
1–577) has been previously described (Amieva et al., 1999). -actinin–
GFP and paxillin-GFP were gifts of Dr. A.F. Horwitz (University of Vir-
ginia, Charlottesville, VA). VASP-GFP, PLC-PH-GFP, and GRP1-PH-GFP,
were provided by Dr. J.V. Small (Institute of Molecular Biology, Salzburg,
Austria), Dr. T. Balla (National Institutes of Health, Bethesda, MA), and Dr.
A. Gray (University of Dundee, Dundee, U.K.), respectively.
Transiently transfected HUVEC were generated by electroporation at 200 V
and 975 F using a Gene Pulser (Bio-Rad Laboratories) and adding 20 g of
each DNA construct. These cells were used 24–48 h after transfection.
Flow cytometry analysis, immunofluorescence, and 
confocal microscopy
For flow cytometry analysis and immunofluorescence experiments, cells were
treated as previously described (Yáñez-Mó et al., 1998). Rhodamine Red-
X-Affinipure goat anti–mouse IgG (HL), Alexa Fluor 488 rabbit anti–mouse
or goat anti–rabbit IgG (H  L) conjugate highly crossadsorbed, Alexa Fluor
488 streptavidin, and Phalloidin Alexa Fluor 568 were used as fluorescent re-
agents (Molecular Probes). Staining with the 297S mAb was performed as pre-
viously described (Hayashi et al., 1999). Series of optical sections were ob-
tained with a Leica TCS-SP confocal laser scanning unit equipped with Ar and
He/Ne laser beams and attached to a Leica DMIRBE inverted epifluorescence
microscope (Leica Microsystems), using a 63 oil immersion objective. Colo-
calization histograms were obtained using the Leica Confocal Software.
Immunoprecipitation, Western blot, in vitro translation, and 
protein binding assays
Lysates from activated HUVEC, immunoprecipitation, and Western blot
were performed as described (Serrador et al., 2002). The pCR3 plasmids
carrying the inserts of untagged moesin and ezrin NH2-terminal regions
(amino acid residues 1–310) were transcribed, translated, and isotope la-
beled in vitro using a TNT-coupled rabbit reticulocyte lysate system
(Promega). Then, binding assays using these isotope-labeled recombinant
proteins and the GST fusion proteins (GST–VC, GST–IC3, GST–Y9, and
GST alone) were performed as previously described (Serrador et al., 2002).
Adhesion and transendothelial migration assays
For cellular adhesion assays, HUVEC were grown to confluence in 96-
microwell plates (Costar) and activated with TNF- for 20 h. K562 cells were
labeled with 1 M of BCECF-AM for 15 min at 37C, preincubated with
different purified mAb, and allowed to adhere to activated HUVEC for 15
min at 37C as previously described (Yáñez-Mó et al., 1998). Fluorescence
intensity was measured in a microplate reader (Biotek FL500). T lympho-
blast migration through a confluent monolayer of activated HUVEC was
assayed in 3-m pore Transwell cell culture chambers (Costar). HUVEC
were seeded and grown to confluence on these Transwell inserts pre-
coated with 1% gelatin and activated with TNF- for 20 h. Cultured lym-
phoblasts (2  105 in 100 l of complete 199 medium/well) were incu-
bated with 10 g/ml of different purified mAbs for 20 min at 4C, and then
added to the upper chambers. In the lower well, 600 l of complete 199
medium were poured. Cells were incubated for 90 min at 37C, and mi-
grated cells were recovered from the lower chamber. The relative number
of migrated cells was estimated by flow cytometry.
Time-lapse fluorescence confocal microscopy
HUVEC transfected with different GFP constructs were grown to conflu-
ence on glass-bottom dishes (WillCo Wells) precoated with Fn (20 g/ml).
Then, cells were activated with TNF- for 20 h, and placed on the micro-
scope stage. 4M7 cells or T lymphoblasts resuspended in 500 l of com-
plete 199 medium were added. Plates were maintained at 37C in a 5%
CO2 atmosphere using an incubation system (La-con GBr Pe-con GmbH).
Confocal series of fluorescence and differential interference contrast (DIC)
images, distanced 0.4 m in the z axis, were simultaneously obtained at
30-s or 1-min intervals, with a 63 oil immersion objective. Images were
processed and assembled into movies using the Leica Confocal Software.
Parallel plate flow chamber analysis of 
endothelial-PMN interactions
The parallel plate flow chamber used for leukocyte adhesion and transmi-
gration under defined laminar flow has been described in detail (Luscinskas
et al., 1994). PBLs (106/ml) were drawn across activated confluent mono-
layers at an estimated wall shear stress of 1.8 dynes/cm2 for perfusion times
from 30 s to 10 min. Lymphocyte rolling on the endothelium were easily vi-
sualized as they travelled more slowly than free-flowing cells. Lymphocytes
were considered to be adherent after 20 s of stable contact with the mono-
layer. Transmigrated lymphocytes were determined as being beneath the
endothelial monolayer. Lymphocytes were considered to be detached
when they returned to free-flowing after having been completely arrested
on endothelium. The number of rolling, adhered, transmigrated, and de-
tached cells was quantified by direct visualization of 4 different fields (40
phase-contrast objective) at each time point of every independent experi-
ment. Coverslips were fixed immediately in PFA 4% at room temperature
for 10 min, washed with HBSS, and stained for VCAM-1, ICAM-1, or ezrin.
Online supplemental material
All videos are available at http://www.jcb.org/cgi/content/full/
jcb.200112126/DC1. Video 1 (corresponding to Fig. 4 A, a–f) shows a
lymphoblast that contacts with a moesin–GFP-transfected endothelial cell,
and immediately transmigrates and moves beneath the endothelium.
Moesin is clustered around the lymphoblast along the whole process.
Video 2 (corresponding to Fig. 4 A, g–l), shows a lymphoblast (upper site)
that adheres to, spreads on, and moves toward a lateral junction of the
VCAM-1–GFP-transfected endothelial cell. It then transmigrates and
moves beneath the endothelium, whereas another lymphoblast (lower site)
remains spread on the endothelial cell. VCAM-1 is clustered around lym-
phoblasts adhered to the apical surface of endothelium (arrows), but it is
not concentrated around migrating lymphocytes beneath the endothelium
(arrowheads). Video 3 (corresponding to Fig. 4 B), shows a lymphoblast
that adheres to, spreads on, and moves toward a lateral junction of the
ICAM-1–GFP-transfected endothelial cell (black arrows). It then transmi-
grates and moves beneath the endothelium (white arrows). ICAM-1 is clus-
tered around the lymphoblast along the whole process. In all videos, the
apical endothelial surface is at a plane remote from the observer.
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1. ABSTRACT
Leukocyte transendothelial migration during
homing and inflammation requires drastic cell
morphological changes, involving cytoskeletal-directed
clustering of adhesion receptors in specialized protrusive
membrane structures in leukocytes and endothelial cells.
Extravasation is an active process not only for leukocytes
but also for endothelial cells, which promote the rapid and
efficient entry of leukocytes to the target tissues, without
disturbing the integrity of the endothelial barrier. Herein,
we have revised the specialized protrusive structures
(microvilli, endothelial docking structures, leukocyte
lamellipodia and uropod) involved in the different stages of
leukocyte extravasation. The adhesion receptor
redistribution, cytoskeletal remodelling and intracellular
signaling events that participate in this phenomenon are
also discussed.
2. INTRODUCTION
Cell adhesion receptors regulate many cellular
processes such as activation, migration, growth,
differentiation and death (1, 2), by both signal transduction
and the modulation of intracellular signaling cascades
triggered by different growth factors (3). Cellular
interactions are critical for regulation of hematopoiesis (4,
5) and inflammatory responses (6, 7). The coordinate
function of adhesion receptors, cytoskeleton and signaling
molecules is crucial for leukocyte extravasation, a central
process in immunity. Hence, the correct integration of
“outside-in” and “inside-out” signals in leukocytes and
endothelium during each stage of extravasation is critical to
allow the completion of this phenomenon, the so-called
“multi-step paradigm” (6, 8). The present review focuses
on the molecular mechanisms and the specialized
protrusive structures that govern this dynamic process in
both leukocytes and endothelial cells.
3. INITIAL INTERACTIONS BETWEEN
CIRCULATING LEUKOCYTES AND THE
ENDOTHELIUM: TETHERING AND ROLLING
Free-flowing leukocytes contact with and adhere
to the vascular wall under shear forces to initiate an
inflammatory response or to migrate into a secondary
lymphoid organ (homing). Leukocyte tethering and rolling
on activated endothelial cells are the first steps of the
sequential process of extravasation, followed by the firm
adhesion and transendothelial migration of leukocytes (9).
Protrusive structures in leukocyte extravasation
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Figure 1. The first step of  the extravasation process. As shown in the diagram, free-flowing leukocytes establish transient
contacts with activated endothelial cells (tethering), being slowed down. These initial contacts allow leukocytes to roll on the
endothelial wall to become activated and finally arrest. The main molecules that participate during this process are presented in
detail in the inset: E- and P-selectin in endothelium as well as L-selectin and PSGL-1 in leukocytes are localized at specialized
protrusions (microvilli) supported by the actin cytoskeleton, which is linked to the adhesion receptors via ERM proteins, alpha-
actinin and other cytoskeletal components. All these molecules interact with their corresponding receptors through carbohydrate
residues such as Sialyl Lewisx. Thus, L-selectin binds to several endothelial counterreceptors (E-selectin among them) and
leukocyte PSGL-1 interacts with endothelial E- and P-selectin. In addition, The binding of PSGL-1 with its ligands allows the
recruitment of the tyrosine kinase Syk via ERM proteins, which triggers signaling cascades that culminate in the activation of
expression of several genes (e.g., SRE and c-fos) in leukocytes.
These initial contacts are largely mediated by selectins and
their ligands. All the issues addressed in this chapter are
schematically depicted in Figure 1.
3.1. Selectins and their ligands as critical mediators of
tethering and rolling
Selectins (P-, E- and L-selectin) are cell adhesion
molecules that predominantly mediate the initial
interactions of leukocytes with endothelium. They are type
I transmembrane glycoproteins that bind to sialylated
carbohydrate moieties present on ligand molecules in a
calcium-dependent manner. Selectins and their ligands
interact with variable affinity, and due to their rapid
association and dissociation rates mediate transient contacts
between leukocytes and endothelium (“tethering”) (10, 11).
Tethering results in the slowing of leukocytes in the
bloodstream and their rolling on the surface of
endothelium, which favors subsequent interactions with
endothelial cells mediated by integrins and their ligands,
increasing the adhesiveness of leukocytes, that leads to
their final arrest on the vessel wall (12).
 P-selectin, which is constitutively expressed by
platelets and endothelial cells in secretory granules, is
translocated to the cell surface within minutes upon cell
activation (13). Once expressed on the surface of
endothelial cells, P-selectin is rapidly internalized by
endocytosis. Therefore, this adhesion receptor has an
important role in early leukocyte recruitment during
inflammation (14). E-selectin is also expressed by
endothelial cells, but it is synthesized de novo upon cell
activation (15). After stimulation with IL-1 or TNF-alpha,
it is maximally expressed on the membrane at 4h, and then
is slowly internalized and degraded (16). L-selectin is
constitutively present in most leukocytes, but it is rapidly
shed upon cell activation, thus facilitating the progression
to adhesion and transendothelial migration (TEM) (17-19).
It was first described as a lymphocyte homing receptor, but
Protrusive structures in leukocyte extravasation
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it also participates in leukocyte recruitment at later stages
of the inflammatory response (20).
The best characterized selectin ligand is PSGL-1
(P-selectin glycoprotein ligand-1), a homodimeric
sialomucin expressed by almost all leukocytes (21) and
platelets (22). PSGL-1 is an important functional ligand in
vivo for all three selectins (23-26). In addition, CD24 and
ESL-1 (E-selectin ligand-1) seem to be ligands in myeloid
cells for P-selectin and E-selectin, respectively (27-29).
Finally, it has been described that E-selectin, GlyCAM-1,
MAdCAM-1, CD34 and Sgp200 specifically interact with
L-selectin (reviewed in 30).
Although selectins and their ligands are the
primary mediators of leukocyte rolling, alternative cell
adhesion pathways are involved in this phenomenon. It has
been described that alpha4beta1 (VLA-4) and alpha4beta7
integrins can also mediate leukocyte tethering, rolling and
arrest through their interaction with VCAM-1 and
MAdCAM-1 in the absence of selectins (31). On the other
hand, the interaction of LFA-1(alphaLbeta2)/ICAM-1
cooperates with L-selectin in leukocyte rolling by
stabilizing the tethering phase and decreasing the rolling
velocity (32, 33). In addition, the chemokines CX3CL1
(fractalkine) and CXCL16 also mediate both rolling and
firm adhesion by interacting with CX3CR1 and CXCR6,
respectively (34-37).
3.2. Membrane topography of adhesion molecules
involved in rolling
Adhesion receptor distribution on cell membrane
has a key role in leukocyte interactions and is an important
regulatory mechanism for leukocyte trafficking (38).
Selectins are clustered at the tips of microvilli, and this
localization is critical for tethering and rolling.
L-selectin is anchored to the actin cytoskeleton
through the constitutive association of its cytoplasmic tail
to alpha-actinin, and its cell activation-dependent binding
to moesin (39, 40). Although the association with alpha-
actinin is not essential for its targeting to microvilli (39), its
cytoplasmic anchorage to the actin cytoskeleton is
necessary to control L-selectin function (41, 42). PSGL-1 is
also localized at the tips of microvilli, and this subcellular
distribution has been found to be important for the
initiation of tethering and rolling of leukocytes (43, 44).
Furthermore, the capability of alpha4, but not beta2
integrins, to initiate leukocyte adhesion under flow is also
explained by its selective topographic localization at
microvilli (30). Finally, less is known about the
involvement of cytoskeleton in the efficient presentation in
microvilli of E- and P-selectin by endothelial cells.
However, it has been described that leukocyte adhesion
induces E-selectin linkage to the actin cytoskeleton through
alpha-actinin, paxillin, vinculin, and FAK, but not talin
(45).
3.3. Selectins and PSGL-1 as signaling receptors
It has been demonstrated that L-selectin activates
multiple signaling pathways involved in the reorganization
of the actin cytoskeleton, such as the MAPK cascade (46),
the tyrosine kinase p56lck and Ras (47) or the Rho GTPase
Rac2 (48). In this regard, it has been described that
neutrophils from Rac2-/- mice show deficient actin
polymerization and L-selectin-mediated rolling (49). On
the other hand, PSGL-1 activates the MAPK pathway (50),
and acts as a negative regulator of human hematopoietic
progenitor cells (5). In addition, it has been demonstrated
that PSGL-1 induces a rapid synthesis of uPAR and
different cytokines such as TNF-alpha, IL-8 and MCP-1 in
neutrophils, monocytes and T cells (51-54). Moreover, it
has been shown that PSGL-1 induces activation of beta-2
integrins and binding to ICAM-1 in neutrophils (55, 56).
Our group has also described the interaction of PSGL-1
with ERM proteins, which link membrane molecules with
the actin cytoskeleton (57, 58). This interaction is of critical
importance for the leukocyte activation that occurs before
extravasation, because it allows the recruitment of the
tyrosine kinase Syk by association to ERM proteins
through their phosphorylated ITAM-like motifs. Therefore,
after PSGL-1 ligation to P-selectin or E-selectin, Syk
conveys rolling-emanating signals to the activation of gene
expression programs (59).This phenomenon suggests that
the intracellular signals induced through PSGL-1 have a
priming effect on leukocyte activation, up-regulating the
expression of different molecules further involved in
extravasation and effector functions (60). Since it has been
demonstrated that the cytoplasmic tail of L-selectin also
interacts with moesin (40), it is very likely that selectins
use a similar strategy to trigger intracellular signaling
cascades. In this regard, it has been shown that E-selectin is
dephosphorylated upon endothelial cell interaction with
leukocytes, supporting its role as a signal transduction
molecule (61). In addition, P-selectin also functions as a
signaling receptor, mediating stimulation through its
interaction with ligands expressed by leukocytes (62).
4. ACTIVATION, ARREST AND FIRM ADHESION
OF LEUKOCYTES
During their rolling, leukocytes are stimulated by
chemokines and integrin ligands expressed on the surface
of endothelial cells. These outside-in signals induce an
important increase in the affinity and/or avidity of
leukocyte integrins (inside-out signals) that allows the
shear-resistant arrest of these cells and their firm adhesion
to activated endothelium. The adhesion mediated by
integrins and their ligands, and their subsequent signaling
processes involve a profound remodelling of cytoskeleton
in both endothelial cells and leukocytes. In Figure 2, the
major adhesive, structural and signaling molecules that
participate in the leukocyte firm adhesion to endothelium
are summarized.
4.1. Chemokines trigger the arrest of leukocytes on
endothelium
The main in situ modulators of integrin function
are chemokines. These chemotactic cytokines act through
G-protein-coupled receptors (GPCR), and induce an array
of activatory signals within fractions of seconds, leading to
an enhancement of adhesion and shape changes in
leukocytes (63, 64). Since it is unlikely that soluble
chemokine gradients present in the blood flow regulate
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Figure 2. Activation, arrest and firm adhesion of leukocytes on endothelium: The slowing-down of leukocytes facilitates their
interaction with chemokines exposed on endothelium, triggering the activation of leukocyte integrins by increasing their affinity
and avidity to allow the final arrest of adherent leukocytes. This activated state involves a drastic morphological change from the
round shape of circulating leukocytes to the polarized shape typical of migrating cells. The acquisition of polarity implies the
segregation of adhesion molecules (ICAM-1, ICAM-3, CD43, CD44, PSGL-1, etc) to the rear pole of the cell (uropod), which is
lumen-orientated for the recruitment of bystander leukocytes; whereas the integrins localized to the contact area with
endothelium to allow the spreading of the cell body onto the vascular wall. On the other hand, the endothelium also plays an
active role in firm adhesion by creating docking structures around the attached leukocytes. These endothelial docking structures
are formed as a result of VCAM-1 and ICAM-1 engagement by their integrin counterreceptors (VLA-4 and LFA-1, respectively),
and are supported by a cortical actin scaffold in which ERM proteins, alpha-actinin, vinculin,VASP and other actin-related
proteins participate. In addition, members of the tetraspanin family also cooperate with the endothelial adhesion receptors in the
docking structure formation. The principal regulatory molecules involved in the formation of the above-mentioned structure and
in leukocyte integrin activation (as discussed in the text) are also shown in the inset.
leukocyte trafficking to specific target tissues, it is thought
that chemokines mainly function immobilized at the
emigration site (65). At sites of inflammation or in
secondary lymphoid tissues, chemokines are present in the
subendothelial tissues, as well as in the luminal surface of
endothelium. These chemokines are synthesized or
transported (transcytosis) by endothelial cells and bound to
glycosaminoglycans (GAGs) and, possibly, to the Duffy
antigen/receptor for chemokines (DARC) (66). Chemokine-
binding sites are concentrated on endothelial microvilli, as
occurs with chemokine receptors in leukocytes (67). The
presence of particular subsets of chemokines on
endothelium contributes to the selective recruitment of
leukocytes, a critical phenomenon for the inflammatory
response and lymphocyte homing (reviewed in 68).
Chemokines may differentially modulate distinct integrins
in the same microenvironment, leading to transient or
sustained adhesion of leukocytes (69). Furthermore,
CXCL12 (SDF-1alpha), CCL19 (MIP-3beta), CCL21
(SLC) and CCL20 (MIP-3alpha) have all been shown to
induce LFA-1-mediated cell arrest in different lymphoid
subpopulations (63, 65, 70). In addition, SDF-1alpha up-
regulates VLA-4 affinity for VCAM-1, promoting
monocyte arrest (71). The mechanism involved in such
regulation is not clear, but may involve small Ras GTPases
such as Rap1 (72-74), Rho GTPases (75) and other
signaling molecules.
4.2. Integrin affinity and avidity changes as leukocyte
strategies to achieve firm attachment and spreading
Integrins comprise a family of alpha-beta
heterodimeric transmembrane molecules whose activation
can be tuned to bind to different Ig-like or extracellular
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matrix ligands. Integrin-mediated cell adhesion is tightly
regulated by conformational changes (affinity) and
clustering (avidity), being independent of surface
expression levels (76). Circulating leukocytes avoid non-
specific contacts with vascular walls by maintaining their
integrins in non-adhesive states. The in situ activation of
integrins during leukocyte rolling can be driven by multiple
factors. Among affinity regulatory signals, divalent cations
such as Mn2+, Mg2+ or Ca2+ (77-79) rank as important
elements at least in vitro. On the other hand, the binding of
integrins to endothelial ligands can be enhanced
independently of integrin affinity by increasing receptor
density (avidity) at the contact area. Integrin avidity can be
defined as a rapid interplay between preformed, ligand-
induced, and chemokine-triggered avidity states (reviewed
in 42). Other potential modulators of VLA-4 and LFA-1
avidity at dynamic contacts, requiring concomitant
chemokine triggering, seem to be CD47 and L-selectin (80,
81). There is still another level of regulation known as
integrin cross-talk. Thus, the interaction of high affinity
VLA-4 with VCAM-1 may trigger LFA-1 clustering,
enhancing its avidity to ICAM-1, and promoting leukocyte
firm adhesion to endothelium. On the contrary, LFA-
1/ICAM-1 engagement decreases the binding of VLA-4 to
VCAM-1, allowing leukocyte migration towards the
transmigration sites (82, 83).
The clustering of integrins is dependent on their
release from the actin cytoskeleton. In this regard, there are
relevant differences between VLA-4 and LFA-1. LFA-1
may preform microclusters stabilized by H-ras and
cytohesin-1, which are activated via PI3-K or PKC (84-86).
However, the macroclustering of LFA-1 prior to ligand
engagement is prevented by cytoskeleton anchorage, with
the involvement of non-phosphorylated PKC substrates and
talin. Consequently, it is necessary the activation of  PKC
and calpain to release LFA-1 from the actin cytoskeleton
(87). Conversely, VLA-4 clustering cannot be induced
prior to ligand binding. Furthermore, although PKC signals
participate in the release of VLA-4 from cytoskeleton,
calpain or PI3-K are not implicated. In addition, it has been
described that VLA-4 constitutively interacts with paxillin,
while LFA-1 is able to interact with alpha-actinin
(reviewed in 42).
Once integrin avidity has been up-regulated and
an effective engagement with ligand occurs, the integrin
anchorage to actin cytoskeleton is restored and outside-in
signaling leads to actin remodelling and cell spreading.
Then, leukocytes undergo a profound change in their
morphology, acquiring a polarized, motility-related shape
(reviewed in 88). This cell shape change favors leukocyte
extravasation, and is also involved in the recruitment of
bystander leukocytes through the trailing edge (uropod)
(89).
4.3. The docking structure: the endothelial contribution
to the leukocyte  firm adhesion process
Endothelium had been considered as a mere
physiological barrier, a passive partner for leukocytes
during TEM. However, it is now evident that endothelium
is a key active element in different physiological processes,
including leukocyte extravasation. Our group has
contributed to gain insight into the molecular mechanisms
underlying the active role of endothelial cells in the TEM
of leukocytes. We have found that activated endothelial
cells generate “docking” structures that efficiently attach
leukocytes, partially engulfing them. VCAM-1 and ICAM-
1, together with cytoskeletal and signaling molecules, are
essential constituents of these cup-like structures based on
microspikes that emerge from the endothelial apical
surface, and which are dynamically involved in capturing
leukocytes prior to TEM (90).
4.3.1. VCAM-1 and ICAM-1 play an essential role in
leukocyte capture
VCAM-1 and ICAM-1, members of the Ig
superfamily, are the two major endothelial adhesion
molecules involved in the binding to leukocyte integrins
VLA-4 and LFA-1, respectively (91, 92). ICAM-1 but not
VCAM-1 is expressed at low levels in resting endothelium,
and both molecules are induced upon cell activation by pro-
inflammatory cytokines such as IL-1 and TNF-alpha(93,
94). We have recently found that these integrin ligands are
laterally associated with different tetraspanins (CD9, CD81
and CD151), forming protein microdomains in the apical
surface of endothelium (Barreiro and Yáñez-Mó,
unpublished data). Furthermore, it has been described that
VCAM-1 and ICAM-1 are anchored to the actin
cytoskeleton through members of the ERM family, mainly
ezrin and moesin (90, 95, 96). All these molecules, which
are clustered at endothelial microvilli and microspikes,
contact and surround the adherent leukocyte, as key
elements of the docking structure. The cytoskeletal linkage
of VCAM-1 and ICAM-1 is critical for the generation of
this structure upon leukocyte adhesion, but it is not
necessary for the proper presentation of VCAM-1 and
ICAM-1 at the apical surface, since this localization seems
to be independent of ligand engagement and actin
anchorage (Barreiro and Yáñez-Mó, unpublished data).
Dynamic experiments have demonstrated the
involvement of ICAM-1 (through its interaction with LFA-
1) not only in the firm adhesion of leukocytes but in their
transendothelial migration and subsequent movement
underneath the endothelial monolayer. Moesin has a similar
behaviour, suggesting that ICAM-1 is anchored to the actin
cytoskeleton via ERM proteins during the whole process.
On the contrary, VCAM-1 is excluded of the late steps of
leukocyte extravasation and only participates in the
formation of the endothelial docking structure that firmly
attaches the lymphocyte to the endothelium (90).
4.3.2. Structural components and signaling pathways
involved in the generation and maintenance of the
docking structure
The sequential steps involved in the generation of
the endothelial docking structure could be as follows. The
initial interaction of VCAM-1 and ICAM-1 with their
ligands (VLA-4 and LFA-1 integrins, respectively) triggers
their clustering at the leukocyte-endothelium contact area,
together with phosphorylated activated ERM proteins.
Then, these adaptor proteins in concert with alpha-actinin
and vinculin participate in the rearrangement of the actin
cytoskeleton to generate the docking structure. The
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participation of other focal adhesion proteins such as talin
or paxillin remains to be elucidated. On the other hand, it
has been also described that VASP, which cooperates with
the WASP-Arp2/3 complex in actin polymerization at
nascent protrusions (97), is concentrated at the docking
structure (90). These data suggest that this endothelial
structure is supported by actin polymerization. However,
microtubules do not appear to be involved in this process.
Interestingly, the endothelial docking structure seems to be
reminiscent of nascent complement receptor-mediated
phagosomes, in that the subcellular distribution of all these
structural proteins is similar in both structures (98).
Regarding the signaling pathways involved in the
generation and maintenance of the docking structure, it has
been described the preferential accumulation of PI(4,5)P2 at
the tips of the microspikes of this structure, where could
participate in the activation of the ERM proteins.
Furthermore, the essential role of the Rho/p160 ROCK
signaling pathway in the formation of this protrusive
structure, has been also documented (90). These results
concur with the regulation of the VCAM-1, ICAM-1, and
E-selectin clustering by the GTPase Rho during monocyte
adhesion (99). Finally, further analyses are necessary to
understand the mechanisms underlying the disruption of the
endothelial docking structure to allow leukocyte diapedesis.
4.3.3. VCAM-1 and ICAM-1 outside-in signaling
VCAM-1 and ICAM-1 are capable of transducing
signals after ligand binding. VCAM-1 is involved in the
opening of the “endothelial passage” through which
leukocytes can extravasate. In this regard, VCAM-1
ligation induces NADPH oxidase activation and the
production of reactive oxygen species (ROS) in a Rac-
mediated manner, with subsequent activation of matrix
metalloproteinases and loss of VE-cadherin-mediated
adhesion. This signaling pathway can be blocked by
TGFbeta1 and IFNgamma (100-103). On the other hand,
cross-linking of both VCAM-1 and ICAM-1 induces a
rapid increase in intracellular Ca2+ concentration (62, 104).
ICAM-1-mediated calcium signaling has been mostly
studied in brain endothelial cells. In this cellular model, it
has been found that ICAM-1-mediated calcium increase
triggers activation of Src and subsequent phosphorylation
of cortactin (104). ICAM-1 is also able to activate RhoA
inducing stress fiber formation (105) and phosphorylation
of FAK, paxillin and p130Cas, which in turn trigger
different signaling pathways involving JNK or p38 (106-
108). Moreover, ICAM-1 cross-linking stimulate c-fos and
rhoA transcription (105). As reported for PSGL-1 (59),
ICAM-1 might enhance c-fos expression through the
recruitment of Syk to the ICAM-1/ERM complex, but such
possibility deserves further investigation. Finally, the
ICAM-1 cross-linking can induce its own expression as
well as that of VCAM-1, as a regulatory mechanism to
facilitate leukocyte TEM (109).
5. TRANSENDOTHELIAL MIGRATION
The signals involved in the firm adhesion of
leukocytes to endothelium must be reverted, weakening the
original contact sufficiently to allow the migration and
extravasation of leukocytes. During TEM, endothelial
junctions must be loosen to a limited extent, thereby
avoiding cell monolayer damage or important changes in
permeability. Thus, the leukocyte and endothelium
membranes are kept in close contact and show prominent
associated cytoskeletal structures. Subsequently, the
endothelial membranes reseal their connections over the
trailing end of the leukocyte.
5.1. Leukocytes undergo drastic cytoskeletal
rearrangements to extravasate across the endothelial
barrier
In leukocytes, integrin-dependent adhesion is
required for changes in cytoskeleton plasticity and cell
motility (110). In addition, it has been recently described
that immobilized chemokines play a pivotal role in this
process, since SDF-1alpha presented on the apical surface
of endothelial cells can trigger lymphoid TEM under shear
stress conditions in the absence of a chemoattractant
gradient across the endothelium, whereas soluble
chemotactic gradients do not. This process has been
designated as “chemorheotaxis” (111). However,
monocytes (112) and neutrophils (113) do not require
endothelial apical chemokines to undergo TEM, hence
postulating this phenomenon as lymphocyte-specific.
The regulation of the deformation of the
leukocyte cytoskeleton during TEM has not been well
studied. The possible activation of regulators of the actin
cytoskeleton such as small Rho GTPases by integrins or
chemokines remains to be elucidated. However, an
attractive hypothesis would comprise the activation of
Cdc42 by integrins or chemokines, which would cause the
extension of a thin exploratory pseudopodium between
endothelial cells that, by sequential Rac1 activation, would
evolve into a lamella squeezed within an endothelial
monolayer gap. This leading lamella and the leukocyte
membrane in contact with endothelium are enriched in
LFA-1 (114, 115). Finally, the stretching of cell body and
tail retraction would result from delayed, tail-oriented
RhoA-ROCK activation and actomyosin-based contraction
(116).
5.2. Endothelial cell lateral junctions regulation
 The components of the endothelial lateral
junctions can be divided in tight, adherens and gap
junctions, each containing distinct molecular constituents,
although they do not exhibit a well-organized basolateral
organization as in epithelium. These molecular complexes
are dynamically organized, associate with the actin
cytoskeleton and, except for gap junctions, actively
participate in leukocyte TEM. Recent reports strongly
suggest that leukocytes and endothelium communicate each
other during TEM. The most characterized intracellular
signals generated by TEM in endothelium are the
mobilization of intracellular Ca2+ and the reorganization of
actin, myosin and associated molecules (117, 118).
Figure 3 establishes a comparison between the
interendothelial junctions in the vascular wall and the
heterotypic leukocyte-endothelium interactions during
transendothelial migration. The morphological changes that
leukocytes undergo to pass across the endothelial barrier, as
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Figure 3. Comparison between the interendothelial junctions in the vascular wall and the heterotypic leukocyte-endothelium
interactions during transendothelial migration. Only the molecules involved in both processes are shown, including members of
the tight junctions (ESAM and the JAM family), the VE-cadherin complex and other molecules such as PECAM-1 and CD99. Most of
them interact homophilically, being express by the endothelium as well as by leukocytes. On the other hand, the processes of
lamellipodia formation at the leukocyte leading edge and tail retraction, the phenomenon of chemorheotaxis and the existence of a
subendothelial soluble chemoattractant gradient to guide the extravasated leukocytes to the target tissue are also illustrated.
well as the effect of chemokines and chemoattractant
gradients in this process, have been also specified.
5.2.1. Tight junction proteins: role of JAM family in
transendothelial migration
Among the components of tight junctions
(occludin, claudins, ZO-1, -2, -3, etc), two novel groups of
adhesion molecules belonging to the Ig superfamily have
been recently identified: ESAM (Endothelial cell-Selective
Adhesion Molecule) and JAM (Junctional Adhesion
Molecule) proteins. In contrast with other members of tight
junctions, they play a role in paracellular permeability as
well as in lymphocyte homing and TEM. ESAM is
involved in the homotypic interaction of endothelial cells,
but no heterophilic ligands have been described yet (119,
120).To date, three members of the JAM family have been
identified: JAM-1, huJAM-2 (which corresponds to
mJAM-3) and huJAM-3 (which corresponds to mJAM-2)
(reviewed in 121). JAM-1 is expressed in epithelium,
endothelium, erythrocytes, PMNs, monocytes, lymphocytes
and platelets; huJAM2 is preferentially expressed in high
endothelial venules (HEV); and JAM3 is detected in
endothelium and activated T lymphocyte subsets (122-
27). All members of the family contain a PDZ-binding
motif in their cytoplasmic tail, which is involved in their
association with components of the tight junctions such as
ZO-1 and AF-6, suggesting a role for these molecules in
recruiting and stabilizing JAMs to site of junction
formation (128, 129). The JAM family proteins can
interact homophilically at endothelial tight junctions to
regulate paracellular permeability or heterophilically with
counterreceptors from leukocytes to support TEM. In this
regard, it has been described that JAM-1 is capable to
interact with itself or with LFA-1 (130). huJAM-2 and
huJAM-3 are binding partners, and this interaction could
have relevance for lymphocyte homing, due to the
restricted expression of huJAM-2 in high endothelial
venules (124). Furthermore, huJAM-3 is also capable to
interact with itself (131) and with alphaMbeta2 and
alphaXbeta2 integrins (132). In turn, huJAM-2 interacts
with alpha4beta1 integrin (133). The fact that all the
members of the JAM family interact with leukocyte
integrins and that are relocalized towards the apical
surface upon endothelium activation argues for their
fundamental role in the regulation of leukocyte
adhesion.
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5.2.2. Adherens junction disappearance at leukocyte
contacts: proteolysis or displacement?
Adherens junctions are primarily involved in the
regulation of endothelial cell monolayer permeability. The
main component of these molecular complexes is VE-
cadherin, which mediates Ca2+-dependent homophilic
adhesion with its extracellular domain and actin
cytoskeleton linkage through the interaction of its
cytoplasmic tail with alpha-, beta-, gamma-catenin, and
p120/100 (134). During leukocyte TEM, VE-cadherin
complexes are locally disrupted, generating a localized gap
necessary for leukocyte passage, which reseals after TEM.
According to these observations, VE-cadherin acts as a
“gatekeeper” for leukocyte transmigration. Whether or not
this disruption of adherens junctions involves protein
degradation has been extensively discussed (135-137).
However, the rapid recovery of adherens junctions after the
passage of leukocytes seems to point to the existence of a
zipper mechanism, which implies the local and transient
displacement of molecular complexes from the leukocyte-
endothelium area (“trapdoor model”) (138, 139). However,
the possibility of a certain degree of complex proteolysis
cannot be excluded. Moreover, other alternative
mechanisms such as transcytosis or preferential passage
through tricellular corners, where tight junctions and
adherens junctions are less organized, cannot be ruled out
(140-142).
5.2.3. Other molecules with a major role in the passage
of leukocytes across endothelium
Apart from the above-mentioned molecules, there
are other endothelial proteins critical for leukocyte TEM
that do not belong to tight junctions or adherens junctions
complexes. PECAM-1 is another member of the
immunoglobulin superfamily that is expressed in
endothelium as well as in leukocytes, and that actively
participates in TEM (143). It can associate homophilically
or with alphavbeta3 in cis- (144, 145). PECAM-1
transduces negative intracellular signals via the ITIM motif
of its cytoplasmic tail (146). In addition, PECAM-1 can
regulate adherens junctions by associating to beta-catenin
(147). Finally, a recent report describes the existence of a
molecular network just below the endothelial plasma
membrane that is connected at intervals with the junctional
surface. PECAM-1 has been found in this compartment,
constitutively recycling along the endothelium borders.
During TEM, PECAM-1 recycling molecules are targeted
to points of contact with leukocytes. This mechanism could
explain how endothelial cells change their borders rapid
and reversely, but remaining tightly apposed to leukocytes
to allow their migration (148).
CD99, a highly O-glycosylated type I
transmembrane protein, has been found to play a critical
role in monocyte TEM, acting at a later stage than
PECAM-1 (149). This protein is expressed in leukocytes,
where triggers the activation of alpha4beta1 integrin and
regulates the activity of LFA-1, and endothelium,
interacting homophilically at interendothelial contacts
(reviewed in 145). However, little is known about its
precise function on endothelial cells or its involvement in
signaling transduction .
6. CONCLUDING REMARKS AND PERSPECTIVES
Over the last decade, a huge effort has been made
for the study of the basic adhesive mechanisms underlying
vascular function. In this regard, the dissection of the
phenomena involved in leukocyte extravasation has
significantly improved our knowledge of different
pathophysiological conditions. The recent description of
new molecular complexes and subcellular structures
implicated in this process, as well as the characterization of
new intracellular signaling pathways or cytoskeletal
components, have added more complexity to the
extravasation mechanism and opened new insights to future
investigations. Furthermore, molecules that are newly being
involved in this process could constitute potential
molecular targets for therapeutic intervention. Finally,
some controversies and obscure points regarding, e.g.,
differences in the behaviour of monocytes, neutrophils or
lymphocytes during TEM or the regulation of
interendothelial junctions to allow the passage of
leukocytes still remain partially unsolved.
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Endothelial tetraspanin microdomains regulate leukocyte firm adhesion
during extravasation
Olga Barreiro, Marı´a Ya´n˜ez-Mo´, Mo´nica Sala-Valde´s, Marı´a Dolores Gutie´rrez-Lo´pez, Susana Ovalle, Adrian Higginbottom, Peter N. Monk,
Carlos Caban˜as, and Francisco Sa´nchez-Madrid
Tetraspanins associate with several trans-
membrane proteins forming microdo-
mains involved in intercellular adhesion
and migration. Here, we show that endo-
thelial tetraspanins relocalize to the con-
tact site with transmigrating leukocytes
and associate laterally with both intercel-
lular adhesion molecule-1 (ICAM-1) and
vascular cell adhesion molecule-1 (VCAM-
1). Alteration of endothelial tetraspanin
microdomains by CD9–large extracellular
loop (LEL)–glutathione S–transferase
(GST) peptides or CD9/CD151 siRNA oligo-
nucleotides interfered with ICAM-1 and
VCAM-1 function, preventing lymphocyte
transendothelial migration and increas-
ing lymphocyte detachment under shear
flow. Heterotypic intercellular adhesion
mediated by VCAM-1 or ICAM-1 was aug-
mented when expressed exogenously in
the appropriate tetraspanin environment.
Therefore, tetraspanin microdomains
have a crucial role in the proper adhesive
function of ICAM-1 and VCAM-1 during
leukocyte adhesion and transendothelial
migration. (Blood. 2005;105:2852-2861)
© 2005 by The American Society of Hematology
Introduction
Plasma membrane contains small organized microdomains (lipid
rafts) in which restricted repertoires of proteins are arranged
together.1,2 In resting cells, lipid rafts are estimated to be around
100 nm in diameter, including a few dozen proteins, and are distributed
randomly on the cell surface, covering up to 50% of the plasma
membrane. Upon cell activation, raft domains coalesce, recruiting and
excluding different receptors, and allowing the proper organization of
signaling complexes for efficient signal transduction.1,2
Tetraspanins comprise a large number of small palmitoylated
polypeptides that span the plasma membrane 4 times,3-6 and form
microdomains that contain a restricted repertoire of proteins.
Biochemically, they share some properties with lipid rafts, but
tetraspanin microdomains are based on protein-protein interac-
tions.7-10 Tetraspanins have a highly conserved structure with a
short and a large extracellular loop (LEL) where 2 or 3 disulfide
bonds can be formed.11 This large loop interacts noncovalently with
other tetraspanins and transmembrane proteins, including integrins
and adhesion receptors of the immunoglobulin (Ig) superfamily.
Although all mammalian cells express different tetraspanins,
genetic approaches have been elusive and their function has not yet
been fully elucidated. However, their role in antigen presentation
and sperm-egg binding has been recently underscored.12-20
The association of certain plasma membrane proteins to the
cortical actin cytoskeleton is critical for their proper localization
and function. Thus, the concentration of selectins and their ligands
on the tip of microvilli21,22 both at the leukocyte and the apical
surface of endothelial cells favors their interaction during the
rolling phase of leukocyte extravasation. Likewise, vascular cell
adhesion molecule-1 (VCAM-1) and intercellular adhesion mole-
cule-1 (ICAM-1), which are relevant in the subsequent leukocyte
firm adhesion step, are also displayed anchored to actin through
ezrin-radixin-moesin proteins (ERMs)23,24 at the apical surface on
endothelial cells. Upon leukocyte firm adhesion, the engagement of
VCAM-1 and ICAM-1 triggers the reorganization of the endothe-
lial cortical actin cytoskeleton, building up a 3-dimensional
docking structure that prevents the detachment of leukocytes by
shear stress.22,23 Here, we show that ICAM-1 and VCAM-1 are
included in tetraspanin microdomains that regulate their membrane
expression and the efficient adhesive function necessary for proper
leukocyte transendothelial migration under flow conditions.
Materials and methods
Cells and cell cultures
Human umbilical vein endothelial cells (HUVECs) were obtained and
cultured as previously described.25 Cells were used up to the third passage
in all assays. To activate HUVECs, tumor necrosis factor- (TNF-; 20
ng/mL)(R&D Systems, Minneapolis, MN) was added to the culture media
20 hours before the assays were performed. T lymphoblasts were derived
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from freshly isolated human peripheral blood lymphocytes (PBLs) by
activation with phytohemagglutinin-L (PHA-L) (1 g/mL; Sigma, St Louis,
MO) for 24 hours followed by culture for 7 to 14 days in the presence of
recombinant human (rh) interleukin-2 (IL-2; 50 U/mL) obtained from M.
Gately (Hoffmann-LaRoche, Nutley, NJ) was provided by the National
Institutes of Health AIDS Research and Reference Reagent program,
Division of AIDS. Human PBLs, monocytes, neutrophils, and K562
erythroleukemic cells stably transfected with the 4 or lymphocyte
function–associated antigen-1 (LFA-1) integrins were obtained and cul-
tured as described.23 Adhesion of K562 LFA-1 transfectants to Colo320
colocarcinoma cell line was performed in the presence of 1mM Mn2 to
induce integrin activation. Colo320-CD9 and chimeric Colo320-CD9  82
and Colo320-CD82CCG9 are stably transfected clones derived from those
previously described.26 Approval was obtained from the Hospital Universi-
tario de la Princesa institutional review board for these studies. Informed
consent was provided according to the Declaration of Helsinki.
Antibodies and recombinant DNA constructs and proteins
Monoclonal antibodies (mAbs) anti-CD151 (LIA1/1), anti–1 integrin
(TS2/16), anti–vascular endothelial (VE)–cadherin (TEA1/31), anti–E-
selectin (TEA2/1), anti-CD44 (HP2/9), anti-CD63 (Tea3/18), and anti-CD9
(VJ1/20) have been previously described.25,27-29 The 4B9 and P8B1
(anti–VCAM-1), Hu5/3 (anti–ICAM-1), 10B1 (anti-CD9), TS82 (anti-
CD82), 8C3 (anti-CD151), and I.33.22 (anti-CD81) mAbs were kindly
provided by R. Lobb (Biogen, Cambridge, MA), E. A. Wayner (Fred
Hutchinson Cancer Research Center, Seattle, WA), F. W. Luscinskas
(Brigham and Women’s Hospital and Harvard Medical School, Boston,
MA), E. Rubinstein (INSERM U268, Villejuif, France), K. Sekiguchi
(Osaka University, Japan), and R. Vilella (Hospital Clinic, Barcelona,
Spain), respectively. The IgG1, mAb from the P3  63 myeloma cell line
was used as negative control. Anti-GST goat polyclonal Ab was purchased
from Amersham Biosciences (Uppsala, Sweden), and anti-vimentin mAb
was purchased from Sigma.
ICAM-1, VCAM-1, CD9, and CD151–green fluorescent protein (GFP)
tagged proteins have been described.23,30 The LEL-GST peptides of wild-type
human CD9 or the mutated forms in the Cys residues have also been described.31
The corresponding CD151-LEL-GST peptide presented a low rate of proper
folding in solution which precluded its use in functional studies.
Flow cytometry analysis, immunofluorescence, and
confocal microscopy
For flow cytometry analysis and immunofluorescence experiments, cells
were treated as previously described.25 Paraformaldehyde solution (4%)
was used as a fixative in all samples. Alexa Fluor 488 goat anti–mouse IgG
conjugate and rhodamine red–X-Affinipure streptavidin were used as
fluorescent reagents (Molecular Probes, Eugene, OR). A series of optical
sections were obtained with a Leica TCS-SP confocal laser scanning unit
equipped with Ar and He/Ne laser beams and attached to a Leica DMIRBE
inverted epifluorescence microscope (Leica Microsystems, Heidelberg,
Germany), using a PL APO 63 /1.32-0.6 oil immersion objective.
Time-lapse fluorescence confocal microscopy
Transiently transfected HUVECs were generated by electroporation at 200
V and 975 F using a Gene Pulser (Bio-Rad Labs, Hercules, CA), and
adding 20 g of each DNA construct. These cells were grown to confluence
for 24 to 48 hours on glass-bottom dishes (WillCo Wells, Amsterdam, the
Netherlands) precoated with fibronectin (20 g/mL; Sigma). Cells were
activated with TNF- for 20 hours; then, T lymphoblasts resuspended in
500 L of complete 199 medium (BioWhittaker, Verviers, Belgium) were
added. During the observation time, plates were maintained at 37°C in a 5%
CO2 atmosphere using an incubation system (La-con GBr Pe-con GmbH,
Erbach, Germany). Confocal series of fluorescence and differential interfer-
ence contrast (DIC) images, distanced 0.4 m in the z-axis, were
simultaneously obtained at 30-second or 1 minute intervals with a  63 oil
immersion objective. Images were processed and assembled into movies
using Leica Confocal software.
Coimmunoprecipitation assays
Coimmunoprecipitation experiments were performed as previously de-
scribed25 with TNF-–activated HUVEC lysates obtained in 1% Brij96
(Sigma) in 1 mM Ca2 and 1 mM Mg2 Tris-buffered saline (TBS) with
protease inhibitors.
Small interference RNA assay
To selectively knock down the expression of endothelial tetraspanins CD9
and CD151, a screening of different target sequences for each protein was
performed using siRNA expression cassettes (Ambion, Austin, TX). We
found the silencing sequences GAGCATCTTCGAGCAAGAA and CATGT-
GGCACCGTTTGCCT for CD9 and CD151, respectively. RNA duplexes
corresponding to these target sequences, as well as a negative oligonucleo-
tide that does not pair with any human mRNA, designed by Eurogentec
(Seraing, Belgium), were used. Oligos were transfected in HUVECs with
oligofectamine (Invitrogen, Carlsbad, CA) following manufacturer’s instruc-
tions. For CD9 interference, cells were transfected on day 0, further split on
day 2, and retransfected on day 3. In parallel, on day 3, cells were
transfected only once for CD151 knocking down. Then, cells were
trypsinized on day 6 and negatively selected with anti-CD9 or anti-CD151
magnetic coated beads (Dynabeads M450 Goat anti-Mouse IgG; Dynal
Biotech ASA, Oslo, Norway) for 3 to 5 minutes at 4°C under rotation to
enrich the tetraspanin low-expressing population. Cells thus selected were
counted and seeded onto fibronectin to confluence for the different
experiments, since its receptor 51 expression was not altered by
tetraspanin knocking down (not shown).
Paracellular monolayer permeability measurements
HUVEC monolayer paracellular permeability measurements were per-
formed in 0.4-m pore diameter Transwells (Costar, Corning, NY) with 77
kDa fluoroscein isothiocyanate (FITC)–labeled dextran (Sigma) as
described.32
Adhesion and transendothelial migration assays
Adhesion of human PBLs to HUVEC monolayers was performed in static
conditions for 15 minutes at 37°C and measured as described.23
PBL migration through a confluent monolayer of activated HUVECs
was assayed in 3-m pore Transwell cell culture chambers (Costar).
HUVECs were grown to confluence on Transwell inserts precoated with 1%
fixed gelatin or 20 g/mL of fibronectin and activated with TNF- for 20
hours in the presence or not of 150 g/mL of the LEL-GST fusion proteins
or after knocking down tetraspanin proteins. Monolayers were washed and
freshly isolated PBLs (2  105 in 100 L/well) were added to the upper
chambers. In the lower well, 600 L of complete 199 medium, with or
without 100 ng/mL of human recombinant stromal cell–derived fac-
tor-1 (SDF-1; R&D Systems, Minneapolis, MN) were poured.
Chambers were incubated for 2 to 7 hours at 37°C. Migrated lympho-
cytes, ranging from 5% to 20%, were recovered from the lower chamber
and estimated by flow cytometry.
Parallel plate flow chamber analysis of endothelial-PBL
interactions and detachment experiments
The parallel plate flow chamber used for leukocyte adhesion and detach-
ment under defined laminar flow has been described in detail.33 PBLs
(1  106/mL) were drawn across activated confluent monolayers at an
estimated wall shear stress of 1.8 dyn/cm2 for 10 minutes. Lymphocyte
rolling on the endothelium was easily visualized since they traveled more
slowly than free-flowing cells. Lymphocytes were considered to be
adherent after 20 seconds of stable contact with the monolayer. Transmi-
grated lymphocytes were determined as those being beneath the endothelial
monolayer. Lymphocytes were considered to be detached when they
returned to a free-flowing state after having established a transient contact
with the endothelium. The number of rolling, adhered, transmigrated, and
detached cells was quantified by direct visualization of 6 different fields
( 20 phase-contrast objective) for 30 seconds starting at 3.5 minutes and
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ending at 6.5 minutes. Digitalization was performed with Optimas
software (Bioscan).
For detachment experiments, peripheral blood lymphocytes were
allowed to adhere for 15 minutes at 37°C to activated HUVEC monolayers,
either incubated with LEL-GSTs for 20 hours, or transfected with siRNA
oligos. Then, shear stress was applied by pulling assay buffer (Hanks
balanced salt solution [HBSS] buffer with 2% fetal calf serum [FCS])
through the flow chamber with a programmable syringe pump, starting at 2
dyn/cm2 and increasing up to 30 dyn/cm2 at 1-minute intervals. The number
of cells attached after each shear stress interval was quantified in 4 to 8
fields ( 20 phase-contrast objective). Cell detachment was obtained from
the difference in adhered cells after substracting the percentage of cells that
had transmigrated during the assay.
Heterotypic intercellular binding assays
Colo320 colocarcinoma cells or different stable transfectants derived from
this cell line were transiently transfected with ICAM-1-GFP or VCAM-1-
GFP by electroporation in an ElectroSquarePorator ECM 830 (BTX, VWR,
San Diego, CA). A total of 5  105 cells of each condition were mixed with
with 2  105 of K562 cells, either untransfected or stably transfected with
4 or LFA-1 integrins, which had been previously loaded with the
CM-TMR (5-(and-6)-(((4-chloromethyl)benzoyl)amino)tetramethylrhoda-
mine) red fluorescent dye (Molecular Probes). Then, cells were allowed to
adhere at room temperature under rotatory conditions for 90 minutes in
RPMI medium without supplements. The relative number of heterotypic
intercellular binding was estimated by flow cytometry.
Results
Tetraspanins are components of the endothelial docking
structure for adherent leukocytes by their association with
ICAM-1 and VCAM-1
Tetraspanin proteins are low-molecular-weight polypeptides that
are able to associate with a variety of transmembrane proteins via
their extracellular domain, forming multiproteic domains in the
plasma membrane. They have been involved in several cellular
functions including intercellular homotypic and heterotypic adhe-
sion;6 however, genetic approaches directed to tetraspanins did not
render clear-cut information on their individual funcional roles.
HUVECs express several of these proteins (CD9, CD81, CD151,
CD63), both at intercellular contacts and intracellular vesicles.25,34
On the other hand, T lymphoblasts express CD81 and low levels of
CD151, whereas the expression of CD9 is heterogeneous, ranging
from completely negative to high expressing cells, and the relative
amount of each population varies in different human donors. Upon
T lymphoblast adhesion onto activated HUVEC monolayers,
endothelial tetraspanins redistributed, together with ICAM-1 and
VCAM-1, to the docking structure that emerges from the apical
surface to firmly attach the transmigrating cell22,23 (Figure 1A-B,
and data not shown). Tetraspanin redistribution was also observed
under flow conditions around adherent peripheral blood lympho-
cytes, neutrophils, or monocytes (Figure 1C for CD9, and data
not shown).
To determine the subcellular localization of endothelial
tetraspanins during the whole transendothelial migration pro-
cess, T lymphoblasts were allowed to transmigrate across
TNF-–activated HUVEC monolayers. CD9 clustering was
evident in those lymphocyte-endothelial interactions occurring
at the apical surface of the monolayer (Figure 1D, white
arrows). In contrast, almost no redistribution of CD9 could be
observed at the ventral surface of endothelial cells in contact
with transmigrated lymphoblasts (Figure 1D, gray arrows). On
the other hand, CD151 relocalization around lymphoblasts was
clearly detected at both the apical and basal surface of the
endothelial cell (Figure 1D; white and gray arrows, respec-
tively), paralleling the behavior of ICAM-1. Similarly to that
observed with the endogenous protein stainings, CD9-GFP was
more clearly relocalized to the contact site with T lymphoblasts
at the endothelial apical surface, although some clustering
occurred around transmigrated lymphoblasts locomoting under-
neath the endothelium (Supplemental Video S1; see the Supple-
mental Video link at the top of the online article on the Blood
website). On the other hand, CD151-GFP was strongly concen-
trated at the contact with lymphoblasts throughout all the
transmigration process (Video S2). These data point to the
existence of different tetraspanin microdomains at the apical and
ventral endothelial surfaces and suggest a complex dynamic
regulation of these membrane domains.
Tetraspanin interactions are biochemically detected by extrac-
tion with Brij 96/97 detergents. Although HUVEC tetraspanins
were mostly associated with EWI-F and 1 integrins (Ya´n˜ez-Mo´
et al25 and data not shown), CD9 and CD151 were also able to
pull down ICAM-1 and VCAM-1 (Figure 1E). Conversely,
ICAM-1 mAbs were also able to coprecipitate CD9, whereas
VCAM-1 mainly coprecipitated CD151. No detectable signal
for ICAM-1 was observed in 1 immunoprecipitates (not
shown), suggesting that tetraspanin-integrin complexes are
different to tetraspanin/ICAM-1/VCAM-1 complexes. Coprecipi-
tation of CD9 and CD151 with ICAM-1 and VCAM-1 could
also be faintly detected upon extraction with 1% digitonin (not
shown), conditions in which most interactions among tetraspan-
ins are lost and direct tetraspanin-partner associations are
observed.35 These results indicate that ICAM-1 and VCAM-1
are included into tetraspanin microdomains.
Tetraspanin microdomains are critical for a proper expression
and function of ICAM-1 and VCAM-1
In order to gain insights into the relevance of the inclusion of
ICAM-1 and VCAM-1 into tetraspanin microdomains at endothe-
lial cells, we used an siRNA approach against tetraspanins CD9 and
CD151 in primary human endothelial cells. Endothelial tetraspanin
CD9 and CD151 expression was considerably knocked down with
specific siRNA oligos. In no case was the expression completely
abolished, but a significant reduction (40%-70%) was attained
(Figure 2A and B; flow cytometry analysis depicted in logarithmic
scale and mean fluorescence quantified in Figure 2C). In immuno-
fluorescence analyses a clear reduction of tetraspanin staining
could be observed, with some cells showing expression levels
even below the detection threshold (Figure 2D). A compensation
effect on the expression of other tetraspanins was observed
(Figure 2B-D).
HUVECs thus treated were viable and clearly responded to
TNF-, increasing ICAM-1, VCAM-1, and E-selectin expres-
sion over resting levels (ICAM-1 expression increased 10- to
30-fold upon TNF- treatment, whereas VCAM-1 and E-
selectin were undetectable in resting cells; Figure 3A, dotted
line). The siRNA transfection procedure slightly affected the
inducible expression of these adhesion receptors when com-
pared with untransfected cells, as determined with a negative
oligonucleotide control that does nor pair with any human
mRNA (not shown). In CD9 or CD151 tetraspanin-interfered
cells, a selective reduction in the expression of ICAM-1 and
VCAM-1, but not that of E-selectin or CD44 was observed
(Figure 3A, thick versus thin line). This reduction was of 60%
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for ICAM-1 and 80% for VCAM-1 when compared with their
expression in negative oligonucleotide-transfected cells to ex-
clude any off-target effect caused by siRNA transfection (Figure
3B). These data further emphasize the importance of tetraspanin
microdomains in ICAM-1 and VCAM-1 expression and suggest
that their association with tetraspanins occurs early in the
biosynthetic processing of these Ig adhesion molecules, or that it
is necessary for their proper membrane insertion or retention.
Figure 1. Endothelial tetraspanin proteins relocalize to the contact site with adherent leukocytes and associate with ICAM-1 and VCAM-1. (A) T lymphoblasts were
adhered to TNF-–activated HUVEC monolayers, fixed, and double-stained for CD9 and VCAM-1 or ICAM-1. Maximum projections of the relevant sections from the confocal
stacks and the merge of both channels are shown. Asterisks in differential interference contrast (DIC) images highlight the T lymphoblasts around which the docking structures
shown in the 3-dimensional (3D) reconstructions are formed. Scale bars equal 10 m. (B) T lymphoblasts were adhered to TNF-–activated HUVEC monolayers, fixed, and
stained with antitetraspanin mAbs VJ1/20 (anti-CD9), I.33.2.2 (anti-CD81), and LIA1/1 (anti-CD151). Confocal stacks were obtained and representative apical horizontal and
vertical sections together with the corresponding DIC images are shown. Arrows point to the positions of the adhered lymphoblasts. Arrowheads and lines point to the position
of the adhered lymphoblasts shown in the vertical sections. Scale bar equals 10 m. (C) Human PBLs, neutrophils, or monocytes were perfused at physiologic flow rate (1.8
dyn/cm2), fixed, and stained with anti-CD9 VJ1/20 mAb. Confocal stacks were obtained and maximum projections of the whole series or a representative section together with
the corresponding DIC images are shown. Arrows point to the position of the adhered leukocytes. Scale bar equals 20 m. (D) Analysis of the localization of endogenous
endothelial CD9 or CD151, compared with ICAM-1, at apical and ventral contact sites with transmigrating lymphocytes. Human T lymphoblasts were allowed to transmigrate
through TNF-–activated HUVECs, fixed, and double-stained with antitetraspanin mAbs and biotin-conjugated anti–ICAM-1. Confocal stacks were obtained and
representative sections at apical or ventral positions of the same field together with the corresponding DIC image are displayed. White arrows and asterisks mark apically
adhered lymphocytes, and gray arrows and black asterisks mark those lymphocytes that have transmigrated. Arrowheads and lines point to the position of the adhered or
transmigrated lymphoblast shown in the vertical sections. Scale bar equals 10 m. (E) ICAM-1 and VCAM-1 are associated with tetraspanins in TNF-–activated HUVECs.
Cell lysates were obtained in 1% Brij96 and immunoprecipitated with the different mAbs specific for endothelial adhesion molecules or tetraspanins. After washing,
immunoprecipitates were resolved in sodium dodecyl sulfate–polyacrylamide gel electrophosphoresis (SDS-PAGE) gels and revealed by Western blot for VCAM-1 (P8B1),
ICAM-1 (HU5/3), CD151 (8C3) or CD9 (VJ1/20).
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Although ICAM-1 and VCAM-1 expression was lower in
tetraspanin-interfered HUVECs, no difference was observed in
peripheral blood lymphocyte (PBL) adhesion to interfered monolay-
ers when performed under static conditions (Figure 3C). However,
when HUVECs treated with siRNA oligos were seeded onto
Transwell insets to perform chemotactic transmigration assays with
human PBLs, a strong inhibition of lymphocyte transmigration was
observed with both CD9 and CD151 siRNA-treated endothelial
monolayers as compared with cells transfected with the negative
control oligonucleotide (Figure 3D).
Given that ICAM-1 and VCAM-1 are components of a docking
structure whose relevance in leukocyte firm adhesion was unveiled
under flow conditions,23 we assessed the role of tetraspanin
microdomains on the strength of lymphocyte adhesion to endothe-
lial cells by measuring their resistance to detachment under
increasing shear stress. After 15 minutes, PBL adhesion to TNF-–
activated HUVECs was highly resistant to laminar flow, and most
cells still remained attached at 10 dyn/cm2 (5-fold more than
physiologic shear stress) in control HUVEC monolayers (Figure
3E). In contrast, a great proportion of the PBLs adhered on
tetraspanin-intefered monolayers started to detach even at low flow
rates (Figure 3E).
When extravasation assays using tetraspanin-interfered endothe-
lium were performed under physiologic flow conditions, a signifi-
cant reduction in the number of adherent lymphocytes was also
observed (Figure 3F). Furthermore, a tendency to decrease was
consistently observed in rolling and transmigration. All these
differences might be related to the lower ICAM-1 and VCAM-1
expression levels in tetraspanin-interfered cells or, additionally, the
insertion of these molecules into tetraspanin-based microdomains
might be critical for their proper function under shear stress
conditions.
Tetraspanin-soluble peptides interfere with ICAM-1 and
VCAM-1 function without affecting their surface expression
Tetraspanin associations with other transmembrane proteins
occur through their LELs.11 We thus generated soluble GST-
LEL peptides from human CD9 (Figure 4A) and point mutants
to Ala of any of the 4 Cys residues in the LEL of CD9, which
show altered disulphide bond formation and tertiary conforma-
tion (Figure 4A). Although some degree of degradation of the
soluble peptide occurs, a great proportion of the material eluted
from the columns was reactive with CD9 mAb in Western blot
under nonreducing conditions (Figure 4A). Incubation of
HUVECs with GST-LEL peptides affected neither the expres-
sion levels of ICAM-1 and VCAM-1 induced by TNF- (Figure
4B), nor cell viability (Figure 4C) or monolayer permeability
(Figure 4D). The soluble peptides were added to the prepara-
tions at the time of addition of TNF- so that they were
accessible at the earliest time of inducible expression of both
adhesion receptors. Thus, these peptides allowed us to interfere
with tetraspanin-based microdomains without altering the expres-
sion levels of ICAM-1 or VCAM-1 induced by TNF-. Incuba-
tion of HUVECs with CD9-LEL-GST, but not the mutated
forms, significantly inhibited transendothelial migration of
lymphocytes (Figure 5A), whereas they did not affect lympho-
cyte chemotaxis across nude Transwells (data not shown). When
adhered PBLs were subjected to increasing shear stress, a higher
PBL detachment rate was also observed upon treatment of
HUVECs with CD9-LEL-GST (Figure 5B), but not with the
point mutants. In these experiments the number of lymphocytes
that transmigrated along the assay was also significantly reduced
in those preparations treated with CD9-GST (not shown). All
these data demonstrate that tetraspanin microdomains are impor-
tant not only for proper ICAM-1 and VCAM-1 expression on the
plasma membrane but also for their efficient adhesive function
under flow conditions.
Enhanced ICAM-1 and VCAM-1 adhesive function requires an
appropriate tetraspanin environment
To address the relevance of the repertoire of tetraspanin microdo-
mains in the presentation of ICAM-1 and VCAM-1 adhesion
molecules, we used Colo320 colocarcinoma cells and a CD9 stable
transfectant in this cell line. Colo320 cells express similar levels of
CD151, CD81, CD63, and CD82 on the plasma membrane than
endothelial cells, without expression of CD9, ICAM-1, or VCAM-1
(Figure 6A). A down-regulation of CD81 and CD63 was also
observed upon stable transfection of these cells with CD9 (Figure
6A). Then, Colo320 and Colo320-CD9 were transiently transfected
with VCAM-1-or ICAM-1–GFP to allow their heterotypic binding
to 4- or LFA-1–transfected K562 cells. The levels of ICAM-1 and
VCAM-1 expression attained by transient transfection varied
among the different cell lines and experiments, but only cells with
comparable high expression were analyzed in functional assays.
Figure 2. siRNA knocking down of tetraspanins CD9 and CD151 in HUVECs. (A)
Analysis by Western blot of the expression of tetraspanins CD9 and CD151 in
total-cell lysates of siRNA-transfected cells. Loading control for vimentin is also
shown. Densitometric analysis of the experiment shown gave a reduction in the total
protein amount of 70% for CD151 and 40% for CD9 expression. (B) Flow cytometry
analysis of the expression of tetraspanins (anti-CD9 VJ1/20, anti-CD151 LIA1/1,
anti-CD81 I.33.2.2) in tetraspanin siRNA-treated HUVECs. Negative siRNA-treated
cells are shown in thin lines. Thick lines correspond to the expression in tetraspanin
siRNA-transfected cells. Negative control PX63 is shown in dotted lines. The
histograms are depicted in a logarithmic scale. (C) Quantitative analysis of the mean
fluorescence intensity of CD9, CD151, and CD81 in tetraspanin siRNA-transfected
cells. Data represent the mean of 2 independent experimentsSD as the percentage
of the expression referred to that of negative control siRNA-transfected cells. (D)
Immunofluorescence analysis of CD9 (i-iii), CD151 (iv-vi), and CD81 expression
(vi-ix) and localization in HUVECs transfected with siRNA specific for endothelial
tetraspanins CD9 and CD151 as well as the negative oligonucleotide. Images were
acquired by confocal microscopy using the same photomultipliers parameters in
control and tetraspanin-interfered cells. Maximum projection of the whole confocal
image stack is shown. Scale bar equals 40 m.
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This cell system allowed us to assess the adhesion mediated
independently by ICAM-1 or VCAM-1 in the presence or the
absence of CD9. As shown in Figure 6B, binding of K562
transfectants to Colo320 cells was selective and completely
dependent on the expression of ICAM-1 or VCAM-1, since no
significant binding was observed with untransfected K562 cells or
to untransfected Colo320 or Colo320CD9 cells (Figure 6B, and
data not shown). Interestingly, VCAM-1– and ICAM-1–mediated
binding was augmented by the presence of CD9 on Colo320 cells
(Figure 6B). In the case of ICAM-1/LFA-1 binding, the experi-
ments required the addition of Mn2 for LFA-1 activation on K562
cells, which resulted in a strong aggregation with Colo320 cells
that partially masked the effect of CD9 (Figure 6B).
To further assess the specific contribution of CD9 in the
generation of adhesion molecule/tetraspanin microdomains, we
assayed the heterotypic binding of K562 4 transfectants with
Colo320 cells that stably express chimeric proteins made up of
CD9 and CD82. All chimeric proteins were efficiently expressed at
the plasma membrane (Figure 6C, flow cytometry analysis).The
first chimera used coded for the N-terminal region of CD9 and the
whole LEL and fourth transmembrane region belonged to CD82
(Colo320-CD9  82) and behaved as Colo320 wild-type (wt) cells
in regard to VCAM-1–mediated binding (Figure 6C). To map the
functionally relevant region of CD9, we used a second chimera
with a chimeric LEL comprising the first half of CD82 LEL and the
second half of CD9 LEL, where important residues for association
with other transmembrane proteins reside (Colo320-CD82CCG9).
This chimeric protein was able to enhance VCAM-1–mediated
adhesion, even though not to the same extent as wild-type CD9.
These data suggest that CD82 is not capable of replacing CD9 in
the organization of endothelial-like tetraspanin-based domains in
Colo320 cells and confirm that the LEL is an important functional
region in CD9. Altogether, these data indicate that proper tet-
raspanin microdomains are necessary for the adhesive function of
VCAM-1 and ICAM-1.
Discussion
It is well established that tetraspanins interact in multiproteic
domains with other transmembrane proteins.3,4,6,36 Moreover, anti-
body crosslinking of tetraspanins usually triggers the same cellular
responses as antibodies directed to their associated partners,
indicating that they conform functional entities.5,36 Herein, we
Figure 3. Tetraspanin interference affects ICAM-1 and VCAM-1 expression and function. (A) Flow cytometry analysis of the expression of adhesion molecules ICAM-1
(HU5/3), VCAM-1 (P8B1), E-Selectin (TEA2/1), and CD44 (HP2/9) in tetraspanin siRNA-treated HUVECs. TNF-–activated negative siRNA-treated cells are shown in thin
lines. Thick lines correspond to the expression in TNF-–activated tetraspanin siRNA-transfected cells. Expression of the different adhesion molecules in resting cells is shown
in dotted lines. The histograms are depicted in a logarithmic scale. (B) Quantitative analysis of the mean fluorescence intensity of ICAM-1, VCAM-1, and E-selectin in
TNF-–activated tetraspanin siRNA-transfected cells. Data represent the mean of 2 independent experiments SD as the percentage of the expression referred to that of
TNF-–activated negative control siRNA-transfected cells. (C) Analysis of the adhesion of PBLs to tetraspanin-interfered cells under static conditions. PBLs were loaded with
BCECF-AM (2,7-bis(2-carboxyethyl)-5(6)-carboxyfluorescein acetoxymethyl ester) fluorescent probe and allowed to adhere in serum-free medium on confluent
TNF-–activated HUVEC monolayers for 15 minutes at 37°C. After washing, the percentage of adhesion was quantified in a fluorimeter and depicted as the mean SD with
respect to the adhesion levels of the negative siRNA-transfected cells in 3 different experiments performed in triplicate. (D) siRNA-transfected HUVEC monolayers were
seeded onto Transwell insets and activated with 20 ng/mL of TNF- for 20 hours. Then, human peripheral blood lymphocytes were added to the upper compartment and
SDF-1–containing medium (100 ng/mL) was added to the lower compartment. Cells were allowed to migrate for 2 hours and analyzed by flow cytometry. Data represent the
mean SD of a representative experiment performed in triplicate. **P 	 .005 in a Student t test. (E) Tetraspanin interference augments PBL detachment under shear stress.
The percentage (mean SD) of remaining adherent cells is represented for the different flow rates in 4 fields of a representative experiment. f indicates negative siRNA; Œ,
CD9 siRNA; and , CD151 siRNA. *P 	 .02; **P 	 .005 in a Student t test. (F) Effect of tetraspanin siRNA on lymphocyte adhesion and transmigration under flow conditions.
Activated endothelium transfected with specific siRNA oligos for tetraspanins CD9 or CD151 or the negative control oligonucleotide were activated with TNF-. Thereafter,
PBLs were allowed to adhere and transmigrate under physiologic flow conditions (1.8 dyn/cm2) for 10 min. Quantification of rolling, adhesion, transmigration, and detachment
events was performed from minute 3.5 to minute 6.5 of perfusion. Values correspond to the arithmetic meanSEM of the total number of PBLs interacting with the endothelial
monolayer in the 6 different fields analyzed ( 20 objective) from a representative experiment. The total number of PBLs (n) interacting with the HUVEC monolayer in each
condition is depicted in the legend of the x-axis. *P 	 .02 in a Student t test.
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describe the lateral association of ICAM-1 and VCAM-1 with
tetraspanins at the contact area between leukocytes and endothe-
lial cells. Remarkably, the function of these endothelial adhe-
sion molecules can be directly modulated by the tetraspanin-
associated moieties.
In contrast to lipid rafts, tetraspanins form a network based
on protein-protein interactions, which might be modulated by
differential protein expression or posttranslational modifica-
tions. In addition, tetraspanins are palmitoylated proteins that
interact directly with cholesterol8-10,37 and under certain condi-
tions are also recovered in the light fractions of sucrose
gradients.7 Thus, tetraspanin webs or microdomains could be
envisioned as a subtype of lipid rafts. In this regard, it has been
suggested that the size of tetraspanin-based microdomains can
be as small as lipid rafts.16 Moreover, tetraspanin microdomains
can be also important for intracellular signaling events, since
they are able to associate with phosphatidylinositol 4-kinase
(PI4-K)38 and protein kinase C (PKC).39 Our studies indicate
that the composition of endothelial tetraspanin microdomains
changes during the transmigration process. Thus, apical do-
mains would be enriched in CD9, whereas in ventral domains
CD151 is more highly represented. On the other hand, tetraspan-
ins are also associated with integrin receptors at intercellular
junctions.25,40 These data suggest the existence of different
tetraspanin microdomains, which might coalesce and diverge
during cell activation, adhesion, or transmigration. Furthermore,
both ICAM-1 and VCAM-1 are anchored to the actin cytoskel-
eton through the association of ERM proteins to their cytoplas-
mic tails.23,24 The linkage of Ig receptors to the cytoskeleton
might indicate that tetraspanin microdomains are not floating
freely on the plasma membrane but are connected to the cortical
actin cytoskeleton.
Tetraspanins have been implicated in several cellular func-
tions, mainly by the use of monoclonal antibodies.3-6 Our results
show that soluble CD9-LEL-GST peptides or tetraspanin-
specific siRNA inhibit leukocyte transmigration and enhance
their detachment by shear stress, supporting the functional role
of tetraspanins in transendothelial migration. Similar GST
fusion proteins have been reported to be inhibitory in sperm-egg
fusion assays.31,41 These LEL-GSTs are a valuable tool, without
the effects of detergents or cholesterol-depleting agents, which
affect the physical properties of the plasma membrane. The
tertiary structure of these LEL proteins is very dependent on the
proper disulphide bond formation. Thus, mutation of any of the
4 Cys in CD9 greatly reduces the recognition in Western blot by
an anti-CD9 mAb and completely abolishes functional activity.
Endothelial tetraspanins are highly expressed and show a very
slow turnover, so that partial protein knocking down by siRNA is
observed only after 3 to 6 days. Although no complete abrogation
of tetraspanin expression was attained, it turned out to be more than
sufficient to exert a significant functional effect. Interestingly, a
compensatory effect on other tetraspanin expression was observed,
suggesting that a tight regulation of the overall tetraspanin load at
Figure 4. Characterization of the soluble peptide CD9-LEL-GST and its mu-
tants. (A) LEL-GST fusion proteins of human CD9, as well as point mutations to Ala of
Cys 152, 153, 167, and 181 were generated, produced in bacterial cultures, and
isolated by affinity columns of Glutathione-Sepharose. Eluted purified proteins were
then analyzed by Ponceau staining and Western blot against CD9 (VJ1/20 mAb) or
GST. (B) Flow cytometry analysis of the expression of ICAM-1 and VCAM-1 in
HUVECs preincubated with CD9-GST or its point mutants. Thin lines in the upper
panels correspond to the expression of resting cells. Thin lines on the following
panels correspond to cells treated with TNF- alone. Thick lines correspond to the
expression in cells treated for 20 hours with TNF- alone (top row) or in combination
with the different soluble LEL-GST peptides. (C) Propidium iodide profiles of cells
treated for 20 hours with TNF- alone or in combination with the different soluble
LEL-GST peptides. (D) Paracellular permeability analysis of HUVEC monolayers
preincubated with the different soluble LEL-GST peptides. Thrombin was added at
0.1 U/mL at the time of addition of the fluorescent dextran. Data represent the
meanSD of a representative experiment performed in duplicate.
Figure 5. CD9-LEL-GST inhibits leukocyte transendothelial migration and
promotes cell detachment under flow. (A) CD9-LEL-GST peptide inhibits transen-
dothelial lymphoid migration in Transwells. HUVEC monolayers were activated with
TNF- alone or in combination with the different LEL-GST peptides. Then, human
PBLs were added to the upper compartment and allowed to migrate for 5 to 7 hours.
Cell migration was analyzed by flow cytometry and represented as the mean SEM
with respect to control untreated monolayers, of 4 independent experiments per-
formed in duplicate. **P 	 .005 in a Student t test. (B) Preincubation with CD9
LEL-GST fusion protein augments detachment under flow conditions. The percent-
age of detachment of PBLs was analyzed in 8 to 10 fields under increasing flow rates
and represented as the mean SEM.  indicates untreated cells; , C152A; f,
CD9-GST; and Œ, C153A. **P 	 .005 in a Student t test.
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the plasma membrane exists. Nevertheless, as demonstrated also by
the heterologous Colo320 cell system, the repertoire of tetraspanins
is also crucial for the proper adhesive function of ICAM-1 and
VCAM-1. Tetraspanin siRNA affected ICAM-1 and VCAM-1
expression, which suggests a possible role for tetraspanins in early
biosynthetic events. In this regard, it has been previously described
that CD9 associates with the 1 integrin precursor prior to reaching
the plasma membrane.42 In a similar way, CD19 expression was
selectively reduced in CD81-deficient mice, being the defect
located after the endoplasmic reticulum.43 However, tetraspanin
interference only affected ICAM-1– and VCAM-1–mediated adhe-
sion when assayed under stringent flow conditions. Moreover,
CD9-LEL-GST peptide incubation had no effect on ICAM-1 and
VCAM-1 induction but it did affect their function under shear
stress. These data make both experimental approaches complemen-
tary and strongly suggest that membrane presentation into the
appropriate microdomains of these receptors is functionally rel-
evant for their proper adhesive function. Furthermore, the direct
regulation of ICAM-1 and VCAM-1 adhesive function by the
proper tetraspanin environment is revealed in the heterologous
system of aggregation between Colo320 cells and K562 transfec-
tants. Our data with Colo320 cells also rule out the possible
involvement of a putative tetraspanin ligand on leukocytes, since
their heterotypic adhesion is completely dependent on ICAM-1 or
VCAM-1 expression.
The fact that ICAM-1 and VCAM-1 are included in tetraspanin-
based microdomains might favor the efficient transition from the
rolling step, in which VCAM-1 is involved,44,45 to the firm
adhesion of leukocytes via both VCAM-1 and ICAM-1 liga-
tion,46,47 to finally proceed to diapedesis. The possibility that
selectins or other endothelial adhesion molecules are constituents
of these endothelial tetraspanin microdomains cannot be ruled out.
Another endothelial Ig adhesion molecule such as PECAM-1, also
involved in transmigration,48 is partially redistributed to the
docking structure (not shown). In this regard, the effect of
tetraspanin knocking down during the rolling and transmigra-
tion steps deserves further analysis using experimental settings
specifically designed for the study of these processes. In this
scenario, it could be postulated that tetraspanin microdomains
would act as specialized platforms that cluster the appropriate
adhesion receptors necessary for the rapid kinetics of leukocyte
extravasation process.
Inclusion of ICAM-1 and VCAM-1 into tetraspanin domains is
necessary for their proper function under dynamic conditions such
as shear stress. This phenomenon could be explained by a possible
role of tetraspanins in the preclustering or avidity regulation of
endothelial adhesion receptors. Avidity regulation of the mitogenic
activity of the membrane-anchored heparin-binding epidermal
growth factor–like growth factor (HB-EGF) by its association with
CD9 has been demonstrated.49,50 Recent observations show that
tetraspanin networks are able to cluster class II major histocompat-
ibility complex (MHC) molecules bearing restricted repertoires of
peptides,16 thus facilitating antigen peptide presentation. Further-
more, CD81 also regulates very late antigen (VLA)–4– and
VLA-5–mediated adhesion by enhancing integrin avidity indepen-
dently of ligand binding.51 This phenomenon also facilitated
leukocyte firm adhesion by strengthening VLA-4–VCAM-1 inter-
action acting on the leukocyte side.
The inclusion of adhesion receptors into tetraspanin domains
could also affect their conformation, up-regulating their binding to
integrins. In this regard, we have recently described a monoclonal
antibody that preferentially recognizes CD9 when associated with
61 integrin.26 The possibility of reciprocal conformational changes
in tetraspanin-associated proteins cannot be excluded. In this
regard, CDw78 mAbs recognize human leukocyte antigen
(HLA)–DR only when included into tetraspanin domains,52 al-
though the possibility of a conformational change in HLA-DR
Figure 6. Enhanced ICAM-1 and VCAM-1 adhesive function requires an
appropriate tetraspanin environment. (A) Flow cytometry analysis of the expres-
sion of 1 integrin (TS2/16 mAb), tetraspanins (anti-CD9 VJ1/20, anti-CD151 LIA1/1,
anti-CD81 I.33.2.2, anti-CD82 TS82, and anti-CD63 TEA3/18 mAbs), ICAM-1
(HU5/3), and VCAM-1 (P8B1) in Colo320 cells (thin lines) or CD9 stably transfected
Colo320 cell line (thick lines). Negative control PX63 is shown in dotted lines. (B)
Heterotypic intercellular binding of K562 cell lines (parental and K562 4 and K562
LFA-1 integrin transfectants) to Colo320 and Colo320CD9 cells transiently trans-
fected with GFP-tagged versions of VCAM-1 and ICAM-1. Data are calculated as the
ratio of double-positive aggregates (GFP-Colo320/CM-TMR K562) versus the nonag-
gregated GFP cells. Graph depicts the relative binding referred to the aggregation
obtained with parental K562 cells (that ranged from 10% to 20% of the total GFP
cells in the different transient transfections in the experiment shown) in a representa-
tive experiment out of 6 performed. (C) Heterotypic intercellular binding of K5624
integrin–stable transfectant to VCAM-1–GFP transiently transfected Colo320 cells
and the different chimeric clones of CD9/CD82. Data are calculated as the ratio of
double–positive aggregates (GFP-Colo320/CM-TMR K562) versus the total number
of GFP cells. Graph depicts relative binding referred to the aggregation of
Colo320–VCAM-1–GFP cells in a representative experiment out of 3 (11% of the total
GFP cells in the experiment depicted). On the right, flow cytometry analysis of the
expression with anti-CD9 (10B1, which also recognizes the chimeric CD9/CD82 loop;
thin lines) and CD82 (TS82; thick lines) of the different chimeric clones is shown.
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because of its interaction with tetraspanins has not been deter-
mined. Lately, CD151 knock-out mice show a mild deficiency in
outside-in activation of IIbIII integrin in platelets,53 whereas
human CD151 deficiency causes a more aggressive phenotype with
renal, skin, hearing, and erythropoiesis defects54. Thus, several
lines of evidence support a functional role for tetraspanin-based
microdomains in different cellular functions. In this report we
demonstrate by different complementary experimental approaches,
both on primary cells and assessing endogenous proteins, and in an
heterologous system, that the adhesive function of ICAM-1 and
VCAM-1 is directly modulated by their inclusion in a microdomain
containing the appropriate repertoire of tetraspanins. This effect
was shown to be crucial in an important physiologic process such
as leukocyte extravasation and may have a great relevance not only
in homing and inflammation but also in haematopoietic developmen-
tal stages at the bone marrow.55-57
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Role of Tetraspanins CD9 and CD151 in Primary Melanocyte
Motility
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Tetraspanins CD9 and CD151 have been implicated in cellular motility and intercellular adhesion in several cellular
types. Here, we have studied the subcellular localization and the functional role of these molecules in primary
melanocytes. We found that endogenous tetraspanins preferentially clustered in areas of melanocyte homotypic
intercellular contacts and at the tips of dendrites. These observations were further conﬁrmed using time-lapse
ﬂuorescence confocal microscopy of melanocytes transfected with CD9– and CD151–GFP (green ﬂuorescent pro-
tein) constructs, suggesting an involvement of these proteins in cellular contacts and migration. Cell adhesion and
migration assays performed using blocking monoclonal antibodies against CD9 and CD151 showed no significant
effect on cell–extracellular matrix adhesion, whereas the migration of melanocytes was significantly enhanced. The
regulation of the migratory capacity of melanocytes by CD9 and CD151 was further conﬁrmed knocking down the
endogenous expression of these tetraspanins with small interference RNA oligonucleotides. Therefore, tetraspanin
molecules are localized at motile structures in primary human melanocytes regulating the migratory capacity of
these cells.
Key words: CD151/CD9/cell adhesion/cell migration/intercellular contacts/melanocytes
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Tetraspanins comprise a numerous group of proteins that
contain four putative membrane-spanning domains and,
characteristically, the presence of a large divergent extra-
cellular loop between the third and fourth membrane-span-
ning domains (Wright and Tomlinson, 1994). They have been
implicated in the regulation of cell development, prolifera-
tion, activation, and motility and have been shown to couple
to signal transduction pathways (Berditchevski, 2001;
Boucheix and Rubinstein, 2001; Hemler, 2001; Stipp et al,
2003). In this regard, it has been suggested that the main
role of tetraspanins is to organize other proteins into signal-
transducing complexes at the cell surface (Berditchevski,
2001; Ya´n˜ez-Mo´ et al, 2001; Tarrant et al, 2003). Tetraspan-
ins have been shown to coprecipitate with several trans-
membrane proteins, and with b1 integrins in particular
(Berditchevski et al, 1996; Hemler et al, 1996; Rubinstein
et al, 1996; Maecker et al, 1997). In epidermal cell adhesion
and migration, b1 integrins play a critical role (Watt and
Hertle, 1994). To participate in those functions, integrins
may not only bind to intracellular proteins and extracellular
ligands (Clark and Brugge, 1995) but may also laterally
associate with other transmembrane proteins such as
those from the tetraspanin superfamily (Berditchevski, 2001;
Boucheix and Rubinstein, 2001; Hemler, 2001; Stipp et al,
2003).
The migration of melanocytes represents a fundamental
requirement in a wide variety of physiological and patho-
logical scenarios. Melanocytes migrate from the neural
crest to the skin during the first trimester of the embryo-
genesis. In physiological conditions, melanocytes migrate
to display a homogeneous distribution in the epidermis,
which have been designated as an ‘‘epidermal melanin unit’’
(Fitzpatrick and Breathnach, 1963). But insights into the
cellular and molecular mechanisms underlying such organ-
ization, however, remain unknown (Hoath and Leahy, 2003).
In adults, melanocytes also migrate during the process of
wound healing and to cover the white areas of patients with
vitiligo. Although integrins (Morelli et al, 1993) and cadherins
(Hsu et al, 2000) are both implicated in adhesion and move-
ment of melanocytes, little is known about other factors that
regulate both functions. Tetraspanins have been found on
normal epidermis (Okochi et al, 1997; Sincock et al, 1997),
expressed by keratinocytes (Jones et al, 1996; Okochi et al,
1997; Pen˜as et al, 2000). We have previously demonstrated
that tetraspanin molecules have an important role in kera-
tinocyte motility (Pen˜as et al, 2000). On the other hand, CD9
has been functionally associated with tumor cell motility
(Ikeyama et al, 1993) and melanoma invasion (Longo et al,
2001). Nevertheless, no formal study of tetraspanins has
been performed in human primary melanocytes. In this
study, we describe the subcellular localization of CD9 and
CD151 tetraspanin molecules and their functional role in
melanocyte motility.1These authors equally contributed to this work.
Abbreviations: ECM, extracellular matrix; GFP, green fluorescent
protein; mAb, monoclonal antibody; siRNA, small interference RNA
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Results
Melanocytes express CD9 and CD151 tetraspanin pro-
teins at intercellular contacts and tips of dendrites We
analyzed the expression of tetraspanins CD9, CD63, CD81,
and CD151, and integrins avb3, b1, a2, and a3 by flow
cytometry in normal human melanocytes. These primary
cells express high levels of b1 integrin and CD9, and lower
levels of a2 and a3 chains of integrins and tetraspanins
CD81, CD151, and CD63 (Fig 1).
Immunofluorescence studies showed that CD9 and
CD151 are distributed throughout the cell body and the
dendrites of the melanocyte, their clustering at points of
intercellular contact and at the tips of dendrites being re-
markable, where they preferentially colocalized with b1 in-
tegrins (Fig 2a and b). The colocalization percentage
obtained considering the overall surface of the me-
lanocytes, however, is rather average (ranging from 14%
to 28%), and not all contacts and tips contained accumu-
lation of both molecular types (data not shown). CD81 ex-
hibits a staining pattern similar to that of CD9 and CD151,
but no clear CD63 membrane expression was found, al-
though it was highly represented in intracellular vesicles as
it has been found in other cell types such as endothelial
cells and keratinocytes (data not shown) (Ya´n˜ez-Mo´ et al,
1998; Pen˜as et al, 2000).
We found footprints in the immunofluorescence studies
with CD9 but almost no staining with CD151 (data not
shown). These footprints are made of rests of plasma
membrane containing receptors for extracellular matrix pro-
teins that remain attached to the ligands as the cell moves.
We and other authors have described this phenomenon,
also termed ripping, in keratinocytes (Pen˜as et al, 2000) and
other cell types (Palecek et al, 1996).
As these findings suggested an implication of tetraspan-
ins in adhesion to the extracellular matrix, we performed
adhesion experiments on collagen. We used TS2/16 (an
anti-CD29 that activates integrins b1) and VJ1/14 (an anti-
CD29 that inhibits integrins b1) monoclonal antibodies
(mAb) as positive and negative controls of adhesion, re-
spectively. Differences between both TS2/16 (enhancing
adhesion) and VJ1/14 (inhibiting adhesion) were significant
(po0.005) but moderate (  15% from the control). When
melanocytes were incubated with anti-tetraspanin mAb, we
also found a reproducible but very mild modification of ad-
hesion (p15%) compared with control cells without anti-
body treatment, suggesting the lack of implication of CD9
and CD151 in adhesion to collagen (data not shown) as
described for other cell types (Ya´n˜ez-Mo´ et al, 1998).
Tetraspanins CD9 and CD151 are involved in me-
lanocyte–melanocyte interactions To ascertain the kinet-
ics of the localization of tetraspanins in intercellular
homotypic contacts of melanocytes, we erformed time-
lapse fluorescence confocal microscopy with CD9–GFP
(green fluorescent protein) and CD151–GFP-tagged pro-
teins. Using CD9–GFP we found that this molecule showed
a diffuse pattern of accumulation at transient cell–cell con-
tact sites (Fig 3a, Fig S1). CD151–GFP was rapidly and
highly concentrated as soon as dendrites of different me-
lanocytes come into contact (Fig 3b, Fig S2). Both findings
suggest that CD9 and CD151 transiently cluster at the ho-
motypic intercellular contacts during the scanning of the
melanocyte cell surface.
Tetraspanins are implicated in melanocyte motility On
the other hand, another specific area of accumulation was
the tips of the dendrites, which are enriched in ruffles. We
found enhanced expression of CD9–GFP (Fig 4a, Figure S3)
and CD151–GFP (Fig 4b, Fig S4) at the tip of dendrites when
melanocytes explore the surrounding milieu. This localiza-
tion was dynamic and was displayed by all dendrites; those
that directed the movement of the melanocyte and those
that were retracting.
As these results suggested that CD9 and CD151 may be
involved in the movement of melanocytes, they prompted us
to formally explore the functional involvement of tetraspanins
in melanocyte motility using Transwell chambers with fibr-
onectin in the lower chamber as a stimulus for melanocyte
motility. Blocking monoclonal antibodies against CD9 and
CD151, as determined in other cellular types (Ya´n˜ez-Mo´
et al, 1998; Pen˜as et al, 2000), enhanced melanocyte mo-
tility, whereas anti-avb3 integrin inhibited the migration of
melanocytes. The activatory anti-b1 integrin TS2/16 de-
creased the migration of melanocytes, whereas the inhibi-
tory anti-b1 integrin VJ1/14 increased it (Fig 5a). To evaluate
the influence of b1 integrins in CD9 and CD151-mediated
effect on melanocyte migration, we combined the use of
TS2/16 and VJ1/14 with anti-CD9 and anti-CD151 (Fig 5b).
Figure1
Human primary melanocytes express tetraspanins CD9, CD63,
CD81, and CD151. (a) Representative profiles of flow cytometry anal-
ysis corresponding to CD9 and CD151 tetraspanins in melanocytes. (b)
A quantitative analysis of the membrane expression of b1, a2, a3, and
avb3 integrins and CD9, CD63, CD81, and CD151 tetraspanin proteins
expressed as mean fluorescence intensity measured by flow cytometry
(meanþSEM of six to nine experiments). X-63 was used as negative
control.
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We found that the enhanced effect of CD9 and CD151 on
melanocyte migration was more pronounced when com-
bined with VJ1/14, and was partially reversed by TS2/16.
To further assess the functional role of tetraspanins in
melanocyte motility, tetraspanin expression was knocked
down in melanocytes using small interference RNA (siRNA)
against CD9 and CD151. We obtained a significant inhibi-
tion in the expression of CD9 and CD151 using specific
siRNA (Fig 6a), without affecting the morphological charac-
teristics of siRNA-treated melanocytes (data not shown).
We performed similar migration assays using fibronectin as
a stimulus of melanocyte motility with these interfered cells
and found that siRNA against CD9 and CD151 significantly
(po0.05) stimulates melanocyte migration (Fig 6b). Alto-
gether these data underscore the involvement of tetras-
panin in melanocyte migration through regulation of b1
integrin function.
Discussion
The role of tetraspanins in keratinocytes has been explored
previously (Pen˜as et al, 2000). Tetraspanins are implicated in
keratinocyte motility, and a possible implication of these
molecules in inter-keratinocyte contacts has been suggest-
ed. Although CD9, CD81, and CD151 have been described
in melanoma cells (Radford et al, 1996; Longo et al, 2001),
no description of the expression or functional implications
of tetraspanins in normal human melanocytes has been re-
ported before.
This work addresses the expression, subcellular distri-
bution, and functional role in cell adhesion and motility of
the tetraspanins CD9 and CD151 in primary human me-
lanocytes. The accumulation of both tetraspanins at the tips
of the melanocyte dendrites and in the intercellular contacts
with other melanocytes was remarkable. Moreover, some
ripping was found. These findings suggested the involve-
ment of CD9 and CD151 in melanocyte adhesion to the
extracellular matrix, in the exploration of the environment
and in homotypic interactions. CD63, a component of
melanosomes also known as lysosome-associated mem-
brane protein (LAMP)-3, has been described in melanocytes
and melanoma, and implicated in melanoma progression
(Ota et al, 1998). As expected, CD63 showed low plasma
membrane and high intracellular expression in primary me-
lanocytes.
Figure 2
Tetraspanins and b1 integrins colocal-
ize at intercellular contacts of me-
lanocytes and at tips of dendrites. (a)
Representative horizontal confocal sec-
tions showing the subcellular distribution
of CD9 or CD151 (green fluorescence)
compared with b1 integrin (red fluores-
cence), together with the overlay images
are depicted. Scale bar¼ 20 mm. (b) Zoom
images from the representative horizontal
confocal sections shown in the previous
panel are depicted. Co-clustering of tet-
raspanin proteins with b1 integrin at inter-
cellular contacts are indicated with white
arrowheads and at the tips of the dend-
rites are indicated with white arrows.
Scale bar¼ 10 mm.
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The role of tetraspanins in adhesion to the ECM varies
among different cell types, and it has been suggested that
tetraspanins are not involved in cellular adhesion in most
cells (Berditchevski, 2001). In this regard, CD9 did not affect
MDA-MB 231 (Sugiura and Berditchevski, 1999), human B
cells (Shaw et al, 1995) or hepatic cells (Mazzocca et al,
2002) adhesion. Accordingly, our data show that tetraspan-
ins slightly modulate the adhesion of melanocytes to col-
lagen. But CD151 increased adhesion to collagen and
fibronectin of the erytroleukemia cell line HEL (Fitter et al,
1999) but did not affect many other cell lines and human
primary cells (Yauch et al, 1998; Fitter et al, 1999; Sugiura
and Berditchevski, 1999; Mazzocca et al, 2002). It is re-
markable that a defective CD151 protein has been impli-
cated as the cause of epidermolysis bullosa in two patients,
suggesting that this tetraspanin could play a role in kera-
tinocyte adhesion (Karamatic Crew et al, 2004).
Tetraspanins are important in intercellular contacts
(Ya´n˜ez-Mo´ et al, 2001; Tarrant et al, 2003) since they are
clearly accumulated in areas of cell–cell contact in most
cellular types, both in homo- and heterotypic interactions
(Pen˜as et al, 2000; Longo et al, 2001). In fact, the CD151-
a3b1 integrin complex has been shown to regulate cad-
herin-mediated adhesion (Chattopadhyay et al, 2003). We
have found that melanocytes express CD9 and CD151 in
melanocyte–melanocyte contacts and in melanocyte–kera-
tinocyte interactions (unpublished results). Immunofluores-
cence staining of intercellular homotypic interactions was
very conspicuous but not constant, suggesting a dynamic
and transient clustering of the tetraspanins at these sites.
This effect has not been described on keratinocytes or
endothelial cells, where the expression was permanent in
homotypic interactions and absent in cellular areas with
no cell contact. These data, together with the findings of
the time-lapse confocal microscopy with CD9–GFP and
CD151—GFP, suggest that tetraspanins are involved in
some of the phases of the cell–cell contact, perhaps in-
volved in finding the path of other cells.
Regarding the expression of CD9 and CD151 at the tip of
melanocyte dendrites, our findings also suggest a role in the
exploration of the external milieu. On cells of neural origin,
localized expression of tetraspanins CD9 and CD151 on the
tips of the neurites has been implicated in neurite formation
(Smith et al, 1996; Banerjee et al, 1997; Stipp and Hemler,
2000). Our immunofluorescence studies showed that local-
ization of CD9 and CD151 at the tip of melanocyte dendrites
was not permanent, and suggested a dynamic clustering of
both tetraspanins and b1 integrins. The use of GFP-tagged
versions of CD9 and CD151 allowed us to analyze the dy-
namic clustering of these tetraspanins. Although we cannot
exclude that the expression of tetraspanins at the tips of
melanocyte dendrites is related to a role in dendrite forma-
tion, our data on CD9 and CD151 suggest the involvement
of tetraspanins in motility-related structures for the explo-
ration of the environment.
Tetraspanins have been implicated in the motility of many
cell types (Berditchevski, 2001), including melanoma cells
(Longo et al, 2001). The mechanism is still in the process of
being elucidated but, as we have previously described in
keratinocytes, CD9 and CD151 are present at motility-re-
lated structures and not in adhesive contacts to extracel-
lular matrix (Pen˜as et al, 2000). We have found that the anti-
CD9 mAb VJ1/10 enhances the motility of melanocytes in
migration assays and that it is further enhanced with the
anti-b1 integrin VJ1/14. Moreover, CD9 siRNA treatment
enhances the migration of these cells, supporting our find-
ings that CD9 expression is involved in the negative regu-
lation of melanocyte migration. In human melanoma cells
expressing high levels of CD9, anti-CD9 VJ1/10 slightly in-
hibited cell migration, although anti-CD9 VJ1/10 and VJ1/20
Figure 3
CD9—GFP (green fluorescent pro-
tein) and CD151–GFP are dynamical-
ly expressed in intercellular contacts.
Melanocytes transfected with CD9–
GFP or CD151–GFP constructs were
seeded on coverslips and time-lapse
fluorescence confocal microscopy was
started after 4 h. Series of optical sec-
tions distanced 0.4 mm on the z-axis
were acquired every 10 min (CD9) or 15
min (CD151) for a total time of 7 h. a) All
the micrographs depicted show the
transient accumulation of CD9–GFP at
the tip of the dendrite when it contacts
with another untransfected melanocyte
(white arrowheads). A maximum pro-
jection of the relevant sections from the
confocal stack of the GFP and the
merged image also composed with the
corresponding DIC image from each
selected time point of the videose-
quence are shown. Scale bar¼ 10 mm.
(b) The images show the accumulation
of CD151–GFP on the membrane of
the melanocyte as soon as the cell
contacts the dendrite of another highly
transfected melanocyte (T: 00:15, 02:00, 03:00, 03:45, 06:30). When there is no contact, fluorescence intensity returns to basal levels (T: 00:00,
01:30, 04:15). A maximum projection of the relevant sections from the confocal stack of the green signal (GFP) from each corresponding time point
of the videosequence is shown. Scale bar¼20 mm.
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presented a strong inhibitory effect of transendothelial mi-
gration (Longo et al, 2001). Nevertheless, in human and
mouse melanoma cells, low CD9 expression has been re-
lated to enhanced motility, and transfection of mouse me-
lanoma cells with CD9 lowered their metastatic potential
and motility (Ikeyama et al, 1993). It is remarkable that mAb
anti-CD9 inhibited the migration of human keratinocytes
(Pen˜as et al, 2000), endothelial cells (Ya´n˜ez-Mo´ et al, 1998),
and hepatic stellate cells (Mazzocca et al, 2002), whereas it
enhanced the migration of Schwann cells (Anton et al, 1995)
and melanocytes, both of neuroectodermal origin.
On the other hand, the use of anti-CD151 mAb also en-
hances the migration of melanocytes. In contrast, anti-
CD151 mAb inhibited human keratinocyte (Pen˜as et al,
2000), endothelial (Ya´n˜ez-Mo´ et al, 1998), neutrophil (Yauch
et al, 1998), and hepatic stellate cell (Mazzocca et al, 2002)
migration. Our finding that CD151 siRNA treatment also in-
creased the migration of melanocytes supports that the role
Figure 4
CD9–GFP (green fluorescent protein) and CD151–GFP are expressed on the tips of dendrites of melanocytes during cell migration.
Melanocytes transfected with CD9–GFP or CD151–GFP constructs were seeded on coverslips and time-lapse fluorescence confocal microscopy
was started after 4 h. Series of optical sections distanced 0.4 mm on the z-axis were acquired every 15 min (CD9) or 5 min (CD151) for a total time of
7 h. (a) The micrographs show the dynamic accumulation of CD9–GFP at the tips of the dendrite (T: 00:00, T: 01:30, T: 02:30, T: 04:15) during the
exploration of the extracellular environment. A maximum projection of the relevant sections from the confocal stack of the green signal (GFP) from
each corresponding time point of the videosequence is shown. Scale bar¼20 mm. (b) The micrographs show the dynamic accumulation of CD151–
GFP at the tip of the dendrite as the melanocyte migrates on the coverslip. CD151 clusters can be found both on the front (00:30, 01:20, 1:45, 2:10)
and rear (T: 00:05; 00:30, 00:50) dendrites. A maximum projection of the relevant sections from the confocal stack of the green signal (GFP) from
each corresponding time point of the videosequence is shown. Scale bar¼20 mm.
TETRASPANIN MOLECULES IN MELANOCYTES 1005125 : 5 NOVEMBER 2005
of CD151 in melanocyte motility is different from what has
been previously described for other cell types.
We have found that tetraspanins modulate migration of
melanocytes. Melanocytes express a2b1, a3b1, a5b1, and
avb3 (Zambruno et al, 1993; Hara et al, 1994). Tetraspanins
have been shown to interact with a2b1 and a3b1 integrins in
many cell types, but not with avb3 (Berditchevski, 2001).
The effect of CD9 and CD151 is partially reverted with TS2/
16 (activating anti-b1 integrin mAb), and it is additive to the
effect of VJ1/14 (inhibitory anti-b1 integrin mAb).
In conclusion, CD9 and CD151 are dynamically clustered
at the tips of dendrites and also in homotypic intercellular
contacts of melanocytes. The inhibition of CD9 and CD151
using mAb or siRNA leads to enhanced motility of the cells.
Nevertheless, CD9 and CD151 do not seem to be involved
in melanocyte adhesion to the extracellular matrix. In ker-
atinocytes, tetraspanins are also involved in motility and are
expressed in intercellular contacts (Pen˜as et al, 2000). It is
therefore tempting to suggest that the expression of tetra-
spanins in cell contacts could be negatively regulating me-
lanocyte migration and, therefore, aiding in the process of
homogeneous redistribution of melanocytes in the normal
epidermis or in the migration of melanocytes to restore the
epidermis damaged during wound healing.
Materials and Methods
Cells Neonatal foreskins obtained within 24 h of elective circum-
cision were used to culture human melanocytes as described pre-
viously (Gilchrest et al, 1984; Park et al, 1993). In brief, epidermal
strips were isolated using dispase 1.2 U per mL (Boehringer Man-
nheim, Mannheim, Germany) for 12 h at 41C. After incubation of
epidermal strips in 0.05% trypsin/0.02% EDTA (Cambrex, Vervies,
Belgiun) for 25 min at room temperature, epidermal cells were
seeded onto plastic dishes (Corning Incorporated, Corning, New
York) at 40,000 cells per cm2. The culture basal medium consisted
in 4:1 Dulbecco’s modified Eagle’s medium (DMEM) with glutamine
and pyruvate (Gibco, Paisley, Scotland, UK) and HAM’S F12 (Gib-
co) complemented with fetal bovine serum 10%, adenine 18 mM
(SIGMA, St Louis, Missouri), hydrocortisone 0.5 mg per mL (SI-
GMA), apo-transferrin 5 mg per mL (SIGMA, Steinheim, Germany),
insulin 5 mg per mL (SIGMA), and choleric toxin 10 ng per mL
(SIGMA). In the first passage, a selective tripsinization was per-
formed and the melanocytes were cultured in a melanocyte-spe-
cific medium: MCDB153 (SIGMA) 5% fetal bovine serum, bovine
Figure 5
Anti-CD9 and -CD151 monoclonal antibodies (mAb) influence me-
lanocyte motility. Melanocyte migration assays were performed in 8-
mm pore Transwell chambers. Fibronectin was added in the lower
chamber as a chemoattractant. The cells that crossed the membrane
were counted. (a) Blocking mAb anti-CD9, anti-CD151, and anti-b1
stimulated the migration of cells, whereas anti-avb3 and activating
anti-b1 inhibited the migration. Results were normalized using as
control mAb-untreated cells as 100%. Results are depicted as the
mean  SEM of seven experiments performed in duplicate. po0.05,
po0.005, and p40.0005 with respect to no mAb treatment. (b)
The same experiment was performed combining the anti-CD9 or anti-
CD151 mAb with the activating anti-b1 or the blocking anti-b1 mAb.
Results were normalized using the control with no mAb treatment as
100% (black line). Results are depicted as the mean  SEM of two
experiments performed in duplicate. po0.05 with respect to no mAb
treatment.
Figure6
Knocking down of CD9 and CD151 expression using small inter-
ference RNA (siRNA) enhances melanocyte motility. (a) Melanocytes
were transfected with CD9 or CD151 siRNA and negatively selected
with anti-CD9 or anti-CD151 magnetic-coated beads, in order to enrich
the tetraspanin low-expressing population. We obtained highly inter-
fered melanocyte cells for each tetraspanin. One representative exper-
iment is shown. The mean inhibition was 49% for CD9 and 56% for
CD151. Dotted line: negative oligo siRNA-transfected melanocytes,
solid line: tetraspanin siRNA-transfected melanocytes, gray area: X-63
used as a negative control of expression. (b) The migratory capacity of
these transfected melanocytes was evaluated using 8-mm pore Tran-
swell chambers. Fibronectin was added in the lower chamber as a
chemoattractant. Negative oligo siRNA-transfected cells were used as
control. Results are shown as the mean  SEM of three experiments
performed in triplicate. po0.05 and po0.005 with respect to neg-
ative oligo siRNA treatment.
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pituitary extract (SIGMA) 30 mg per mL, b-fibroblast growth factor
(SIGMA) 0.6 ng per mL, insulin 5 mg per mL, hydrocortisone 0.5 mg
per mL, and PHA 8 nM (SIGMA). Cultures were used between the
second and fourth passages. Approval was obtained from the
Hospital Universitario de la Princesa institutional review board for
these studies. Informed consent was provided according to the
Declaration of Helsinki.
Antibodies MAb used in this study have been described previous-
ly: the activatory anti-b1 integrin chain TS2/16 (CD29) (Arroyo et al,
1992), the inhibitory anti-b1 integrin VJ1/14 (CD29) (Pen˜as et al,
1998), and the anti-CD151 (LIA1/1 and VJ1/16) (Ya´n˜ez-Mo´
et al, 1998). Anti-CD63 (TEA3/18), anti-CD9 (VJ1/20 and VJ1/10),
anti-a2 (TEA1/41), and anti-a3 (VJ1/6) were obtained in our labo-
ratory (Pen˜as et al, 2000). JS-81 (anti-CD81) was purchased from
BD Biosciences (San Diego, California). The anti-avb3 was a kind
gift from Dr S. Vilaro´ (Department of Cell Biology, Universidad de
Barcelona, Spain). The monoclonal Ig (IgG1, k) from the P3X63
myeloma cell line was used as a negative control, and anti-CD45
antibodies (IgG1, IgG2a, and IgG2b) were used as isotype controls
(Pulido et al, 1988)
Flow cytometry Melanocytes were detached with 0.05% trypsin
and 0.02% EDTA, washed, and resuspended in phosphate-buff-
ered saline (PBS). A total of 5  105 cells were incubated with the
corresponding mAb for 30 min at 41C. After this incubation, cells
were washed in PBS and incubated for 20 min at 41C with the
appropriate fluorescein-isothiocyanate (FITC)-conjugated antibody
(anti-mouse Ig from DAKOPATTS, Copenhagen, Denmark or anti-
rabbit Ig from Pierce Chemical, Rockford, Illinois). Cells were
washed and resuspended in PBS with 10 mg per mL propidium
iodide and then analyzed in a FACScan flow cytometer (Becton
Dickinson Labware, Lincoln Park, New Jersey). Cell analysis was
gated both on forward- and size-scatter intensities and propidium
iodide fluorescence to discard dead cells.
Immunoﬂuorescence and laser scanning confocal micros-
copy Normal human melanocytes were plated in complete
medium on glass coverslips, grown, and fixed in 3.7% parafor-
maldehyde in PBS. Nonspecific binding sites were blocked by in-
cubation with TNB (0.1 M Tris-HCl, 0.15 M NaCl, 0.5% blocking
reagent; Boehringer Mannheim GmbH). Coverslips were incubated
with the primary antibody for 1 h at 371C, washed and incubated
with Rhodamine-X goat anti-mouse IgG secondary antibody (Mo-
lecular Probes, Leiden, The Netherlands) for 45 min. Coverslips
were then blocked with mouse serum, incubated with the corre-
sponding biotinylated antibody for 1 h at 371C, washed, and in-
cubated with Alexa Fluor488-labelled streptavidin (Molecular
Probes, Leiden, The Netherlands) for 45 min. Specimens were
examined with a Leica TCS-SP confocal laser scanning unit
equipped with Ar and He/Ne laser beams and coupled to a Leica
DMIRBE inverted epifluorescence microscope (Leica Microsys-
tems, Heidelberg, Germany), using a  63/1.4 NA oil-immersion
objective. A series of optical sections distanced 0.4 mm on the z-
axis were obtained.
Migration assay Melanocyte migration assays were performed in
8-mm pore Transwell chambers (Corning Incorporated, Corning,
NY). Fibronectin has been described as a stimulus of melanocyte
motility (Zambruno et al, 1993); therefore, fibronectin 10 mg per mL
was added to the lower chamber and incubated for 1 h at 371C.
Melanocytes, resuspended in serum-free medium MCDB153, were
then seeded at 15,000 cells/well on the upper chamber. After
30 min, purified monoclonal antibodies were added to the upper
chamber where appropriate. After 18 h, migrated cells onto the
lower surface of the filter were stained with toluidine blue and
counted. Experiments were carried out in duplicate, and four fields
of each transwell were counted with a  40 objective in an Eclipse
E400 microscope (Nikon, Tokyo, Japan).
Regarding the migration assay using siRNA-transfected
cells, cells were recovered from the lower surface of the filter
by trypsinization after the incubation period for migration,
and the number of migrated cells was estimated by flow
cytometry.
Recombinant DNA constructs, transient transfection, and
time-lapse ﬂuorescence confocal microscopy The CD9–GFP
fusion protein construct was obtained by polymerase chain reac-
tion amplification of the CD9 cDNA (a kind gift from Dr E. Rubin-
stein, INSERM, Villejuif Cedex, France) and cloned in pEGFP-N1
Vector (Clontech Laboratories, Palo Alto, California) in EcoRI sites
of the cloning site, as described elsewhere (Longo et al, 2001). The
CD151–GFP fusion protein construct was also obtained by po-
lymerase chain reaction amplification of the CD151 cDNA (a kind
gift from Dr S. Fujita, Ehime University, School of Medicine, Shige-
nobu, Japan) and cloned in pEGFP-N1 Vector (Clontech Labora-
tories) in HindIII–Kpn1 sites of the cloning site (Barreiro et al,
2005).
Primary melanocytes were trypsinized and resuspended in
MCDB 153 medium supplemented with 5% FCS, 37.5 mM NaCl,
and 20 mg of the vector coding for CD9– or CD151–GFP-tagged
proteins. Cells were transfected by electroporation at 975 mF and
200 V in a Gene Pulser II (Bio-Rad, Hercules, California) and were
allowed to grow up to 24–48 h after transfection. Then, cells were
trypsinized and seeded onto an uncoated 25 mm glass coverslip.
Finally, time-lapse videomicroscopy experiments were performed
after 4 h of cell adhesion. Samples were maintained at 371C in a
5% CO2 atmosphere using an incubation system (La-con GBr Pe-
con GmbH, Erbach, Germany) coupled to the Leica TCS-SP con-
focal laser scanning unit. A series of optical sections distanced
0,4 mm on the z-axis were acquired every 5–15 min during a total
experimental time of 7 h. Green fluorescence and DIC images were
simultaneously obtained using a  63/1.4 NA oil-immersion ob-
jective. Images were processed and assembled into movies using
the Leica Confocal Software.
siRNA assay To knock down the expression of CD9 and CD151
selectively, the silencing sequences described previously (Barreiro
et al, 2005) were used. RNA duplexes corresponding to CD9 and
CD151 target sequences, as well as a negative oligonucleotide
that does not pair with any human mRNA were produced by
Eurogentec (Seraing, Belgium). Oligonucleotides were transfected
in primary melanocytes with oligofectamine (Invitrogen, Carlsbad,
California) following the manufacturer’s instructions. For CD9 in-
terference, melanocytes were transfected on day 0, split on day 2,
and retransfected on day 3. For CD151, cells were transfected only
once on day 3. Then, cells were trypsinized on day 6 and negatively
selected with anti-CD9 or anti-CD151 magnetic-coated beads
(Dynabeads M450 Goat anti-Mouse IgG, Dynal Biotech ASA, Oslo,
Norway), in order to enrich the tetraspanin low-expressing popu-
lation. Cells thus selected were counted and seeded for the dif-
ferent experiments.
Statistical analysis Data were compared using the Student’s t
test or one-way analysis of variance.
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Supplementary Material
The following material is available online for this article.
Figure S1. Video S1 (from Fig 3a). Primary human melanocytes
transiently transfected with CD9-GFP were seeded on a coverslip
for 4 h.
Figure S2. Video S1 (from Fig 3b). Primary human melanocytes
transiently transfected with CD151-GFP were seeded on a coverslip
for 4 h.
Figure S3. Video S1 (from Fig 4a). Primary human melanocytes
transiently transfected with CD9-GFP were seeded on a coverslip
for 4 h.
Figure S4. Video S1 (from Fig 4b). Primary human melanocytes
transiently transfected with CD151-GFP were seeded on a coverslip
for 4 h.
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Functional insights on the polarized
redistribution of leukocyte integrins
and their ligands during leukocyte
migration and immune interactions
Summary: Cell–cell and cell–matrix interactions are of critical importance
in immunobiology. Leukocytes make extensive use of a specialized rep-
ertoire of receptors to mediate such processes. Among these receptors,
integrins are known to be of crucial importance. This review deals with the
central role of integrins and their counterreceptors during the establish-
ment of leukocyte–endothelium contacts, interstitial migration, and final
encounter with antigen-presenting cells to develop an appropriate immune
response. Particularly, we have addressed the molecular events occurring
during these sequential processes, leading to the dynamic subcellular
redistribution of adhesion receptors and the reorganization of the actin
cytoskeleton, which is reflected in changes in cytoarchitecture, includ-
ing leukocyte polarization, endothelial docking structure formation, or
immune synapse organization. The roles of signaling and structural actin
cytoskeleton-associated proteins and organized membrane microdomains
in the regulation of receptor adhesiveness are also discussed.
Keywords: leukocyte integrins, extravasation, migration, immune synapse, polarization,
subcellular localization
Introduction
Trafficking of leukocytes throughout different tissues and
organs and their subsequent interactions with other immune
cells are crucial for the development of innate and adaptive
immunity (1). Integrins have a central role in cell migration by
controlling intercellular and cell–matrix interactions during
homing and inflammation. One of the most important features
of these receptors relies on the regulation of their adhesion
activity independently of their membrane expression. Thus,
leukocytes modify their adhesive properties to be properly
adapted to every immune scenario (2). Hence, free-flowing leuko-
cytes maintain their integrins in non-adhesive conformation, to
avoid unspecific contacts with non-inflamed vascular walls, but
upon encountering localized inflammatory foci, a rapid in situ
activation of leukocyte integrins by endothelium-displayed
activating signals takes place (3). Although integrin-mediated
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adhesion contributes to the initial adhesive contacts between
a T lymphocyte and an activated antigen-presenting cell (APC),
T-cell receptor (TCR) signaling can enhance integrin avidity upon
recognition of an agonist peptide–major histocompatibility
complex (MHC), which further stabilizes the cell conjugate,
allowing the assembly of the immune synapse (IS) (4).
The spatial distribution of integrins and their ligands in
specialized membrane structures is also of key importance for
the proper accomplishment of their adhesive functions. This
topographic organization requires a finely regulated cellular
cytoskeleton that also enables the recruitment of signaling
intermediates and second messengers that lead to cellular acti-
vation (5). This review focuses on the central role of leukocyte
integrins and their counterreceptors during inflammation and
immunity, paying special attention to the spatiotemporal
regulation of their adhesive function.
Molecular features of leukocyte integrins and their ligands
Integrins constitute a large family of 24 heterodimeric adhesion
receptors, each one composed of a and b subunits. These
molecules regulate dynamically their adhesiveness by conforma-
tional changes as well as by redistribution on the cell surface (6).
Recent data predict the existence of three conformational states
for integrins, which differ in their localization on the plasma
membrane and in conformation (folded/low affinity, extended
with intermediate affinity, and extended with high affinity) (7,
8). The overall strength of adhesiveness (avidity) depends on the
affinity of each individual receptor–ligand bond and the number
of these interactions. Therefore, the regulation of integrin avidity
involves both the modulation of receptor and ligand density and
their redistribution on specialized membrane structures (9).
The most relevant integrins for leukocyte adhesion to
endothelium are members of the b2 subfamily, particularly
leukocyte function-associated antigen-1 (LFA-1) (CD11a/
CD18 or aLb2) and the myeloid-specific integrin Mac-1
(CD11b/CD18 or aMb2), as well as the a4 integrins very late
antigen-4 (VLA-4) (a4b1) and a4b7. In addition, LFA-1 plays
a central role in the establishment of the IS. Other integrins, such
as a5b1, a6b1, a2b1, and avb3, have a prominent function
during interstitial cell migration (10).
Most of the cellular counterreceptors for leukocyte integrins
are transmembrane proteins that belong to the immunoglob-
ulin superfamily. LFA-1 binds five distinct intercellular cell
adhesionmolecules (ICAM-1 to -5), although the most relevant
ones seem to be ICAM-1 and ICAM-3 (11). ICAM-1 is found
in leukocytes, dendritic cells (DCs), and epithelial cells and is
expressed at low levels in resting endothelial cells, becoming
highly upregulated upon inflammatory stimuli (12). ICAM-3
is constitutively expressed by all leukocytes (13), whereas the
junctional adhesion molecule-A (JAM-A), an additional ligand
for LFA-1, is selectively concentrated at the apical region of
intercellular tight junctions in endothelial cells (14). Mac-1
interacts with ICAM-1, JAM-C, and the endothelial receptor
RAGE (receptor for advanced glycation end products) (15, 16).
The integrin VLA-4 interacts with vascular cellular adhesion
molecule-1 (VCAM-1) (17), which is expressed de novo upon
endothelial cell activation (18) and also binds JAM-B (19).
Alternatively, VLA-4 interacts with ADAM-28 (a disintegrin
and metalloprotinase domain-28), fibronectin, osteopontin,
thrombospondin, von Willebrand factor, and the bacterial pro-
tein invasin (20). Finally, the a4b7 integrin, apart from its
interaction with fibronectin and VCAM-1, specifically recog-
nizes mucosal addressin cell adhesion molecule-1 (MAdCAM-
1), a receptor expressed in mucosal lymphoid tissues (21).
The extravasation process
Leukocyte migration across the vascular barrier into lymphoid
or inflamed tissues is a multistep process that requires an
orchestrated plethora of adhesion and signaling molecules (22,
23). Blood-borne leukocytes tether and roll over endothelial
cells that express different adhesion receptors. During these
initial contacts, the slowed-down leukocytes encounter local
activation signals for integrins, which trigger their firm
adhesion under shear flow, locomotion toward specific trans-
migration sites, and final diapedesis (24) (Fig. 1).
Role of integrins during tethering and rolling
In addition to selectins and their ligands, a4 integrins, through
their interaction with VCAM-1 and MAdCAM-1, support
leukocyte tethering, rolling, and arrest (25). Moreover, the
interaction of LFA-1–ICAM-1 cooperates with L-selectin in the
tethering and rolling steps (26). Other molecules may also
participate in the initial steps of extravasation, mainly CD44,
which has been recently described as a physiological E-selectin
ligand (27). An additional level of molecular complexity during
leukocyte migration is introduced by the formation of
a cooperative bimolecular complex between CD44 and VLA-4
in activated T cells that reduces CD44-dependent rolling
velocity and stabilizes VLA-4-mediated firm adhesion (28).
Adhesion receptor distribution at the plasma membrane has
a key role in leukocyte adhesiveness and is another regulatory
checkpoint for leukocyte trafficking (29, 30). In leukocytes,
selectins, P-selectin glycoprotein ligand-1 (PSGL-1), b7, and b1
integrins are usually concentrated at surface projections (e.g.
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Fig. 1. Localization of leukocyte integrins and their ligands during
the extravasation process. Upper panel: tethering and rolling of
leukocytes onto endothelium. Free-flowing leukocytes establish
transient contacts (tethering) with activated endothelial cells and begin
to roll on the endothelial wall to become activated and finally arrested.
Some of the molecules that participate during this process are
displayed: L-selectin, VLA-4, LFA-1, and CD44 in the leukocyte and E-
selectin, P-selectin, VCAM-1, and ICAM-1 in the endothelium. All these
receptors are localized in specialized protrusions (microvilli), except
for LFA-1 and CD44 that are preferentially localized at the leukocyte
cell body. Middle panel: leukocyte firm adhesion and endothelial
docking structure. The slowing down of leukocytes during the rolling
phase facilitates their encountering with chemokines exposed on the
apical surface of the endothelium. The inside-out signaling derived
from leukocyte chemokine receptors triggers the activation of integrins,
which in turn can interact with their endothelial ligands to
mediate leukocyte firm arrest. This step requires drastic
morphological changes both in the leukocyte and in the endothelial
cell. The round shape of circulating leukocytes changes into a polarized
shape typical of migrating cells. The acquisition of polarity implies the
segregation of adhesion molecules (ICAM-1, ICAM-3, CD44, etc.) to
the rear pole (uropod), whereas the integrins are preferentially
localized at the contact area with the endothelium. Additionally, the
engagement of endothelial adhesion receptors triggers the
formation of docking structures around adherent leukocytes, which
also contain tetraspanin proteins and are supported by a cortical
actin scaffold. Lower panel: leukocyte transendothelial migration.
Upon firm adhesion, leukocytes migrate toward an appropriate
site for diapedesis. The classical paracellular route of transmigration
is shown in this panel, in which LFA-1 and ICAM-1 actively
participate. JAMA, an alternative ligand for LFA-1, is also
depicted.
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ruffles and microvilli), whereas b2 integrins and CD44 are
primary located on the cell body (31–33) (Fig. 1). Selectin
ligand engagements may favor flattening of microvilli,
rendering previously inaccessible integrins and G-protein-
coupled receptors (GPCRs) on the cell body readily available
to their ligands. However, the strict separation of adhesion
molecules in microvilli or cell body does not reflect physi-
ology, as the dynamic redistribution of these molecules upon
polarization of leukocytes and formation of functional com-
plexes must be taken into account (34).
Central involvement of leukocyte integrins in firm adhesion
and locomotion to endothelium
During the initial establishment of contacts with the vascular
endothelium, leukocytes slow down their rolling velocity and
become activated by encountering immobilized chemokines
and integrin ligands displayed at the endothelial apical surface.
This activation step allows the arrest and firm adhesion of
leukocytes to endothelium under shear flow (35). Leukocyte
activation involves a marked shape change from the round
free-flowing cell to a polarized promigratory morphology with
two distinct regions: the leading edge and the uropod (36).
Leukocyte polarization enables the cell to turn intracellular
forces into net cell locomotion necessary to accomplish the
extravasation process (37).
Chemokine modulation of integrin activity
During the extravasation process, integrin adhesiveness is
modulated by the chemokines coupled to apical endothelial
glycosaminoglycans (38). These chemokines act by signaling
through GPCRs and induce an array of ‘inside-out’ signals
within fractions of seconds, leading to multiple conformational
changes of integrins with important effects on leukocyte
adhesion and morphology (34, 39, 40). Both the endothe-
lium-immobilized chemokines and the chemokine receptors
expressed on leukocytes are concentrated on microvilli to
facilitate their interaction. The presence of specific chemokines
on different vascular beds contributes to orchestrate the
selective recruitment of leukocyte subsets to inflammation foci
or secondary lymphoid organs (41). In addition, chemokines
may exert a differential effect on specific integrins within the
same microenvironment. Accordingly, it has been described
that chemokines can only mediate lymphocyte arrest dependent
on VLA-4/VCAM-1 when binding their GPCRs with high
affinity and with high relative occupancy, but this signal
threshold-dependent effect is not observed with chemokine-
stimulated b2 integrins (42).
Small guanosine triphosphatases (GTPases) play a central
regulatory role in the integrin activation induced by chemo-
kines, mainly through RhoA activation or/and RhoH inactiva-
tion (43–45). It has been also suggested that Rac1 and its
guanine nucleotide exchange factors (GEFs) Vav-1 and DOCK2
are involved in the chemokine-mediated activation of integrins
in human T andmouse B cells (46–48). However, other authors
propose that DOCK2 is mainly involved in microvilli collapse,
lamellipodium formation, and lateral mobility induced by
chemokines (49). Alternatively, the ras-like small GTPase Rap1
can regulate integrin activation through RapL (regulator of
adhesion and cell polarization enriched in lymphoid tissues)
that binds to the cytoplasmic tail of the LFA-1 a-chain (50, 51).
The important role of Rap1 in integrin activation has been
recently underscored by a deficiency in lymphocyte adhesive-
ness (LAD III), which correlates with a selective impairment in
the activation of Rap1 induced by chemokines (52). Further-
more, the activation of phosphatidylinositol 3-OH kinase
(PI3K) and protein kinase C z (PKC-z) by chemokines is
involved in LFA-1 clustering at areas of low ICAM-1 density
(39, 43, 53). In addition, the ARF–GEF cytohesin-1 induces
LFA-1 activation by direct interaction with its b2 cytoplasmic
domain (54, 55). However, there are also negative regulators of
integrin activation, such as PKA, H-ras, and integrin-linked
kinase (ILK) (56–58). Because of the complexity and time
frames of the signaling mechanisms controlling integrin
activation, the existence of preformed compartmentalized
protein networks (‘signalosomes’) in leukocytes encountering
endothelial chemokines is conceivable (59).
Ligand modulation of integrin affinity
Upon the inside-out chemokine-mediated signaling in leuko-
cytes, integrin conformation reversibly and readily switches
from the inactive (folded) to the extended conformation with
intermediate affinity. This event primes the integrin to bind its
endothelial ligand. Integrins containing the ‘inserted’ I-domain
in their a subunits undergo a further conformational shift from
this intermediate affinity extended conformation upon ligand
binding, resulting in full integrin activation and leukocyte arrest
(60–62). Therefore, high-affinity conformational state for
leukocyte immediate arrest requires bidirectional induction
from both immobilized chemokines and integrin ligands (40,
63). However, a4 integrins, which contain an I-like domain
in their b subunits, can spontaneously interact with their
endothelial ligands without previous chemokine stimulation
(64). Therefore, it is possible that these integrins exist in overall
extended conformations with high accessibility to their ligands
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because of their preferential localization at microvilli. Finally,
the ‘outside-in’ ligand-driven signaling results in further
separation of the integrin subunit cytoplasmic tails (unclasp-
ing), which favors their association with the cortical actin
cytoskeleton (8).
Lateral mobility of integrins at the plasma membrane to
promote avidity
Ligand binding enhances the recruitment of additional integrins
(microclustering), further increasing the integrin-dependent
adhesiveness of leukocytes under shear stress, to support their
firm adhesion to endothelium (65). This clustering is dependent
on integrin release from the actin cytoskeleton by PKC and
calpain to increase their lateralmobility (66). In this regard, it has
been suggested that ligand-independent LFA-1 nanoclusters are
present at the plasma membrane of leukocytes, which promote
the efficient formation of ligand-triggered microclusters (67).
Role of cytoskeleton in regulating integrin adhesiveness
The association of the extended forms of integrins with the
cortical cytoskeleton is required to integrate mechanical forces
from shear flow and F-actin and to undergo ligand-induced
strengthening at endothelial contacts. Accordingly, a recent study
has shown that a large proportion of LFA-1 molecules in
extended conformation rather than low-affinity foldedmolecules
are anchored to the cytoskeleton prior to ligand binding (68).
However, key differences between a4 and b2 integrins
regarding their increase in avidity mediated by cytoskeleton may
occur. The a4 integrins can bind paxillin upon dephosphoryla-
tion of Ser988 in their cytoplasmic domain at the sides and rear
pole of the cell, whereas PKA-mediated phosphorylation of these
integrins is confined at the leading edge of the cell. Paxillin
regulates a4 integrin function (tethering and firm adhesion) in
immune cells (69), enhancing their rate of migration and
reducing their spreading. In addition, paxillin–a4 interaction
downregulates the formation of focal adhesions, stress fibers, and
lamellipodia by triggering the activation of different tyrosine
kinases, such as focal adhesion kinase (FAK), Pyk2, Src, and Abl
(70). The a4–paxillin complex inhibits stable lamellipodia by
recruiting an ADP-ribosylation factor (Arf)-GTPase-activating
protein that decreases Arf activity, thereby inhibiting Rac, and
limiting lamellipodia formation to the cell front (71).
It has been described that LFA-1 andMac-1may use the adapter
molecules talin,a-actinin, filamin, and 14-3-3 to properly anchor
to the actin cytoskeleton (72, 73). Regarding the subcellular
localization, the patternof LFA-1 varies from lowexpression in the
lamellipodia to high expression in the uropod. However, it has
been reported that high-affinity clustered LFA-1 is restricted to
a mid-cell zone, termed the ‘focal zone’, different from focal
adhesions and focal contacts. In addition, talin, properly activated
by phosphorylation or phosphatidylinositol-4,5-bisphosphate
(PIP2), is essential for the formation and stability of the focal
zone and for LFA-1-dependent migration (74).
Effect of mechanical forces on integrin activation
Several studies suggest that integrins are directly regulated by
shear stress (75). Shear flow promotes additional stretching of
integrin bonds, increasing outside-in signals that coordinate
leukocyte and endothelial adhesion machineries to promote
productive diapedesis. Recent findings also point to a shear stress-
mediated conformational activation of VLA-4, resulting in
increased affinity (76). The integration of chemokine- and
external force-derived signaling to enhance migration has been
defined as the phenomenon of chemorheotaxis (77). In terms of
subcellular localization, the integrins displayed on leukocyte
microvilli distributemore readily high disruptive forces along the
microvillar axis. Remarkably, the importance has been recently
addressed of shear forces for the integration of signals from apical
and subendothelial chemokines, rendering an increase in
chemotaxis toward the subendothelial compartment (78).
Regulation of leukocyte locomotion by integrins
The signals involved in leukocyte firm adhesion to endothelium
mediated by integrins are subsequently attenuated to allow
leukocyte migration toward an appropriate site of trans-
migration. b2 Integrins appear to have a critical involvement
in this process of locomotion because blockade of these
integrins or their correspondent endothelial ligands results in
random locomotion, failure in correct positioning at the
endothelial junction and defective diapedesis (79).
Integrin-dependent adhesion is required for changes in
cytoskeleton plasticity (polarization and spreading) and cell
motility (34). Upon interaction with their ligands, integrins
activate distinct myosin contractility effectors, actin-remodel-
ing GTPases, and molecules involved in microtubule network
regulation at the leading and trailing edges of motile leukocytes
(80, 81). During cell polarization, Cdc42, myosin light chain
kinase (MLCK), Rac, RapL, Rap1, mDia, myosin-IIA, and
chemokine receptors are redistributed to the cellular front,
participating in the formation of exploratory filopodia and in
the extension of lamellipodia. In contrast, Rho and Rho-
associated kinase (ROCK) (both involved in trailing edge
retraction), the microtubule-organizing center (MTOC), and
the adhesion receptors ICAM-1, ICAM-3, CD44, and CD43
move toward the rear pole (5). The redistribution of integrin
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ligands to the uropod seems to be involved in the recruitment of
bystander leukocytes through this cellular structure (82).
Hence, the integration of signals generated in both cellular
poles leads to a coordinated movement of the leukocyte.
Integrins during transendothelial migration
Once the leukocyte finds a proper site for transmigration, mostly
at intercellular junctions, it extends exploratory pseudopodia in
between the two adjacent endothelial cells. Subsequently,
pseudopodia evolve into a lamella squeezed into the monolayer
gap. During this process, LFA-1 is the integrin with a more
prominent role. This molecule is rapidly relocalized, forming
a ring-like cluster at the leukocyte–endothelial interface, where it
interacts with ICAM-1 and, in some cellular models, with JAM-A
(Fig. 1).When the transmigration process is over, LFA-1 is finally
concentrated at the uropod (83, 84). The NADase/ADP-ribosyl
cyclase CD157 can act in concert with b2 integrins, playing an
important role in transendothelial migration (TEM) (85).
Endothelial integrin ligands and their contribution to the
extravasation process
Endothelium is no longer considered as a passive barrier during
TEM. In fact, endothelial cells form ‘docking’ structures to firmly
attach leukocytes upon the binding of VCAM-1 and ICAM-1 to
their respective leukocyte ligands, VLA-4 and LFA-1. These cup-
like structures are based on microvilli that emerge from the
endothelial apical surface, and their essential constituents
include endothelial adhesion receptors, together with the actin
cytoskeleton, adapter proteins [ezrin–radixin–moesin, a-acti-
nin, vinculin, vasodilator-stimulated phosphoprotein (VASP)],
and signaling molecules (PIP2, Rho/ROCK) (86) (Fig. 1).
Furthermore, it seems that ICAM-1 and VCAM-1 projections
induce linear clusters of integrins along the sides of leukocytes
(87). The relevant role of these structures for leukocyte adhesion
and transmigration has been unveiled in experiments under
flow conditions (86). However, the docking structures should
not be envisioned as static structures because experiments using
green fluorescent protein-tagged versions of ICAM-1 and
VCAM-1 in living cells underscore their dynamic nature (86).
These endothelial receptors are clustered around adherent and
transmigrating leukocytes. While VCAM-1 remains at the apical
endothelial side, ICAM-1 exerts its adhesive function during the
whole transmigration process and also relocalizes around the
leukocytes moving underneath the endothelium (86). This last
observation could point to a role for ICAM-1 and LFA-1 in the
egress of monocytes toward the blood flow (88).
Regarding the organization of the apical endothelial
plasma membrane, the lateral association of VCAM-1 and
ICAM-1 with different tetraspanin proteins (CD9, CD81, and
CD151) as well as the inhibitory effect in leukocyte adhesion
and TEM because of the perturbance of the endothelial
tetraspanin microdomains have recently been described (89).
Tetraspanins form specialized microdomains at the plasma
membrane, a kind of multimolecular platform organizing
transmembrane receptors in concert with intracellular
signaling molecules. The existence is feasible of tetraspanin-
enriched adhesive platforms at the apical surface of endothelial
cells, containing VCAM-1 and ICAM-1, and a variable pro-
portion of most of the receptors involved in the adhesion and
transmigration of leukocytes, including CD44 and platelet-
endothelial cell adhesion molecule-1 (PECAM-1), ICAM-2, and
JAM molecules (O. Barreiro et al., unpublished data). In
addition, tetraspanins can also interact with integrins, regulat-
ing their adhesive properties (90).
In the context of leukocyte transmigration, in addition to the
classical pathway of diapedesis in which the leukocytes cross
through interendothelial junctions without disrupting the
integrity of the endothelium (paracellular pathway), there is
increasing evidence indicating the existence of an alternative
pathway, in which leukocytes could migrate across an individual
endothelial cell (transcellular pathway) (91). It has been
suggested that endothelial docking structures are involved in
the paracellular and transcellular routes of TEM (92). Moreover,
new insights into the mechanism of this process have been
recently reported, involving the translocation of ICAM-1 to
caveolae upon leukocyte adhesion and the subsequent formation
of a sort of multivesicular channel, containing ICAM-1 and
caveolin-1 around the penetrating leukocyte pseudopod. Both
proteins follow the passage of the whole cell, moving toward the
basal side of the endothelial membrane (93). In addition, the
protein of intermediate filaments, vimentin, also seems to play
a role in the transcellular pathway (94). Finally, VCAM-1 and
ICAM-1 are also able to transduce signals upon ligand binding,
inducing activation of Rac1 or RhoA, respectively, as well as
calcium release, and generation of reactive oxygen species and
additional signals that cooperate to increase endothelial perme-
ability and facilitate leukocyte transmigration (95).
Leukocyte navigation into the tissue
Once leukocytes have passed across the endothelial barrier, they
must be able to penetrate the venular wall and migrate into the
interstitial extracellular matrix (ECM), following the chemo-
tactic gradient to sites of injury or infection. Although T
lymphocytes have been extensively studied regarding their
motility and adhesive interactions onto endothelial cells and
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ECM components, the mechanisms of T-cell infiltration and
its regulation have not been fully characterized. Integrins are
the major class of receptors implicated in adhesion to ECM
components, mediating a range of different cell functions such
as cell attachment and polarity, growth and differentiation, as
well as adhesion and migration.
Most ECMs consist of three major classes of macromolecules:
collagens, proteoglycans/glycosaminoglycans, and accessory
glycoproteins such as fibronectin and laminin. ECM proteins play
an important role in the recruitment of inflammatory cells.
Monocytes and neutrophils adhere in vitro to laminin, thrombo-
spondin, and fibronectin (96), and in in vivo animal models of
rheumatoid arthritis, the migration of these cells is dependent on
the presence of fibronectin (97, 98). The role of ECM in the
motility of other leukocyte subsets such as B cells and Langerhans
cells (99, 100) aswell as the effect onT lymphocytemigration and
function have also been described (101–103). In addition,
aberrant thymocyte development is observed in the dy/dymutant
mouse, which lacks laminin-2, and anti-laminin-5 monoclonal
antibodies inhibit mouse thymocyte proliferation as well as their
double-negative–double-positive differentiation (104, 105).
Mechanisms of leukocyte infiltration through ECM
The perivascular basement membrane is mainly composed of
pericytes embedded in a network of ECM proteins, including
laminin-8 and -10, type IV collagen, and entactin. This structure
constitutes an additional important barrier for migrating
leukocytes. Three different mechanisms by which leukocytes
may overcome biophysical matrix barriers have been described:
cell shape changes, contact-dependent matrix remodeling, and
degradation of ECM by proteases. Interestingly, a recent study
showed the existence of regions of venule walls where the
expression of laminin-10, collagen IV, and nidogen-2 is
considerably diminished. Neutrophil transmigration enlarges
the size of these regions, and their protein content is further
reduced, an effect that appears to involve neutrophil-derived
serine proteases (106). Location of proteases at the leukocyte
cell surface occurs through two different mechanisms, either
by endogenous expression as transmembrane proteins or by
binding of extracellular proteases to integral membrane
receptors (Fig. 2). Integrins are shown to act as anchoring
receptors for several proteases including matrix metalloprotei-
nases (MMPs); such interactions have been detected in caveolae,
invadopodia and at the leading edge of migrating cells, where
directed proteolytic activity is required (107). In this regard,
pro-MMP-2 and pro-MMP-9 are bound to aLb2 and aMb2 on
the surface of activated leukemic cells, and the inhibition of
these complexes blocks b2 integrin-dependent leukocyte
migration (108). Pro-MMP-9–aMb2 complexes are primarily
localized into intracellular granules of resting neutrophils, but
after cellular activation, they are relocalized to the cell surface
(109). In the case of DC migration, MMP-9 plays a role both
in vivo and in vitro (110–112). In this context, the migration of
interferon-g-induced DCs is mediated by MMP-9 and its cell-
Fig. 2. Integrin localization on migrating leukocytes on 2D and 3D
ECM substrate. Upper panel: integrin-dependent migration on 2D
substrate. Migrating leukocytes on fibronectin show b1 integrins–
ligand interactions and actin cytoskeleton strongly focalized at the basal
area and the leading edge. During migration, leukocytes form new
attachments at the front and release old ones toward the rear. Released
integrins are internalized into endocytic vesicles near the rear and
return to the plasma membrane through the traffic from early
endosomes to the perinuclear recycling compartment, which can be
regulated by Rab11. Lower panel: integrin-independent migration in
3D collagen lattice. b1 Integrins are redistributed toward the uropod,
while b2 integrins are redistributed to the leading edge. Interactions
with collagen occurred independently of coclustering of b1, b2, or b3
integrins with F-actin (118).
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surface receptors CD11b and CD44, suggesting a mechanism
that involves a synergistic activation of c-Jun N-terminal kinase
(JNK) (113). However, it has been described that in three-
dimensional (3D) collagen matrices, T-cell and DC migration
occur along pre-existing fibrillar strands and that areas of dense
network matrix are circummigrated rather than penetrated
(114), in a process independent of proteolytic activity (107).
Activated T and B lymphocytes, monocytes, and neutrophils
synthesize and secrete laminin (115, 116), suggesting that
leukocyte-derived matrix proteins might also contribute to the
process of transmigration. Of relevance, a defect in neutrophil
migration in laminin-8-deficientmice has been reported (116).
Role of integrins in leukocyte migration through ECM
Our knowledge about the role of integrins on leukocytemigration
through the ECM is scarce and largely controversial, perhaps
because of the limitations of the experimental models used to
study this phenomenon. In locomotive cells such as leukocytes,
properly formed focal adhesions do not exist and are rather
replaced by focal contacts, which are frequently of smaller size,
incompletely assembled, and less stable, and which may contain
molecules not present in focal adhesions, like gelsolin (117).
Rapidly migrating leukocytes adopt different morphological
shapes during migration, displaying an amoeba-like movement.
Interactions of lymphocytes with ECM may be too transient to
support the assembly of completely formed focal adhesions
(118).Consequently, inT cells, the highmigration speed seems to
be inversely correlated with focal adhesion formation.
Differences have been described depending not only on the
different leukocyte subsets studied but also on the migration
model used. The current concept of cell migration and adhesion
receptor function is based on the observation of individual
fibroblast-like cellsmigrating on a 2D environment. Because the
limited two-dimensional (2D) nature of planar substrates does
not reflect the 3D architecture of ECM, the leukocyte–cellmatrix
interactions have been further investigated in a 3D tissue
context. Some models mimicking a 3D tissue environment
include collagen lattices, multicomponent matrices that are
supplemented with other ECM components, and Matrigel,
which mimics the complex basement membrane (119). For
direct in vivomonitoring of cell behavior in the tissues, intravital
microscopy allows the observation of native or fluorescently
labeled cells upon TEM or migration in the tissue (120).
It is well known that cross-linking of integrins triggers
a motile behavior in T lymphocytes (121). Although leukocyte
b2 integrins bind fibrinogen following activation (122),
several studies suggest that these integrins are not essential for
interactions with other ECM molecules (123, 124). In vitro,
activated CD18 null neutrophils adhere to fibronectin and
vitronectin through a5b1 and avb3 integrins, respectively,
while adhesion to endothelial laminin-10 is mediated by a6b1
(125). Using 3D collagen lattices, it has been found that
spontaneously migrating CD4þ T lymphocytes distribute b1
integrins toward the uropod, while b2 integrins are redis-
tributed toward the leading edge. Simultaneous blockade of b1,
b2, b3, and av integrins did not affect the number or velocity of
migrating T lymphocytes in collagen matrices (118). However,
the integrin-dependent migration of T cells has also been
described on both 2D and 3D collagen substrata (126). In 3D gel
reconstituted with major ECM glycoproteins and with gradients
formed by RANTES (regulated upon activation, normal T-cell
expressed, and presumably secreted) and interleukin-2 (IL-2),
directional and random locomotion of T cells requires the
activity of a4, a5, and to a lesser degree, a2, and a6b1 integrins
(127). The critical role of b1 but not b2 integrins in neutrophil
locomotion in extravascular tissue has been described in vivo by
intravital microscopy, in the rat mesentery induced by platelet-
activating factor (PAF) (120). In this regard, the integrin a2b1
has been identified as the main receptor used by neutrophils for
migration in extravascular tissue. Furthermore, this integrin is
localized at the anterior lamellipodiumof neutrophilsmigrating
on collagen in response to N-formyl-methionyl-leucyl-phenyl-
alanine (fMLP) (128). Additional integrins have been studied
in the context of polymorphonuclear neutrophil migration,
including Mac-1, the effects of which depend on the collagen
concentration (129). Moreover, the integrin avb3 has been
described to be concentrated at the leading edge of poly-
morphonuclear neutrophil migrating on vitronectin (130).
Recycling of integrins: role in leukocyte migration
Cellmigration involves a dynamic regulation of cell adhesion, in
which new adhesions are formed at the cell leading edge, where
filipodia and lamellipodia are generated as exploratory projec-
tions and, coordinately, adhesions are released from the trailing
edge (131). In this context, the supply of adhesionmolecules to
the site of pseudopodial protrusion must be necessarily
replenished in order to enable the cell to move forward.
Recycling assays show that certain integrins are continually
internalized from the plasma membrane into the endosomal
compartments and that they are then recycled back to the cell
surface (132). In addition, there is evidence that the membrane
trafficking pathways that recycle adhesion receptors contribute
to cell migration (133). In this regard, avb3 is no longer
concentrated at the leading edge of migrating fibroblast but
instead in focal adhesions in cells where integrin recycling was
disrupted by suppression of PKD1 or Rab4 or by expression of
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a mutant b3 integrin that does not bind to PKD1 (134). It has
also been described that the inhibition of b1 integrin recycling
blocks the migration of epithelial cells on 2D substrates and
transmigration chambers (135, 136). Although most of the
studies on integrin recycling and the models of polarization in
migrating cells use fibroblasts as cell model, there is evidence
about the importance of this process in leukocyte migration
(130). It has been reported that a5 integrins are internalized in
motile neutrophils; these receptors are colocalizedwithmarkers
of the endocytic recycling compartment (ERC). Furthermore, as
neutrophils migrate, the ERC, which is located at the cell front,
reorients to retain its localization behind the leading lamella,
indicating that membrane recycling during neutrophil migra-
tion has directionality (137) (Fig. 2). In addition, it has been
shown recently that LFA-1 is internalized and rapidly recycled
in neutrophils upon chemoattractant stimulation by a pathway
involving detergent-resistant membrane microdomains (138).
A dominant-negative Rab11 mutant induces intracellular
accumulation of endocytosed aLb2 and prevents its enrichment
in chemoattractant-induced lamellipodia. The importance of
the regulation of intracellular trafficking of integrins during
leukocytemigration has also been reported in cells fromMyo1f-
deficient mice, which exhibit a diminished adhesion and
reduced motility, as a result of an augmented exocytosis of b2
integrin-containing granules. It is postulated that Myo1f could
inhibit granule exocytosis by modulating cortical actin (139).
Integrins in cognate immune molecular interactions
Establishment of immune contacts between different leukocyte
partners, including DC–naive T lymphocyte, follicular dendritic
cell (FDC)–B lymphocyte, B lymphocyte–CD4þ T cells,
cytotoxic T lymphocyte (CTL)–target cell, as well as natural
killer (NK) lymphocyte–target cell, is required for the
development and maintenance of the immune response. All
these immune interactions require close and long-lasting, cell-
to-cell contact for full activation of the leukocytes. The spatial
organization of molecular aggregates of cell-surface receptors
and cytoplasmic molecules at the interface between the two
interacting cells is referred to as the IS. Integrins, mainly LFA-1,
are crucial anchors for maintaining T–APC cell–cell conjugates.
Integrins at the Immune Synapse
The IS is characterized by the organization of antigen receptors,
costimulatory molecules, and adhesion molecules at the T cell–
APC interface. The TCR and peptide–MHC complexes are
clustered together with costimulatory molecules (CD4, CD2,
and CD28) at the center of the contact zone, the central
supramolecular activating complex (cSMAC) (140). The
intracellular signaling molecules PKC-y, lck, Fyn, and z-
associated protein of 70 kDa (Zap70) are also localized at the
cSMAC in the inner side of the T-cell membrane. Although
signal transduction could occur outside this zone, the organized
cSMAC seems to significantly contribute to sustained intracel-
lular signaling and to the internalization of engaged receptors.
This cSMAC is surrounded by a ring of LFA-1–ICAM-1 in an area
known as the peripheral SMAC (pSMAC) (140). The integrin
VLA-4 is also localized at the pSMAC (141), but in contrast to
LFA-1, the classical ligands described for VLA-4 are not present
at the IS. LFA-1 at the pSMAC is linked to the actin cytoskeletal
protein talin (4) and to RapL (142). In addition, other intra-
cellularmolecules that regulate integrin function are localized at
pSMAC such as Mst1, adhesion and degranulation-promoting
adapter protein (ADAP), Src kinase-associated phosphoprotein
of 55 kDa (SKAP55), WAVE2, and Tec kinases. In contrast,
tetraspanins and integrins are segregated into different regions
of the IS; for example, the tetraspanin CD81 is localized at the
cSMAC in T and B cells, colocalizing with CD3 and MHC class II
molecules, respectively (143).
The concentric cSMAC/pSMAC organization has been
described in different ISs, including those formed between T
cells and B-cell lines or with lipid bilayers containing ICAM-1
andMHCmolecules. Using living T-cell–lipid bilayer models, it
has been shown that initially LFA-1–ICAM-1 are concentrated
at the center of the IS, surrounded by a ring of TCR–MHC
molecules. This organization is rapidly inverted, forming the
definitive SMAC, with TCR–MHC at the center and LFA-1–
ICAM-1 at the periphery (4). CTLs interacting with target cells
show a double cSMAC, where the TCR and secretory apparatus
are juxtaposed and surrounded by LFA-1 and talin (144).
Localization of LFA-1 at the pSMAC has been corroborated in vivo
in CTLs during the lysis of virally infected astrocytes (145). In
contrast, the cSMAC is not formed by naive CD8þ T cells during
the IS, whereas the formation of the integrin ring has not been
addressed in this cellular system (146). The synapses formed
between NK lymphocytes and target cells under conditions
where killing is prevented by inhibitory receptors adopt several
topologies: (i) a concentric structure with a center of adhesion
molecules surrounded by a ring of NK receptors, (ii) a multi-
focal structure, or (iii) a diffuse organization without apparent
structure (147). A multifocal IS has been also observed at the
cell-to-cell interphase of thymocytes and thymic epithelial cells
(148). Similarly, in planar lipid bilayers that contain ICAM-1
and MHC molecules, thymocytes generate multicentric and
dynamic MHC clusters that are surrounded by ICAM-1 (149).
Although confocal fluorescence studies show that the T cell–DC
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ISmay form a clear-cut cSMAC/pSMAC segregation (150, 151),
it has been reported also that DCs form multifocal ISs (152).
Integrin functions during the IS
Integrins during the initial scanning of APCs by T cells
It has been shown that initially, theT cell adheres transiently to the
APC, scanning its surface for the presence of specific MHC–
peptide complexes (Fig. 3). Several pairs of adhesion molecules
are involved in these initial adhesive interactions such as CD2–
LFA-3, LFA-1–ICAM-1, LFA-1–ICAM-3, or ICAM-3–DC-SIGN
(153). Evenwhen activated, LFA-1 has a relatively low affinity for
its ligands, which facilitates a rapid adhesion and cell detachment
(154). It has been previously described that ICAM-3 is highly
expressed by naive T cells and that, by interacting with its ligand
on DCs, LFA-1 provides the weak adhesive contact necessary for
the scanning of the APC surface by T cells (155). Interestingly,
ICAM-3–LFA-1 interaction on DCs induces the lateral mobility
and redistribution of MHC class II molecules to the contact zone.
Thus, LFA-1 not only mediates the initial adhesion with DCs but
also facilitates the priming of T cells by peptide–MHC class II
molecules (151). T-cell scanning of the DC surface in vitro occurs
rapidly and in a few minutes, and in the presence of cognate
antigen, the T cell immediately establishes an IS. However, in vivo
antigen-specific interactions of T lymphocytes with DCs are
unstable the first 8 h, stable between 8 and 24 h, and again
transient by24–36h (156). The stable interactionobserved in the
8- to 24-h period very likely corresponds to the organization and
maintenance of the IS, allowing a complete T-cell activation.
Whether LFA-1 interactions mediate these initial transitory
contacts in vivo remain to be determined.
One special feature that distinguishes DCs from other APCs is
their ability to trigger antigen-independent responses in T cells.
Immature DCs, in the absence of antigen, can induce some
responses on T cells, such as increased motility, calcium release,
and upregulation of the activation marker CD69. DC-SIGN does
not appear to play any role in the induction of these antigen-
independent T-cell responses, whereas ICAM-1–LFA-1 interac-
tions and the presence of chemokines CCL17 and CCL22, which
are constitutivelyproduced by immatureDCs, are required (157).
However, LFA-1 does not appear to be necessary in vivo for the
contact ofT lymphocytes andDCs in the absence of antigen (158).
Integrins in conjugate stabilization: on the effector cell side
Following the initial scanning contacts between the T cell and
DC, the signaling through the TCR inhibits T-cell motility (the
stop signal) (159), allowing stable cell conjugate, IS formation,
and SMAC segregation (Fig. 3). T cells, upon antigen recogni-
tion, rapidly activate the small GTPase Rap1, which binds to
RapL forming a multimolecular complex with LFA-1 at the
pSMAC, modulating its clustering and adhesion activity (50).
Recently, it has been described that the Ser/Thr kinase Mst1 is
a downstream effector molecule of RapL and that the silenc-
ing of both molecules inhibits conjugate formation (142).
Engagement of cytotoxic T-lymphocyte antigen-4 (CTLA-4)
(CD154) also induces LFA-1 clustering and adhesion through
Rap1 (160), but it also enhances T-cell motility, reducing
contact periods between T cells and APCs (161).
Additional signaling molecules that couple TCR occupancy
and LFA-1 clustering, promoting T cell–APC conjugation, have
been reported, including Vav-1, Src homology 2 leukocyte-
specific phosphoprotein of 76 kDa (SLP-76), ADAP, and
SKAP55. Upon antigen recognition by the TCR, ADAP is
phosphorylated and concentrated at the pSMAC. Overexpres-
sion of ADAP and SKAP55 increases T–APC conjugates, whereas
knocking-down SKAP55 impairs T cell–APC conjugation. Using
a mutant form of ADAP, it has been found that the binding of
SLP-76 to ADAP is necessary for pSMAC formation and for IL-2
production (162). Recently, it has been described that the
complex ADAP–SKAP55 recruits activated Rap1 to the plasma
membrane to mediate integrin activation (163). Moreover,
engagement of LFA-1 induces the formation of an F-actin ring-
based structure that colocalizes with LFA-1 and tyrosine-
phosphorylated proteins. The formation of this structure is
dependent on LFA-1 interactions with ADAP (164). Tec kinases
(itk, tec, and rlk) also participate in LFA-1 activation upon
antigen stimulation. In this regard, Itk/ cells show decreased
conjugate formation with antigen-loaded APCs and are unable
to recruit LFA-1 to the IS (165). An additional role for LFA-1 in
the recruitment of Vav-1, PKC-y, and Pyk2 to the IS in an Itk-
dependent manner has been suggested because a defective re-
cruitment of thesemolecules to the IS is observed in Itk/ T cells.
LFA-1 and ICAM-1 also participate in the adhesion of CTLs and
target cells and in the formation of the pSMAC. However, cSMAC
formation does not seem to be required for cytolytic killing by
CD8þ T cells because killing can be triggered by a single antigenic
peptide, far fewer than what is required to form the cSMAC
(166). Whereas LFA-1 is in an inactive form in resting CD4þ T
cells, this integrin is constitutively active in CD8þ CTLs. Binding
of LFA-1 on CTLs to target cells initiates the formation of
a peripheral ring junction, where LFA-1 and CD3 colocalize. The
formation of this ring is antigen independent, but the recognition
of antigen by the TCR induces the accumulation of phosphor-
ylated proteins as well as the redistribution of the MTOC toward
the contact site (167). In accordance, using planar bilayers
containing ICAM-1, it has been described that CTLs form an
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antigen-independent ring junction, where PKC-y and LFA-1 are
colocalized (168). These data suggest that the formation of the
antigen-independent ring junction by CTLs constitutes a func-
tional presynapse that favors immune surveillance.When antigen
is encountered, CTLs rapidly form an IS, ensuring the release of
cytotoxic granules and the lysis of target cells only within an area
surrounded by the adhesive gasket.
Integrins in conjugate stabilization: on the target cell side
In contrast to T cells, few reports describe the adhesion events
that occur in APC during the formation of the IS. In vitro, the APC
can be mimicked by a lipid bilayer containing peptide-bound
MHC class I/II molecules and ICAM-1, and this expression is
sufficient for pSMAC and cSMAC segregation (4). However,
blockade of ICAM-1–LFA-1 interactions interferes with MHC
Fig. 3. Integrin roles during cognate in-
teractions. Cognate immune interactions
require close cell-to-cell contact to permit
full activation of the T cell. The interface
between the two cells is referred to as the IS.
Integrins, mainly LFA-1, are thought to be
crucial anchors for maintaining T–APC cell–
cell conjugates. Functionally, LFA-1 integrin-
mediated adhesion contributes to the initial
adhesive contact that the T cell makes when it
encounters an activated APC and promotes
MHC class II clustering at the DC contact area.
Upon recognition of an agonist peptide–
MHC complex, TCR signaling can induce
integrin clustering, which further stabilizes
the conjugate. Once a stable conjugate is
formed, the IS assembles and T-cell activation
ensues. IS maturation is characterized by the
positioning of T-cell MTOC at the vicinity of
contact site. Signaling through integrins also
promotes costimulatory signals during T-cell
activation facilitating Th1 differentiation.
Finally, integrin downmodulation could
facilitate T–APC detachment and IS
termination.
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class II concentration in synapses. In addition to its role in the
accumulation of MHC class II molecules at IS, integrins seem to
be necessary for productive contacts of T cells (169–171).
Regarding the role of integrins in DCs, it has been described that
active b2 integrins are not necessary for the antigen-presenting
capacity of DCs (172). However, it has been shown that LFA-1
molecules of DCs are actively concentrated at the IS (151).
The interaction of B cells with FDCs ismediated by VLA-4 and
LFA-1 expressed on the B cells and VCAM-1 and ICAM-1
expressed on the FDCs. In addition to establishing physical
contact, LFA-1 and VLA-4 of B cells lower the threshold of
activation of these cells (173). Although integrins are in a low-
avidity state in naive B cells, B-cell receptor (BCR) signaling
activates LFA-1 and VLA-4 upon antigen recognition. The
inside-out signaling pathway that mediates VLA-4 activation by
the BCR involves the consecutive activation and/or generation
of lyn, syk, PI3K, Bruton’s tyrosine kinase (Btk), phospholipase
Cg2, inositol-1,4,5-triphosphate (IP3), and PKC (174). In
contrast to T lymphocytes, B-cell adhesion is independent of the
adapter protein ADAP. Moreover, in the B cell IS, VCAM-1 and
ICAM-1 are localized in multiple projections that emerge from
the APC (175) resembling the endothelial docking structure
(86), while the T cell IS is characterized by a flat interface.
Integrins and MTOC translocation
The regulation of MTOC translocation has been previously
reviewed (176). It has been reported that engagement of CD3–
TCR by antibody-coated beads is sufficient for inducing MTOC
translocation on T cells (177). However, different data support
a connection between integrins and T cell MTOC translocation
during the IS. InT cell–APCconjugates formedbyVav-1-deficient
T cells, LFA-1 function is absent, and the MTOC fails to polarize
toward the IS (178). In contrast, RapL is able to interactwith LFA-
1 andmicrotubules (179), and by regulating these interactions, it
could act as a bridge between the pSMAC and the MTOC.
MTOC during IS maturation is polarized to the contact
zone, near to the pSMAC ring (180). Dynamic processes of
acetylation/deacetylation in microtubules are required for the
correct spatial organization of TCR–CD3 and LFA-1 at the IS.
Thus, HDAC6 tubulin deacetylase is localized at the pSMAC, and
its overexpression in T cells impairs CD3 and LFA-1 localization
at the IS, MTOC translocation, and IL-2 production (181). LFA-
1 interacts with Mac-MARKS, which binds to microtubules by
interacting with dynamitin, a subunit of the dynactin complex
(182). The scaffolding protein AKAP450, which associates with
tubulin and predominately localizes at the MTOC and Golgi
complex, is also physically associated with LFA-1 on T cells
(183). This association has been described in T cells upon LFA-1
cross-linking, but it could be possible that it also occurs when
LFA-1 is concentrated at the pSMAC and thus could be acting as
a linker of this integrin and MTOC.
It has been reported recently that the loss of ADAP leads to
a severe defect in MTOC translocation and dynein localization at
the pSMAC. However, in the same report, it was shown that T
cells that lack LFA-1 have no deficiencies inMTOC translocation
(184). Moreover, controversial data exist regarding the role of
LFA-1 during the polarization of lytic granules in the NK cell IS.
The engagement of LFA-1 is sufficient to induce the polarization
of lytic granules and perforin release (185). In contrast, it has
been reported that CD28 but not LFA-1 signaling is necessary
for MTOC and cytolytic granule polarization to the NK cell IS
(186). Mac-1 has been reported to be essential for Fc receptor-
mediated neutrophil cytotoxicity and conjugate formation
between neutrophils and target cells (187).
Integrin signals drive T-helper 1 cell differentiation
Several integrins participate in the transduction of costimula-
tory signals in T cells (188). Engagement of VLA-4 with
monoclonal antibody delocalizes this integrin from the pSMAC
and delivers costimulatory signals that drive T-helper 1 cell
(Th1) polarization (141). Moreover, the administration of an
anti-a4 monoclonal antibody in vivo dampens Th2-mediated
immune diseases (141). LFA-1 signaling also induces a polar-
ization of T cells toward a Th1 phenotype (189), and the
blockade of this integrin favors Th2 cytokine production (190)
(Fig. 3). LFA-1 promotes Th1 differentiation through two
independent signaling pathways involving JAB-1(Jun activation
domain-binding protein 1)–c-Jun and signaling of Erk1/2
(extracellular signal-regulated kinase 1 and 2) through
cytohesin-1 (191). DNA accessory molecule 1 (DNAM-1)
physically associates with LFA-1 upon CD3 stimulation, and this
association is involved in Th1 differentiation (192). Because
Fyn is responsible for DNAM-1 phosphorylation induced by
LFA-1 signal (193), this kinase may also play an important role
in Th1 polarization. In support of this hypothesis, it has been
described that Th2 clones in mice express low levels of Fyn
(194) and that naive CD4þ T cells from the Fyn-deficient mice
tend to polarize toward the Th2 cells, even in absence of IL-4
and IL-13 (195). Tec kinases could be also involved in Th cell
differentiation driven by integrins because in addition to their
role in the control of integrin function, these molecules are
important in the differentiation of Th cells (196).
With regard to anti-adhesion-based therapies, anti-a4 and
anti-aL monoclonal antibodies have been found to be bene-
ficial in several animal models of autoimmune and inflam-
matory disorders, and humanized antibodies have been
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approved for the therapy of multiple sclerosis and psoriasis
(197, 198). It has been assumed that their therapeutic effect is
a consequence of the inhibition of leukocyte adhesion to
endothelium, thus preventing leukocyte extravasation to the
inflammatory foci. However, the role of these integrins in
mediating leukocyte activation and Th1/Th2 polarization
should be also taken into account, mainly because autoim-
mune and inflammatory diseases are usually associated with
Th1/Th2 imbalance (199).
Integrins in IS termination
Little information is available on the mechanisms that mediate
the detachment of T lymphocytes and APCs and the termination
of the IS. One postulated mechanism includes the down-
modulation of LFA-1 adhesion. Mature DCs downregulate LFA-
1 adhesion by the cytohesin-interacting protein (CYTIP) (200).
CYTIP binding to cytohesin-1 results in the relocalization of
both from the membrane to the cytosol, which is accompanied
by reduced adhesion (201). CYTIP is induced during mat-
uration of DCs, and accumulation of CYTIP at the contact
zone of DCs and T cells can be observed with a maximum at 30
min after the onset of cell-to-cell interaction. Accordingly,
CYTIP silencing results in stronger adhesion of DCs to T cells.
This mechanism seems to be restricted to the DC–T cell
interaction because binding of DCs to endothelial cells is not
affected by silencing CYTIP (200). However, overexpression of
CYTIP in CD4þ T cells mediates the loss of adhesiveness of LFA-
1 to ICAM-1 (201). In contrast, CYTIP-deficient mice have no
defects in T-cell and DC activation or differentiation (202).
Signaling through CD4 can downregulate LFA-1 adhesion by
dissociation of LFA-1 and cytohesin in a p56lck and PI3K-
dependent manner (203, 204). A novel mechanism for LFA-1
downregulation suggests that thromboxane A2, produced by
DCs, could negatively regulate DC–T cell interactions and
therefore be involved in IS dissolution (205).
The dynamic regulation of integrin adhesiveness is critical for
the generation of an immune response. This has been recently
shown using a mouse strain with a deletion of the conserved
GFFKR sequence in the LFA-1 aL subunit cytoplasmic domain
(Lfa-1d/d mice). This mutation results in a constitutive activa-
tion of LFA-1, associated with a defective disassembly of
LFA-1-mediated adhesion. Immune responses, including T-
cell proliferation and CTL activation, are impaired by the
Lfa-1d/d mutation (206). Moreover, Lfa-1d/d mice show a similar
phenotype to Lfa-1/mice, with splenomegaly, reduced lymph
node sizes, impaired proliferative response of T cells, and reduced
NK cell cytotoxicity. These results suggest that the regulation of
LFA-1 activation seems to have a key role for the generation of the
immune responses. Accordingly, the stabilization of LFA-1 in its
active form inhibits the antigen-specific proliferative response of
T cells (207). Likewise, the sustained activation ofb2 integrins on
DCs by divalent cations prolongs contact times of DCswith T cells
but inhibits T-cell proliferation (172).
Concluding remarks
Over the last 20 years, there has been an intensive effort to
understand the complex biology of integrins, including their
structure, function, and regulation. The implementation of new
biophysical andmicroscopy techniqueswill allow investigators to
gain further insight in immune adhesion phenomena. Moreover,
the development of a newgeneration of biological agents directed
to modulate integrin function will lead to novel therapeutic
approaches against inflammatory and autoimmune diseases.
Important breakthroughs in this fieldwill come in the near future.
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ABSTRACT  
 
Endothelial VCAM-1 and ICAM-1 are fundamental receptors involved in 
leukocyte firm adhesion and transendothelial migration during inflammation. These 
adhesion molecules are recruited toward the leukocyte-endothelium contact site at the 
apical membrane of activated endothelial cells. Here we show that this recruitment is 
independent of ligand engagement, actin cytoskeleton anchorage and heterodimer 
formation, and is instead due to the inclusion of VCAM-1 and ICAM-1 within 
tetraspanin-enriched microdomains, which act as specialized endothelial adhesive 
platforms (EAP). Using complementary analytical microscopy techniques (fluorescence 
recovery after photobleaching, fluorescence correlation and cross-correlation 
spectroscopy, and fluorescence lifetime imaging-fluorescence resonance energy 
transfer), we have characterized the diffusional properties, nanoscale organization and 
specific intra-domain molecular interactions of EAP in primary endothelial living cells. 
This analysis provides compelling evidence for the existence of EAP as physical 
entities at the plasma membrane distinct from classical biochemically-defined lipid 
rafts. Scanning electron microscopy combined with the use of a specific tetraspanin 
blocking peptide identified EAP-induced nanoclustering of VCAM-1 and ICAM-1 as a 
novel mechanism of supramolecular organization that regulates the efficient leukocyte 
integrin binding capacity of both endothelial receptors. 
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 INTRODUCTION 
 
  How cells physically organize and compartmentalize receptors and signaling 
molecules into specialized, efficient, regulated networks is of critical importance to our 
understanding of the complexity and dynamics of biological processes. In this regard, 
cholesterol and sphingolipid-enriched rafts have been proposed as platforms for the 
sorting of specific membrane components such as glycosylphosphatidylinositol (GPI)-
anchored proteins and to provide sites for the assembly of cytoplasmic signaling 
complexes (Anderson and Jacobson, 2002; Simons and Toomre, 2000). Recent 
biochemical, proteomics and structural studies bolstered the idea that tetraspanin-
enriched microdomains (TEM) at the plasma membrane play a key role in organizing 
molecular complexes with protein compositions different from those of typical lipid 
rafts (Hemler, 2005; Le Naour et al., 2006; Min et al., 2006; Nydegger et al., 2006). 
The existence and physical properties of lipid rafts have been extensively studied using 
innovative analytical methods (Kenworthy et al., 2004; Larson et al., 2005; Sharma et 
al., 2004; Suzuki et al., 2007a; Suzuki et al., 2007b). However, there have so far been 
no documented studies demonstrating the existence of tetraspanin-enriched 
microdomains on the plasma membrane of living cells and characterizing their dynamic 
features at molecular level.  
Tetraspanins are ubiquitous low molecular weight proteins that span the plasma 
membrane four times and are able to organize themselves by homo- and hetero-
oligomerization (Kovalenko et al., 2005; Stipp et al., 2003). These molecules can also 
associate laterally at the plasma membrane with a plethora of integral membrane 
receptors, modulating their functions. These partners include leukocyte and endothelial 
adhesion molecules (Barreiro et al., 2005; Feigelson et al., 2003; Levy et al., 1998; 
Mannion et al., 1996; VanCompernolle et al., 2001), intercellular junction- and 
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extracellular matrix-related integrins (Berditchevski, 2001; Lammerding et al., 2003; 
Yanez-Mo et al., 1998), CD19/CD21-B cell antigen receptor complex (Cherukuri et al., 
2004), MHC-peptide complex (Kropshofer et al., 2002; Vogt et al., 2002), Fc receptors 
(Moseley, 2005), G-protein-coupled receptors (Little et al., 2004), and 
metalloproteinases (Andre et al., 2006; Takino et al., 2003; Yan et al., 2002). 
Tetraspanins also associate intracellularly with a number of cytoplasmic signaling 
mediators such as type II PI4K or different PKC isoforms (Yauch and Hemler, 2000; 
Zhang et al., 2001). Thus, the proposed existence of TEM is based on the ability of 
tetraspanins to simultaneously interact among themselves and with a wide range of 
molecules, organizing discrete dynamic plasma membrane compartments. Apart from 
acting as adapters for membrane organization, tetraspanins also regulate trafficking and 
the biosynthetic processing of associated receptors (reviewed in (Berditchevski and 
Odintsova, 2007). Although TEM seem to be different from lipid rafts, they are not 
devoid of lipid interactions, since tetraspanins are highly palmitoylated proteins that 
bind cholesterol and gangliosides (Charrin et al., 2003; Hakomori, 2002; Yang et al., 
2004). The composition of tetraspanins and associated partners, as well as other 
specific TEM characteristics, may vary with cell type. Gene deletion, knock-down, 
over-expression, and mutation experiments have revealed key functional roles for 
tetraspanins in many fundamental physiological processes, among which are egg-sperm 
fusion (Le Naour et al., 2000; Rubinstein et al., 2006), antigen presentation 
(Delaguillaumie et al., 2004; Levy and Shoham, 2005b; Mittelbrunn et al., 2002; 
Unternaehrer et al., 2007), viral cell entry and budding as well as virus-promoted 
syncytia formation (Gordon-Alonso et al., 2006; Martin et al., 2005; Pileri et al., 1998), 
metalloproteinase activity (Fujita et al., 2006; Hong et al., 2006; Hong et al., 2005; 
Takino et al., 2003), angiogenesis (Takeda et al., 2007; Wright et al., 2004), renal 
 6
function (Sachs et al., 2006), neurite outgrowth (Stipp and Hemler, 2000), 
hemidesmosome organization (Sterk et al., 2000), exosome targeting to dendritic cells 
(Morelli et al., 2004), and cell adhesion, migration and invasion (Barreiro et al., 2005; 
Chattopadhyay et al., 2003; Garcia-Lopez et al., 2005; Hemler, 2003; Kovalenko et al., 
2007; Longo et al., 2001; Yanez-Mo et al., 1998; Yanez-Mo et al., 2001). The fact that 
there are few ligands suggests that regulation of tetraspanins is likely to occur 
indirectly, through binding to their laterally-associated partners (Hemler, 2001). 
However, the molecular mechanisms underlying the regulatory activity of tetraspanins 
still remain elusive. 
Leukocyte extravasation from the bloodstream to sites of infection and 
inflammation involves a dynamic interaction with the endothelium which is mediated 
by an array of leukocyte and endothelial cell surface receptors. This process consists of 
sequential steps of tethering, rolling, firm adhesion, locomotion and diapedesis, with 
specialized receptor/ligand pairs involved in each (Butcher, 1991; Springer, 1994). Our 
earlier studies showed that, to prevent leukocyte detachment under hemodynamic flow, 
endothelial cells form actin-based structures that cluster VCAM-1 and ICAM-1 
adhesion molecules, tetraspanins and actin-binding proteins at the contact area with 
leukocytes (Barreiro et al., 2005; Barreiro et al., 2002). In the present work, we 
demonstrate the existence, prior to leukocyte binding, of specialized endothelial 
microdomains containing tetraspanins together with VCAM-1 and ICAM-1, which we 
have termed endothelial adhesive platforms (EAP). EAP promote nanoclustering of 
adhesion receptors to enhance their adhesive properties during leukocyte firm adhesion 
to endothelium. We have used an array of innovative, complementary analytical 
microscopy techniques to accurately determine the molecular characteristics, dynamics 
and biophysical properties of EAP. FRAP (fluorescence recovery after photobleaching), 
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FCS (fluorescence correlation spectroscopy) and FCCS (fluorescence cross-correlation 
spectroscopy) were used to determine diffusion coefficients, degree of anomality in 
diffusion, and multimer formation among EAP components at both microscopic and 
nanoscopic scale. Furthermore, TCSPC-FLIM (time-correlated single photon counting-
fluorescence lifetime imaging) was used to unequivocally determine FRET events 
within the EAP, thereby unraveling their specific inter-molecular organization. Finally, 
using scanning electron microscopy in combination with tetraspanin blocking peptides, 
we show that tetraspanin microdomains make an essential contribution to the avidity 
regulation of endothelial adhesion receptors, tuning their adhesive properties.  
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MATERIALS AND METHODS 
 
Cells and cell cultures 
Human umbilical vein endothelial cells (HUVEC) were obtained and cultured as 
previously described (Yanez-Mo et al., 1998). Cells were used up to the third passage 
in all assays. To activate HUVEC, TNF-α (20 ng/ml) (R&D Systems, Minneapolis, 
MN) was added to the culture media 20 h before the assays.  K562 erythroleukemic 
cells, which endogenously express β1 integrin, were stably transfected with integrins 
α4 or LFA-1 (Lymphocyte Function-associated Antigen-1) (Munoz et al., 1996; Nueda 
et al., 1995) and grown in RPMI 1640 medium (Gibco BRL, Gaithersburg, MD) 
supplemented with 10% FCS, 50 IU/ml penicillin, 50 µg/ml streptomycin, and 1 mg/ml 
G418 (Calbiochem, La Jolla, CA). T lymphoblasts were derived from freshly isolated 
human peripheral blood lymphocytes (PBLs) by activation with phytohemagglutinin-L 
(PHA-L) (1 µg/ml; Sigma-Aldrich, St Louis, MO) for 48 h followed by culture for 5-7 
days in the presence of recombinant human interleukin-2 (rhIL-2; 100 U/ml) provided 
by the National Institutes of Health AIDS Research and Reference Reagent Program 
(Division of AIDS, National Institute of Allergy and Infectious Diseases). Integrin 
inhibitors BIO5192 and BIRT377 were kindly provided by Biogen Idec (Cambridge, 
MA) and Boehringer-Ingelheim Pharmaceuticals (Ridgefield, CT), respectively.  
 
Antibodies  
Anti-CD151 (LIA1/1), anti-VE-Cadherin (TEA1/31), and anti-CD9 (VJ1/20) 
monoclonal antibodies (mAb) have been described previously (Yanez-Mo et al., 1998). 
P8B1 (anti-VCAM-1), MEM-111 and Hu5/3 (anti-ICAM-1), and 8C3 (anti-CD151) 
mAbs were kindly provided by Dr. E. A. Wayner (Fred Hutchinson Cancer Research 
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Center, Seattle, WA), Dr. V. Horejsi (Academy of Sciences of the Czech Republic, 
Prague, Czech Republic), Dr. F. W. Luscinskas (Brigham and Women’s Hospital and 
Harvard Medical School, Boston, MA), and Dr. K. Sekiguchi (Osaka University, 
Japan), respectively. Anti-caveolin Ab was purchased from Sigma. The 40 nm gold-
coupled anti-mouse antibody and 15 nm gold-coupled streptavidin were purchased 
from British Biocell. International (Cardiff, UK).  
 
Recombinant DNA constructs and proteins and transfections 
ICAM-1-, VCAM-1-, CD9-, and CD151-EGFP tagged proteins have been 
described (Barreiro et al., 2002; Garcia-Lopez et al., 2005; Longo et al., 2001). The 
construct encoding VCAM∆Cyt, a C-terminally truncated VCAM-1 protein in which 
the first cytoplasmic charged residue is retained to ensure proper membrane insertion, 
was generated by PCR using the human VCAM-1 cDNA as template, and 
[CTCGAGTCTCATCACGACAGCAAC] and [CTATCTTGCAAAGTAAATTATC] 
as 5’ and 3’ primers, respectively. The PCR product, containing a stop codon at 
position 722, was cloned into pcDNA3.1/V5-His-TOPO (Invitrogen, Carlsbad, CA) and 
correct expression of VCAM∆Cyt at the plasma membrane was tested. The equivalent 
ICAM-1-tailless construct was a kind gift of Dr. W.F. Luscinskas (Yang et al., 2005). 
For the FCS, FCCS, and FLIM-FRET studies, monomeric green and red variants of 
ICAM-1, VCAM-1, CD9 and CD151 were generated. Monomeric EGFP (mEGFP) 
constructs were obtained by A206K point mutation (Zacharias et al., 2002; Zhang et al., 
2002) using the Quick Mutagenesis Kit (Stratagene, La Jolla, CA). The mRFP1 variants 
were generated by subcloning the corresponding EGFP constructs into an mRFP1 
vector kindly provided by Dr. Tsien (UCSD, La Jolla CA). The GPI-EGFP construct 
was a kind gift of Dr. M.A. del Pozo (CNIC, Madrid, Spain). 
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The large extracellular loop (LEL) of wild-type human CD9 was cloned into the 
pGX-KG vector and expressed in protease negative BL21 cells. LEL-GST fusion 
proteins were obtained as previously described (Barreiro et al., 2005).  
HUVEC were transiently transfected by electroporation at 200 V and 975 µF 
using a Gene Pulser (Bio-Rad Labs, Hercules, CA) with 20 µg of each DNA construct, 
or using lipofectin (Invitrogen) according to the manufacturer’s protocol. Transfected 
cells were grown to confluence for 24-48 h on glass-bottomed dishes (WillCo Wells, 
Amsterdam, The Netherlands) pre-coated with fibronectin (FN) (Sigma) (20 µg/ml). 
Cells were activated with TNF-α for 20 h and subsequently used for FRAP, FLIM-
FRET or FCS experiments. 
 
Cell adhesion assays 
HUVEC were grown to confluence on coverslips pre-coated with FN (20 µg/ml) 
and then activated with TNF-α (20 ng/ml) for 20 h. Medium was removed and K562 
stable transfectants or T lymphoblasts, resuspended in 500 µl of complete 199 medium, 
were added. Adhesion of K562 LFA-1 transfectants to activated HUVEC monolayers 
was assayed in the presence of 1mM Mn2+ to activate integrins. Where indicated, T 
lymphoblasts were treated with BIO5192 (10 µg/ml) or BIRT377 (10 µM) for 5 min 
before adhesion assays. After incubation (5-10 min for lymphoblasts, at least 30 min for 
K562 cells), samples were washed and fixed with 4% paraformaldehyde and processed 
for immunofluorescence analysis. 
Alternatively, TNF-α-activated HUVEC were incubated for 30 min with 
dynabeads coated with anti-tetraspanin, anti-VCAM-1 or anti-VE-cadherin mAb 
(Dynal Biotech ASA, Oslo, Norway), and then fixed and stained with biotinylated anti-
ICAM-1 mAb.  
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Sucrose density gradient fractionation 
Confluent TNF-α-activated HUVEC were rinsed with phosphate-buffered saline 
(PBS) and lysed for 20 min in 250 µl of 25 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 % 
Brij96 at 4°C. The cell lysate was homogenized by passing the sample through a 22-
gauge needle. The extract was brought to 40% sucrose (w/w) in a final volume of  4 ml 
and placed at the bottom of an 8-ml 5-30% linear sucrose gradient. Gradients were 
ultracentrifuged to equilibrium for 20 h at 39,000 rpm at 4°C in a Beckman SW41 rotor 
(Beckman Coulter, Fullerton, CA). Fractions (1ml) were harvested from the bottom of 
the tube. Aliquots from each fraction were subjected to SDS-PAGE and Western blot 
with appropriate Abs.  
 
Immunofluorescence and confocal microscopy 
Immunofluorescence was carried out as previously described (Yanez-Mo et al., 
1998). Rhodamine Red-X-Streptavidin and Alexa Fluor 488 highly cross-adsorbed goat 
anti-mouse IgG (H+L) were used as fluorescent reagents (Molecular Probes, Eugene, 
OR). Series of optical sections were obtained with a Leica TCS-SP1, SP2 or SP5 
confocal laser scanning unit (Leica Microsystems, Heidelberg, Germany), using a 63x 
oil or glycerol immersion objective (NA: 1.4 or 1.3, respectively). Image analysis was 
performed with Leica Confocal Software.  
 
Fluorescence Recovery after Photobleaching  
Cells transfected with EGFP-fusion proteins (VCAM-1-, ICAM-1-, CD9-, 
CD151-, ICAM-1∆Cyt-, GPI-EGFP) were plated on 25mm glass coverslips coated with 
20 µg/ml of FN. After 24h, cells were stimulated with 20 ng/ml TNF-α in the presence 
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or absence of CD9-LEL-GST and FRAP experiments were performed before 48h after 
plating. To analyse FRAP at the endothelial docking structure, an adhesion assay was 
conducted under static conditions using K562 cells expressing VLA-4 (α4β1) or LFA-1 
(αLβ2) at the plasma membrane. Live-cell microscopy was performed with a Leica 
SP2 laser scanning confocal microscope using the 488-nm Ar laser line and an X 63 
glycerol objective. During the observation period, plates were maintained at 37ºC in a 
5% CO2 atmosphere using an incubation system (La-con GBr Pe-con GmbH). Laser 
power for bleaching was maximal, whereas it was attenuated to 10% of the bleach 
intensity for imaging. Ten single-section prebleach images were acquired, followed by 
three iterative bleach pulses of 1.686 sec each. Then, ten single-section images were 
collected at 1.686 sec intervals, followed by 20 images collected every 10 sec and, 
finally, 15 images every 30 sec for a total experimental time of 650 sec aprox. 
Fluorescence recovery in the bleached region was measured as average signal 
intensity. Although the size of the measured region was dependent on docking structure 
dimension, it was very homogenous. Signal loss in unbleached regions during the 
recovery period was less than 5 % of the initial fluorescence signal. All recovery curves 
were generated from background-subtracted and bleaching-corrected images. 
Fluorescence signal measured in a region of interest (ROI) was normalized to the 
prebleach signal in the same ROI.  
The mobile fraction (Mf) corresponds to the final value of the recovered 
fluorescence intensity, and the immobile fraction is obtained as 1-Mf. 
The half-time of recovery is the time from the bleach to the time point where the 
fluorescence intensity reaches the half of the final recovered intensity. All these three 
variables were directly obtained from the normalized mean fluorescence recovery 
curves. To assess the statistical significance of differences found between two given 
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families of curves characterized by measurements at identical time-points, a point-to-
point comparison based on a Student’s t-test was implemented. The Benjamini and 
Hochberg (BH) method (Benjamini and Hochberg, 1995) was employed to control for 
the false discovery rate associated with multiple testing. The analysis was accomplished 
using R (R Development Core Team, 2006). A representative example of statistical 
analysis is shown in Suppl. Fig. 3. 
 
Hetero-fluorescence resonance energy transfer by donor fluorescence lifetime 
imaging microscopy in intact living cells  
HUVEC were single transfected with different mEGFP standards or co-
transfected with combinations of mEGFP-mRFP1 pairs and seeded on FN-coated glass-
bottomed Petri-dishes as described above. After 24h, and without TNF-α treatment, 
culture medium was replaced with phenol red-free medium for optimal image 
acquisition. FLIM was performed using a laser scanning microscope assembled at the 
Laboratory for Fluorescence Dynamics, (Irvine, CA, USA) using the photon counting 
regime of the photomultiplier detector in conjunction with time-resolved frequency-
domain data acquisition hardware (Colyer et al., submitted). The data is processed 
automatically by software which accumulates a phase histogram of photon counts 
across the cross-correlation period, and then automatically calculates the phase and 
modulation of the emission. From the phase and modulation, the fluorescence lifetime 
ensembles in live cells was analyzed using the phasor-FLIM approach recently 
described (Digman et al., submitted; Caiolfa et al., 2007).  The system was based on an 
Olympus Fluoview 1000 microscope, connected to a modulated ISS 471nm diode laser 
and equipped with a 470 +/- 5 nm excitation filter and a BA 505-525 nm emission filter 
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(ISS Inc., Champaign, IL, USA). The laser was guided into the microscope by x-y 
galvano-scanner mirrors (Model 6350; Cambridge Technology, Watertown, MA), 
driven in a raster scan movement using the ISS 3-axis card (ISS, Inc. Champaign, IL) 
and synchronized with data acquisition with a Becker and Hickl SPC830 card. Data 
were acquired and processed by the SimFCS software developed at the LFD. A 
photomultiplier tube (R7862, Hamamatsu Photonics, Battlesboro, NJ) was used for the 
detection in the photon counting mode. The objective was a 40X water immersion 
(Zeiss, Germany) with 1.2 N.A. The scan area (256x256 pixels) corresponds to 32x32 
µm2. Before measurement, a slide with concentrated fluorescein at pH 9 was measured. 
The lifetime of fluorescein, 4.04 ns, was determined separately in an ISS Inc 
fluorometer.  
 
Fluorescence Correlation Spectroscopy 
Endothelial cells were transiently single or double transfected as for FLIM 
analysis. The dual-channel confocal fluorescence correlation spectrometer, ALBA (ISS 
Inc., Champaign, IL, USA), was equipped with avalanche photodiodes and interfaced 
to a Nikon TE2000 inverted microscope equipped with a dichroic set C-74610 
(z488/594 dbx z488/594rpc) + emission filter z 488/594m (Chroma Technology, USA). 
The objective used was a 60X Plan Apo (1.2 NA, water immersion).  Excitation at 488 
nm was provided by a tunable argon ion laser (Melles Griot, USA) and at 594 nm by a 
HeNe Laser (Melles Griot, USA). The diameter and power of the two beams were 
controlled by the ISS laser launcher system. The two laser lines were combined by a 
suitable external dichroic mirror (Chroma Technology, USA). Inside the ALBA box an 
additional dichroic (Chroma Technology, USA) separated the mRFP1 and mEGFP 
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emissions in the two channels (set C74612 (570 dclp, 520/30m, 610 lp). Every day, the 
power of the light passing through the objective in the absence of any immersion liquid 
was adjusted to 1 microW. An x,y,z computer-controlled piezoelectric actuator with a 
step resolution of less than 50 nm warranted the nanometric positioning. An ISS 
acquisition card received the data stream from the detectors. Data were stored for 
further processing by VISTA (ISS Inc.) and simFCS (LFD). Acquisition was in time-
mode, and sampling frequency was 20 kHz. The waist (ω0) of the excitation beam was 
calibrated before each day’s experiments using Rhodamine 110 at 488 nm and 
Sulphorhodamine at 594 nm. Typical ω0 values were 0.34-0.38 µm.  
The autocorrelation functions (ACFs) were best-fitted using the anomalous 
diffusion model (Banks and Fradin, 2005), according to the equation:  
where N is the average number of molecules in the excitation volume, τD is the diffusion 
time, and α is the anomality coefficient.  
Accordingly, the diffusion coefficient (D) is derived from the relationship:  
                                                           D= ω2/4τα 
 
Scanning electron microscopy 
Endothelial monolayers were activated for 20h with TNF-α 20 ng/ml in the 
absence or presence of 250 µg/ml of active or heat-inactivated (5 min, 90ºC) CD9-
LEL-GST peptide. Cells were then fixed in 2% paraformaldehyde in PBS and subjected 
to regular immunolabeling with P8B1 (anti-VCAM-1), Hu5/3 (anti-ICAM-1) or 
biotinylated MEM-111 (anti-ICAM-1) as primary antibodies and 40 nm gold-coupled 
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anti-mouse antibody or 15 nm gold-coupled streptavidin (BBInt.) as detection reagents. 
After immunolabeling, samples were fixed in 2.5% glutaraldehyde in PBS and then 
dehydratated by sequential passages through 30, 50, 70, 90%, and absolute ethanol.  
The ethanol was substituted by liquid CO2, and the specimens were critical-point dried 
using a Polaron E3000 apparatus. Then, samples were transferred onto appropriate 
microscope slides and covered with a carbon layer up to 5 nm using a high vacuum 
evaporator (Edwards 12E6/1266). Images were obtained with a Hitachi S-4100 
scanning electron microscope at an acceleration voltage of 12kV and a working 
distance of 4mm. Images were processed with Metamorph software (Universal Imaging 
Corporation, Molecular Devices Corporation, Downington, PA). Receptor clustering 
was evaluated by nearest neighbour analysis using a custom-written software based on 
R software. The developed method allowed us to establish similarities and 
discrepancies between different treatments in terms of aggregation and dipersion of the 
objects (gold particles) in the images. 
 
Statistical Analysis 
 All statistical analyses were performed with R software or GraphPad Prism 
(GraphPad Software Inc., San Diego, CA). 
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RESULTS 
 
Endothelial ICAM-1 and VCAM-1 cluster at the docking structure independently 
of counterreceptor engagement and actin anchorage  
At contacts with adherent leukocytes, activated endothelial cells form three-
dimensional actin-based docking structures which cluster endothelial VCAM-1 and 
ICAM-1. To analyze the mechanisms regulating the dynamic recruitment of adhesion 
molecules to these endothelial docking structures, we induced their formation with 
K562 leukocytes stably expressing either α4β1 (K562 α4) or αLβ2 (K562 LFA-1) 
integrins,which adhere to activated endothelial cells exclusively via VCAM-1 or 
ICAM-1, respectively. Remarkably, both ICAM-1 and VCAM-1 clustered at the 
docking structure formed around both types of K562 transfectant cells, regardless of 
whether they were directly engaged by their corresponding integrin receptor (Fig. 1A). 
Furthermore, similar co-recruitment effects were observed in a more physiological 
setting, in which lymphoblasts, which express significant amounts of LFA-1 and VLA-
4, were treated with specific inhibitors of either LFA-1 (BIRT377) or VLA-4 
(BIO5192) (Fig. 1B). 
To assess the extent to which this ligand-independent adhesion molecule 
clustering is dependent on the actin cytoskeleton, we transiently transfected resting 
HUVEC with a cytoplasmic tail-truncated mutant of VCAM-1 (VCAM∆Cyt). Under 
these conditions, HUVEC bear low levels of ICAM-1 and negligible levels of 
endogenous VCAM-1. Upon engagement of VCAM∆Cyt by either K562 α4 cells or 
anti-VCAM-1 coated beads, discrete clusters containing VCAM∆Cyt and ICAM-1 
were observed around adhered cells, but in no case was a well developed three-
dimensional structure formed (Fig. 1C and data not shown). In contrast, when ICAM-1 
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was directly engaged by K562 αLβ2 transfectants, a proper docking structure was 
formed, also containing VCAM∆Cyt (Fig. 1C). These data indicate that the engagement 
of one endothelial adhesion receptor (ICAM-1 or VCAM-1) by its corresponding 
leukocyte integrin is sufficient to induce the co-recruitment of the other endothelial 
receptor towards the contact area with the leukocyte. This co-clustering must involve 
the extracellular and/or transmembrane domains of both adhesion molecules, because it 
occurs with cytoplasmic-truncated forms. However, the subsequent reorganization of 
the endothelial actin cytoskeleton into the protrusive cup depends on actin anchorage of 
the cytoplasmic tail of the endothelial adhesion molecule bound to its ligand, as 
indicated by quantitative analysis of the formation of VCAM-1-mediated docking 
structures in VCAM-1wt- vs. VCAM-1∆Cyt-transfected resting HUVEC (50.33% vs. 
6%, respectively).  
 
Analysis of ICAM-1 and VCAM-1 hetero- and homo-dimers in living endothelial 
cells  
Since cytoskeletal anchorage cannot account for adhesion receptor co-recruitment, we 
investigated the potential formation of VCAM-1/ICAM-1 heterodimers at the apical 
membrane of intact, living primary endothelial cells. This analysis was based on hetero-
FRET, assessed by the donor fluorescence lifetime quenching in TCSPC-FLIM 
measurements. We generated functional VCAM-1 and ICAM-1 chimaeras fused to 
monomeric enhanced green (mEGFP, donor, termed also green) or red (mRFP1, 
acceptor, termed also red) fluorescent proteins (Campbell et al., 2002; Zacharias et al., 
2002). The spontaneous dimerization of EGFP, which could interfere with “bona fide” 
protein-protein interactions, was avoided by introducing the A206K point mutation in 
the sequence. The constructs were transiently co-transfected into primary HUVEC 
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under resting conditions, to prevent up-regulation of endogenous VCAM-1 and ICAM-1 
expression and thus minimize possible interference that might decrease the efficiency of 
dimmer formation by exogenous molecules. We analyzed the percentage of FRET 
efficiency (FRETeff) of the following pairs: ICAM-1mEGP/ICAM-1mRFP1, VCAM-
1mEGFP/VCAM-1mRFP1, ICAM-1mEGFP/VCAM-1mRFP1 and VCAM-
1mEGFP/ICAM-1mRFP1, comparing the fluorescence lifetime of the donor (mEGFP 
construct) in each co-transfection with that of ICAM-1mEGFP or VCAM-1mEGFP in 
single transfections. Representative experiments are shown in Fig. 2 and Supplemental 
Figure 1 (for donor standards). For each donor/acceptor pair in Figure 2, the 
fluorescence intensity image (in pseudocolour scale), phasor plots and the 
corresponding FLIM images (pink mask) are shown. As previously described (Caiolfa 
et al., 2007) for this representation, the fluorescence decay of the donor molecule in 
each pixel of the image gives a point in the phasor plot. The ensemble of these donor 
phasors is represented as contour plot. This plot can be scanned by software (Digman et 
al., submitted) for localizing in the image pixels at high as well as low FRETeff. The 
black circle in the phasor plot selects a sub-population of pixels in which similar FRET 
efficiencies were observed, and highlights them in the correspondent image.  For the 
ICAM-1-mEGFP/ICAM-1-mRFP1 pair depicted in Fig. 2, the majority of pixels do not 
show significant FRET (selection average < 8% FRET).  However, a small 16% of the 
pixels in the image, do show FRET efficiency in the range of 24 + 8% (fairly above the 
detection limit of the FRET analysis), which are localized in clusters at the membrane. 
We analyzed 4 replicate experiments and obtained average FRET efficiencies in the 
range from 5 to 15.5 in 65% of clustered pixels. In contrast, the other pairs of proteins, 
VCAM-1-mEGFP/VCAM-1-mRFP1, ICAM-1-mEGFP/VCAM-1-mRFP1 and VCAM-
1-mEGFP/ICAM-1-mRFP1, did not show any significant quenching of the donor 
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fluorescence lifetime (i.e., FRET) (Fig. 2), as compared to the phasor distribution of 
“pure” donor control cells (Suppl. Fig. 1). This analysis demonstrates that, under these 
conditions, VCAM-1/VCAM-1 homodimers and VCAM-1/ICAM-1 heterodimers are 
absent from the plasma membrane.  
  These data thus suggest a separate organization of VCAM-1 and ICAM-1 at the 
plasma membrane, excluding the formation of VCAM-1/ICAM-1 heterodimers as a 
prerequisite for the recruitment of one of these receptors to the docking structure in the 
absence of integrin engagement and cytoskeleton anchorage. 
 
Tetraspanin microdomains mediate the association of endothelial adhesion 
receptors to form specialized endothelial adhesive platforms 
Since ICAM-1 and VCAM-1 co-clustering at the docking structure is dependent 
on their extracellular and/or transmembrane domains, but does not result from direct 
interaction, we examined the possible intermediary involvement of tetraspanin proteins. 
Several tetraspanins, such as CD9 and CD151, are concentrated at docking structures 
around primary human leukocytes together with VCAM-1 and ICAM-1, and can co-
precipitate with these endothelial adhesion receptors (Barreiro et al., 2005). Tetraspanin 
proteins were also recruited to docking sites in the K562 α4 and LFA-1 adhesion 
models (Supplemental Fig. 2). However, no specific tetraspanin ligand has been 
described in leukocytes. Furthermore, ICAM-1 and VCAM-1 were both recruited when 
either CD9 or CD151 was engaged with specific antibodies coupled to magnetic beads. 
In parallel, anti-VCAM-1- and anti-ICAM-1-coated beads were also able to cluster 
each other and the tetraspanins, whereas anti-VE-cadherin-coated beads did not induce 
significant recruitment of ICAM-1, VCAM-1 or tetraspanins above basal levels (Fig. 
3A, quantified in Fig. 3B, and data not shown). 
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To assess the relationship between endothelial adhesion molecules and 
tetraspanin microdomains in more detail, Brij96 lysates of TNF-α-activated HUVEC 
were fractioned on a continuous 5-40% sucrose gradient. Most tetraspanins were 
soluble under these conditions and migrated with the heavy fractions (F1-F7) together 
with ICAM-1 and VCAM-1, which were not found in fractions containing caveolin 
(used as a marker of detergent-resistant membrane fractions, containing lipid rafts) 
(Fig. 3C). These results suggest that endothelial tetraspanin microdomains, containing 
VCAM-1 and ICAM-1 adhesion receptors, clearly stand apart from classical 
biochemically-defined lipid rafts and are in fact distinct organized membrane 
structures, which we term endothelial adhesive platforms (EAP). 
 
Diffusional properties of endothelial adhesive platforms at nude membrane and at 
docking structures 
Experimental evidence for the existence of tetraspanin microdomains is mainly 
based on biochemical approaches or microscopy techniques that analyze fixed cells 
(Claas et al., 2001; Min et al., 2006; Nydegger et al., 2006). In an attempt to 
demonstrate the existence of tetraspanin-based EAP in living cells, as physical entities 
with specific molecular dynamic features distinct from lipid rafts, we made use of the 
fluorescence recovery after photobleaching (FRAP) technique. First, we analyzed the 
dynamic behaviors of EGFP-tagged versions of CD9, CD151, VCAM-1 and ICAM-1 at 
the apical plasma membrane of primary HUVEC and compared these behaviors with 
that of GPI-EGFP, used as a lipid raft marker (Kenworthy et al., 2004; Sharma et al., 
2004) (Fig. 3D). Quantification of recovery half-time data indicated that tetraspanin 
CD9 and CD151 diffuse 2-3 times more slowly than GPI-EGFP, and that VCAM-1 and 
ICAM-1 are even slower (3-4 times longer recovery half-time as compared with GPI-
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EGFP) (Fig. 3E). The differences observed between the diffusional behaviors of 
tetraspanin proteins and endothelial adhesion receptors might be due to differential 
anchorage to the actin cytoskeleton. To examine this possibility, we analyzed the 
dynamics of a C-terminally truncated EGFP-tagged ICAM-1 protein, ICAM-1∆Cyt-
EGFP, which lacks the cytoplasmic domain and, therefore, lacks actin-cytoskeleton 
linking activity (Fig. 3F). This truncated ICAM-1, freed of cytoskeletal constraints, 
diffused more rapidly than the full-length receptor. Furthermore, ICAM-1∆Cyt-EGFP 
diffused faster than CD9, but in this case the difference was not significant, 
strengthening the notion of EAP as organized lateral-association domains at the plasma 
membrane.  
To assess the influence of leukocyte adhesion on the dynamic behaviour of each 
EAP component, FRAP was used to examine endothelial docking structures induced by 
binding of α4+- or LFA-1+-K562 cells (Fig. 4A). The most notable effects were that, 
when endothelial adhesion receptors were dynamically and specifically bound to their 
ligands, a greater proportion were included in the immobile fraction and the mobility of 
the mobile fraction was retarded (Fig. 4B and C, for ICAM-1 and VCAM-1, 
respectively, as well as Suppl. Fig. 3B). The rest of EAP components analyzed were 
affected to a lesser extent, exhibiting a variable slow-down in fluorescence recovery 
compared with the FRAP analyses of the same molecules at other regions of the plasma 
membrane (Suppl. Fig. 3). Statistical analyses showed that the effect on CD9 mobility 
was greater upon engagement of ICAM-1, while CD151 was more affected by 
engagement of VCAM-1 (Numerical data on Fig. 4B and C). These data thus reveal a 
degree of specificity among tetraspanin-partner interactions within the endothelial 
tetraspanin microdomains. In contrast, GPI-EGFP diffusion was not altered at docking 
structures (data not shown). 
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The tailless ICAM-1 mutant IC1∆Cyt-EGFP showed a faster fluorescence 
recovery rate than the wild-type molecule at docking sites with LFA-1+-K562 cells, 
which indicates that stabilization of the interaction between ICAM-1 and LFA-1 also 
occurs on the endothelial side, by the anchorage of ICAM-1 to the F-actin cytoskeleton 
(Fig. 4D). 
 
Diffusional characteristics of individual endothelial adhesive platform constituents 
determined by FCS and FCCS single-molecule measurements 
Because of technical limitations of FRAP, we could not accurately measure the 
diffusion coefficients of EAP components, which exhibit an anomalous diffusion 
because of cytoskeleton and ligand binding constraints. To overcome this limitation, we 
applied fluorescence correlation spectroscopy (FCS) on fluorescent protein-tagged 
ICAM-1, VCAM-1, CD9 and CD151 expressed in primary human living endothelial 
cells (Fig. 5A). The autocorrelation functions were always best-fitted using the 
anomalous diffusion model (see Materials and Methods section). The range of the 
diffusion (D) and anomality (α) coefficients was similar for all tested proteins (Fig. 5B). 
Nevertheless, the analysis in Fig. 5B indicates that, the diffusion of VCAM-1 and 
ICAM-1 is overall slower than that of CD9 and CD151. Hence, the FCS measurements 
of each individual EAP component was in agreement with previous FRAP analyses, 
indicating that tetraspanins are characterized by faster lateral mobility than adhesion 
receptors. Further analyses will be performed to sub-classify the results as 
corresponding to fast and slow molecular subsets. On the other hand, most of the D 
coefficients obtained for all these proteins are much slower than those reported for 
prototypic lipid raft proteins (Lenne et al., 2006). Finally, evidence of dynamic 
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membrane complexes containing several EAP constituents was attained by fluorescence 
cross-correlation spectroscopy, as shown in Suppl. Fig. 4. 
 
Complexity of inter-molecular interactions within endothelial adhesive platforms 
The colocalization studies previously performed with a conventional spectral 
confocal microscope, which has an optical resolution limit of 200-250 nm, cannot allow 
us to further discriminate between direct and indirect interactions within EAP. To 
explore the complex inter-relationships which might take place within the endothelial 
adhesive platforms and could account for the recruitment of adhesion receptors, we 
extended the FLIM-FRET analysis to determine whether direct associations occur 
among CD9, CD151, ICAM-1 and VCAM-1 molecules. First, we confirmed the 
formation of tetraspanin homo- and heterodimers (CD9mEGFP-CD9mRFP1 and 
CD9mEGFP-CD151mRFP1) (Fig. 6A), which was previously suggested mainly on the 
basis of biochemical studies (Hemler, 2005). We then assessed the direct association of 
tetraspanins with their endothelial partners. Again, a certain degree of specificity was 
found inside the microdomains, indicating that CD9 preferentially interacted with 
ICAM-1 and CD151 with VCAM-1; moreover, the FRET efficiencies of these 
associations were close to those of tetraspanin pairs (Fig. 6B). In contrast, VCAM-
1/CD9 and ICAM-1/CD151 pairs exhibited low occurrence of high FRETeff, and 
FRET in the remaining pixels of the cell was very close to the detection threshold of the 
technique (data not shown). Control experiments examining interaction between 
ICAM-1 and uPAR, a cell-surface receptor related to lipid rafts, showed the absence of 
interaction between these two molecules from distinct membrane microdomains (Suppl. 
Fig. 1B). These results confirm the suggested specific intra-domain interactions in EAP 
observed in FRAP analysis and in the fluorescence cross-correlation measurements.  
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Modulation of nanoclustering and diffusion within the endothelial adhesive 
platforms by tetraspanin blocking peptides 
The spatial organization of VCAM-1 and ICAM-1 receptors at the plasma 
membrane of endothelial cells was studied by immunogold labeling combined with 
scanning electron microscopy (SEM) (Fig. 7A i). Both ICAM-1 and VCAM-1 form 
heteroclusters at the plasma membrane (Fig. 7A ii), and localized higher-density 
clustering was found at the microvilli of docking structures around adherent leukocytes, 
as shown for ICAM-1 (Fig. 7A iii). 
To shed light on the mechanism that controls the tetraspanin-mediated co-
clustering of adhesion receptors at the apical plasma membrane of endothelial cells, we 
used a tetraspanin-derived blocking peptide (CD9-LEL-GST). This soluble peptide 
interferes with the various functions regulated by CD9-containing tetraspanin 
microdomains, such as egg-sperm fusion or HIV infection (Ho et al., 2006; Zhu et al., 
2002), and decreases VCAM-1- and ICAM-1-mediated lymphocyte adhesion strength 
and transmigration under flow conditions (Barreiro et al., 2005). Although the 
functional effect of these peptides has been well documented, there have been no 
reported insight into the molecular mechanism through which CD9-LEL-GST exerts its 
inhibitory action. Nearest neighbour analysis of immunogold-labeled adhesion 
receptors in the presence of CD9-LEL-GST showed that receptor spacing augmented in 
comparison with samples treated with heat-inactivated CD9-LEL-GST. This effect 
might be due to the insertion of functional blocking peptides within the EAP, 
competing with endogenous CD9 for association with partners (Fig. 7B). Consistently, 
FCS analysis revealed that the CD9-LEL peptide, but not heat-inactivated CD9-LEL, 
decreased the diffusion coefficient of CD9mEGFP molecules. Furthermore, the 
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diffusion coefficient of CD151 was also affected, showing that blocking peptide 
insertion in EAP modifies the general dynamics within the platforms due to the 
increasing molecular crowding (Fig. 7C). Together these data suggest that the blocking 
peptide compete with endogenous CD9 for binding to partners and other tetraspanins. 
This prevents adequate interactions and imposes steric hindrance, resulting in a net 
slower diffusion and reduced receptor clustering.  
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DISCUSSION 
Endothelial adhesive platforms as a model for the biophysical study of 
tetraspanin-enriched microdomains                      
The existence of organized membrane domains distinct from those based on lipid-
protein interactions (lipid rafts) has not been demonstrated previously in living cells. 
Biochemical analysis and microscopy studies on fixed samples have indicated that a 
network of specific protein-protein interactions may occur at cell membranes between 
tetraspanin members and associated partners (Levy and Shoham, 2005a). In the current 
study, we have used an array of cutting-edge analytical microscopy and spectroscopy 
techniques, including single molecular analysis, to characterize in depth the dynamic 
features and biophysical properties of TEM in living cells. The transiently transfected 
primary human endothelial cells used in this study are a physiologically relevant cell 
model that expresses an appropriate repertoire of membrane tetraspanins and adhesion 
receptors. In addition, the study of four proteins in combination, two tetraspanins and 
two essential endothelial adhesion receptors, provides a valuable global overview of the 
behavior of the specialized type of TEM named endothelial adhesive platforms (EAP).  
Endogenous expression of CD9 and CD151 tetraspanins and ICAM-1 and 
VCAM-1 adhesion receptors in endothelial cells reduces the probability of interaction 
between transiently-transfected tagged proteins in the FLIM-FRET analyses. To 
minimize this problem, FLIM quantifications were performed in resting HUVEC, in 
which tetraspanin expression is unaltered, ICAM-1 levels are low and VCAM-1 
expression at plasma membrane is negligible. Given that the expression of CD151 and, 
especially, CD9 is much higher than ICAM-1 in resting cells, it is possible that 
FRETeff values from measurements involving tetraspanin proteins might be 
underestimated. Furthermore, in the case of CD9, CD151 and ICAM-1, which are able 
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to homodimerize, the possible association of two green or two red molecular species 
makes the occurrence of heteroFRET even more improbable. Finally, another potential 
problem, dimerization of chimeric proteins through their fluorescent tags, was 
overcome by using monomeric versions of EGFP and mRFP1. Despite the drawbacks 
of FRET analysis in complex living cell systems, high FRETeff was detected for 
ICAM-1/CD9, VCAM-1/CD151, CD9/CD9, CD9/CD151 and ICAM-1/ICAM-1 pairs 
and clear-cut differences were detected with respect to non-interacting pairs (VCAM-
1/ICAM-1, VCAM-1/VCAM-1). Examination of average FRETeff values and the 
percentage of pixels exhibiting the highest FRETeff values for each pair showed that 
tetraspanin homo- and heterodimers and tetraspanin-partner interactions occur 
preferentially compared with ICAM-1 dimers, strengthening the concept of EAP as the 
basic organization of endothelial adhesion receptors on the endothelial apical plasma 
membrane. In fact, the existence of ICAM-1 dimers had been described before as a 
small proportion from the whole molecular ICAM-1 population using biochemical 
approaches (Miller et al., 1995). Besides, BIAcore affinity measurements revealed that 
a single ICAM-1 monomer, not dimeric ICAM-1, represents the complete, fully 
competent LFA-1-binding surface (Jun et al., 2001). 
The innovative technique used to quantify FRET was completely independent of 
the concentration of fluorescent species, and is therefore well-suited to analyze and 
compare data from different transient transfections. Furthermore, the FLIM-FRET 
approach permitted us to spatially resolve the fretting population within a whole cell, 
generally yielding a patchwork pattern for the higher FRETeff population. To further 
substantiate the experimental data on the absence of ICAM-1-VCAM-1 heterodimer 
formation, ICAM-1 or VCAM-1 was indistinctly used as donor in FLIM-FRET 
experiments. We inverted the labeling fluorophores on the two receptors, showing that 
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the lack of FRET was not due to artifacts introduced by the fluorescent constructs. 
Additional control experiments also demonstrated that the protein in the mEGFP 
constructs affects negligibly the fluorescence lifetime distribution of the fluorophore 
(i.e., the phasor distribution in phasor-FLIM analysis).  
Finally, the observations that the GPI-anchored protein, uPAR, used as a marker 
of lipid rafts, did not interact with ICAM-1 (used as an EAP marker) in FLIM-FRET 
experiments, and that the two receptors were sorted to the plasma membrane in 
different vesicles (data not shown), further sustain the notion that tetraspanins might 
form discrete and specific microdomains at the cell membrane. 
The diffusional behaviour of the EAP components was investigated by combining 
FRAP and FCS analyses. The possible perturbation of membrane dynamics that might 
result from exogenous expression of tagged proteins was overcome in FRAP 
experiments by making a large number of measurements in several batches of 
transiently-transfected primary cells and making an exhaustive statistical analysis of the 
data. Photobleaching experiments were all performed under pro-inflammatory 
conditions (TNF-α treatment) in order to promote proper formation of docking 
structures around adherent leukocytes mostly through the mediation of endogenous 
VCAM-1 or ICAM-1. Although the integrin-expressing K562 adhesion model used in 
our experiments is a simplification of the dynamic physiological firm adhesion process 
that takes place under hemodynamic flow conditions, this model has allowed us to 
perform diffusion analyses that would be unfeasible under more physiological but 
complex conditions.  
FRAP analysis examines the diffusion rate of an overall molecular population 
within a microscopic area. These experiments have provided us with valuable 
information on the global diffusional behavior of VCAM-1, ICAM-1, CD9, CD151 and 
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GPI molecular subsets in comparable areas of nude membrane and at sites of leukocyte 
anchorage. A mixed steady-state molecular population (comprising proteins bound or 
unbound to cytoskeleton, coupled to partners, in the form of dimers, and so on) is 
considered for each measurement. From FRAP data collected at nude plasma 
membrane, we could distinguish differences in the net mobilities of tetraspanins and 
receptors. Tetraspanins showed the fastest diffusion rate, although this did not differ 
significantly from the rate for ICAM-1, whereas VCAM-1 population was slower and 
displayed a higher immobile fraction. The reason for this difference in diffusion 
behaviour between the two adhesion receptors remains still unsolved. Close interaction 
between ICAM-1 and CD9 is supported by the experiments with the C-terminally 
truncated ICAM-1, ICAM-1∆Cyt, which is unable to interact with the actin 
cytoskeleton via ERM proteins (Barreiro et al., 2002). The lateral mobility of ICAM-
1∆Cyt-EGFP was not significantly different from that of CD9, supporting the notion 
that these molecules can interact in the absence of ICAM-1 cytoplasmic tail. 
Conversely, GPI-EGFP, a prototypic lipid raft- related molecule widely used in 
microscopy studies (Kenworthy et al., 2004; Varma and Mayor, 1998), moved much 
faster and its recovery was complete, with no significant immobile fraction. Moreover, 
the diffusion properties of CD9, CD151, ICAM-1 and VCAM-1 were altered in the 
context of docking structures, whereas GPI-EGFP is unaffected by engagement of 
integrin-bearing leukocytes. These observations strongly argue in favor of these 
proteins being constituents of physical entities with intrinsic properties and biophysical 
features distinct from classical lipid rafts.  
The delay observed for non-ligand-engaged EAP components at the docking 
structures could be well due to their transient interaction with ligand-immobilized 
ICAM-1 or VCAM-1. In this way, these immobile complexes at docking sites could act 
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as physical constraints on the mobility of the overall molecular populations analyzed, 
which would produce a net reduction in diffusion rate (Suppl Fig. 3). The fact that 
VCAM-1 is no more affected than tetraspanins by ligand engagement of ICAM-1 
supports a model in which VCAM-1 is co-recruited to ICAM-1/LFA-1-mediated 
docking structures as a result of both VCAM-1 and ICAM-1 being components of the 
EAP. The same argument is applicable to the recruitment of ICAM-1 into VCAM-
1/VLA-4 induced docking structures.  
Remarkably, our data show that CD9 mobility is more strongly affected by the 
engagement of ICAM-1, while CD151 is more affected by engagement of VCAM-1, 
confirming the results of previous biochemical analyses, in which ICAM-1 
preferentially associated with CD9 and VCAM-1 associated with CD151 (Barreiro et 
al., 2005). FRET analysis confirmed a degree of specificity inside the preexisting EAP 
prior to leukocyte binding. The preferential interactions of ICAM-1 with CD9 and 
VCAM-1 with CD151 are evident in the FRETeff for these pairs, which are close to 
those of tetraspanin pairs, even though in tetraspanin-partner interactions there are 
fewer obstacles that can reduce FRETeff.  
The diffusional analyses by FCS complemented the FRAP data. Thus, FRAP 
provided a general view of diffusion within EAP in the presence or absence of adherent 
leukocytes and in comparison with lipid rafts at a microscopic level, and FCS allowed 
us to move toward the nanoscopic scale to precisely determine diffusion coefficients of 
EAP proteins at the single-molecule level. The amounts of exogenously expressed 
fluorescently-labeled proteins on the surface of cells used for FCS and FCCS analyses 
was negligible compared with the corresponding endogenous proteins, assuming that 
there were no alterations in dynamic behaviour due to increased molecular density at 
the membrane. However, the existence of a mixture of endogenous and exogenous 
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protein populations precludes determination of the stoichiometry of submicron-size 
endothelial tetraspanin domains, even though the FCCS studies did provide insights 
into the lifespan of tetraspanin-partner complexes. 
In conclusion, this study performed with this particular type of TEM from the 
apical membrane of endothelium constitutes the first description of tetraspanin 
microdomains as physical entities in living cells, with dynamic features that clearly 
differ from lipid rafts. 
 
Regulation of the avidity of endothelial adhesion receptors by their inclusion in 
tetraspanin-enriched endothelial adhesive platforms    
It is a common error to assume that the demonstration of co-localization of 
molecules at the microscopic level provides irrefutable evidence of spatial association; 
the optical resolution limit of classical confocal fluorescence microscopy techniques 
falls far short that required to identify molecular interactions that take place over a 
distance of few nanometers. Our data from advanced microscopy techniques 
demonstrate that the co-localization of two tetraspanins and two receptors at the nude 
endothelial apical plasma membrane and at specialized adhesive structures does indeed 
correspond to highly specific and organized interactions among them. Furthermore, this 
organization confers the appropriate spatial distribution for ICAM-1 and VCAM-1 
receptors to exert their efficient adhesion functions. 
The regulation of leukocyte integrin activity has been extensively characterized. 
These proteins can be regulated by conformational changes (affinity) and/or clustering 
at the plasma membrane (avidity) (Carman and Springer, 2003; Luo et al., 2007). In 
contrast, no regulatory mechanism, apart from the transcriptional level, has been 
described previously  for the adhesive function of endothelial integrin ligands (Collins 
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et al., 1995). Our study thus provides novel insights into adhesion receptor regulation, 
showing how the insertion of two key endothelial receptors, ICAM-1 and VCAM-1, 
into tetraspanin-enriched microdomains promotes the homo- and hetero-clustering of 
both molecules at the contact area with the adhered leukocyte, independently of ligand 
binding and actin cytoskeleton anchorage. The tetraspanin-mediated clustering of 
endothelial receptors enhances firm adhesion, since disturbance of interactions using 
tetraspanin blocking peptides or alteration in composition by tetraspanin knock-down 
decreases the adhesive properties of VCAM-1 and ICAM-1 in transendothelial 
migration experiments performed under flow conditions and in detachment experiments 
under increasing shear flows (Barreiro et al., 2005). Whether ICAM-1 or VCAM-1 can 
undergo any conformational alteration due to their interaction with tetraspanins remains 
undetermined, in the absence of appropriate reagents to tackle this possibility.  
The ability of tetraspanins to mediate the homo- and hetero-clustering of adhesion 
receptors, which is enhanced by integrin engagement, arises from their ability to 
laterally associate with each other and with non-tetraspanin partners simultaneously. 
Therefore, CD9 could promote ICAM-1 homo-avidity by interacting with other CD9 
molecules bound to this receptor, whereas CD151 could reproduce the same effect with 
VCAM-1. Then, the hetero-clustering of ICAM-1 and VCAM-1 could be explained by 
the interaction of CD9 with CD151. The involvement of other tetraspanins in these 
organized microdomains cannot be ruled out; indeed, we have observed the inclusion of 
tetraspanin CD81 at EAP (Barreiro et al., unpublished observations). Conceptually, 
endothelial receptor homo-avidity would be similar to the avidity phenomenon 
described for their counter-receptors, the integrins α4β1-VLA-4 (for VCAM-1) and 
αLβ2-LFA-1 (for ICAM-1) integrins. In fact, a role has been reported for CD81 as 
homeostatic avidity facilitator of multivalent VLA-4 strengthening in the adhesion to 
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VCAM-1 (Feigelson et al., 2003). Therefore, it is also conceivable that such 
tetraspanin-mediated co-organization of specific VLA-4 and LFA-1 integrin subsets 
takes place within leukocyte membranes. Futhermore, the novel concept of hetero-
clustering raised here for VCAM-1 and ICAM-1 can be envisaged as a kind of 
tetraspanin-mediated cross-talk between adhesion receptors; that is, a cellular 
mechanism to spatio-temporally organize molecules with similar characteristics and 
functions so as to facilitate their efficient co-ordinated action in critical processes such 
as extravasation, which occurs over a short time-frame. Moreover, VCAM-1 and 
ICAM-1 are unlikely to be the only receptors inserted in these tetraspanin 
microdomains at the apical endothelial plasma membrane; we have also identified other 
adhesion proteins such as CD44, PECAM-1 and, more importantly, E-selectin in 
association with EAP (Barreiro et al., unpublished observations). These organized 
membrane microdomains thus appear to integrate a plethora of adhesion receptors 
involved in subsequent steps of the extravasation process, and for this reason we have 
named them endothelial adhesive platforms. These organized platforms are dynamic, 
since they coalesce or diverge depending on the stimuli received (ligand engagement by 
tetraspanin partners, and so on).  
In sum, our data clearly demonstrate that tetraspanin microdomains account for 
the specific recruitment of endothelial adhesion receptors to the leukocyte contact area, 
providing a mechanism to increase avidity at these sites and enhance firm adhesion. 
This constitutes a novel supramolecular level of regulation in the function of VCAM-1 
and ICAM-1 endothelial receptors not envisaged previously for integrin ligands. In the 
light of these observations, new pharmacological agents that could specifically prevent 
the interaction of tetraspanin with endothelial adhesion receptors in vivo could 
 35
constitute novel therapeutical estrategies for the treatment of chronic inflammatory and 
autoimmune diseases.   
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LEGENDS TO FIGURES 
 
Figure 1: VCAM-1 and ICAM-1 are co-presented at lymphocyte-endothelium 
contact independently of ligand binding and actin anchorage. A. VCAM-1 and 
ICAM-1 co-localize at the endothelial docking structure in the absence of integrin 
engagement. K562 transfected with α4 or LFA-1 integrin were allowed to adhere to 
TNF-α-activated HUVEC for 30 min, and cells were fixed and double stained with 
anti-VCAM-1 (P8B1) and biotin-conjugated anti-ICAM-1 (MEM111). Confocal stacks 
were obtained and orthogonal maximal projections and vertical 3D reconstructions of 
the whole series are displayed. Scale bars = 20 µm. B. VCAM-1 and ICAM-1 are co-
recruited to the endothelial contact area with human T lymphoblasts previously treated 
to inactivate VLA-4 or LFA-1. Human T lymphoblasts were pre-treated for 5 minutes 
with the LFA-1 inhibitor BIRT377 (10µM) or the VLA-4 inhibitor BIO5192 (10µg/ml) 
and then added to a TNF-α activated HUVEC monolayer for 5 min. Cells were fixed 
and double stained for VCAM-1 and ICAM-1 as in 1A. Confocal stacks were obtained 
and a representative section from each treatment is shown together with its 
corresponding colocalization histogram and a mask showing the distribution within the 
cell of double green-red pixels from the region marked on the histogram. Scale bars = 
10 µm. C. VCAM∆Cyt is co-recruited to ICAM-1-mediated docking structures but is 
unable to trigger the formation of VCAM-1-mediated docking structures. Resting 
HUVEC were transfected with the VCAM∆Cyt construct and incubated either with 
K562 leukocytes expressing VLA-4 (K562 α4) or LFA-1 integrin or with T-
lymphoblasts. Cells were then fixed and double stained with anti-VCAM-1 
(VCAM∆Cyt being the only VCAM-1 molecular species detected) and biotin-
conjugated anti-ICAM-1. Confocal stacks were obtained and a representative section or 
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vertical reconstructions of the whole series are displayed. Arrows point to the position 
of the adhered leukocytes. Scale bars = 20 µm.  
 
Figure 2: VCAM-1 and ICAM-1 are not displayed as heterodimers at the plasma 
membrane. Endothelial cells were co-transfected with different mEGFP-mRFP1 pairs 
(ICAM-1/ICAM-1, VCAM-1/VCAM-1, ICAM-1/VCAM-1 and VCAM-1/ICAM-1). 
FLIM-FRET analysis was performed using the phasor-FLIM analysis as explained in 
Material and Methods. For each pair of proteins, a representative analysis of a co-
transfected cell is shown. The fluorescence intensity images of the scanned sections are 
in pseudocolour scale (left panels) and correspondent mEGFP lifetime distributions are 
shown in contour plots after the phasor transformation (phasor plots, right panels). In 
each phasor plot, the experimentally derived green-line represents the mean phasor 
distribution for unquenched mEGFP fluorescence lifetimes with different contribution 
of cell autofluorescence (see Suppl. Fig. 1). The yellow line marks the computed 
trajectory of mEGFP donors quenched by 50% FRET (Föster distance) and at different 
contribution of autofluorescence (Caiolfa et al., 2007). In the ICAM-1/ICAM-1 cell, 
two major phasor distributions are observed and selected in the phasor plot (black 
circles). The first one includes the majority, more than 80%, of the pixels in the image. 
In these pixels, which are rather homogenously distributed at the cell membrane (their 
localization is shown in the FLIM image, pink mask), FRET is negligible (< 8%). The 
second distribution includes only 16% of pixels in which FRET varies from 16 to 32% 
(mean 24%), and localize few clusters on the cell membrane. The other protein pairs do 
not show significant quenching due to FRET, as their phasor distributions are not 
distinguishable from that of the correspondent pure donor cells (Suppl. Fig. 1). In each 
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of these examples, more than 95% of pixels are selected (black circles) in the non-
FRET area of the phasor plot and are localized in the correspondent FLIM image. 
 
Figure 3: Dynamic behaviour of EAP components at the “nude” plasma 
membrane. 
A. Anti-tetraspanin-coated beads recruit both VCAM-1 and ICAM-1. TNF-α-activated 
HUVEC were incubated with magnetic beads coated with anti-CD9, anti-CD151, anti-
VCAM-1 or anti-VE-cadherin for 30 min and then, stained with biotinylated anti-
ICAM-1 mAb. Representative confocal sections are shown. Arrows point to the 
position of the attached beads. B. Quantification of ICAM-1-, VCAM-1- or CD9-EGFP 
clustering around beads coated with the indicated antibodies and attached to transfected 
resting or TNF-α-activated HUVEC. Data are the means ± S.D. of two independent 
experiments. C. ICAM-1 and VCAM-1 are recovered together with tetraspanins in the 
heavy fractions of a continuous sucrose gradient. TNF-α-activated HUVEC were lysed 
in 1% Brij96 and lysates were loaded onto a continuous 5-40% sucrose gradient. After 
ultracentrifugation, samples were recovered in 1 ml fractions and analyzed by Western 
blot for VCAM-1, ICAM-1, CD151, CD9, or caveolin. Fractions were recovered from 
the bottom of the gradient, so that the soluble non-floating fractions were collected first. 
D. FRAP analysis showing differences in the diffusion of tetraspanins and adhesion 
receptors compared with the lipid raft marker GPI at the plasma membrane. Endothelial 
cells were transiently transfected with the indicated EGFP-tagged protein constructs 
and activated with TNF-α 20h before microscopy observation. Mean fluorescence 
recovery curves for CD9-, CD151-, ICAM-1-, VCAM-1- and GPI-EGFP were 
calculated (n ranged from 5 to 21 independent experiments for each protein) and are 
depicted together on the same graphic. Statistical significance was assessed by a point-
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to-point comparison based on a Student’s t-test. p values were adjusted for multiple 
testing by using the Benjamini and Hochberg method to control for false discovery rate 
(fdr). Tests were considered to be significant when adjusted p values from 80% of the 
points out of the plateau were < 0.05. This ensures that the expected fdr is < 5%. (See 
Suppl. Fig. 3) E. Comparison of mobility parameters among tetraspanins, adhesion 
receptors and GPI-anchored protein at the endothelial plasma membrane. The average 
half-time recovery rate was calculated considering the mean mobility fraction for each 
protein. F. The retarded mobility of adhesion receptors compared with tetraspanins can 
be explained by their differential engagement to the actin cytoskeleton. Mean 
fluorescence recovery curves of ICAM-1∆Cyt-, ICAM-1- and CD9-EGFP were 
calculated (n ranged from 12 to 21) and are compared on the same graph. Deletion of 
the ICAM-1 cytoplasmic tail significantly increased recovery rate compared with wild-
type protein. Statistical analysis was performed as in D. 
 
Figure 4: Dynamic behavior of endothelial adhesive platform components within 
the endothelial docking structure. A. Representative FRAP analysis of an endothelial 
docking structure. The prebleaching image shows a TNF-α-activated endothelial cell 
transiently transfected with ICAM-1-EGFP; docking structures formed around attached 
K562 LFA-1 cells are visible as circles of concentrated EGFP fluorescence. The 
docking structure in the boxed area, shown at high magnification in the inset, was 
selected for photobleaching measurements show the fluorescence recovery at the 
structure over time. Scale bar = 20 µm. B. CD9 mobility is tightly regulated in ICAM-
1-mediated docking structures. Mean fluorescence recovery curves are shown for 
ICAM-1-, VCAM-1-, CD9- and CD151-EGFP at docking structures formed around 
K562 cells expressing LFA-1 (activated by 1 mM Mn2+, which does not affect 
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endothelial molecule mobility); n ranged from 4 to 16 experiments for each transfected 
protein. Statistical analysis was based on p value adjusted for multiple testing (see 
Methods and Fig. 3D for details). C. CD151 and VCAM-1 mobilities are correlated at 
VCAM-1-mediated docking structures. Mean fluorescence recovery curves are shown 
for ICAM-1, VCAM-1-, CD9- and CD151-EGFP at docking structures formed around 
K562 cells expressing VLA-4 (K562 α4);  n ranged from 5 to 16 experiments for each 
protein. Statistical analysis was performed as in B. D. Actin-cytoskeleton anchorage 
stabilizes the interaction of ICAM-1 with its ligand LFA-1. Mean fluorescence 
recovery curves are shown for ICAM-1∆Cyt- and ICAM-1-EGFP at ICAM-1-mediated 
docking structures (n=7 for both proteins). Statistical analysis was performed as in B. 
 
Figure 5. FCS analysis on the components of endothelial adhesive platforms. A. 
The panels show representative FCS measurements performed at the plasma membrane 
of transiently-transfected primary endothelial cells expressing very low levels of 
ICAM-1-, VCAM-1-, CD9-, and CD151-mEGFP. For each experiment are 
documented: the fluorescence intensity image, the point in which the laser beam was 
positioned for the measurement (white circle), the ACF (black line), the best-fitted 
curve (red line), and the fitted parameters, diffusion time (TauD) and anomality 
coefficient (α, ranging from 0 to 1), from which the diffusion coefficient (D) was 
derived as described (See under Materials and Methods section). The corresponding 
scale bar is shown in each image. kCPS: kilo counts per second. B. Scatter plots of the 
diffusion and anomality coefficients determined by FCS analysis on the four proteins of 
interest. Each point is an individual measurement. Horizontal lines = medians.  
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Figure 6. Direct and indirect interactions within endothelial adhesive platforms. 
Endothelial cells were co-transfected with different mEGFP-mRFP1 pair constructs (A: 
CD9/CD9 and CD9/CD151; B: ICAM-1/CD9 and VCAM-1/CD151). FLIM-FRET 
analysis was performed as described (Material and Methods, Fig. 2 and Suppl. Fig. 1). 
For each FRET pair, the figure shows: the fluorescence intensity image of the scanned 
section (in pseudocolour scale), the phasor plot, and the FLIM image correspondent to 
the cursor selection of phasors (black circle) illustrating the pixel localization of phasor 
selection. Two selections are shown for each FRET pair corresponding to phasors at 
low (11-14%) and high (24%) FRET efficiency.  
 
Figure 7. Tetraspanin regulates endothelial adhesion receptor nanoclustering.  
A. i) TNF-α activated endothelial cells were fixed and stained with anti-VCAM-1 
(P8B1) or anti-ICAM-1 (Hu5/3), followed by 40 nm gold-immunolabeling. Then, 
samples were processed for SEM observation. Representative SEM negative images of 
1.75 µm2 areas of the endothelial plasma membrane are shown. ii) TNF-α-activated 
endothelial cells were fixed and double stained with anti-VCAM-1 (P8B1) and 
biotinylated anti-ICAM-1 (MEM-111), followed by 40 nm and 15 nm gold-labeling, 
respectively. Then, samples were processed for SEM observation. The left-hand panel 
shows a representative SEM negative image of 0.35 µm2 area of the endothelial plasma 
membrane displaying VCAM-1 (40 nm gold particles) and ICAM-1 (15 nm gold 
particles, white asterisks). High magnification images show detail of VCAM-1 and 
ICAM-1 heteroclustering. iii) T lymphoblasts were allowed to adhere to an activated 
endothelial monolayer for 5 min. Cells were then fixed, stained with anti-ICAM-1 
(Hu5/3) followed by 40 nm gold-inmunolabeling, and subjected to SEM processing. A 
representative SEM positive image shows the preferential localization of gold particles 
 48
at the microvilli of the endothelial docking structure formed around a lymphoblast. The 
inset shows the leukocyte-endothelial contact area at lower magnification. Scale bar = 
1.50 µm. B. i) Endothelial cells were activated for 20h with TNF-α in the presence of 
250 µg/ml of active or heat-inactivated (5 min 90ºC) CD9 blocking peptide (CD9-LEL-
GST). Cells were then fixed and stained for VCAM-1 or ICAM-1 as in A i). 
Representative images of 1.75 µm2 areas of the endothelial plasma membrane are 
shown. ii) Gold particles in SEM images were counted, and coordinates were assigned 
to each object using Metamorph software. Inter-particle distances were calculated using 
a custom-written k-nearest neighbour (knn) distance algorithm based on R software. 
The differences in receptor nanoclustering among samples subjected to different 
treatments were assessed in terms of aggregation and separation evaluated by means of 
a knn (k-nearest neighbour) profile. The knn profile is a k-points curve (for our analysis 
k=15), where each point in the curve is the mean of the nearest neighbour distances for 
the whole N points in the data set. Dist (title y-axis) corresponds to euclidean distances 
(considering each point by their x,y coordinates). Graphs show knn distances from 2 
representative images of each condition (VCAM-1 or ICAM-1 staining with active or 
inactive CD9 blocking peptide). C. i) Panels show representative FCS measurements 
performed at the plasma membrane of endothelial cells transiently-transfected with 
CD9- or CD151-mEGFP and treated with 250 µg/ml of active or heat-inactivated CD9-
LEL-GST. For each experiment are documented: the fluorescence intensity image, the 
point in which the laser beam was positioned for the measurement (white circle), the 
ACF (black line), the best-fitted curve (red line), and the fitted parameters, diffusion 
time (TauD) and anomality coefficient (α), from which the diffusion coefficient (D) 
was derived. The corresponding scale bar is shown in each image. kCPS: kilo counts 
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per second. ii) Scatter plots of the diffusion and anomality coefficients determined by 
FCS analysis. Each point is an individual measurement. Horizontal lines = medians.  
 
LEGENDS TO SUPPLEMENTAL FIGURES 
Supplemental Figure 1 
A. Standards for the phasor-FLIM analysis of FRET. Cells expressing only the 
mEGFP-tagged chimeras of ICAM-1, VCAM-1-or CD9 were used for defining the 
phasor distributions (i.e., fluorescence lifetime distributions) of each FRET-unquenched 
donor protein. ICAM-1-mEGFP is the reference for ICAM-1-mEGFP/ICAM-1-mRFP1, 
ICAM-1mEGFP/VCAM-1mRFP1 and ICAM-1mEGFP/CD9mRFP1 pairs. VCAM-
1mEGFP is the reference for VCAM-1mEGFP/VCAM-1mRFP1, VCAM-
1mEGFP/ICAMmRFP1 and VCAM-1mEGFP/CD151mRFP1. CD9mEGFP is the 
reference for CD9mEGFP/CD9mRFP1 and CD9mEGFP/CD151mRFP1. 
Fluorescence lifetime decays were acquired in the classical TCSPC-FLIM mode 
and transformed in the phasor representation as described (Digman et al., submitted; 
Caiolfa et al., 2007). Briefly, by this novel analytical approach, the fluorescence decay 
in each pixel of the image gives a point in the phasor plot. The phasors ensemble of the 
image is shown in contour plot. The phasor plot is simply a polar, s,g, coordinate graph, 
in  which only single exponential decays fall on the universal circle (right top panel), 
and different molecular species occupy distinct positions in the plots (Digman et al., 
submitted). As in our cells seeded on fibronectin matrices, if the decay at one pixel is a 
convolution of lifetimes, due to multiple species (i.e., unquenched donor + cell 
autofluorescence) contributing the fluorescence intensity in that pixel, the phasor falls 
inside the universal circle, and it is simply the algebraic sum of phasors from each 
component (Clayton et al., 2004; Gratton et al., 1984; Redford and Clegg, 2005) (right 
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top panel). The phasor distribution in donor-transfectected cells indicates the presence 
of pixels at different contribution of mEGFP and autofluorescence lifetimes. The latter 
was evaluated in independent experiments on untrasfected cells and the mean of its 
phasor distribution is reported in the phasor plot (+, right top panel). As it was recently 
shown (Digman et al., submitted), the phasors corresponding to the fibronectin 
background and the cellular autofluorescence are spread over a larger area of the phasor 
plot, due to the low intensity images, the fibronectin background and also the pixel 
heterogeneity for the cellular autofluorescence are detected. Despite that, the majority 
(> 95%) of pixels is included in a narrow, distinct area of the plot (black circle in the 
phasor plot), and are uniformly localized in the image, regardless the variability of the 
local fluorescence intensity.  In these pixels, mEGFP is the predominant species that 
gives rise to the measured fluorescence lifetime decays. The phasor distribution of the 
three donor constructs (top, mid and bottom panels) is comparable and depicts the area 
in the phasor plot in which mEGFP-constructs localize in the presence of fibronectin 
and cell autofluorescence and in the absence of quenching due to FRET (green line).  
Once we know the phasors of the unquenched donors and of the fibronectin-cell 
autofluorescence, we can calculate the FRET trajectory in the phasor plot according to 
the classical relationship: FRET eff = [1- (tau donor-acceptor)/tau donor], and define the mean 
phasors of mEGFP-constructs quenched by 50% FRET and with different contributions 
of fibronectin-cell autofluorescence (yellow line). In all our experiments, phasors 
resulting from any combination of unquenched-donors, FRET-quenched-donors and 
fibronectin-cell autofluorescence have been found within the area delimited by the 
green and yellow lines in the phasor plot.  
B. uPAR/ICAM FRET pair confirming the non interaction of a lipid raft-related 
protein and an EAP constituent. FLIM-FRET analysis of uPARmEGFP and ICAM-1-
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mRFP1 in HEK 293 cells. The intensity image (in pseudocolour scale), the phasor plot 
and the FLIM image correspondent to the cursor selection (black circle) are shown. This 
result indicates that FRET does not occur between the two proteins, as the phasor 
distribution of uPAR-green is identical to that of single transfected cells (data not 
shown, Caiolfa et al., 2007). It also shows that the localization and distribution of the 
phasors of mEGFP-constructs is not affected by the kind of protein linked to the 
fluorophore and by the cells in which they are expressed; while the contribution of other 
species such as fibronectin (not present in HEK293 samples) and cell autofluorescence 
varies depending on the cell culture conditions and expression levels of the tagged-
proteins.  
 
Supplemental Figure 2. Tetraspanins are localized at docking structures mediated 
by the engagement of ICAM-1 or VCAM-1. LFA-1+ or α4+ K562 cells were allowed 
to adhere to a TNF-α−activated endothelial monolayer for 30 min. Left panels: Cells 
were fixed and double stained for VCAM-1 (P8B1, red) and CD9 (biotinylated VJ1/20, 
green). Right panels: Cells were stained for CD9 (VJ1/20, green) and ICAM-1 
(biotinylated MEM-111, red). Confocal stacks were obtained and orthogonal maximal 
projections and vertical 3D reconstructions of the whole series are displayed. White 
arrows point to endothelium-leukocyte contact areas (docking structures). 
 
Supplemental Figure 3. A. Example statistical analysis of a FRAP experiments. For 
each time point, the table shows mean fluorescence intensities for ICAM-1 and ICAM-
1∆Cyt (measured at the plasma membrane) raw p values, and adjusted p values obtained 
for multiple testing using the Benjamini and Hochberg’s (BH) method.  
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Typically, an acceptance criterion of a single event takes the form of a 
requirement that the observed data be highly unlikely under a default assumption (null 
hypothesis). As the number of independent applications of the acceptance criterion 
begins to outweigh the high unlikelihood associated with each individual test, it 
becomes increasingly likely that one will observe data that satisfies the acceptance 
criterion by chance alone (even if the default assumption is true in all cases). These 
errors are considered false positives because they positively identify a set of 
observations as satisfying the acceptance criterion while that data in fact represents the 
null hypothesis. Many mathematical techniques have been developed to counter the 
false positive error rate associated with making multiple statistical comparisons. To 
avoid these multiple comparison problems, we used the Benjamini and Hochberg’s 
(BH) method for the statistical analysis of our FRAP experiments. 
 The accompanying graph shows mean fluorescence recovery curves of ICAM-1 
and ICAM-1∆Cyt at the plasma membrane. The adjusted p values shown in the table 
correspond to the maximum adjusted p value out of the plateau region. The plateau 
region is marked on the table and the graph and was not considered for the statistical 
analysis. 
 B. Comparison of dynamic behaviors of each EAP constituent at nude plasma 
membrane and at ICAM-1- and VCAM-1-mediated docking structures. The graphs 
show the mean fluorescence recovery curves at nude plasma membrane and at ICAM-1 
and VCAM-1-mediated docking structures for each EAP component studied: CD9-, 
CD151-, VCAM-1- or ICAM-1-EGFP. Statistical analysis was performed as indicated 
in A. 
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Supplemental Figure 4. Examples of Fluorescence Cross-correlation Spectroscopy 
measurements within endothelial adhesive platforms. The figure shows 
representative measurements performed at the plasma membrane of HUVEC double 
transfected with ICAM-1mEGFP/ICAM-mRFP1 (A) or CD9mEGFP/CD151mRFP1 
(B). For each experiment are documented: the fluorescence intensity image from both 
channels (red and green), the point in which the laser beam was positioned for the 
measurement (white circle), the ACF (black line), the best-fitted curve (red line), the 
cross-correlation function for the pair, and the fitted parameters, diffusion time (TauD) 
and anomality coefficient (α), from which the diffusion coefficient (D) was derived. 
The corresponding scale bar is shown in the images. kCPS: kilo counts per second. 
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